The utility of the auditory brainstem response in children with atypical saccadic eye movements by Campbell, Pauline Elizabeth
  
 
 
 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation from the 
thesis and no information derived from it may be published without the author's prior consent. 
  
  
 
 
 
THE UTILITY OF THE AUDITORY BRAINSTEM 
RESPONSE IN CHILDREN WITH ATYPICAL 
SACCADIC EYE MOVEMENTS 
 
By 
 
PAULINE ELIZABETH CAMPBELL 
 
 
A thesis submitted to the University of Plymouth  
in partial fulfilment for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
School of Psychology 
Faculty of Science and Technology 
 
 
December 2011 
 
  
 
 
1 
Abstract 
Lesions in the brainstem result in widespread damage to a number of sensorimotor 
systems including oculomotor and auditory neural circuits. Although these systems are 
spatially separate and highly specialised, they are also co-located. This thesis, investigates 
whether lesions in the oculomotor system will also cause co-morbid dysfunction in the 
auditory pathways. Specifically, we investigated the usefulness of the Auditory Brainstem 
Response (ABR) in two oculomotor conditions: slow saccades in Gaucher disease (GD) 
and opsoclonus in Dancing Eye Syndrome (DES).  
We present four empirical studies. In our first study we systematically investigated 
the ABR in GD. We found that multimodal testing can better delineate underlying 
neurological deficits in neuronopathic GD (nGD) and distinguish between phenotypes.  In 
the second study we examined the ABR's utility as a longitudinal, objective marker of 
disease burden and in a randomised clinical control trial. ABRs continued to deteriorate 
regardless of treatment. In our third study we assessed audiological function in DES. We 
found that at least 43% of DES patients have hyperacusis. We also found subtle 
abnormalities in the auditory brainstem, as shown by the ABR. Our final study explored the 
onset-offset response in the ABR and assessed its utility as a clinical marker. Overall, this 
thesis provides new evidence that auditory pathways are also affected in diseases which are 
traditionally assumed to be „oculomotor‟ in nature.  We believe that there is sufficient 
evidence to warrant the inclusion of audiological testing, such as the ABR, as part of the 
standard assessment of newly diagnosed GD patients and that they undergo these tests prior 
to commencing treatment. These tests may also have a wider application as longitudinal 
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outcome measures for use in clinical trials or as markers of neurological burden in GD and 
we believe may be useful in other metabolic diseases; we found that current therapies for 
GD have low efficacy. Understanding the underlying neurological deficits in these 
debilitating illnesses can only help to improve treatments and the long-term outlook for 
these patients. 
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General Introduction 
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1.1 The normal brainstem 
“Up until then I had never even heard of the brainstem. I‟ve since learned that it is an 
essential component of our internal computer, the inseparable link between the brain and 
the spinal cord. I was brutally introduced to this vital piece of anatomy……. In my case, 
blinking my left eyelid is my only means of communication” (Bauby) 
  
The brainstem is a highly organised, intricate network. Neuroscientists often refer to 
the brainstem as the neural gateway between the brain and the body. With the exception of 
olfaction, all sensory information that is sent to the brain, from the body is obliged to travel 
through this remarkable system. As such, the brainstem plays a central role in a number of 
life-supporting functions including sensorimotor control, respiration, alertness and 
consciousness, to name a few.  
Despite the high clinical significance of the brainstem, this phylogenetically older 
part of the nervous system is often dismissed as comparatively primitive – incapable of 
demonstrating the same degree of neural plasticity that is evident in higher cortical 
structures. However, recent studies in the auditory brainstem complex are now challenging 
this prevailing idea (Tzounopoulos and Kraus, 2009).  
These studies have clearly shown that the auditory brainstem is not a „passive‟ 
structure (Kraus and Chandrasekaran, 2010). This multifaceted system does not simply 
extract core acoustical features, through a series of successive „bottom-up‟ processes as 
sound travels from the outer ear to the auditory cortex. It has a dynamic role, actively 
interacting with other higher cortical processes, influencing important non-sensory factors 
such as linguistic experience (Krishnan et al., 2005), musical expertise (Musacchia et al., 
2007, Wong et al., 2007, Musacchia et al., 2008) and attention (Galbraith et al., 1998, 
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Galbraith et al., 2003). Moreover the output of this intricate sub-cortical network has been 
shown to change with auditory training, reflecting a real-time transformation (Song et al., 
2008b). These converging lines of evidence clearly show that the brainstem demonstrates 
neural plasticity and is not „primitive‟ at all; these facts have re-ignited scientific interest in 
studying this area of the brain.  
But how do we study the brainstem? One well established approach is to compare 
healthy brain activity with brains that have, either deliberately or through injury or 
neurological disease, been made dysfunctional and where normal interrelating pathways are 
partial or absent (Bear et al., 2001). This lesion-based approach provides us with a powerful 
method of revealing the brain‟s internal structures and identifying the essential pathways 
responsible for their various functional activities.  
Lesion studies are typically the result of two possibilities: experimentally induced, 
e.g. through chemical or surgical ablation, or they can occur as the result of naturally 
occurring disease processes (Bear et al., 2001). These studies are based on the assumption 
that a measurable change in behaviour – as indexed by clinical sign or symptom – can help 
identify where the brain is damaged and also allow us to learn about normal function 
through dysfunction, i.e. brainstem deficits provide a unique window to observe the 
relationship between brain and behaviour (Griffiths et al., 1997, Griffiths, 1999). 
One major drawback to the use of lesion studies is that they fail to show how co-
located anatomical areas, such as the oculomotor and auditory brainstem regions, are 
functionally integrated. This is because the effects of human lesions, as a result of disease, 
are difficult to estimate. For example, isolated lesions involving only the auditory 
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brainstem are rare. Because the auditory pathway is closely related to key motor and 
sensory tracts, co-morbid dysfunction is often observed in other sensory modalities and as a 
result of these shared neural substrates, a typical brainstem lesion affecting the auditory 
pathway will also involve multiple areas and levels of the brain (Griffiths, 1999).  
The challenge is how to capture any deficits that may arise as the result of a 
brainstem lesion in the auditory brainstem. Of particular interest to this thesis, is how do we 
undertake this in the developing brain of a young child? 
 
1.2 Abnormalities and brainstem dysfunction: signs and symptoms 
Brainstem dysfunction often results in a wide range of signs and symptoms 
including visual disturbances, hearing difficulties, altered sensation, muscle weakness, 
vertigo, swallowing and speech difficulty, voice change, and co-ordination problems.  
Although there are innumerable signs of brainstem abnormalities, in this thesis we 
are concerned only with eye movement and auditory signs as the neural substrates that 
control them are co-located in the brainstem. The literature is replete with case reports and 
small scale studies of patients with established brainstem lesions that exhibit both eye 
movement and auditory abnormalities. For example, abnormal auditory brainstem and 
atypical visuomotor signs have been reported in demyelinating diseases such as Pelizaeus-
Merzbacher disease (Nezu, 1995), Fisher‟s syndrome (Minoda et al., 1999), the 
leukodystrophies (Inagaki et al., 2006), degenerative diseases such as the spinocerebellar 
ataxias (Rub et al., 2008, Schols et al., 2008), metabolic diseases such as Gaucher disease 
(Bamiou et al., 2001), Tay-Sachs disease (Bembi et al., 2006), Niemann-Pick disease 
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(Patterson et al., 2007), neurodevelopmental disorders such as Cornelia de Lange syndrome 
(Harris et al., 1996) and autism (Rosenhall et al., 1988); this list is not exhaustive. Although 
many of these clinical conditions are known to affect both eye movement circuits in the 
brainstem and subcortical auditory structures, few systematic studies have actually 
examined this issue. 
 
1.2.1 Eye movement signs 
The primary aim of all eye movement systems is to maintain an optimal retinal 
image on the fovea – a small area located centrally on the retina – which has the greatest 
density of photoreceptors. Six eye movement sub-systems have been identified: fixation, 
the vestibulo-ocular reflex (VOR), the optokinetic reflex (OKR), saccades, smooth pursuit 
and vergence eye movements (Leigh and Kennard, 2004). The saccadic, smooth pursuit and 
vergence eye movement systems are important in „acquiring‟ the target of interest. The 
VOR and OKR sub-systems are activated during head movement. These reflexes play a 
substantial role in stabilising a moving target, by ensuring that the eyes are directed on the 
target during head movement. We will provide some background about each of these 
subsystems in the following chapter. 
At this juncture we elaborate on our core concern – saccadic eye movements in the 
context of brainstem disease. Saccades are highly stereotyped eye movements that enable 
the visual system to shift gaze from one object, in the line of sight, to another point of 
interest (Leigh and Zee, 1999a). Saccadic movements have evolved a very elegant strategy 
of foveal compromise – balancing the need for a large visual field and the requirement for 
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high visual acuity. This has been described as “cutting up the visual continuum into a 
series of stills” thus allowing the world to appear stable (Ings, 2007).  
The study of saccades has become an increasingly popular method to probe 
brainstem function (Sparks, 2002, Leigh and Kennard, 2004), for a variety of reasons. 
Firstly, there is a wealth of data from lesion and unit recording studies in nonhuman 
primates, using oculomotor paradigms, which have identified the neural circuitry 
responsible for the generation of saccadic behaviours (Strassman et al., 1987, Ohtsuka and 
Noda, 1995, Colby et al., 1996, Kaneko, 1996, Munoz and Istvan, 1998, Takagi et al., 
1998, Buttner-Ennever et al., 1999, Everling and Munoz, 2000, Hanes et al., 2005). 
Secondly, saccades depend on very circumscribed populations of neurons and are highly 
sensitive to brainstem disease (Zee, 1986, Noda, 1991, Munoz et al., 2000, Sparks, 2002, 
Leigh and Kennard, 2004, McDowell et al., 2008, Linzenbold et al., 2011). Finally, 
saccades can be measured accurately, across a wide age spectrum, using eye-movement 
tasks that typically require very little instruction (Cassidy et al., 2000a). This means that 
such tasks can be used with young children and in difficult-to-test clinical populations – 
providing precise information about the temporal dynamics of information processing. 
Saccadic abnormalities can be identified by measuring three robust characteristics. 
These include changes in velocity (e.g. saccades may deteriorate and become either too 
slow or too fast, or demonstrate different velocities between each eye in terms of magnitude 
or direction), latency (e.g. prolongation, or shortening or asymmetry between eyes) and 
accuracy (e.g. saccades can overshoot or undershoot the desired target). In brainstem 
disease, many of these well defined parameters are abnormal. 
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In this thesis, we will examine two types of saccadic disturbance: slow saccades 
and, at the other end of the velocity spectrum, opsoclonus (see Section 2.2 for a more 
detailed overview). We have chosen these abnormalities as they represent the two extremes 
of saccadic eye movements.  
 
1.2.2 Auditory signs  
The brainstem also has a very important function in the auditory system. It is at the 
level of the brainstem that monaural pathways converge, first in the region of the pons and 
then again in the midbrain, resulting in binaural processing. This type of processing 
involves a fine-grained comparison of intensity and phase cues that originate independently 
at each ear. Lesions in the auditory brainstem have been shown to cause disruption in this 
processing; resulting in weakened representations of temporal, spectral and spatial auditory 
patterns (van der Poel et al., 1988, Furst and Algom, 1995, Furst et al., 1995, Griffiths et 
al., 1997, Griffiths et al., 1998).  An example of disruption in binaural processing has been 
clearly documented in a patient with a well-circumscribed, central pontine lesion involving 
the trapezoid body (Griffiths et al., 1997). The patient reported difficulties with listening to 
speech during background noise, but also goes on to describe:  
“….a difficulty with sound localisation such that she had become unable to detect 
which of three well separated telephones in her office was ringing. …and also had difficulty 
with the perception of moving sounds. For example, she was unable to detect which way a 
train was travelling when she was standing on a platform, on the basis of sound alone” 
(Griffiths et al., 1997, p522). 
 
As mentioned earlier, lesion-based approaches have been used extensively to study 
the auditory brainstem (van der Poel et al., 1988, Furst and Algom, 1995, Furst et al., 1995, 
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Griffiths et al., 1997, Griffiths et al., 1998). A number of different techniques (e.g. 
psychophysics; brain imaging, electrophysiological measures) in human adult studies have 
been used to make inferences about the role of the auditory brainstem and the effect of any 
disturbances on auditory performance. However these studies are usually undertaken in 
adults and provide limited information about the function of the developing brain. In this 
thesis, rather than concentrating on the study of disorders solely in adults, which is most 
commonly the case, we study disorders in children. By measuring the developing brainstem 
early we are able to construct a better picture of how different phenotypes of brainstem 
disorder may unfold. 
 
1.2.3 Multimodal approach to studying the brainstem  
We have mentioned above that eye movements and audiological functions are both 
compromised early on in a number of brainstem disorders, although systematic studies in a 
host of neurologic conditions is lacking. Often eye movement and auditory signs are still 
considered in isolation. Why is this the case and why are there only a relatively small group 
of investigators working at this juncture of disciplines? A partial explanation may be found 
in the differing research methods and „scientific jargon‟ used across the two fields. Another 
key issue is the length and depth of the necessary training required in each field (i.e. eye 
movements or audiology) to develop the required expertise for undertaking measurements.  
Others have strongly argued that administering multimodal tests is beyond the scope 
of clinical practice in Audiology. For example, 
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“Do we, as audiologists, have sufficient training in these related areas to do this? 
Should we be trained in these areas, considering our unique role as specialists in auditory 
and vestibular system function and the access to other professionals whose scopes of 
practice and areas of expertise encompass these areas?”(Musiek et al., 2005, p131).  
We argue that such an assertion is inaccurate as saccadic eye movements are 
regularly assessed in Audiology clinics as a part of routine vestibular investigations (Hall, 
2007).  
The argument in favour of studying the brain using a multimodal approach remains 
a highly contentious issue in auditory neuroscience (McFarland and Cacace, 1997, Cacace 
and McFarland, 1998, 2005, Katz and Tillery, 2005, Musiek et al., 2005, Rosen, 2005). 
Cacace and McFarland (2005) have called for modality specific testing as a „means 
of differentiating auditory processing problems from more generalized supramodal 
dysfunction‟ (Cacace and McFarland, 2005, p 117). Other researchers have raised 
objections to this viewpoint, arguing that this approach is „unrealistically narrow‟ and 
„exclusive‟ (Salvi et al., 2002, Poremba et al., 2003, Musiek et al., 2005, Rosen, 2005).  
In this thesis, we will present new data to show that the application of auditory 
testing in conjunction with eye movement studies, has an even wider application, for 
example, in baseline diagnostic assessment, longitudinal monitoring and in clinical drug 
trials.   
1.3 Why study auditory signs and symptoms in saccadic eye movement 
disorders? 
In section 1.2.1 we presented reasons for the use of eye movements in identifying 
brainstem dysfunction. In this section we will present the reasons why are we advocating 
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the additional use of auditory tools in this thesis and account for why eye movement tests 
are not sufficient. 
Eye movement studies have a number of serious drawbacks, which auditory tests 
may overcome. Firstly, we mentioned that the instructions for most saccadic tasks are 
relatively uncomplicated, with a low cognitive load. Simple instructions, however, should 
not imply that the task is easy. Eye movement studies require considerable co-operation on 
the part of the patient – this is particularly so in the nonverbal patient (Cassidy et al., 
2000a). The advantage of the auditory measures, for example, the Auditory Brainstem 
Response (ABR) is self-evident. This non-invasive, electrophysiological measure is 
routinely used to assess the integrity of brainstem pathways requires no overt response and 
is typically best measured while the subject is sleeping (Hall, 2007). We will discuss the 
ABR in some detail in the following chapters. (see Chapters 2 and 3).  
Secondly, the success of eye movement recordings are critically dependent on the 
visibility of the target and/or the ability to fixate on that target
1
 whereas the ABR makes no 
demands on verbal or motor abilities (Hall, 2007). Thirdly, an important consideration is 
neural maturation. The saccadic system is not fully developed until the age of 1 year and 
can be absent at birth (Cassidy et al., 2000a), however, the ABR can be reliably recorded in 
infants from birth (Moore, 1987a, Musiek et al., 1988, Moore et al., 1995, Moore et al., 
1996, Ponton et al., 1996, Moore and Linthicum, 2001, Hall, 2007, Moore and Linthicum, 
                                               
1 Typically, during saccadic eye movement testing, the subject is tasked to „follow a target with your eyes‟. 
Although the cognitive load of these instructions is low, there is always the question whether (a) the subject 
can understand these simple instructions and (b) whether the subject is able to actually generate the 
appropriate eye movement to fixate on the target. There is also the inherent assumption that the subject is able 
to see the target. Indeed, Cassidy et al., (2000) make the point that children who cannot move their eyes may 
appear blind because of saccade initiation failure.   
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2007). Fourthly, saccades can be difficult to interpret and require considerable expertise to 
both administer the tests  and analyse the results (Leigh and Zee, 1999a).  
Given these reasons, we argue in this thesis that the development of a non-invasive, 
inexpensive, marker of early brainstem damage, such as the ABR would be valuable 
addition in informing and planning the management of younger patients.  
We have chosen to focus our attention on two clinical conditions: Gaucher disease 
(GD) and Dancing Eye Syndrome (DES). We have selected these conditions for three 
reasons. First, there are widespread anecdotal patient reports of auditory difficulties in 
children with these two conditions. Secondly, there is literature, albeit limited (and 
incomplete in many cases) that suggest that children with GD and DES may also have 
abnormal ABRs. Finally, given the co-location of the auditory and eye movement centres in 
the brainstem, it might also be expected that auditory pathways would also be affected.  
 
1.3.1 Why study auditory signs and symptoms in Gaucher disease (GD)? 
An autosomal recessively inherited lysosomal storage disorder, GD is characterised 
by deficient activity of the lysosomal enzyme ß-glucosidase, resulting in the accumulation 
of its substrate, glucosylceramide. This leads to multi-system disease involving 
enlargement and dysfunction of the spleen and liver, bone destruction and in severe cases, 
pulmonary infiltration. In some patients, there is also widespread involvement of the 
brainstem (Beutler and Grabowski, 1995, Scriver, 2001)
2
. Among the well-described 
                                               
2 GD is traditionally subdivided into the following groups: GD1 (non-neuronopathic) in which there is an 
absence of CNS involvement; GD2 (acute infantile) in which there is a rapid neurological progression leading 
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primary neurological signs, eye movement abnormalities
3
 are considered to be the universal 
indicator of the neuronopathic GD-subtypes (nGD).  
Audiological abnormalities have also been described in nGD (Dreborg et al., 1980, 
Bamiou et al., 2001, Grasso et al., 2006), although there is still no agreement as to whether 
audiological investigations could be considered reliable tests of neurological involvement 
in GD. Clearly further studies examining the potential role of auditory studies, particularly 
those that test the integrity of brainstem pathways are required. 
We have chosen to study GD because it remains one of the most attractive 
candidates, among the inherited lysosomal storage diseases, for developing effective 
therapeutic interventions (Butters et al., 2003, Platt and Jeyakumar, 2008). As such, novel 
insights in this area may be directly applicable to other disease conditions.  
 
1.3.2 Why study auditory signs and symptoms in Dancing Eye Syndrome (DES)? 
Dancing eye syndrome (DES)
4
 is a rare disease which is characterised by a jerky 
ataxia, shivering movements, and bursts of multi-directional conjugate eye movements 
along both horizontal and vertical axes (opsoclonus)
5
 (Mezey and Harris, 2002). These 
initial symptoms often appear to resolve after a few days, or weeks, making diagnosis of 
                                                                                                                                               
to death, usually by 2 years of age; GD3 (subacute neuronopathic) in which there is a slower and more 
variable neurological progression. 
 
3  Eye movement abnormalities include horizontal saccade initiation failure (SIF) (also known as „ocular 
motor apraxia‟), horizontal saccade slowing, vertical saccade initiation failure (especially downward), 6th 
nerve paresis (in some cases) and in rare cases decreased gain of the vestibulo-ocular reflex. We will consider 
each of these later in Chapters 2 and 4. 
4 DES is known by many names including opsoclonus - myoclonus, opsoclonus ataxia, Dancing Eye and 
Dancing Feet, myoclonic encephalopathy or Kinsbourne‟s disease. 
 
5 These are the primary features of DES; however there are a number of other associated signs and symptoms 
which we will discuss later in chapter 6. 
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DES extremely difficult. The disease is usually seen in young children (aged typically 
between 10 months and three years) with no preceding history of neurological disease 
(Dale, 2003). There is little clear evidence as to the cause of DES and treatment options are 
limited (Pang et al., 2010).  
The inability to accurately identify the site of lesion in DES is a major gap in our 
clinical knowledge. Eye movement studies have implicated the brainstem (Harris, 1997, 
Mezey and Harris, 2002) and the cerebellum (Shawkat et al., 1993). Auditory studies in 
DES are scant, although there is a suggestion that hyper-excitability is present within the 
brainstem pathways (Maeoka and Maegaki, 1998). Whatever the underlying cause of DES, 
it is crucial that we identify which parts of the brain are affected by the disease.  
The more we understand the neurobiological basis of impairment, the easier it 
becomes to develop tools to capture a clearer picture of the intricate relationships that exist 
between brain and behaviour. Furthermore, the presence of a documented auditory deficit 
leads to a diagnosis of auditory dysfunction that may be amenable to auditory 
rehabilitation. 
We have chosen to concentrate our efforts on the utility of the ABR in both of these 
conditions because we believe this test could translate successfully from laboratory to 
clinic. The ABR test is relatively straightforward, easy to administer, score, and interpret. It 
uses equipment that is commonly available in clinical practice. We will further develop this 
aspect of the thesis in the next chapter, where we will also locate it within the emerging 
literature.  We now provide an overview of the thesis before summarising the contributions 
that it makes to the field. 
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1.4 Thesis overview 
The questions that motivated this thesis are: 
(1) Do children diagnosed with GD and DES with documented saccadic eye movement 
abnormalities, originating in the brainstem, also have auditory problems?  and   
(2) How can the application of the auditory brainstem response be used to complement 
eye movement studies?  
In the next chapter, we present the relevant background literature to the thesis. This 
is followed by a description of the general methods and procedures that were used 
throughout the thesis (Chapter 3). The next four chapters focus on the experimental work 
undertaken. Chapters 4, 5 and 6 concentrate on developing an audiological profile in 
children with atypical saccadic eye movements; Chapter 7 examines the ABR when offset 
stimuli are employed. We now briefly summarise the content and main results of the thesis.  
 
1.4.1 Chapter 2: Background 
We begin by outlining the saccadic eye movement and auditory brainstem systems 
and draw attention to the neural substrates most relevant to the thesis. We then present an 
overview of current eye movement and audiological techniques that are used to examine 
the brainstem. This will set the scene for our discussion in later chapters.  
We then proceed to examine the established literature concerning eye movement 
studies and audiology signs, specifically, those that are concerned with slow saccades and 
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opsoclonus. Our goal here is to examine whether there is a documented association between 
auditory deficits in children with these atypical eye movements. 
 
1.4.2 Chapter 3: General Methodology 
We explain in detail all of the general methods that we have employed during our 
studies that are described in Chapters 4, 5 and 6.  We have chosen to use audiological 
investigations that test overlapping efferent and afferent pathways in the peripheral and 
central auditory nervous system, in an attempt to evaluate the extent and degree of 
brainstem lesions. We will also provide detailed justifications for each of the assessments 
used.  
 
1.4.3 Chapter 4: Audiological profile of Gaucher Disease 
We begin by providing a detailed clinical description of GD, paying particular 
attention to the abnormal eye movements which are considered a hallmark of nGD (Harris 
et al., 1996, Harris et al., 1999). We then outline what is known experimentally about the 
use of eye movement and audiological techniques from the published literature relating to 
the diagnosis of GD, and draw attention to those results most relevant to the thesis. Finally, 
we will present our first set of results, constructing an „audiological profile‟ of GD by 
carrying out investigations on a wide range of Gaucher patients, with known oculomotor 
status.  
Our aims in this study are twofold. Firstly we wish to investigate whether 
audiological tests can detect subtle brainstem involvement and whether they point to focal 
lesions consistent with saccadic eye movement disturbances, or whether there is more 
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widespread degeneration. Secondly, we wish to examine whether there is a similar 
continuum between neuronopathic and non-neuronopathic disease by using combined eye 
movement and auditory investigations.  
In this chapter, we show that when audiological tests are coupled with eye 
movement studies, they can be used to provide reliable subclinical and pre-symptomatic 
tests of neurological involvement in GD. 
 
1.4.4 Chapter 5: The use of audiological assessments in the longitudinal monitoring 
of GD 
We build on the results presented in Chapter 4 by asking whether these combined 
techniques can be used to measure the disease burden for those patients on treatment.  Two 
key questions arise: 
(1) Can the ABR be used for long term monitoring of any neurological progression in 
GD? Little is known about the fluctuations in the ABR over time and if we hope to 
exploit the full potential of the ABR for longitudinal monitoring, then it is 
imperative that we address this issue.  
(2) If the ABR is shown to be a sensitive and reliable longitudinal measure of 
subclinical neurological disease burden, then can the ABR be used to capture any 
drug efficacy over the limited time frame of clinical trials? Such work is important. 
Our ability to test the neurological efficacy of new therapies is very limited, if not 
absent, for the young or cognitively impaired child. 
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We present two experimental studies. Our first study is concerned with our question 
of whether the ABR can be used to reliably measure the disease burden in the 
neuronopathic subtypes of GD. We present data, for the first time, of serial ABR recordings 
in type 2 and type 3 GD. A preliminary account of this work has appeared in two papers 
(Campbell et al., 2003, Campbell et al., 2004). 
In our second study, we take an in-depth look at an emerging and promising 
treatment, i.e., substrate reduction therapy (SRT), an alternative approach to the current 
enzyme replacement therapy. We then present our data on use of the ABR as a secondary 
outcome measure in the substrate restriction therapy GD3 trial.  
 
1.4.5 Chapter 6: Audiological profile of Dancing Eye Syndrome 
We begin this chapter by presenting a synopsis of the signs and symptoms that are 
seen in DES and a summary of previous eye movement and auditory studies that are 
pertinent to this thesis. This is then followed by two experimental studies. In our first study, 
we present our preliminary findings from a parental questionnaire that was administered to 
families of DES throughout the UK. Our core goal in this experiment is to determine 
whether the hyper-excitability expressed in the eye movement system, as opsoclonus, is 
mirrored in the auditory system, i.e. do children with DES have hyperacusis?  
In our second study, we present for the first time a systematic audiological 
evaluation of DES. Here, we are chiefly interested in identifying whether children with 
DES have auditory deficits, and if so, whether there is any evidence of longer-term 
brainstem disease, particularly in the absence of any overt eye movement abnormalities. 
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In this chapter, we show that children with DES do have auditory problems, 
including an abnormal sensitivity to ordinary environmental sounds. Furthermore, these 
deficits can be reliably measured by the ABR. We also show that auditory tests, such as the 
ABR, in addition to eye movement studies, can result in an improved understanding of the 
pathophysiology underlying DES.  
 
1.4.6 Chapter 7: The ‘offset ABR’ in saccadic eye movement disorders 
In the final experimental chapter we are concerned with the first stages of 
understanding the importance of the “offset” of sound using the ABR. The offset of sound 
is an important acoustic cue in consonant identification (Pind, 1998), discriminating sound 
duration (Schlauch et al., 2001) and in the acoustic startle reflex (Ison and Allen, 2003). 
Despite the obvious importance of these phenomena, there has been relatively little study of 
the offset response. The paucity of work undertaken in this area may be a reflection of the 
technical challenges to accurately evaluate and record the offset response.  
One technique that has been used sporadically, to address this problem, is the use of 
the „offset ABR‟ (Kodera et al., 1977b, Van Campen et al., 1997). In this chapter, we begin 
by presenting an in-depth review of all „offset-ABR‟ studies undertaken in the last 30 years. 
We then present offset-ABR data from a series of different experiments, employing a wide 
range of frequencies (and rise-fall times) and polarity (rarefaction, condensation) in normal 
hearing participants. This work replicates and extends previous studies (Van Campen et al., 
1997). Finally, we present, for the first time, a clinical application of the offset ABR. This 
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application involves recording the offset ABR in our two eye movement disorders (GD and 
DES) that have been the subject of our previous chapters. 
 
1.4.7 Chapter 8: General Discussion and Conclusions 
In this concluding chapter, we summarise our main findings in this thesis. Although 
the technique introduced in Chapter 7 requires more research, the emerging message from 
our thesis is unambiguous; there is ample evidence that the use of audiological assessment 
in children with aberrant saccadic eye movements would contribute to clinical practice.  
Finally, we suggest possible directions for future work, and ways in which the ABR 
could be used to complement other studies. This may lead to improved early detection and 
may allow for new, meaningful rehabilitative intervention. 
 
1.4.8 Main contributions of the thesis 
These are as follows: 
1. Our ABR investigations, using onset and offset stimuli, have clearly shown that 
there are aberrant electrophysiological characteristics in two diverse eye movement 
disorders (GD and DES). These findings have not previously been documented.  
2. Objective measurement of neurological dysfunction remains a major challenge 
when testing new drugs, especially in young children. Nowhere is this more obvious 
than when testing the new drug therapies that are emerging for the treatment of 
metabolic diseases. Although it is unlikely that one single outcome measure can 
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capture all aspects of the disease process, we present new data highlighting the 
potential for the ABR as a clinical trial biomarker. 
3. A novel use of the „offset‟ clinical ABR is presented for the first time. The atypical 
„offset‟ ABR response to stimulus cessation may account for some of the persistent 
learning difficulties that are reported in some children with atypical saccadic eye 
movements. 
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2 Chapter 2 
Background 
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2.1 Introduction  
The eye is not a lonely miracle. It is a sense organ, similar in application to an ear,  
or a nose. Of course there are differences between seeing and hearing 
 and smelling but there are common features too, and these are important.  
(Ings, 2007, p15) 
 
The brainstem is a small but extremely significant part of the brain. Sensory and 
motor nerve connections, from the main part of the brain to the rest of the body, pass 
through the brainstem. Located posteriorly, the brainstem is structurally continuous with 
the spinal cord, providing the main sensorimotor innervation via the corticospinal tract, the 
spinothalamic tract and the posterior column-medial lemniscus pathway. The brainstem is a 
continuously adapting structure which rapidly modulates and shapes incoming messages, 
controlling the way that information, particularly sensory data, is transformed, encoded and 
routed.  
In this chapter we will focus on two experimental approaches by which the 
brainstem has been investigated: namely the study of eye movements and auditory circuits. 
We begin this chapter by providing an overview of the brainstem, followed by a detailed 
discussion of the neurology of the saccadic and auditory systems; the neural substrates most 
relevant to this thesis. Here, we will confine our review to saccadic eye movements. The 
reason we have chosen to focus on saccadic abnormalities is that they are the most 
stereotyped eye movements and the ones that are least influenced by the external stimuli. 
Our emphasis in this chapter is on two abnormal oculomotor developments: slow saccades 
and opsoclonus.  
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We will then present a brief overview of current eye movement and audiological 
techniques that are used to examine the brainstem. This will set the scene for our discussion 
in later chapters. We then proceed to briefly review eye movement studies, specifically, 
those investigating slow saccades and saccadic intrusions (i.e. opsoclonus). Our goal here is 
to examine whether there is a documented association between auditory deficits in children 
with these atypical eye movements. 
 
2.2 A gross anatomical description of the brainstem 
The brainstem is composed of three major structures: the medulla oblongata, pons 
and the midbrain. Each of these areas within the brainstem, incorporate a number of 
important, highly specialised regions of the auditory and oculomotor systems. Because of 
the relevance of these structures to our thesis, we now provide a brief outline of the major 
brainstem subdivisions (for a more comprehensive treatment see e.g., Standring et al., 
2008). These structures and their spatial relationships are shown in Figure 2.1. An 
understanding of these structural relationships is critical for our later discussion, where we 
examine whether the auditory system is also implicated in different eye movement 
disorders.  
The medulla oblongata is the most caudally located part of the brainstem. It extends 
from the inferior pontine sulcus to the spinal cord. The boundary between them is the 
region where the lateral walls of the fourth ventricle converge in a V shape at the midline 
obex, at the level of the foramen magnum. The ventral surface of the medulla displays the 
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anterior midline ﬁssure, bordered on each side by the pyramids and crossed by the 
pyramidal decussations, connecting the right and left pyramids to each other. Lateral to 
each pyramid are the olivary bodies – olive pit-shaped swellings. These paired structures 
can be divided into the inferior olivary nucleus, which is involved in cerebellar motor-
learning and function, and the superior olivary nucleus, a critical part of the auditory system 
that has an important role in sound localisation. We will discuss the functional significance 
of this region later in this chapter (see section 2.3.4.5). 
Figure 2-1 Gross anatomy of the human brain 
 
 
Figure has been removed due to copyright restrictions 
 
As can be seen in Figure 2.1, above, the cerebellum overlies and hides the dorsal 
aspect of the brainstem, but its ventral aspect, the pons, is clearly evident. Rostrally, the 
superior pontine sulcus acts as the boundary between the pons and the midbrain and the 
inferior pontine sulcus as the boundary between the pons and the medulla. Part of the ﬂoor 
of the fourth ventricle is formed by the dorsal aspect of the pons. This is known as the 
pontine tegmentum, a structure that incorporates the nuclei of the trigeminal (V), abducen 
(VI), facial (VII), and vestibulocochlear (VIII) cranial nerves. Three of these cranial nerves 
have significant functional importance in the oculomotor and auditory systems. The 
abducens nerve is important in the control of the lateral rectus muscle (see section 2.3.2.2) 
and the facial and vestibulocochlear nerves are important structures involved in the 
  
 
 
63 
ascending and descending subcortical auditory brainstem.  These three nerves exit the 
brainstem at the level of the inferior pontine sulcus, whereas the trigeminal nerve exits the 
brainstem through the middle cerebellar peduncle. 
The midbrain is the smallest segment of the brainstem. It is a relatively narrow 
structure that extends from the thalamus to the pons, close to the cerebral aqueduct. The 
midbrain can be subdivided into two regions: the midbrain tegmentum, an area of the 
midbrain below the cerebral aqueduct, and the tectum, which houses the paired superior and 
inferior colliculi. These structures are closely associated with the lateral and medial 
geniculate bodies, respectively, and as we will show later in this chapter, they collectively 
play an important role in visual and auditory functions. The trochlear nerve (CN IV) 
controls one of the extraocular muscles (the superior oblique muscle) of the eye. This 
cranial nerve is the only one to exit the midbrain tectum, just below the inferior colliculus. 
The other cranial nerves exit the ventral aspect of the brainstem.  
The brainstem is connected to the cerebral hemispheres by two large ﬁbre tracts – 
the cerebral peduncles (cerebral crus). The depression between the peduncles (the 
interpeduncular fossa) is the site of origin of the oculomotor nerve (CN III) which is 
responsible for eye movement control, pupil constriction and maintaining an open eyelid. 
We discuss the mechanics of eye movement control later in this chapter (see section 
2.3.2.2). 
2.3 The neurology of oculomotor and auditory systems 
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In our previous section, we briefly described the neuroanatomical spatial 
relationships of the auditory and eye movement centres within the brainstem. In the 
following sections, we describe in more detail the neural substrates of each of these 
systems. We begin with an introduction to the study of eye movements.  
 
2.3.1  An introduction to the oculomotor system 
Eye movements have evolved in order to maintain a stable image of the world. 
However, the human brain is not able to support a visual system that is capable of 
maintaining a high resolution over an entire field of vision. These competing requirements 
have resulted in the human oculomotor system evolving a highly sensitive „compensatory‟ 
strategy. Objects of interest are targeted on the fovea, an area on the retina where visual 
acuity is optimised, due to the high density of photoreceptors.  
In order to achieve this „foveal compromise‟ the oculomotor system has evolved six 
specialist subsystems. These can be functionally subdivided into two groups: (a) eye 
movements that are responsible for maintaining a steady target on the retina, including 
fixation, vestibular (VOR) and the optokinetic systems and (b) subsystems that direct the 
fovea onto an object of interest which include saccades, smooth pursuit and vergence 
systems. Each of these eye movements are characterised by a unique set of properties and 
involve different parts of the brain which we have summarised below in Table 2.1. 
Table 2-1 Functional classification of the six eye movement systems 
Adapted from Leigh and Zee (1999) 
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Function 
Eye movement 
system 
Physiological function 
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Fixation 
Responsible for holding the image of a stationary object on the 
fovea when the head is not moving 
Vestibular Maintains a stable retinal image during brief head movements 
Optokinetic Maintains a stable retinal image during sustained head movements 
D
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 Saccades 
Ensure that the image of an object of interest is brought rapidly 
into view on the fovea. 
Smooth pursuit Maintains the image of a small moving target on the fovea 
Vergence 
Moves the eyes in an opposite direction (i.e. convergence or 
divergence) so that images of a single object are held 
simultaneously on both foveae. 
 
Since this thesis investigates whether children with atypical saccades also have 
associated abnormalities in the auditory brainstem, we will concern ourselves only with the 
saccadic eye movement (SEM) system. For a comprehensive review of the other five eye 
movements see Leigh and Zee, 1999 or Carpenter, 1981. 
In the next section, we will outline the functions and characteristics of saccades. We 
then describe the anatomy and physiology of the brainstem circuits that are responsible for 
generating horizontal, vertical and torsional saccades. Finally, we briefly discuss the higher 
level neural control of the saccadic system.  
2.3.2 Organisation of the saccadic system 
Saccades are rapid conjugate eye movements that move the line of sight between 
successive points of fixation. It is estimated that we make in excess of 100 000 saccades per 
day (Leigh and Zee, 1999b), the majority of these are made unconsciously and 
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spontaneously. Their highly stereotyped behaviour and well defined temporal properties 
have resulted in the saccadic system being the most intensively studied oculomotor 
subsystem (Sparks, 2002). Moreover, saccades are diverse – they are not only triggered by 
visual targets, but to auditory targets as well as memorised targets. The most common SEM 
are summarised in Table 2.2.  
Table 2-2 Classification of different types of saccades 
Adapted from Leigh and Zee, 1999)  
 
Text has been removed because of copyright restrictions 
In order to help us understand the importance of the saccadic eye system, the 
analogy of the eye as a „camera with a slow shutter speed‟ is a useful one. Shutter speed is 
related to the length of time that we actually visualise or „see‟ the scene that we are 
interested in capturing. Slow shutter speeds on a camera, result in a fuzzy photo. In the 
absence of a normal functioning saccadic system, our view of the world would be 
significantly distorted.   
 
2.3.2.1 Functions and characteristics of saccades 
Saccades are characterised by a unique set of properties that can be reliably 
measured and our ability to accurately quantify these behaviours – velocity, latency and 
accuracy – has significantly contributed to our understanding about what constitutes normal 
and abnormal brainstem function (Leigh and Zee, 1999a, Sparks, 2002, Leigh and Kennard, 
2004). Here, we consider each of these unique properties in more detail.  
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2.3.2.1.1 Velocity 
Saccades are fast. Not only are they the fastest of the oculomotor subsystems, but 
these remarkable movements are the quickest generated by the human body. Some studies 
have report peak velocity measures in a normal adult subject in excess of 650 degrees/sec
6
. 
A core reason for using saccades to examine the brain is the striking consistency shown in 
their relationship between magnitude, speed and duration. The size of a saccade is closely 
linked to velocity and duration, thus “the bigger the saccade, the greater its peak velocity 
and the longer its duration
7 ” (Leigh and Kennard, 2004, p463). This relationship – 
between amplitude and peak velocity (and sometimes amplitude and duration) – is referred 
to as the main sequence. Examples of the main sequence relationships between peak 
velocity, duration and amplitude are shown in Figure 2.2.  
Deviation from the main sequence allows clinicians to be able to determine whether 
(a) a saccade is actually made and (b) whether the velocity of a saccade falls within the 
normal range or demonstrates abnormal characteristics (e.g. too fast or too slow). Abnormal 
velocity is the hallmark of a number of brainstem disorders. For example, the slow 
                                               
6 Peak velocity is reported in a number of studies as 30 – 700 degrees/sec for amplitudes varying over 0.5-40 
degrees. Saccades can vary depending on a number of subject factors (e.g. age, alertness) and technical 
factors (e.g level of illumination, sequence of target presentation). Saccadic velocity also depends upon the 
direction of the movement, and the initial and final eye position. These factors require consideration when 
comparing saccadic behaviour in patients with normal subjects. 
7  Saccadic duration is another quantitative measure of saccadic performance that is sometimes reported.  
Studies have shown that the relationship between amplitude and duration is nearly linear and it varies from 30 
– 100ms, for amplitudes of 0.5 to 40 degrees. 
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horizontal saccades which are observed in patients with neuronopathic Gaucher disease 
(Figure 2.2). 
 
2.3.2.1.2 Latency 
Another measure commonly used to analyse saccades is latency. This is defined as 
the interval between stimulus onset and the start of saccadic execution (Leigh and Zee, 
1999a). Latency is extremely variable – in normal adults, the latency for medium amplitude 
saccades (5°-10°) is usually around 200ms. However, it can range from as low as 100ms, or 
as high as 350ms, depending upon the paradigm that has been used to elicit the response 
(e.g. luminance, cognitive load of the task) and the arousal level of the subject. For 
example, attention or active fixation on a target increases the latency of a saccade (Hoffman 
and Subramaniam, 1995)
8
. 
Figure 2-2The main sequence of horizontal saccades in Gaucher disease 
A) The relationship between duration and amplitude of saccadic eye movements. The green symbols show the 
main sequence for a child with GD1 and shows a normal relationship. The red symbols are the abnormal main 
sequence recorded from a child with GD3 shows markedly longer duration saccades. B) The relationship 
between peak velocity and amplitude. The relationship for the GD1 patient is normal, but the GD3 patient 
shows markedly abnormally slow saccades. Figure reproduced from Harris et al., (2003). 
 
 
Figure has been removed due to copyright restrictions 
 
 
Study of saccadic latency has also been used extensively to examine other aspects 
of saccadic programming such as visual processing and target selection (Kowler, 2011). 
This is supported by recent clinical studies which have shown that saccadic latency is 
                                               
8  There is an emerging literature about the role of attention and top-down processing on saccadic eye 
movements-for a recent review of this topic see Noudoost et al., (2010). 
  
 
 
69 
abnormal in disorders, particularly those affecting cortical areas concerned with vision, 
cognitive function and eye movements (Perneczky et al., 2011).  
 
2.3.2.1.3 Accuracy 
The ability to „accurately‟ execute a saccade is another highly stereotyped 
behaviour of the saccadic system. Accuracy is generally subdivided in one of the three 
following categories: (a) orthometria – in which the saccade is executed without any errors; 
(b) hypometria – in which the saccade falls short or „undershoots‟ the initial target and 
requires additional corrective saccades so that the image of interest is on the fovea or (c) 
hypermetria – in which the saccade overshoots the initial target and secondary, corrective 
saccades are needed. Saccadic hypermetria, when conjugate is considered is typically 
associated with disease affecting the cerebellum, especially the fastigial nucleus or its 
projections (Selhorst et al., 1976, Noda, 1991).  
It is not uncommon for normal subjects to display a small degree of saccadic 
hypometria, especially when a larger movement (>10°) is generated but as Harris (1997) 
clearly points out, in healthy adults and children, the initial saccade is usually within 90-
100% of the target distance. This „marginal error‟ becomes more prominent with increased 
age, fatigue and inattention. Hypometria has been described in association with ocular 
motor apraxia (Harris et al., 1996) and in basal ganglia disease (Armstrong et al., 2002).  
 
2.3.2.2 The mechanical properties of the oculomotor system 
  
 
 
70 
In our previous sections, we outlined the characteristics that have made the 
measurement of SEM so popular in Neuroscience. In this section, we describe the 
mechanics or the process by which a saccade is generated. In order for us to explain this 
successfully, we present a brief overview of the anatomical structures that enable the eye to 
move.  Due to practical constraints, we cannot provide a comprehensive review of the 
anatomy of the eye and we limit our discussion here to a brief anatomical overview of the 
motor apparatus (i.e. the structures that allow the eye to move
9
).  
The motor apparatus of the eye includes six eye muscles arranged into three 
reciprocally activated pairs. These are controlled by three cranial nerves – the oculomotor 
nerve (CN III), the trochlear nerve (CN IV) and the abducens nerve (CN VI) (Angelaki and 
Hess, 2004). Each agonist-antagonist pair is responsible for the rotation of the eye in 
different directions – horizontal, vertical and torsional (i.e. around the line of sight) 
rotations (Angelaki and Hess, 2004, Demer, 2006). Figure 2.3 shows the different eye 
muscles, rotation and relationship to the respective cranial nerve(s).  
In addition to the eye muscles, passive tissue structures such as the fascia bulbi, 
exert elastic and viscous forces on the eye, affecting the dynamics of eye movements and 
the steady-state muscle activity required to keep the eye at a given orientation (Demer, 
2006, 2007). 
 
                                               
9 The study of ocular kinematics is steadily growing in popularity following recognition that this system 
involves a series of highly complex behaviours see Demer (2006, 2007); Angelaki and Hess (2004). For a 
complete description of the sensory apparatus (i.e. anatomical structures at the front end of the visual system 
such as the retina and lens) see Standring et al., (2008). 
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Figure 2-3 Anterior view of the right eye and associated eye muscles. 
The Oculomotor nerve (CN III) innervates four of the six eye muscles: the superior rectus musle, the medial 
rectus muscle, the inferior rectus muscle and the inferior oblique muscle. The superior oblique muscle is 
innervated by the Trochlear nerve (CN IV). The lateral rectus muscle is innervated by the Abducens nerve 
(CN VI). Rotation of the eye is described in brackets. Image reproduced with permission from Patrick J. 
Lynch, medical illustrator; C. Carl Jaffe, MD, cardiologist under the creative commons license (2006). 
 
 
 
 
2.3.2.3 Pulse-step of innervations for Saccadic eye movement 
Robinson (1973) postulated that saccades are the product of two commands: an eye 
velocity command, called the pulse, and an eye position command, termed the step. The 
pulse is a high-frequency burst of phasic activity in the motor neurons of the agonist 
extraocular muscles. This allows the eye to move rapidly from one position to another 
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against the viscous drag of the orbit. Once the eye is in the new position, agonist motor 
neurons operate at a new level of tonic innervation, higher than the original resting level. 
This sustained innervation is the step component and it allows the eye to stay in its new 
position against orbital elastic recoiling forces (Buttner and Buttner-Ennever, 2006).  
The saccadic step, an eye position command, is created from the pulse (an eye 
velocity command) by a neural network (the neural integrator or NI) that mathematically 
integrates these commands into the appropriate position-coded information for the 
oculomotor neurons. For horizontal movements, the putative NI consists of the medial 
vestibular nucleus and the nucleus prepositus hypoglossi in the brainstem. The NI for 
vertical and torsional movements is localised to the interstitial nucleus of Cajal, in the 
midbrain (Harris, 1997, Buttner and Buttner-Ennever, 2006).  
The pulse-step innervation applies to all types of eye movements although the 
demand for speed, as required by the saccadic system means that the phasic component is 
naturally greater than that seen in other eye movement circuits. The pulse-step relationship 
is illustrated in Figure 2.4. 
Understanding the relationship between the pulse and step has allowed saccadic 
disorders to be modelled in terms of pathophysiological mechanism. These models have 
been developed in an attempt to explain how the brain specifies a command for a saccade 
before it starts. Early models were originally based on the premise that saccades were 
ballistic, and simply „played out‟ during the movement (Ramat et al., 2007). However, it is 
clear that saccades are not pre-programmed and a number of very sophisticated models 
  
 
 
73 
describing saccadic behaviour have been described. Further, these models have been 
applied to explain clinical disorders. A discussion of these models is beyond the scope of 
this thesis but this topic has been extensively reviewed (see e.g. (Leigh and Zee, 1999a, 
Sparks, 2002, Leigh and Kennard, 2004, Ramat et al., 2005, 2007, Chen et al., 2011). 
Figures 2.4 and 2.5 show two models of saccadic control. 
Figure 2-4 A. Early model of saccadic control. B. The pulse-step relationship and neural generators. 
Image reproduced from (Ramat et al., 2007) 
Figure has been removed due to copyright restrictions 
 
2.3.2.4 Brainstem saccade generation 
Saccadic pathways are widespread and complex and the relative role of each 
pathway in generating and suppressing various types of saccades is still unclear. The 
essential machinery required for generating saccades resides in the brainstem. Imaging 
studies and animal models have identified two distinct neural circuits – neurons located 
within the pons are mostly concerned with the horizontal component of saccades, whereas 
the midbrain controls vertical and torsional components (Sparks, 2002, Buttner and 
Buttner-Ennever, 2006, Linzenbold et al., 2011).  
Figure 2-5 The neural control of saccades  
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EBN generate a pulse, which is integrated to 
create a new eye position command (the step) 
by the velocity to position NI. The pulse-step of 
innervation is sent to the motor neurons to 
move and maintain the eye in a new position 
(Wong, 2007). 
EBN also activates IBN, which inhibit 
antagonist motor neurons and OPN during the 
saccade. When the eye position matches the 
target, BN cease firing, the OPN resume their 
tonic activity and the saccade stops. 
 
Figure has been removed due to 
copyright restrictions 
 
 
Abbreviations: III = oculomotor nerve; INC = interstitial nucleus of Cajal; io = inferior olive; MLF = medial 
longitudinal fasciculus; nIII = oculomotor nucleus; nIV = trochlear nerve; nVI = abducens nucleus; PC = 
posterior commissure; PN = pontine nuclei; NPH = nucleus prepositus hypoglossi; PPRF = paramedian 
pontine reticular formation; ri = rostral interstitial nucleus of the MLF; SC = superior colliculus; 
VN = vestibular nuclear complex. Other areas shown: EW = Edinger-Westphal nucleus; mb = mammillary 
body; nD = nucleus of Darkschewitsch; PTc = pyramidal tract decussation; rn = red nucleus. Adapted from 
Büttner-Ennever and Büttner, 1992. 
Two types of neurons have been identified – burst neurons and omnipause neurons 
Burst neurons can be divided into excitatory or inhibitory types. Excitatory burst neurons 
(EBN) can be further subdivided into medium-lead burst neurons and long-lead burst 
neurons (Figure 2.5). We will consider each of these in more detail in the following 
sections. 
2.3.2.4.1 Burst neurons  
 Medium-lead burst neurons (premotor burst neurons) activate the motor neurons at 
a high frequency, innervating agonist muscles approximately 8-15 ms before and during 
saccades. The characteristics of medium lead burst neurons are summarised in Table 2.3 
(Ramat et al., 2007).  
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These neurons are inactive during fixation, pursuit, and vestibular and optokinetic 
eye movements. These neurons are located in the brainstem – in the nucleus reticularis 
pontis caudalis (nRPC) situated within the paramedian pontine reticular formation (PPRF) 
for horizontal saccades. The BN responsible for generating vertical and torsional saccades 
have been localised in the rostral interstitial nucleus of the medial longitudinal fasciculs 
(riMLF). Figure 2.5 shows a sagittal view of the human brainstem showing the location of 
structures important in the control of saccades.  
Long-lead burst neurons activate medium-lead EBN and inhibit OPN to release 
their tonic inhibition on EBN. They discharge at irregular intervals – up to 100 msec prior 
to the onset of a saccade. They are located predominantly in the rostral PPRF and the 
mesencephalic reticular formation. The characteristics of long-lead burst neurons are 
described in further detail below in Table 2.4 (Ramat et al., 2007). 
 
Table 2-3 Characteristics of medium-lead burst neurons 
 
Text has been removed because of copyright restrictions 
 
  
Table adapted from (Ramat et al., 2007) 
Burst neurons can also be inhibitory (IBN). These neurons inhibit motor neurons to 
antagonist muscles – discharging just before and during saccadic activity. They are located 
in the nucleus paragigantocellularis dorsalis in the PPRF, for horizontal saccades. For 
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vertical and torsional saccades, IBN are located in the interstitial nucleus of Cajal (INC) 
and possibly within the riMLF. 
Table 2-4 Characteristics of long-lead burst neurons  
 
Text has been removed because of copyright restrictions 
 
Table adapted from (Ramat et al., 2007) 
 
2.3.2.4.2 Omnipause neurons 
Omnipause neurons (OPN), also called pause neurons, are glycinergic neurons that 
have been shown to fire tonically in animal models (Strassman et al., 1987, Horn et al., 
1994). In primates, OPNs are located near the midline within the nucleus raphe interpositus 
(rip) in the PPRF (Buttner-Ennever et al., 1999). They are thought to inhibit medium-lead 
burst neurons bilaterally in the pons and midbrain however, their exact role is still poorly 
defined – particularly in disorders of saccadic triggering (Harris, 1997). 
 
 
 
Table 2-5 Characteristics of omnipause neurons  
 
Text has been removed because of copyright restrictions 
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Table adapted from (Ramat et al., 2007) 
OPN have been shown to stop discharging or to „pause‟ 12-18 ms before and during 
saccades in the cat model (Yoshida et al., 1999) and 12-25 ms in primates (Keller, 1974). 
This initial observation led Robinson, (1975) to suggest that their function was simply to 
act as an „inhibitory gate‟ for the driving system in saccades. However, experimental 
studies involving chemical lesions damaging the RIP in the rhesus macaque resulted in 
slower saccades with normal latency and accuracy – not the saccadic oscillations as 
predicted by Robinson‟s model (Robinson, 1975, Kaneko, 1996). The data suggests that 
OPNs must contribute, in some way, to the drive signal for saccade generation, possibly by 
reducing the firing rate of EBN. Computational models have also suggested that OPNs 
have a complex neuromodulatory role  (Miura and Optican, 2006).  
 
2.3.2.5 Brainstem generation of horizontal saccades 
 The brainstem horizontal saccadic centres are ipsilateral to the eye and consist of a 
variety of units in the pontine tegmentums that have saccade-related burst activity. 
Horizontal saccades are generated by EBN and IBN units and OPN. The OPN fire tonically 
and inhibit EBNs and their activity inhibits the triggering of saccades. The EBNs project 
directly to the ipsilateral sixth nucleus, and to interneurons that relay the premotor signal 
via the contralateral medial longitudinal fasciculus (MLF) to the contralateral third nucleus. 
EBNs also drive IBNs which inhibit the contralateral sixth motorneurones and 
interneurones (Leigh and Zee, 1999a, Ramat et al., 2007). 
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2.3.2.6 Brainstem generation of vertical and torsional saccades 
The premotor circuitry for vertical saccades resides in the midbrain, particularly the 
rostral interstitial nucleus of the MLF (riMLF), where upward and downward control are 
separated – upward control is more medial than downward control. The posterior 
commissure is an important link in the generation of upward saccades. Vertical circuitry 
does not have its own pause neurones, and depends to some extent on the integrity of the 
lower brainstem horizontal saccade structures. However, the vertical system appears to be 
more independent of the horizontal saccade system in humans than in the monkey (Leigh 
and Zee, 1999a). 
 
2.3.2.7 Superior colliculus  
 
The superior colliculus (SC) is a paired structure, located within the midbrain. The 
SC is multi-layered, with neurons laid out in a topographic map of the visual system 
(retinographic map). Cells located within the superficial layer have been shown to have 
well-defined receptive fields and these neurons are activated only in relation to visual 
events. The intermediate and deeper layers of the SC contain two major types of neurons 
that are active in response to visuomotor events (Munoz et al., 2000).  
The role of the SC in the generation of saccades remained the subject of 
considerable debate until the mid 1990s. Early SC lesion studies in the monkey were shown 
to cause deficits in the generation of saccadic eye movements. This lead to the widespread 
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assumption, that the SC was important in the control of saccadic amplitude, direction and 
trajectory. This view was subsequently challenged by Schiller et al., (1980) who pointed 
out that the differences observed between early studies was likely to reflect the “variety, 
size and configuration” in SC lesions (Schiller et al., 1980, p1188).  
The current consensus is that the SC is important in the target selection and target 
initiation. Lesion studies have also shown that the SC also contributes to the speed of a 
saccade but not the accuracy of the saccade (Hanes et al., 2005).  
 
2.3.2.8  Cerebellar control of saccades 
The importance of the cerebellum, particularly in determining saccadic accuracy is 
well documented (Jenkinson and Miall, Ron and Robinson, 1973, Optican and Robinson, 
1980, Zee, 1986, Noda, 1991, Ohtsuka and Noda, 1995, Takagi et al., 1998, Robinson and 
Fuchs, 2001, Helmchen et al., 2003c, Leigh and Kennard, 2004). Several areas within the 
cerebellum have been shown to have an important strategic role in modifying saccades. 
These include the vermis (and paravermis) and the underlying deep cerebellar nuclei 
(fastigial, interpositus and dentate).  
The area of the cerebellum that has been most thoroughly studied is the vermis: a 
narrow structure divided into nine lobules and located between the hemispheres of the 
cerebellum. Studies have shown that electrical stimulation of lobule V in an alert monkey 
evokes upward to horizontal saccades, while stimulation of lobule VI evokes saccades that 
range from horizontal to downward (Ron and Robinson, 1973).  
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Within lobules VI and VII is another area that has important relevance to the 
saccadic system  and is called the dorsal „oculomotor‟ vermis  (DV) 10  (Noda, 1991). 
Neurophysiological and lesion studies in primates, as well as neuroimaging studies in 
humans, that have clearly shown that the DV is critical for saccadic adaptation and 
plasticity (Ron and Robinson, 1973, Optican and Robinson, 1980, Robinson and Fuchs, 
2001).  These cells have been shown to discharge 15ms before saccades in a preferred 
direction  (Ohtsuka and Noda, 1995). Lesions of the DV, which spare the deep nuclei 
structures, impair the ability to rapidly adapt the amplitude of saccades. After such lesions, 
both leftward and rightward saccades were between 20-30% hypometric, with gains that 
were twice as variable as the baseline measured pre-lesion (Takagi et al., 1998, Barash et 
al., 1999). Clinical studies have also shown that damage to this area, results in dysmetric 
and slow saccades (Leigh and Zee, 1999a, Leigh and Kennard, 2004).  
Purkinje cells (P-cells) located within the DV inhibit neurones in the caudal part of 
the fastigial nuclei (FN). The FN is an ellipsoidal region which is important in the control 
of saccade accuracy and consistency. Projections of the FN decussate within the cerebellum 
to reach the brainstem, where they terminate onto BN, OPN and the rostral pole of the SC.   
Other important areas that contribute to the continuous adaptive control of saccades 
include the flocculus (Fl) and paraflocculus (PFl). These regions are crucial in „repairing‟ 
saccadic inaccuracies. The flocculus and paraflocculus are important for the adaptation of 
                                               
10 There is a large literature on the role of the DV and the modification of saccades (see Robinson et al., 2001 
for a review). 
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the pulse and pulse-step mismatch for saccades. Lesions of the flocculus and paraflocculus 
results in post-saccadic drift because adaptation to pulse-step mismatch of saccades is lost. 
The flocculus receives inputs through mossy fibres arising in numerous sources in 
the brain stem and through climbing fibres from the inferior olive (Noda, 1991, Robinson 
and Fuchs, 2001, Buttner and Buttner-Ennever, 2006). Climbing fibres from the inferior 
olive extend into the cerebellar cortex. The role of the climbing fibres is still not entirely 
clear but all relevant signals (e.g. eye position and velocity, target position and velocity) 
needed to control saccades arrive in the cerebellar cortex on mossy fibres.  
 
2.3.2.9 Cortex and basal ganglia 
Multiple cortical and subcortical areas have been identified as important in saccadic 
programming. These include the frontal eye field (FEF); the supplementary eye field (SEF), 
the pre‐SEF, the parietal eye field (PEF); the dorsolateral prefrontal cortex (DLPC) and the 
posterior parietal cortex (PPC). These pathways and connections between the brainstem, 
basal ganglia and cerebellum are shown in Figure 2.6.  
Frontal and parietal cortical areas project directly to the superior colliculus and 
frontal areas project indirectly through a basal ganglia pathway. The frontal areas also 
project, via pontine nuclei such as NRTP to the DV and FN of the cerebellum (Leigh and 
Kennard, 2004).  
Leigh and Kennard (2004) have hypothesised that there is an unexplored functional 
dichotomy between the neurons in the cerebral cortex and basal ganglia and those in the 
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brainstem, and cerebellar saccadic circuits. They argue that the generation of saccades by 
the premotor burst neurons and the control of the size of saccades by the FN are both 
performed by units whose discharge is related temporally to the eye movement. Thus, the 
maximum discharge rate of burst neurons correlates with the saccade‟s top speed and the 
timing of discharge of FN neurons correlates with saccade start and end. This contrasts with 
spatial coding of saccade‐related neurons in cortical areas. The concept of a „spatial–
temporal transformation of sensory‐to‐motor signals‟ offers an interesting framework for 
further scientific study, further discussion  regarding of the function of these higher centres 
is beyond the scope of this thesis – for a review see (Leigh and Kennard, 2004).  
 
 
 
 
 
 
Figure 2-6 Areas of cerebral cortex and their projections that contribute to generation of saccades.  
Cortical areas important for eye movements in human brain. (B) Major structures that project to the brainstem 
saccade generator Abbreviations: IML = intramedullary lamina of thalamus; MST = medial superior temporal 
visual area; MT (V5) = middle temporal visual area V5; NRTP = nucleus reticularis tegmenti pontis; 
STN = subthalamic nucleus; V1 = primary visual cortex.*Image reproduced from Leigh and Zee (1999) 
 
Figure has been removed due to copyright restrictions 
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2.3.3 An introduction to the auditory system  
The auditory system is a highly sophisticated system and is able to process complex 
sound patterns across a number of dimensions – frequency, time, amplitude and space 
(Griffiths, 1999). In order to make sense of the acoustic landscape, the human auditory 
system is tasked with three objectives. Firstly, it must deliver sound to the end receptors in 
the auditory periphery. Secondly, it must faithfully transduce the stimulus from an air-filled 
medium into a fluid-filled medium – converting these „vibrations‟ into an electrical signal. 
Finally, it must transmit these neural signals to downstream sub-cortical and cortical 
stations for further (serial and parallel) processing, in order that our brain can extract 
meaningful information such as speech. 
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How the auditory system accomplishes each of these tasks is the subject of much of 
the next section – an understanding of these central concepts is essential for much of our 
later discussion in this thesis. In the following sections we will briefly overview the 
anatomy and physiology of the ascending „classical‟ auditory pathway – from the auditory 
periphery, brainstem up to the primary auditory cortex – focusing on the sub-cortical 
auditory brainstem network which is our primary concern in this thesis.  
The accounts of both structure and function given here are necessarily simplified; 
more detailed reviews on the anatomical and physiological characteristics of each of these 
structures can be found in a number of extensive reviews, see e.g., Hackett (2011); Pickles 
(2008).  
 
2.3.3.1 The peripheral auditory system 
The peripheral hearing mechanism is generally divided into three distinct 
components: the outer, middle and inner ear, according to both anatomical position and 
function. Figure 2.7 shows a cross-sectional view of the auditory periphery. The primary 
role of the outer ear is to collect impinging sound waves and, acting as a passive sound 
amplifier, to „funnel‟ the resulting eardrum vibrations towards the middle ear. Two ears 
provide us with the means for capturing two samples of sounds, allowing for a direct 
comparison in time and intensity – fundamental cues for sound localisation (Gelfand, 
2004).  
Figure 2-7 General anatomy of the peripheral auditory mechanism.  
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The outer ear is composed of the pinna (or 
auricle); external ear canal (or external 
auditory meatus) and the eardrum (or 
tympanic membrane). It performs two 
different physiological functions: auditory 
(acoustic) and non-auditory functions 
(Gelfand, 2004). The main components of 
the middle ear system are: the tympanic 
cavity (tympanum); the ossicles (malleus, 
incus and stapes); the middle ear muscles 
(tensor tympani and stapedius); ligaments 
and the eustachian tube. The middle ear 
system has four functions: to protect the 
inner ear; to conduct, transduce and to 
amplify the incoming acoustic signal 
(Pickles, 2008). The inner ear is composed 
of the semicircular canals, the vestibule 
and the cochlea. Image reproduced from 
www.blockedear.net 
 
Figure has been removed due to copyright restrictions 
 
The middle ear (Figure 2.7), acts as a mechanical transformer, modifying the 
acoustic spectrum of sounds by transforming air-borne sounds into pressure waves in the 
fluid-filled compartments of the inner ear (Jahn and Santos-Sacchi, 2001, Gelfand, 2004, 
Pickles, 2008). The inner ear is composed of the semicircular canals, the vestibule and 
the cochlea (Figure 2.7). However, it is the cochlea which houses the „organ of hearing‟ and 
which we shall consider in more detail in our next section.  
 
2.3.3.2 The cochlea 
The basic structure of the cochlea is similar across a number of mammalian species. 
The cochlear canal is divided into three chambers: the scala vestibule and scala tympani – 
which are filled with perilymph; these areas are able to communicate via the helicotrema. 
The scala media is separated by Reissner‟s membrane and is filled with endolymph – a 
substance similar in composition to intracellular fluid. The essential components of the 
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organ of Corti, which is located on the basilar membrane (BM) within the cochlea, is 
shown in a cross-sectional view below in Figure 2.8.  
Figure 2-8 Schematic of the organ of Corti  
 
Figure has been removed due to copyright restrictions 
 
The BM separates the scala 
tympani and scala media. The 
organ of Corti, which is attached 
to the BM, consists of hair cells, 
supporting cells and neurons that 
innervate these cells. OHCs have 
a cylindrical form, with 50-150 
stereocilia arranged in „V‟ or „W‟ 
patterns. The OHC stereocilia are 
in contact with the Tect 
membrane (shown incorrectly 
here in this figure) and are in 
contact with both efferent and 
afferent nerve endings. Image 
reproduced from (Oghalai, 2004) 
 
Displacement waves are produced by the incoming „acoustic‟ vibrations and travel 
along on BM. As it travels, the wave – commonly referred to as the travelling wave – 
increases in amplitude, peaking at a maximum displacement and then dying out. The 
location of maximum BM motion is significant.  
Figure 2-9 Transduction and cochlea mechanics 
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Figure has been removed due to copyright 
restrictions 
 
The cochlea is shown here uncoiled (normally 
coiled structured as in the inset). Different 
frequencies excite different regions along the 
cochlea. This is shown in kHz and in humans the 
dynamic range is from 0.1 to 20 kHz. Images 
reproduced from (Fettiplace and Hackney, 2006) 
 (a) In the human auditory system, there are two 
types of sensory cells: one row of IHC and 3 rows 
of OHCs. IHC are flask shaped with 
approximately 60 stereocilia. The IHCs are the 
dominant transducer of sensory input, as they are 
innervated by a high proportion of cochlear 
afferents. 
Incoming acoustic stimuli cause the BM to 
vibrate, which results in a movement of the hair 
cells relative to the gelatinous membrane 
(tectorial membrane). 
 
(b) The number of SGC varies significantly 
among species but in humans is thought to 
number between 25000 and 30000 (Gelfand, 
2004). The majority of SGC are large bipolar, 
myelinated (type I) neurons that synapse directly 
with IHCs. Approximately 20 afferent fibres 
innervate each IHC such that there is a „many-to-
one‟ connection. This is in direct contrast to the 5-
10% smaller, unmyelinated (type II) neurons 
which make dendritic contact with 10-20 
clustered OHC. The function of the type II cells is 
still unknown (Pickles, 2008).  
 
Because of the unique properties of the BM, the location of the maximal amplitude 
displacement is a function of stimulus frequency and each cochlear site has a characteristic 
frequency (CF), to which it responds maximally. In essence, the cochlea performs a 
frequency decomposition of the incoming signal, with the result that information is sent to 
the brain via frequency-specific neural channels. Thus high frequency stimulus elements 
selectively vibrate the basal end of the membrane (near the stapes), while low frequency 
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acoustic energy selectively vibrates the basilar membrane at its apical end. This is shown 
above in Figure 2.9. 
Hair cells located along the organ of Corti (Figure 2.9) are responsible for 
transducing these signals from a mechanical to an electrical signal (executed by IHCs) and 
actively altering the dynamics of the BM (performed by OHCs). Auditory nerve fibres that 
innervate the IHCs transmit information to the brain about the amplitude and temporal cues 
within only its own narrow frequency range. 
A further discussion of cochlear structure and mechanics is beyond the scope of this 
thesis but several review papers and texts have dealt with this topic in depth (e.g. Cochlear 
structure and mechanics (Oghalai, 2004, Fettiplace and Hackney, 2006); for a general 
overview of the cochlea (Geisler, 1998, Jahn and Santos-Sacchi, 2001, Gelfand, 2004, 
Pickles, 2008). 
 
2.3.3.3 The auditory nerve 
The sole input pathway of auditory information from the cochlea to the CANS is via 
the auditory nerve (VIII CN).  This is composed of three discrete groups of axons including 
the afferent axons of (a) the spiral ganglion cells (SGC) and (b) vestibular neurons and (c) 
the efferent axons of the olivocochlear bundle (Palmer, 1987, Pickles, 2008).   
The afferent fibres leave the inner ear through the internal auditory canal located on 
the posterior surface of the petrous part of the temporal bone. They enter the brainstem at 
the level of the cerebellopontine angle (CPA) and terminate in the cochlear nucleus (CN). 
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The cell bodies of the efferent fibres are located in the SOC (in the periolivary and 
preolivary nuclei) (Hall, 2007). Most of these fibres synapse with outer hair cells (OHCs). 
A small percentage synapse with the dendrites of the afferent fibres beneath the IHCs 
(Nadol et al., 1990, Pickles, 2008).  
The tonotopic arrangement of the cochlea is preserved in the cochlear nerve – the 
high frequencies are near the periphery (surface) of the nerve while the low frequencies are 
located deeper – thus the frequency-to-place conversion seen in the cochlea is maintained 
in the auditory nerve. Moreover, it is this precise temporal locking of the excitatory 
response to sound, particularly the onset response, which provides the neural synchrony 
which allows us to record far-field (from the scalp) auditory evoked potentials. 
Two theories dominate the way in which the auditory system encodes the 
frequency: the frequency code and the place code (Gelfand, 2004). There is strong evidence 
to suggests that the frequency code is maximally efficient for frequencies <50 Hz whereas 
the place code operates at frequencies above 1000 Hz (Palmer, 1987, Geisler, 1998)
11
. 
There are also two main theories regarding how the auditory system encodes intensity 
information: the firing rates of neurons and the number of neurons that fire (Gelfand, 2004, 
Fettiplace and Hackney, 2006). For a comprehensive treatment of how the auditory system 
encodes simple and complex sound see (Pickles, 2008; Geisler, 1998; Palmer, 1987). 
2.3.4 Organisation of the auditory brainstem system 
“The human soundscape is characterized by complex sounds with rich harmonic 
structures, dynamic amplitude modulations, and rapid spectrotemporal fluctuations. 
                                               
11 Both of these mechanisms appear to play a role for frequencies between 50-1000 Hz. 
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This complexity is represented by an exceptionally precise temporal and spectral 
neural code within the auditory brain stem, an ensemble of nuclei belonging to the 
efferent and afferent auditory systems”  Skoe et al., (2010). 
 
The auditory brainstem consists of a series of spatially separate nuclei which 
include the cochlear nuclei (CN), the superior olivary complex (SOC), the lateral lemniscus 
(LL) and the inferior colliculus (IC).  
Figure 2-10 The major auditory nuclei and pathways in the human brainstem. 
Image reproduced from Moore et al., (1987). 
 
Figure has been removed due to copyright restrictions 
 
 
 
Figure 2.10 shows the major nuclei of the human auditory brainstem. In the 
following sections, we will consider the unique properties of each of these „relay‟ stations 
and how they interact with each other. 
 
2.3.4.1 Cochlear Nucleus 
The cochlear nucleus (CN) is the first obligatory „relay station‟ in the ascending 
auditory pathway – all fibres from the auditory nerve terminate here. The CN is 
functionally divided into three nuclei: the anteroventral CN (AVCN), posteroventral CN 
(PVCN) and the dorsal CN (DCN). Afferent fibres that enter CN bifurcate, with the 
ascending branch terminating in the AVCN and the descending branch in the PVCN and 
DCN. These two pathways are thought to represent different processing streams: the ventral 
(„where‟) stream and the dorsal („what‟) stream. For example, the projection from the 
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rostral AVCN has been shown to preserves temporal data necessary for sound localisation 
(Palmer, 1987).  
The output from the DCN is strongly influenced by spectro-temporal inhibitory 
interactions, which are important for identifying which (or „what‟) aspects of complex 
sounds are important in our understanding of speech (Arnott et al., 2004). Thus the 
tonotopical organization that started in cochlea is well preserved in the CN.  
Our understanding of the function of the CN is far from complete. The CN contains 
a number of principal cells which are “characterised by their diversity” (Palmer, 2007, 
p221). More than 20 cell types have been identified but the significance of these remains 
unclear. Examples of some of these cells are shown in Figure 2.11.  
Recent cellular electrophysiological studies in the DCN have,  
“revealed synaptic plasticity at synapses between parallel fibers and their targets: 
the principal cells (fusiform) and feedforward inhibitory interneurons (cartwheel cells) 
located in the molecular layer” (Tzounopoulos and Kraus, 2009, p465).  
These studies are an exciting development in auditory neuroscience – challenging 
traditionally held views of a „passive‟ auditory brainstem. 
 
Figure 2-11 Auditory brainstem circuitry and function  
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Projections to the SOC derive 
mainly from the AVCN and 
terminate in the medial 
superior olive (MSO) 
bilaterally, in the ipsilateral 
lateral superior olive (LSO) 
and in the contralateral medial 
nucleus of the trapezoid body.  
Some neurons of the superior 
olive send their myelinated 
axons via the efferent olivo-
cochlear bundle (OCB) of the 
8th nerve mostly, but not 
exclusively, to the outer hair 
cells (OHCs) of both 
cochleas, with a considerably 
larger contralateral than 
ipsilateral projection. 
Activation of the OCB 
inhibits the OHCs inhibiting 
their activity. Olivocochlear 
axons do not make direct 
contact with the IHCs, only 
with the dendrites of the type 
I spiral ganglion cells that 
synapse with the IHCs. Image 
reproduced from 
(Tzounopoulos and Kraus, 
2009) 
 
Figure has been removed due to copyright restrictions 
 
 
Projection axons from the DCN form the dorsal acoustic stria of Monakow. They 
join the contralateral lateral lemniscus (LL) and terminate in the inferior colliculus (IC). 
Projections from the PVCN form the intermediate acoustic stria of Held. They project 
bilaterally to the superior olivary complex (SOC) and to the nuclei of the LL. A few PVCN 
axons travel through the ventral stria (trapezoid body) and project to the contralateral IC. 
Projection axons from the AVCN form the ventral stria and project to the ipsilateral lateral 
nucleus of the SOC (LSO), to the ipsilateral and contralateral medial nucleus of the SOC 
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(MSO) and to the contralateral nucleus of the trapezoid body, which in turn projects 
ipsilaterally to the LSO (Palmer, 1987, Pickles, 2008).  
 
2.3.4.2  Superior olivary complex 
The SOC consists of several nuclei including the LSO, the MSO, the medial nucleus 
of the trapezoid body (MNTB) and the periolivary and preolivary nuclei. These are shown 
schematically in Figure 2.11. The functions of many of these nuclei are still unclear 
(Guinan, 2006),  although the SOC is the first major convergence site for binaural 
information. There is strong evidence to show that the SOC has a very important role in 
localisation of sound by exploiting differences based on timing and intensity cues. Here we 
are restricted to a relatively cursory treatment of the role of the SOC nuclei in sound 
localisation, but detailed reviews are available see e.g. Guinan et al., (2006) and Pickles, 
(2008). The LSO is the largest nucleus within the SOC and plays an important role in 
comparing interaural level (intensity) differences (ILD) from both ears. Several distinct cell 
types have been identified in the LSO (see Pickles, 2008 for an overview). These cells 
receive excitatory input from small spherical bushy cells in the ipsilateral VCN and 
inhibitory input from the MNTB on the same side. The MNTB receives excitatory input 
from the bushy cells of the contralateral CN. Because of a number of structural features of 
this pathway, for example, large synaptic endings and thick axons, ensure that information 
arriving will coincide with arrival from the ipsilateral pathway.  
There is significant evidence from cellular recordings – single cell and population 
studies – that the LSO responds preferentially to high-frequencies, although the lateral part 
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of the LSO has been shown to respond to low frequency input (Gifford and Guinan, 1983, 
Backus and Guinan, 2006, Guinan, 2006, 2010). For a detailed discussion of the 
mechanisms involved in ILD see Pickles et al., (2008). 
The functions of the LSO are complemented by the functions of the MSO, a thin 
sheet of cells that lie medial to the LSO. The MSO is involved in detecting the interaural 
time differences (ITD), which is particularly useful for locating low frequency sounds. The 
MSO has two principal cell types which provide (mainly) ipsilateral excitatory input to the 
central nucleus of the IC and the dorsal nucleus of the lateral lemniscus. A model for 
interaural time delay (ITD) was proposed by Jeffress (1948) suggested that cells within the 
MSO performed coincidence detection between incoming excitatory inputs from each side.  
He suggested that input to the coincidence detector was delayed with respect to the other 
side which is supported by biological evidence to show that principal cells in the MSO lack 
sensitivity to ILD or the onset time delay (Palmer, 1987). Although a number of aspects of 
the Jeffress model are well established, activity in the MSO is difficult to study and our 
knowledge of this structure is limited to a small number of studies.  
 
2.3.4.3 Lateral lemniscus 
The output from the SOC joins fibres ascending from the CN to the IC to form the 
lateral lemniscus (LL) tract. The LL is located within the rostral pons – where the CN and 
pontine reticular formation (PRF) crossover – is composed of three nuclei: the dorsal 
(DnLL), ventral (VnLL) and intermediate (InLL) nuclei.  
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The VnLL and the InLL comprises part of the „monaural‟ sound identification 
stream (Batra and Fitzpatrick, 2002). Comparative studies show that this area is poorly 
developed in humans (see (Moore, 1987b) for a review). The VnLL receives input from all 
cell types from contralateral VCN. The function of the vnLL is not entirely clear but several 
studies have shown that cells are sensitive to timing and amplitude fluctuations. There is no 
input from the LSO or MSO so it is unlikely that the vnLL is involved in sound 
localisation. Other studies have also shown that VnLL is thought to have an important role 
in the primary startle reflex pathway (Kofler et al., 2001). 
The DnLL receives input from the ipsilateral MSO; ipsilateral and contralateral 
LSO and the contralateral CN (Stabler et al., 1996, Pickles, 2008). The DnLL is thought to 
constitute part of the sound localisation stream; however the exact role is unclear but is 
thought to be important in coding ITD. Human data is limited (Levine et al., 1993, Furst et 
al., 2000, Cho et al., 2005). Lesion studies have typically shown that the damage to the LL 
in humans has resulted in dysfunction in ITD to low-frequency stimuli (Levine et al., 
1993). Corroborating evidence from animal models supports the idea that the DnLL is 
important in sound localisation. These studies have shown that damage to cells in the DnLL 
in unanesthetised rabbits resulted in difficulty localising sound especially in the horizontal 
plane (Kuwada et al., 2006).  
The right and left dorsal nuclei of the LL are joined by the commissure of Probst. 
The axons of the dorsal nucleus are primarily inhibitory (GABAergic) and terminate in the 
ipsilateral or the contralateral IC via the commissure of Probst. Other fibres project to the 
contralateral dorsal nLL. 
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2.3.4.4  Inferior Colliculus 
The majority of all ascending fibres from the brainstem synapse in the midbrain at 
the level of the IC. Thus the IC is thought to represent a major site of „re-convergence‟ 
whereby all information from ascending and descending brainstem structures are integrated 
in parallel.  
The IC is composed of several distinct regions including a central area (CIC) 
surrounded by a belt area. The right and left CIC are connected by the commissure of the 
IC. The CIC receives a contralateral projection from each of the subdivisions of the CN 
complex; bilateral projections from the LSO and from the dorsal and intermediate nuclei of 
the LL and an ipsilateral projection from the MSO, the MNTB and the ventral nucleus of 
the LL. Binaural interaction therefore occurs almost simultaneously at several levels of the 
brainstem. 
The belt receives afferent projections from the DnLL and the VnLL and from the 
VCN and DCN. Axons from the IC regroup and form the brachium of the IC. Most cells 
will send their axons in the ipsilateral branch of the brachium IC but a few may send it to 
the contralateral branch through the commissure of the IC. Figure 2.12 shows the 
projections from the IC to the auditory cortex in two mammals (macaque monkey and cat). 
The neurons from the IC exhibit several emergent properties including sensitivity to 
dynamic localisation cues (sound motion) and responses that appear to be a result of 
convergent input from processors of localisation cues at lower levels. The sensitivity of the 
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IC to many complex sounds can be understood by examining the processing that takes 
place at lower levels of the auditory brainstem.  
Figure 2-12 Projections from the IC to the auditory cortex in the macaque monkey (left) and cat (right).  
 
A number of projections link 
core regions with the CIC. 
Image reproduced from Hackett 
et al., (2011). 
 
Figure has been removed due to copyright restrictions 
 
 
 
 
For example, the stellate cells of the VCN may convey directly to the IC the rate-
coded spectra of complex sounds including speech. Onset cells, within the CN are 
specialised to signal transients in complex sounds, including cues that are related to pitch. 
These project to the IC, via the vnLL, which suggests a role in temporal processing. The 
principal cells of the DCN are sensitive to sharp spectral notches and appear to be involved 
in pinna-related localisation cues, which are again relayed directly to the IC, where the sign 
of the response is inverted. There is a large literature concerning the anatomy and 
physiology of the IC (for a more detailed review of this topic see Pickles (2008). 
 
2.3.5 Medial Geniculate Nucleus 
The medial geniculate nucleus (MGN), located in the thalamus is the final sub-
cortical station before the auditory signals reach the primary auditory cortex (Suga and Ma, 
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2003, Pickles, 2008). The MGB consists of several cytoarchitecturally distinct regions 
which are typically subdivided into three main anatomical divisions: the ventral MGB 
(vMGB), dorsal MGB (dMGB) and the medial MGB (mMGB) (Schreiner and Winer, 
2007, Suta et al., 2008). Figure 2.12 shows projections from the MGB to the AC in the 
macaque and cat models. 
Cells in the MGB show a wide variety of response types; however, 
electrophysiological studies have shown that cells in the vMGB are primarily responsive to 
acoustic stimuli; as such this division is often considered to represent the „true‟ part of the 
auditory relay station (Winer and Lee, 2007). The tonotopic relationship established in the 
IC, is preserved in the vMGB, thus low frequencies are presented laterally and high 
frequencies are represented medially. Cells in the other two divisions receive multiple 
inputs and are typically classed as part of the extra-lemniscal pathway with „diffuse‟ and 
non-specific auditory responses (Schreiner and Winer, 2007). These nuclei project to the 
secondary areas of the auditory cortex. 
 
2.3.6 Primary Auditory Cortex 
Following a number of years of confused nomenclature, recent anatomical studies 
have re-structured the primary auditory cortex (PAC) into a single cohesive framework 
based on a core-belt-parabelt network (Kaas and Hackett, 1999, Kaas et al., 1999, 
Romanski and Averbeck, 2009). Auditory stimuli are thought to be analysed first in the 
core areas and subsequently in the belt and parabelt areas. Although there are significant 
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differences across species, it is believed that there are three core areas and up to as many as 
eight separate areas in the surrounding belt regions (Kaas and Hackett, 1999, Kaas et al., 
1999, Griffiths and Warren, 2004, Griffiths et al., 2004, Pickles, 2008, Hackett, 2011). 
Figure 2.13 shows a schematic view of the primary auditory cortex and its association 
areas. 
Detailed anatomical studies have investigated the functional relationships in the 
primate model. These studies have resulted in a functional, auditory-cortical organization 
analogous to the information flow in the visual system (Kaas and Hackett, 1999, Kaas et 
al., 1999, Romanski and Averbeck, 2009, Recanzone and Cohen, 2010). This model 
proposes that auditory information is processed in two parallel and hierarchical streams: 
one stream responsible for processing spatially-related („where‟) information carried in the 
dorsal pathway and a non-spatial processing („what‟) stream (Pickles, 2008, Recanzone and 
Cohen, 2010).  
 
 
 
 
Figure 2-13 A human model of the auditory cortical organisation 
Darkest shading indicates „core‟ 
field including PAC which is 
tonotopically organised from 
high frequencies (H) to low (L). 
The core receives direct input 
from the auditory thalamus and 
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relays that to association areas 
Image reproduced from Pickles 
(2008). 
Abbreviations: AS – arcuate 
sulcus; CS – central sulcus; HG 
– Heschl‟s gyrus; LS – lateral 
sulcus; STG – superior 
temporal gyrus, STS – superior 
temporal sulcus,  
 
 
 
Scientific evidence based on physiological studies (Recanzone, 2002) and 
functional-imaging data (Lewald et al., 2008) has provided strong support for the  „where‟ 
pathway. However, there is conflicting evidence for the „what‟ pathway (Recanzone and 
Cohen, 2010). This may be a direct reflection of the degree of complexity that the original 
research question poses (i.e. how do we define „what‟?) or it may simply reflect differences 
in information processing across species, e.g. primate vs human processing (Recanzone and 
Cohen, 2010). 
The concept of a „dual-stream hypothesis‟ clearly offers a valuable framework for 
further study, however more detailed discussion regarding the function of these higher 
centres is beyond the scope of this thesis. A number of review papers have appeared over 
the years which have addressed this topic in detail (e.g. Recanzone and Cohen (2010); 
Romanski and Averbeck (2009); Smiley and Falchier (2009); Kaas et al., (1999)
12
.  
 
2.4 Measurement of the oculomotor and auditory brainstem systems 
2.4.1  Examination of Saccades 
                                               
12 We have not included a discussion about the interaction pathways within auditory cortices or other sensory 
areas. For an excellent review of this topic see (e.g. Hackett et al., 2011). 
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Earlier in this chapter, we discussed the different parameters (accuracy, velocity and 
latency) that need to be considered when analyzing SEM (i.e. whether they are full, free 
and without impediment). There are many ways of assessing eye movements. Some of 
these are based on clinical observations and are qualitative (the clinical exam). Other 
methods are quantitative and objectively assess the range of ocular movements. Here, we 
provide a brief overview of both approaches that are routinely used to examine saccadic 
function. A more in-depth treatment of both these topics is available in Cassidy et al., 
(2000); Harris et al (1997); Leigh and Zee (2006). 
 
2.4.1.1  Clinical examination of saccades 
 The simplest method to test saccades in a clinical setting or „at the bedside‟ is to 
instruct the patient to look alternatively at two targets. These could be the examiners finger 
tips or two pens (Leigh and Zee, 1999a). A modified approach for assessing children, 
advocated by Cassidy et al., (2000) suggests using a large, bright target with the child sat 
on a parent‟s lap with their head supported. In both scenarios, the target is then suddenly 
presented at a known eccentricity. Several studies have shown that the targets are best 
presented at large angles, as abnormalities are better visualized in larger-amplitude 
saccades (Harris, 1997, Cassidy et al., 2000a). Table 2.6 presents a summary of routine eye 
movement subtests that should be undertaken for a comprehensive clinical exam. 
Table 2-6 The clinical eye movement examination 
1 Establish the range of ocular motility in the horizontal and vertical planes. 
2 Look for nystagmus or saccadic intrusions by asking the patient to maintain a stable fixate in a central 
and eccentric gaze. 
3 Examine horizontal and vertical saccades between two fixed visual targets, making note of initiation, 
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time, speed and accuracy. 
4 Look for “catch-up” saccades by examining horizontal and vertical pursuit of a smoothly moving 
target. 
5 OKN induced with horizontal or vertical motion of a hand-held drum or tape. 
6 Ocular alignment during fixation of a distant target and vergence responses to smooth or stepping 
motion of targets aligned in the patients‟ sagittal plane. 
7 The VOR in response to smooth sinusoidal or sudden, head rotations in horizontal and vertical planes 
(Looking for corrective saccades that accompany or follow a head rotation) 
Table adapted from Leigh and Zee (1999) 
The advantages of the clinical exam are self evident: it is inexpensive, non-invasive 
and can be measured at the bedside. However, the clinical exam has several drawbacks – it 
can often only detect gross abnormalities and is highly dependent upon the examiner 
(Harris et al., 1999).  For a more sensitive measure, an objective assessment of the 
oculomotor system is required. 
 
2.4.1.2 Objective measurement of saccadic eye movements 
The objective measurement of eye movements requires the use of sensitive 
equipment that allows accurate and reproducible measurements. This usually involves the 
detection of a signal which is proportional to the position of the eye in the orbit, and 
changes when the position of the eye changes in some direct way. Four approaches to 
recording eye movements have been developed to obtain reliable recordings. These include 
electro-oculography (EOG), infrared systems, image-based systems or fast frame‐rate 
video‐based techniques and magnetic search coil (Leigh and Zee, 1999a, Frens and van der 
Geest, 2002).  We have provided a brief description of each of these techniques below in 
Table 2.7. 
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The search coil method was first pioneered by Robinson (1963). It is considered the 
gold standard for capturing the dynamic properties of saccades although it is the most 
invasive method – with a number of studies reporting that it is poorly tolerated after 30 
minutes usage. Furthermore, several studies have shown that inserting a coil in the eye 
influences SEM kinematics (Frens and van der Geest, 2002, van der Geest and Frens, 
2002).  
EOG is the most commonly used measure to capture eye movements and when 
combined with video has been shown to be a very useful measure in children (Harris et al., 
1992). However, it is also associated with a number of drawbacks. For example, EOG is 
sensitive to changes in skin impedances; DC drift in corneo-retinal potentials, electrical 
disturbances; EEG and EMG disturbances (Eggert, 2007). We have summarised the 
advantages and limitation of each of these measurements in Table 2.7. For a more in-depth 
coverage of this topic see (Frens et al., 2002; Eggert, 2007; Leigh and Zee, 2006). 
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Table 2-7 Summary of the methods used to measure quantitative eye movements.  
 Description Advantages Disadvantages 
EOG 
Small voltages are recorded from around the 
eyes by carefully placed electrodes.  Eye 
position is recorded based on the potential 
difference between the cornea and the fundus 
which will change as the eye position varies. 
Inexpensive, simple and non-invasive method 
of recording large eye movements. 
Signal can change when there is no eye movement. 
Dependent on the state of dark adaption. Affected 
by metabolic changes within the eye. Prone to drift 
and giving spurious signals 
 
Infra-red 
systems 
Uses photocells positioned over the limbus 
nasally and temporally to record horizontal eye 
movements. The photocells detect the amount of 
infrared light reflected from the surface of the 
eye. 
Not affected by ambient lighting; good spatial 
resolution (the size of the smallest movement 
that can reliably be detected) and temporal 
resolutions of 1ms can be achieved. 
Horizontal measurements better than vertical 
movements. Blinks can be a problem, as not only do 
the lids cover the surface of the eye, but the eye 
retracts slightly, altering the amount of light 
reflected for a short time after the blink. 
Image 
based 
methods 
Typically a video image is combined with 
computer software to calculate the position of 
the pupil and its centre. 
Allows vertical and horizontal eye movements 
to be measured. 
Lower temporal resolutions achieved than with IR 
infrared techniques. Spatial resolution can also be 
limited. 
Scleral 
search coils 
Small coils of wire usually copper are 
embedded in a modified contact lens or annulus. 
This is inserted into the eye after local 
anaesthetic has been introduced. When the 
subject is placed in an AC magnetic field, the 
position of the eye can be determined from the 
amplitude of the induction current in the coil.  
High temporal and spatial resolution allowing 
even the smallest types of eye movements to 
be studied. 
Invasive method, requiring something to be placed 
into the eye. Poor tolerance, other risks if the coil is 
worn too long include corneal oedema and abrasion. 
Also introducing an object in the eye, one changes 
the inertia (by about 5%) and the friction and 
therefore the force that the eye muscles have to 
generate to perform an eye movement.  
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2.4.2 Examination of the auditory brainstem system 
Several measures have been used to measure the integrity of the auditory brainstem 
pathways. The most widely used method is the auditory brainstem response or ABR (Josey 
et al., 1988, Musiek et al., 1988, Stone et al., 2009). Two other objective techniques that are 
also commonly used in the evaluation of auditory brainstem function include the acoustic 
reflex threshold test (Cohen and Prasher, 1988, Cacace et al., 1991, 1992, Cohen and 
Prasher, 1992, Prasher and Cohen, 1993, Hood et al., 2003, Mukerji et al., 2010) and the 
medial olivocochlear suppression test (Prasher et al., 1994, Brashears et al., 2003, Brown et 
al., 2003, Guinan et al., 2003, Backus and Guinan, 2006, Guinan, 2006, Backus and 
Guinan, 2007, Guinan and Cooper, 2008, Lilaonitkul and Guinan, 2009, Guinan, 2010). 
These responses are thought to reflect activity from the auditory nerve and lower brainstem 
pathways. We will discuss each of these in more depth later in Chapter 3.  
Our remaining discussion is concerned with the ABR. This non-invasive 
electrophysiological tool has been used extensively to study the human auditory brainstem 
system since it was first discovered four decades ago (Jewett et al., 1970, Jewett and 
Williston, 1971). Here we begin with a review of the important neurophysiological aspects 
of the ABR including a brief discussion regarding the neural generators that are responsible 
for the ABR. We then discuss the effect of maturation on the ABR, focusing on the 
relationship between the ABR and its developmental time course in the early stages of 
infancy and childhood. Finally, we then present a short discussion to illustrate how auditory 
neuroscientists are using the ABR to provide evidence for neural plasticity within auditory 
brainstem circuitry.  
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2.4.2.1 An overview of the ABR 
The auditory brainstem response (ABR) is a robust far-field measurement of neural 
synchrony. It is evoked by the onset of a brief acoustic stimulus – typically a click stimulus 
– the resultant waveform is thought to reflect the synchronised activity of onset-sensitive 
units of the auditory nerve and brainstem pathways to the level of the midbrain (Gorga and 
Thornton, 1989, Van Campen et al., 1997). The ABR is visualised as a series of low 
amplitude, vertex-positive waves (ranging between 5 and 7 components) that are typically 
seen within the first 10 ms of the onset of a click stimulus in human adults. These peaks are 
generally labelled by the Jewett and Williston convention using sequential capital roman 
numerals although a number of different classification systems have appeared in the 
literature (Jewett and Williston, 1971, Hall, 2007).  Figure 2.14 shows a representative 
ABR waveform that has been recorded to a click stimulus. 
The ABR has a wide clinical application. Because the ABR is unaffected by sleep 
or sedation it has become a very useful measure to obtain hearing thresholds in young 
children and difficult to test patient groups (Stein et al., 1983, Cohen and Prasher, 1988, 
Jiang and Tierney, 1995, Cacace and Pinheiro, 2002, Stone et al., 2009).  
The ABR has also been shown to be a sensitive marker of disease burden in the 
brainstem. Thus it is routinely used to identify lesions (Kaga et al., 1982, Cacace et al., 
1984, Odkvist et al., 1992, Levine et al., 1993, Furst et al., 1995, Manganelli et al., 2006), 
tumours (Stockard et al., 1976, Cohen and Prasher, 1988, Josey et al., 1988, Musiek et al., 
1988), and a diverse number of neurological diseases (e.g. excessive drinking that can 
result in demyelination (Begleiter et al., 1981, Nickel and Riedel, 1987, Cadaveira et al., 
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1994) or other conditions that can cause increased intracranial pressure such as 
hydrocephalus (Kraus et al., 1984). Another application of the ABR is in intra-operative 
monitoring (Cacace et al., 1994, Rodriguez et al., 1999, Hall, 2007). We will revisit the 
issue of the pathologic ABR more detail later in this chapter (see Section 2.6). 
 
2.4.2.2  Neural generators of the ABR 
Several approaches have been used to determined the neural substrates that generate 
the ABR. Studies in humans have involved intracranial recordings during surgery 
(Hashimoto et al., 1981), source localisation studies and lesion studies – relating 
morphological changes in the ABR with pathologies with circumscribed lesions. There is a 
general consensus among these studies that the ABR components are evoked by neural 
activity in structures of the ascending auditory pathways, including the midbrain. Peaks I 
and II are thought to be generated by the auditory nerve. However, the precise anatomical 
correlates of the ABR after wave II remain unclear. Figure 2.14 shows a schematic 
summary of the anatomical location of the neural generators of the ABR.    
This is considerable discussion regarding whether ABR activity is based on activity 
from the nerves and fibre tracts or in nuclei. Wave III is thought to represent activity from 
the CN although there is evidence that, like wave V, it has multiple generators. There is 
some evidence to suggest that wave V is generated by activity in the lateral lemniscus tract 
but because of the complexity of the CANS, it is unlikely that just one structure contributes 
to this component.   
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Figure 2-14 Neural generators of the ABR  
Panel A. Shows a schematic of the neural substrates that are thought to generate the ABR. A comparison of the ABR from the exposed intracranial portion of the 
auditory nerve during microvascular decompression surgery showed that the latency of the compound action potential (CAP) corresponds  to wave II of the ABR (seen 
in panel B) when measured concurrently (Hashimoto et al., 1981). Figure reproduced from Hall (2007) 
Figure has been removed due to copyright restrictions 
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In animal studies, the interpretation of the ABR has been based largely on depth 
electrodes and lesion studies (Moore, 1987a). Comparative studies of the cat and the human 
brainstem pathways reveal that the auditory nerve appears to generate one main peak. This 
may reflect a shorter auditory nerve in some species, smaller head size or the absence of the 
arachnoid space (Fullerton et al., 1987). However, it is generally agreed that peak II in 
animals corresponds to peak III in humans and that peak IV in animals (including primates) 
corresponds to peak V in humans (Kraus et al., 1985, Moller and Burgess, 1986). An 
important caveat to these studies comes from Burkard (2008, p3444) who argues that 
“application of animal data to human function is not entirely valid” and that species 
specific variation must be accounted for (Burkard, 2008).  
 
2.4.2.3 Recording the ABR  
The ABR is a far-field recording, as such it is critically dependent on a number of 
stimulation and recording parameters such as polarity, rate, intensity level and masking to 
name but a few (Hecox and Galambos, 1974, Hecox et al., 1976, Kodera et al., 1977a, b, 
Suzuki and Yamane, 1982, Burkard and Hecox, 1983, Gorga and Thornton, 1989, Purdy et 
al., 1989, Hall, 2007).  
The ABR is also affected by a number of non-pathological issues including age, 
gender and temperature (Keith and Greville, 1987, Hall et al., 1988, Jerger and Johnson, 
1988, Psatta and Matei, 1988, Dehan and Jerger, 1990, Rodriguez et al., 1995, Rodriguez et 
al., 1999, Hall, 2007). A number of review studies examining these issues in detail have 
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been published over the last four decades see (e.g. Gorga and Thornton, (1989); Stone et 
al., 2009).  We will revisit this again later in Chapter 3 (see section 3.5). 
 
2.4.2.4 Interpretation of the ABR 
The issue of interpretation of the ABR is complicated by the fact that human 
auditory centres and their evoked responses are not totally interdependent. Furthermore, the 
determination of threshold and interpretation of ABR traces tends to rest on the subjective 
judgment of the tester. While there are no professionally agreed objective criteria against 
which findings may be judged (Gans et al., 1992, Vidler and Parker, 2004), there is a 
general consensus regarding the response variables that are useful for clinical and research 
purposes. These include latency, amplitude and morphology. Figure 2.15 shows a 
representative ABR waveform illustrating each of these measures and a definition for each 
variable is presented in Table 2.8.  
Latency of different waveforms depends upon the conduction velocity in the VIII 
nerve, synaptic delay and the time course of excitatory post synaptic potentials in nerve 
cells including the hair cells. Studies exploring the relationship between pathology and 
ABR latency have produced heterogeneous responses across disease groups but have 
shown that ABR latency is a sensitive marker of subclinical damage (Cohen and Prasher, 
1988, Josey et al., 1988, Hall, 2007). 
Amplitude is another parameter that is used to make inferences about the integrity 
of the auditory brainstem pathways. Amplitude measures are thought to reflect the degree 
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of synchronisation and temporal coherence generated by the axons in the CANS. 
Amplitude is also sensitive to the number of fibres that are activated (Moller and Burgess, 
1986, Hall, 2007). 
Figure 2-15 Illustration of ABR wave latency and amplitude measurement 
The absolute peak latencies of the various ABR peaks are often determined for clinical and research purposes. 
Waves II, IV and VI or VII are not as reliably present as waves I, III and V so that these latter waves are the 
most commonly evaluated. Measurement of the absolute wave V amplitude measure is shown in green. 
Abbreviations: I – absolute latency of wave I; III – absolute latency of wave III; V – absolute latency of wave 
V; IPL – interpeak latency.  
 
 
 
Morphology refers to the subjective appearance, shape and reproducibility of the 
waveform. This qualitative measure of ABR variability is difficult to evaluate and by its 
very nature is descriptive, as it refers to the clarity, resolution and definition of the ABR 
(either in part or overall). It is influenced by a number of factors including stimulus settings 
(e.g. intensity and polarity); recording settings (electrode montage and the signal-to-noise 
ratio (Gorga and Thornton, 1989)) and subject factors (e.g. high frequency sensorineural 
hearing loss and neuropathology (Hall, 2007). 
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Table 2-8 Definition* of ABR parameters 
 
Text has been removed because of copyright restrictions 
2.4.2.5 Maturation and the ABR 
During the first 2 years of life, the ABR shows a number of highly reproducible 
alterations in the I-V ABR complex (Salamy et al., 1975, Salamy and McKean, 1976). 
These changes are thought to reflect the changes in myelination of the auditory brainstem 
pathways that are occurring concurrently (Moore et al., 1996, Ponton et al., 1996, Moore 
and Linthicum, 2007) (Figure 2.16). Animal and human studies have clearly shown that 
wave I is adult-like (or „complete‟) at birth but that later components, such as wave V is not 
complete until much later into childhood, around 4-5 years of age (Matschke et al., 1994, 
Jiang and Tierney, 1995).  
Interestingly, the progressive myelination of the AC and maturation of later auditory 
evoked potentials is prolonged compared with the other sensory cortices which mature 
within the first year of life (Moore and Linthicum, 2007). The reason for this delay in 
development is not clear but it is well documented that the myelination process of the 
hierarchical auditory circuits continues well into the second decade of life (Moore, 1987a, 
Moore and Linthicum, 2007). The delay probably reflects both its anatomical complexity 
and its changing role in language acquisition.  
The delay in cortical development has lead several researchers to suggest that a 
deficit at the level of the brainstem could adversely alter the processes required for normal 
cortical processing. For example, researchers have argued that deprivation-driven 
disruption could cause different types of behavioural deficits, depending on the phase of 
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development and the system affected (Purdy et al., 2002, Moore and Linthicum, 2007). 
This is supported by studies in children who have experienced sound deprivation because 
of late identification of hearing loss and who demonstrate severe difficulties affecting word 
learning, later in their development (Moore, 2002, Moore and Linthicum, 2007). 
The concept of a bottom-up causal relationship between the midbrain and the 
cortex, has been used to explain how abnormalities detected in ABR studies might 
adversely influence cortical development in autistic children
13
 (Tanguay and Edwards, 
1982) and in children with language-based learning difficulties (Banai et al., 2005, Wible et 
al., 2005). This is further supported by animal studies that have shown that experimentally 
induced perinatal anoxia in rats causes progressively delayed auditory processing from the 
brainstem to the auditory cortex (Strata et al., 2005).  
While it is tempting to postulate that some of these findings are due to a deficit in 
brainstem timing, this is not necessarily the case. Other factors (e.g. environmental or 
genetic factors) leading to abnormal brainstem timing could also cause abnormal cortical 
function. An alternative explanation is that the brainstem could be malleable to top-down 
effects
14
, e.g. experience-dependent plasticity (Krishnan et al., 2005). This challenges the 
long held view, as summarised by Tzounopoulos and Kraus (2009), that: 
“Mechanisms of plasticity have traditionally been ascribed to higher-order sensory 
processing areas such as the cortex, whereas early sensory processing centres have been 
considered largely hard-wired. In agreement with this view, the auditory brainstem has 
                                               
13 The „Whisper of the Bang‟ theory proposed by Tanguay and Edwards (1982)  
 
14 The Reverse Hierarchy Theory (RHT) suggests that conscious perception is typically based on the highest 
possible representation of the stimulus along the perceptual hierarchy. This theory has been used extensively 
as one conceptual framework to explain the effects of top-down processing on sensory based learning. 
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been viewed as a nonplastic site, important for preserving temporal information and 
minimizing transmission delays” (Tzounopoulos and Kraus, 2009, p463) 
Contrary to this view is an emerging literature to support the notion that the 
brainstem is capable of „learning‟ (Tzounopoulos and Kraus, 2009). 
 
2.4.2.6 Auditory brainstem plasticity: Evidence from ABR studies 
The first set of observations supporting neural plasticity in the auditory brainstem 
have shown that long-term synaptic (Fujino and Oertel, 2003, Tzounopoulos et al., 2004, 
Tzounopoulos et al., 2007, Tzounopoulos, 2008) and intrinsic plasticity (Rudy and McBain, 
2001, Zhang and Linden, 2003, Steinert et al., 2008) occur in some auditory brainstem 
nuclei  These studies suggest the ability to form „new memories‟ and the ability to adapt to 
changing demands (see Tzounopoulos and Kraus, 2009 for a recent review). 
Further support for neural plasticity has come from a plethora of auditory 
electrophysiological studies in humans using the ABR recorded using a complex stimulus 
(i.e.) a synthetic speech syllable, /da/ (Chandrasekaran and Kraus, Hornickel et al., Krizman 
et al., Russo et al., Skoe and Kraus, Skoe and Kraus, Song et al., Strait and Kraus, Strait et 
al., Wang et al., Koch et al., 1999, Kraus, 1999, Kraus et al., 1999, Cunningham et al., 
2000, Kraus et al., 2000, Kraus and Cheour, 2000, Kraus, 2001, King et al., 2002, Hayes et 
al., 2003, Nicol and Kraus, 2004, Russo et al., 2004, Banai et al., 2005, Johnson et al., 
2005, Kraus and Nicol, 2005, Russo et al., 2005, Abrams et al., 2006, Musacchia et al., 
2006, Song et al., 2006, Banai et al., 2007, Johnson et al., 2007, Musacchia et al., 2007, 
Johnson et al., 2008a, Johnson et al., 2008b, Musacchia et al., 2008, Russo et al., 2008, 
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Song et al., 2008a, Song et al., 2008b, Banai et al., 2009, Dhar et al., 2009, Hornickel et al., 
2009a, Hornickel et al., 2009b, Kraus et al., 2009, Lee et al., 2009, Parbery-Clark et al., 
2009, Russo et al., 2009, Strait et al., 2009a, b, Tzounopoulos and Kraus, 2009, Wang et 
al., 2009, Kraus and Chandrasekaran, 2010). These studies have uncovered new forms of 
learning and behavioural plasticity that are mediated by auditory brainstem structures.  
Are these studies simply evidence for „automatic sound detection‟? This is unlikely 
as multiple lines of evidence from studies on linguistic experience (Krishnan et al., 2005) 
musical expertise (Musacchia et al., 2007, Wong et al., 2007, Musacchia et al., 2008) and 
attention (Galbraith et al., 1998, Galbraith et al., 2003) all support the existence of a 
dynamic brainstem. Moreover this intricate sub-cortical network has been shown to change 
with auditory training, reflecting a real-time transformation (Song et al., 2008b). 
How these top-down influences may interact with developmental factors and 
brainstem disease is unclear. But other studies suggest that plasticity-induced changes in 
the auditory brainstem may also cause signs and symptoms of disease (e.g. tinnitus and 
hyperacusis (Moller, 2007, Tzounopoulos and Kraus, 2009). Taken together, these findings 
suggest a new role for the auditory brainstem and its modification by experience and 
pathology.  
 
2.5 Pathophysiologic saccades in brainstem disease 
Studies of the ABR have clearly shown that the brainstem is plastic and its 
importance is underscored by the consequences of disease, this is most profoundly seen in 
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disorders of oculomotor control. The importance of the brainstem in oculomotor control is 
underscored by the consequences of brainstem disease that are known to affect their 
function.  Lesions of the pons, medulla and the midbrain can result in a myriad of 
oculomotor signs and symptoms, depending upon the degree of structural involvement 
(Harris, 1997, Leigh and Kennard, 2004, Ramat et al., 2005, Chen et al., 2011).  
For example, the deficits seen in a focal lesion of the pons such as internuclear 
ophthalmoplegia (INO), a unilateral lesion of the MLF, can range from a complete lack of 
adduction of the ipsilateral eye to slow adducting saccades with full range (Harris, 1997, 
Frohman et al., 2008). For a more extensive review of brainstem disorders that are known 
to cause abnormal eye movements, see Harris et al., 1997; Leigh and Zee, (2006); Frohman 
et al., (2008).  
In the following section, we focus on two brainstem saccadic abnormalities that are 
central to our thesis – slow saccades and opsoclonus. These clinically important 
abnormalities are associated with many conditions and represent two extremes along a 
continuum of saccadic eye movements.  
At the one end of the spectrum is opsoclonus, characterised by a „flurry of activity‟ 
– a striking pattern of back-to-back, high frequency saccades with no inter-saccadic 
interval. In some cases, excessively fast saccades have been reported in patients with 
opsoclonus (Bergenius, 1986). Slow saccades, at the other extreme, represent the ultimate 
inefficiency – decreased saccadic velocity. It has been also been argued that both of these 
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eye movement deficits arise because of selective cell vulnerability in the pons (Leigh and 
Zee, 1999b).  
2.5.1 Slow saccades 
Slow saccades have been described in a varied number of clinical disorders 
including diseases of the oculomotor muscles; the oculomotor cranial nerves and a diverse 
group of neurological disorders that directly (and sometimes indirectly) affect a number of 
highly strategic neural circuits, important in saccadic control. A list of possible causes of 
slow saccades is shown in Table 2.9 (Leigh and Zee, 1999b).  
Slow saccades have also been reported as occurring secondary to therapeutic and 
toxic levels of a number of pharmacological agents including benzodiazepines, first- and 
second- generation antipsychotics, anti-cholinergic agents, and anticonvulsant/mood 
stabilising medications (Reilly et al., 2008). Several studies have also shown that non-
pathologic conditions examining alertness (e.g. drowsiness or sleep deprivation) or level of 
attentiveness also strongly correlates with a decrease in saccadic speed (Goldich et al., 
2010, Mazer, 2011).  
Slow saccades coupled with limited ocular motility are usually seen in diseases that 
affect the ocular motor periphery, such as ocular muscle or oculomotor nerve paresis 
(Brazis, 2009), or a lesion of the MLF (Frohman et al., 2008). Slow saccades occurring 
when the oculomotor range is unrestricted are typically caused by central neurological 
disorder (Table 2.9).  
Table 2-9 Aetiology of slow saccades* 
Causes of slow saccades Specific examples 
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Drug Ingestion  
 
Anticonvulsants, Benzodiazepines 
Drowsiness or fatigue  
 
 
Basal ganglia syndromes  
 
Huntington's chorea, Progressive Supranuclear Palsy 
(PSP),Wilson's disease, Parkinson's (advanced cases) 
and related diseases; Lytico-Bodig 
Cerebellar syndromes  
 
Spinocerebellar ataxia‟s especially SCA2, Joseph's 
disease (SCA-3), Ataxia telangiectasia  
 
Peripheral nerve palsy, diseases affecting the 
neuromuscular junction and extraocular muscle, 
restrictive ophthalmopathy  
6th and 3rd nerve palsies, Miller Fisher syndrome,  
Progressive external opthalmoplegia (PEO), 
Mitochondrial myopathy, Thyroid disorders  
 
Lipid storage disorders Niemann-Pick disease, Gaucher disease, Tay-Sachs 
disease 
Wilson's disease  
Lesions of the paramedian pontine reticular 
formation 
 
In dementia: Alzheimer's disease (stimulus-
dependent), and in association with AIDS 
 
White matter diseases 
 
Adrenoleukodystrophy, Internuclear ophthalmoplegia 
(common in MS) 
Other  
 
Wernicke‟s ophthalmoplegia, Tetanus, 
Paraneoplastic syndromes 
Amyotrophic lateral sclerosis (in some cases); 
Whipple's disease 
*Table adapted from Leigh and Zee (1999) 
An important distinction – one that is often difficult to detect clinically unless 
saccadic slowing is severe – is whether horizontal and vertical saccades are affected 
differentially. For instance, horizontal saccades are selectively slower in a number of 
genetic and degenerative disorders such as SCA2 (Geiner et al., 2008, Rodriguez-Labrada 
et al., 2011), neuronopathic Gaucher disease (Harris et al., 1999, Benko et al., 2011), INO 
(Frohman et al., 2008, Tilikete et al., 2011), sixth nerve palsy (Brazis, 2009, Agrawal and 
Singh, 2011), and in disorders of the lateral and medial ocular muscles (Yuksel et al., 2005, 
Yuksel et al., 2010). 
Conversely, examples of disorders which affect vertical saccades (to a greater extent 
than horizontal saccades) include neurodegenerative disorders affecting the midbrain such 
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as Niemann-Pick type C disease (Wybar, 1971, Garbutt and Harris, 2000, Patterson et al., 
2007), and progressive supranuclear palsy (PSP) (Chen et al., 2011), and thyroid-associated 
ophthalmology (Schworm et al., 2011) (Table 2.9).  
However, the distinction between horizontal and vertical involvement, is not always 
a useful diagnostic measure.  A classic example of this is ocular myasthenia gravis, an auto-
immune disorder which can cause weakness in one or all of the ocular muscles, ptosis and 
diplopia (Barton and Fouladvand, 2000, Haines and Thurtell, 2011).   
 
2.5.1.1 Pathophysiology of slow saccades 
Several models have been developed to explain the pathophysiology of slow 
saccades (Leigh and Zee, 1999a, Leigh and Kennard, 2004, Ramat et al., 2005, 2007). 
However, the mechanism of saccadic slowing has been attributed to dysfunction in EBN 
cells directly, or because OPN are lost, indirectly slowing EBN firing (Leigh and Kennard, 
2004).  
However, it is still unclear why midbrain lesions slow only the vertical component 
of saccades, whereas circumscribed lesions of the PPRF result in either slow horizontal 
saccades selectively or a slowing in both horizontal and vertical saccades (Leigh and Zee, 
1999a, Ramat et al., 2007). Another potentially confusing issue is that disturbances of 
higher-level structures, including the SC can also lead to slow saccades (Hikosaka and 
Wurtz, 1985).  
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2.5.2 Opsoclonus 
Opsoclonus
15
 is a highly dramatic oculomotor disorder characterised by chaotic, 
multidirectional bursts of high-frequency oscillations – these include horizontal, vertical 
and torsional components. The frequency of the oscillations typically ranges between 5 – 
13 Hz (Digre, 1986). Each burst of oscillations consists of a series of back-to-back saccades 
that lack an intersaccadic interval (Gresty et al., 1980). When these oscillations are 
confined purely in the horizontal plane, it is known as ocular flutter (Leigh and Zee, 
1999a). Both of these aberrant eye movements are thought to be saccadic in origin because 
they conform to the main-sequence relationship (Ramat et al., 2005). 
Visual disturbances such as oscillopsia and vertigo have been documented in 
affected patients (Ramat et al., 2005). Interestingly, one study describes an increased peak 
velocity in saccadic activity as measured by EOG in 6/8 patients with opsoclonus or ocular 
flutter. This was observed in saccades in both directions in 5/8 cases (Bergenius, 1986). 
Other eye movements are usually preserved, although prolonged post-rotatory VN 
(Shawkat et al., 1993) and abnormal SP have been described (Mitchell et al., 2002). For a 
more in-depth treatment of this topic see e.g. Pranzatelli (1992); Wong et al., (2007); Harris 
(1997) and Leigh et al., (1999). 
The two most common diseases that are associated with opsoclonus are viral 
encephalitis (Sheth et al., 1995, Cassidy et al., 2000b, Bartos and Pitha, 2003, Zaganas et 
al., 2007) and cancer (breast, lung and ovarian) (Anderson et al., 1988, De Luca et al., 
                                               
15 Opsoclonus has also been variously called „saccadomania‟ or dancing eyes. It is important that it not 
confused with other eye movement disorders that have been described in the literature including „lightning 
eye movements‟, ocular dysmetria, ocular flutter and macro-saccadic oscillations. 
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2002, Hassan et al., 2008). It is often considered „an ominous sign‟ when seen in childhood 
(Morad et al., 2004) as it is closely linked with neuroblastoma (and other neural crest 
tumours). We have summarised associated clinical conditions of opsoclonus in Table 2.10.  
Table 2-10 Aetiology of opsoclonus and ocular flutter* 
Causes of opsoclonus and ocular flutter Specific Examples 
Paraneoplastic effect of neuroblastoma and other 
neural crest tumours in children 
 
Paraneoplastic effect of other tumours (in adults)  
Parainfectious encephalitis  
Multiple sclerosis  
Meningitis  
Intracranial tumours  
Hydrocephalus  
Thalamic haemorrhage  
Associated with systemic disease 
 
AIDS, Coeliac disease, Viral hepatitis, Sarcoidosis 
Following allogeneic hematopoietic stem cell 
transplantation 
 
Metabolic conditions Non-ketotic hyperosmolar coma 
Toxins 
 
Herbal remedies, Chlordecone, Organophosphates, 
Strychnine, Thallium, Toluene 
Medication effects 
 
Amitriptyline, Haloperidol, Lithium, Phenytoin, 
Diazepam, Cocaine 
Stroke Thalamic, Pontine haemorrhage, Vertebrobasilar 
insufficiency 
Trauma Usually assoc with sepsis & hypoxia 
Miscellaneous Transient phenomenon of normal infants 
Complication of pregnancy 
*Table adapted from Leigh and Zee (1999) and Wong (2007) 
Acquired opsoclonus is usually seen in combination with myoclonus and ataxia 
which has been described variously as Dancing Eye Syndrome or Opsoclonus Myoclonus 
Syndrome (Pranzatelli, 1992, Dale, 2003, Baets et al., 2006, Gorman, 2010, Brunklaus et 
al., 2011b). We will review this disorder in more detail later in Chapter 6.  
Opsoclonus has also been described in a small number of congenital cases including 
preterm infants (Bienfang, 1974, Hoyt, 1977, Morad et al., 2004). Although these cases are 
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rare and typically resolve spontaneously (by the age of 6 months), some cases are not 
always benign (Bienfang, 1974, Cassidy et al., 2000a). 
 
2.5.2.1 Pathophysiology of opsoclonus 
The pathophysiology of opsoclonus is uncertain. Acquired opsoclonus is thought to 
be an immune-mediated disorder but the neural substrates are unknown. Two mechanisms 
have been proposed to account for eye movement abnormalities in DES: (1) the cerebellar 
hypothesis; which suggests that disinhibition of the FN in the cerebellum causes the 
opsoclonus and (2) the „pontine hypothesis‟ which suggests that the saccadic system 
becomes unstable as a direct result of altered synaptic weighting of burst neuron‟s in the 
brainstem (Wong, 2007).  
The cerebellar hypothesis was initially derived from observations that patients with 
acquired opsoclonus also typically demonstrate signs of ataxia. This has led to researchers 
arguing that opsoclonus is the result of damage to the cerebellum. This hypothesis is 
supported by a number of histopathological and imaging studies. In a recent review, Wong 
(2007) presented the current evidence to support „disinhibition‟ of the FN as the origin of 
opsoclonus. She presented data to show that damage to Purkinje cells in the DV or their 
inhibitory projections to the FN may cause opsoclonus by disinhibiting the FN
16
.  
                                               
16 A number of other studies are presented in this excellent review paper which clearly make a strong case for 
cerebellar involvement (for a detailed review see Wong (2007). 
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However, multiple lines of evidence also support a role for the brainstem in 
opsoclonus. Zee and Robinson (1979) postulated that OPN are targeted in these disease 
processes. This „pontine‟ hypothesis suggests that saccadic oscillations arise because of the 
changes in the synaptic weighting of saccadic burst neuron circuits in the brainstem due to 
disease whenever the OPN cells are inhibited (Ramat et al., 2005, 2007). 
Presently, there is not enough evidence to discount either model. Further, Harris 
(1997) cautions that,  
“it is erroneous to think of a single site for opsoclonus, but rather that structural or 
pharmacological „lesions‟ in a distributed tecto-pontocerebello-tectal loop can lead to 
saccadic oscillations” (p96).  
 
2.6 Auditory signs and symptoms in saccadic eye movement disorders? 
Current eye movement models that have sought to provide an explanation for 
saccadic deficits: particularly those that are of key interest to this thesis (i.e.) slow saccades 
and opsoclonus have implicated the pons – a common neural substrate in both the auditory 
and oculomotor circuitry – in these atypical SEM disorders (Ramat et al., 2007). The pons 
is also an important structure in generating the later components of the ABR. One question 
naturally emerges – is the ABR abnormal in any of the aetiologies that are associated with 
slow saccades and opsoclonus? (Hall, 2007).  
We previously argued in Chapter 1, that the auditory pathway is closely related to 
key motor and sensory tracts. As a result of these shared or co-located neural substrates, it 
is plausible that a brainstem lesion affecting the one sensory pathway such as abnormal eye 
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movements could also result in co-morbid dysfunction in other sensory modalities such as 
the auditory system.  
We explored the scientific literature to see whether both signs and symptoms have 
been reported in conditions. Tables 2.11 and 2.12 present a summary of selected literature 
for aetiologies which are associated with slow saccades and opsoclonus respectively. 
Abnormal ABRs have been reported in many cases but there have been no systematic 
study. Moreover, we found several post-mortem studies to show widespread brainstem 
degeneration involving oculomotor and auditory centres, but few studies that had examined 
both modalities. 
Clearly there is some evidence of auditory neural involvement in children that also 
have slow saccades and opsoclonus, but auditory function has not been defined. In 
summary, there is some evidence to support an association between – clearly has not been 
explored in any depth. In the following chapters we will examine this issue in two specific 
conditions: Gaucher disease and Dancing Eye Syndrome and explore the utility of 
audiological measures in these conditions. 
 
  
 
 
125 
Table 2-11 Summary of selected studies of the ABR in clinical disorders which are also associated with slow saccades 
Aetiology of 
Slow saccades 
 Study n ABR findings Comments 
Multimodal 
Study? 
    Peak IPL   
Basal Ganglia 
Syndromes 
Huntington‟s chorea 
(Ehle et al., 1984) 12 N N 
- 
– 
(Bollen et al., 
1986) 
20 N N 
Abnormal blink reflex 
– 
(Lin et al., 2011) 
 
19 V V 
ABR abnormal consistent with peripheral 
hearing loss. Authors concluded that 
hearing loss thus appears to be an 
symptom of HD 
– 
Progressive supranuclear palsy 
(Pakalnis et al., 
1992) 
8 A A 
Minor abnormalities in ABR 
– 
(Laffont et al., 
1991) 
17 V V 
9/17 patients had normal ABR; 4/17 
patients showed an abnormal III wave; 
3/17 patients showed an abnormal V wave. 
One patient poor ABR morphology 
– 
Parkinson's (advanced cases) and 
related diseases; Lytico-Bodig 
(Yylmaz et al., 
2009) 
20 A A 
PTA results were significantly elevated for 
PD patients at 4 and 8 kHz. PD patients 
also showed significantly increased 
latencies in wave V and I-V interpeak 
latencies 
– 
(Al-Bunyan, 2000) 54 A N 
Prolonged wave I and V in the PD group, 
normal IPLs 
– 
Cerebellar 
syndromes  
 
Spinocerebellar disease 
SCA17 
(Manganelli et al., 
2006) 
9 A A 
Generally dysmorphic waveforms 
– 
SCA6 - 10 A N 
Delayed wave I consistent with peripheral 
impairment in the auditory pathway 
– 
SCA3 (Machado-Joseph disease) 
Kondo et al. 
(1990) (hall p397 
13 A A 
ABR was abnormal in 8 cases; only wave I 
present in 5 cases 
? 
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Aetiology of 
Slow saccades 
 Study n ABR findings Comments 
Multimodal 
Study? 
    Peak IPL   
Ataxia telangiectasia 
(Scarpini et al., 
1996) 
6 V V 
Abnormal ABR in 2/4 cases  
– 
Peripheral 
oculomotor 
nerve or muscle 
weakness 
Miller Fisher syndrome 
(Ogawara et al., 
2002) 
1 A N 
Prolonged wave I 
+ 
(Durand et al., 
2001) 
10 N N 
Normal ABR in all cases – authors found 
no evidence to support any brainstem 
abnormality in any MF case. 
+ 
Metabolic 
disease 
Niemann-Pick disease 
(Aisen et al., 1985, 
Pikus, 1991, 
Higgins et al., 
1992, Lossos et al., 
1997) 
8 A A 
Diverse number of abnormalities 
+ 
Gaucher disease -  A A 
We review the ABR in GD in detail later 
in Chapter 4 
– 
Tay-Sachs disease 
(Bembi et al., 
2006) 
   
 
– 
Wilson‟s disease 
(Das et al., 2007) 18 A A Abnormal ABR in 61.5% cases + 
(Hsu et al., 2003) 30 A A 
Prolonged interpeak latencies of 
brainstem auditory evoked potentials III-
V, I-V in all of the neurological cases 
(n=12); but only 16.6% abnormal ABRs in 
non-neuroolgical cases 
 
(Fujita et al., 1981) 6 V V 
Abnormal ABR in 3 symptomatic cases. 
ABR was normal in asymptomatic cases 
 
(Chu and Yang, 
1987) 
20 V V 
Statistically significant prolonged I-V in 
WD group 
 
Lesions of the 
paramedian 
pontine 
reticular 
formation 
One and a half syndrome 
Koyama et al. 
1998 (10078040) 
1 A A 
ABR findings indicated abnormalities in 
the pontine tegmentum 
+ 
„Vertical‟ one and a half syndrome 
Gulyas et al. 2006  
(16786714) 
1 N N 
Normal ABR 
+ 
One-and-a-half syndrome , Andree‟ et al. 1989 1 A A Prolonged ABR latency + 
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Aetiology of 
Slow saccades 
 Study n ABR findings Comments 
Multimodal 
Study? 
    Peak IPL   
possibly secondary to multiple 
sclerosis 
(2619617) 
Dementia 
Alzheimer's disease (stimulus-
dependent), 
Gates et al. 2010 
(21150347) 
313 ? ? 
„central presbyacusis‟ 
– 
Gimeno-Vilar and 
Cervera-Paz 
(2010) (20112213) 
14 ? ? 
ABR normal when corrected for peripheral 
hearing loss. But HL sig worse in AD 
group than controls 
– 
O‟Mahoney et al. 
(1994) (from Hall 
p408) 
35 NS A 
Significant prolongation in I-V in AD 
group – 
White matter 
diseases 
Adrenoleukodystrophy,  
(Schmidt et al., 
2001) 
8 A A 
Study group was 8 female carriers for X-
link ALD - all cases had abnormal IPL 
 
Miscellaneous 
 
Wernicke‟s ophthalmoplegia 
(Haas and Nickel, 
1991) 
21 A A 
Abnormal ABR waveforms were frequent, 
impossible either to quantify them or 
correlate them with the level of the clinical 
brainstem symptoms. However, IPL 
prolongations were a very reliable 
diagnostic criterion. WE cases diagnosed 
by the characteristic clinical syndrome 
with signs of disturbances of the 
oculomotor system, delayed IPLs, 
particularly a delayed CCT, were found as 
typical signs. 
+ 
Amyotrophic lateral sclerosis (in 
some cases) 
(Radtke et al., 
1986) 
17 V V 
Only 2 cases showed evidence of 
prolonged I-V 
– 
(Matheson et al., 
1986) 
32 V V 
Four cases showed mild ABR 
abnormalities 
– 
Whipple's disease 
(Scheurer et al., 
2010) 
1 NT NT 
Presented with hearing loss 
– 
Tetanus 
(Kagoya et al., 
2011) 
1 N N 
Normal ABR. Head thrust test was 
abnormal, with reﬁxation saccades noted 
+ 
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Aetiology of 
Slow saccades 
 Study n ABR findings Comments 
Multimodal 
Study? 
    Peak IPL   
with head movements both to R and L. 
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Table 2-12 Summary of selected studies of the ABR in clinical disorders which are also associated with opsoclonus and ocular flutter 
Aetiology of 
opsoclonus and 
ocular flutter 
Clinical disorder Study n ABR findings Comments Multimodal 
Study? 
    Peak IPL   
Paraneoplastic 
effect of 
neuroblastoma 
and other neural 
crest tumours in 
children 
Dancing eye syndrome - - - - We review this in Chapter 6 – 
Thalamic 
haemorrhage 
- -  NR NR No auditory investigations – 
Associated with 
systemic 
disease 
 
AIDS (Matas et al., 2010) 73 V V Diverse ABR abnormalities reported in 
children and adults with HIV 
– 
Coeliac disease,  (Deconinck et al., 
2006) 
1 N N  + 
Sarcoidosis  (Souliere et al., 
1991) 
2 A A CPA granuloma in one case. Both cases 
presented with sudden onset HL. 
Abnormal ABR even when corrected for 
HL 
– 
Following 
allogeneic 
hematopoietic 
stem cell 
transplantation 
 Strober et al., 
(2009) 
Bishton et al., 
(2005) 
1 
 
1 
NR NR No auditory investigations  
Metabolic 
conditions 
Non-ketotic hyperosmolar coma Noda et al., (1985) 
and Weissman et 
al., (1989) 
 NR NR Two single case reports  - no mention of 
any auditory 
– 
Toxins Herbal remedies – – NR NR Animal studies only – 
Chlordecone (Kepone) – – NR NR Animal studies only – 
Organophosphates (Jayasinghe and 
Pathirana, 2011) 
70 N N Serial ABRs showed no alteration in IPL 
over a 6 week interval 
– 
Strychnine –  NR NR Animal studies only – 
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Thallium  (Pelclova et al., 
2009) 
2 A A Prolonged I-V IPLwhich improved after 
two years; mild hearing loss in one case 
– 
Toluene (Poungvarin, 1991) 1 A A Sniffed lacquer polish for 5 years produced 
abnormal ABR inter-peak latencies 
– 
(Abbate et al., 
1993) 
300 A A Occupational exposure to toluene – the 
ABR showed a latency delay at two 
different stimulation rates (11/s and 90/s) 
– 
Medication 
effects 
Amitriptyline (Rumpl et al., 
1988) 
2 NR A Two cases of amitriptyline overdose 
showed prolonged IPLs 
– 
Haloperidol – – NR NR Animal studies only – 
Lithium, – – NR NR Animal studies only – 
Phenytoin (Rysz and 
Gajkowski, 1996) 
21 V A Serial ABRs showed prolongation of IPLs 
with long-term treatment 
– 
(Enoki et al., 1996) 7 V V 1/7 had prolonged IPLs – 
Diazepam (Adams et al., 
1985) 
NR NR A Small  but significant increase in IPL I-V – 
Cocaine (Tan-Laxa et al., 
2004) 
4 A A Prolonged absolute peak and IPL in 
prenatally exposed infants 
– 
(Elkardoudi-
Pijnenburg and 
Van Vliet, 1996) 
1 N N Normal ABR reported – no details 
available. 
+ 
Stroke Vertebrobasilar insufficiency (Factor and 
Dentinger, 1987) 
8 A A Initial ABRs showed absence of 
waveforms, prolonged IPLs, and/or 
amplitude reduction. 5/6 patients showed 
reversal of ABR changes to normal; the 
remaining patient returned to near normal. 
– 
(Lee and Baloh, 
2005) 
364 V V 29 patients with VBI were found to have 
various abnormalities on the ABR – 
mainly due to sudden cochlear HL 
– 
Pontine haemorrhage (Nakane et al., 
2006) 
1 A A All waves absent except for wave I; 
sudden onset hearing loss also described 
which showed some improvement 
– 
Abbreviations: A=abnormal; N=normal; NR = not reported; NS = not specific; V=various; * in excess of >100 studies using the ABR; + studies investigating 
oculomotor and auditory findings; – no multimodal reports 
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3 Chapter 3 
General Methodology 
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3.1 Introduction 
One of the primary aims of audiological assessments is to identify hearing loss. On 
the surface of it, this would appear to be a relatively simple undertaking. Indeed, the 
suggestion of having a hearing test often evokes vague childhood memories of being told to 
„press a button when a beeping sound is heard‟. While there is significant merit in 
employing a psychoacoustic test to characterise how well we can hear simple tonal stimuli, 
this simplistic view of testing hearing, per se, is misleading as it fails to reflect the 
complexity of the system we are interested in exploring. Hearing is not a unitary skill and 
capturing how well one hears, or more importantly what is perceived, is exceptionally 
difficult.  
There are several approaches that have attempted to capture this information. Tests 
can be functionally divided on the basis of their anatomical location within the auditory 
pathways (see Chapter 2, section 2.3.3). These include tests of the peripheral auditory 
pathways (e.g. tympanometry measures for middle ear function and otoacoustic emissions 
for measures of the cochlea) and central auditory pathways (e.g. electrophysiological tests). 
More sophisticated tests assess the centrifugal (descending, efferent) auditory pathways; 
e.g. medial olivocochlear suppression testing is used to test the integrity of the efferent 
pathway in the auditory brainstem. A summary of tests that are commonly used in clinical 
practice, and the anatomical areas of the auditory system they are thought to index, are 
shown in Figure 3.1.  
Another useful framework when considering the measurement of the auditory 
system is to distinguish between tests on the basis of their desired response. For example, a 
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measure requiring an overt response would be considered subjective (also referred to as 
behavioural), whilst an objective test would elicit an output that was independent of a 
behavioural response. Examples of objective physiological tests include otoacoustic 
emissions (OAEs) and auditory evoked potentials (AEPs); both of these are used routinely 
to evaluate the integrity of auditory function from the cochlea to the auditory cortex.  
The advantages of objective measures are self evident: they are non-invasive and as 
we have previously described in Chapter 2, they can be used to detect a number of 
neurological disorders. The application of objective measures is also advantageous when 
measuring the auditory function in young children or difficult to test populations – 
particularly those that are unable to provide a response on behavioural tests.  The use of 
combining objective and subjective tests provides a powerful method of validating or „cross 
checking‟ results (Jerger and Hayes, 1976, Turner, 2003).  
In order to assess and evaluate the extent of brainstem lesions and functionality in 
participants with atypical eye movements, we implemented a wide range of audiological 
investigations. These included both objective and subjective measures and tested 
overlapping, but not identical, efferent and afferent pathways and brainstem structures. The 
tests are described in detail below.  
In the following sections, we outline the general methods that we have employed in 
our core experimental chapters 4, 5 and 6. We have organised this chapter into three 
sections: self-assessment questionnaires, subjective measures and objective measures. We 
  
134 
 
provide a brief overview of each technique and follow this with a detailed description of the 
procedure.  
Figure 3-1 Summary of tests commonly used to test afferent and efferent auditory pathways 
 
Abbreviations: ABR – auditory brainstem response; CN – cochlea nucleus; IC – inferior colliculus; ME – 
middle ear; MGB – medial geniculate body; MOCS – medial olivocochlear suppression; OAEs – otoacoustic 
emissions OE – outer ear; OTO – otoscopy; SOC – superior olivary complex; TYMP – tympanometry  
 
3.2 Self assessment measures 
Rosenberg (1978) describes the comprehensive case history as the „first test‟ in the 
auditory battery of assessments. A reliable case history can often provide invaluable 
information about the probable site and nature of the disorder. However, due to the 
inherently unreliable nature of self-reporting, a number of checklists and questionnaires 
have been developed, to guide the patient (and interviewer) in obtaining the important 
details in the case history. The ability to complete the case history was dictated by the age 
of the participant. Older children and adults were asked to complete a face-to-face 
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questionnaire directly. Details about younger children were obtained directly from their 
parents (or guardians). The full case history form and modified listening profile 
questionnaire are shown in Appendix 3. 
All participants were asked about their history of ear disease, neurological disease, 
occupational exposure to noise and organic solvents, hypertension, diabetes, history of 
language/learning disabilities, difficulties in understanding speech in the presence of 
background noise or any other hearing-related difficulty. Additional information was also 
sought regarding prenatal, perinatal and postnatal history in each case. 
Detailed information was sought regarding each presenting symptom or symptoms. 
This included questions about the onset of the symptom(s); whether the symptom was 
constantly present or intermittent; the duration and severity of the symptom(s); did the 
symptom show signs of progression (i.e. did it improve or deteriorate?); was the symptom 
bilateral or unilateral? Finally, did the symptom(s) have any effect on the quality of life of 
the participant?  
 
3.3 Behavioural audiometric measures 
Earlier in section 3.1, we mentioned that one approach to differentiate between 
measures of auditory function is to subdivide tests on the basis of participant co-operation; 
i.e. is a test subjective or objective? (Turner, 2003). The different subjective, or 
„behavioural‟, and objective measures are highlighted in Figure 3.2.  Behavioural measures 
were focused on assessing hearing threshold and physical condition of the outer ear. 
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A double-walled soundproofed room (Industrial Acoustics Corporation, Staines, 
UK), meeting specifications for permissible ambient noise, served as the test environment 
(ISO8253-1, 1998). Behavioural procedures were obtained from all participants in the same 
session in which objective tests were performed.  
 
 
 
 
Figure 3-2 Flowchart 
showing the behavioural 
and objective measures 
used in this thesis 
 
3.3.1 Otoscopy 
Otoscopy is a visual examination of the outer ear. Otoscopy involves inspecting the 
pinna, ear canal (external auditory meatus) and the ear drum (tympanic membrane), to 
ensure that there are no pathologic alterations to any of these anatomical landmarks. For 
example, that there is no wax blocking the tympanic membrane which may result in an 
„artificial‟ conductive hearing loss. Otoscopy was undertaken in all participants prior to 
commencement of any audiological test, following the British Society of Audiology 
recommended procedures (BSA, 2010). 
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3.3.2 Establishing hearing thresholds 
The cornerstone of every audiological investigation is the psychophysical method of 
limits assessment, pure tone audiometry. This test is used to obtain minimal audible hearing 
thresholds across a wide frequency range, typically 0.25 – 8 kHz. Participants are asked to 
detect signals presented with two different transducers: 1) headphones (or insert earphones) 
to measure air conduction (AC) thresholds and 2) bone conductor placed on the mastoid 
bone, to measure bone conduction (BC) thresholds.   
Data from AC testing provides valuable information about the entire auditory 
pathway, whereas BC bypasses the conductive mechanism (i.e.) the outer and middle ear. 
Comparison of the AC and BC thresholds allows for a measure of the „type‟ of hearing loss 
(whether the hearing loss is conductive, sensorineural or mixed).  These data are then 
plotted on an audiogram – a graphical representation of auditory sensitivity as a function of 
frequency. An example audiogram is shown in Figure 3.3.  
The severity or degree of hearing loss is calculated from the AC thresholds and is 
generally classed as normal, mild, moderate, severe or profound (BSA, 2004) (for a more 
detailed discussion of the interpretation of the audiogram (see Section 3.3.2.4).  
Behavioural data suggests that in younger children, responses in conventional 
audiometry are significantly influenced by age, gender and ear; this has implications for 
assessing the accuracy of pure tone audiometry. For example, several studies have shown 
that hearing as assessed by conventional audiometry improves with age (Orchik and 
Rintelmann, 1978, Rahko and Karma, 1989, Buren et al., 1992). This difference has been 
attributed to the consequence of both physical changes and changes in perceptibility and 
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reactivity of a child. (Trehub et al., 1989, Anonymous, 2000). Current international 
standards for hearing thresholds for air conduction audiometry in the conventional range of 
0.125-8 kHz as a function of age and sex for otologically healthy persons have been 
published only for adults (Standardization, 1984). For age groups below 18 years no 
standard exists (Buren et al., 1992).  
Figure has been removed due to copyright restrictions 
 
 
Figure 3-3 An 
audiogram showing 
unmasked air conduction 
and bone conduction 
thresholds.  
By convention, 
increasing intensity 
(which indicates a 
hearing loss), is plotted 
on the y-axis and 
frequency is plotted 
along the x-axis. 
Symbols: circles indicate 
air conduction thresholds 
on the right ear, crosses = 
air conduction thresholds 
on the left ear; shaded 
triangles = masked bone 
conduction thresholds.  
 
Therefore in this thesis, we have measured hearing sensitivity using two age-
appropriate methods. For children younger than three years old, we used visual 
reinforcement audiometry (VRA) and for older participants (age > 3 years), pure-tone 
audiometry (PTA) was used to measure conventional hearing threshold levels. 
3.3.2.1 Pure tone audiometry 
Pure tone audiometry was measured using an audiometer (model GSI 61; Grason-
Stadler, Milford, NH) recently calibrated with earphones equipped with TDH-49 cushions. 
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Test equipment was calibrated for frequency accuracy and sound pressure levels in the 
coupler by an authorised audiometric service (EMIS). 
AC thresholds were measured using a modified Hughson-Westlake ascending 
method of threshold estimation. Participants were initially presented with a suprathreshold 
tone at 1 kHz in the better ear. Short duration tones (1-3 seconds) were randomly presented 
using an up 5dB-down 10dB technique. Briefly, the presentation tone is decreased in steps 
of 10 dB following a positive response, until a hearing threshold level is reached at which 
the subject fails to respond.  Then, the tone is increased (by 5 dB), if the subject hears this 
increment; the tone is reduced by 10 dB.  Threshold is defined as the quietest tone that a 
participant can hear, 50% or more of the time. Inter-stimulus intervals were also 
randomised throughout testing. Frequencies were tested monaurally at 0.25, 0.5, 1, 2, 4, and 
8 kHz, with testing repeated at 1 kHz following the procedure recommended by the British 
Society of Audiology (2004). Testing began with the better ear in all participants.  
 
3.3.2.2 Visual reinforcement audiometry 
Insert earphones connected to a Grason-Stadler (GSI 10) audiometer were used to 
present a series of warble tone stimuli across the frequency range of 250 to 4000 Hz. Two 
loudspeakers were positioned at an equal distance to the right and left of the child, with the 
child seated on an adult's lap. Reinforcer puppets were situated above each loudspeaker. 
Figure 3.4 shows the two-speaker and two reinforcement unit arrangement.  
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Figure has been removed due to copyright restrictions 
 
 
Figure 3-4 Test room 
arrangements used 
when undertaking VRA 
testing 
  
 
Abbreviations:   
L – loudspeaker,  
R – reinforcer cabinet,  
S – participant,  
T1 – tester 1,  
T2 - Tester 
 
 
 
Before commencing VRA, the procedure was clearly explained to the parent(s) with 
suitable cautions about cueing the child to the presence of an auditory stimulus, and the 
need to minimize distracting noise. In order to obtain reliable responses, a 1 kHz warble 
tone was initially presented at a supra-threshold level of 60 dB HL. Visual reinforcement 
was presented when a clear head-turn response was observed. This is referred to as 
„conditioning‟. 
Once two consecutive correct responses were observed, Tester 1 commenced with 
the test trials. Intensity was decreased in steps of 20 dB as long as responses are still 
observed. At the estimated threshold a „10dB down, 5dB up rule‟ was adopted. The criteria 
for accepting a threshold was 2 out of 3 responses at any level. The minimum response 
level at one frequency was defined before moving to another frequency.  
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3.3.2.3 Interpretation of hearing thresholds 
Hearing was considered normal when thresholds were better than 20 dB HL in both 
ears (BSA, 2004). The audiometric type and degree of hearing loss were further analyzed 
according to guidelines published by the British Society of Audiology (BSA) and are 
described in Table 3.1. 
Table 3-1 Description* of audiometry analysis used throughout the thesis 
Audiogram Terminology Description 
Type Sensorineural 
hearing loss 
Average air-bone gap of less than 15 dB for 0.5, 1 and 2 kHz 
Conductive hearing 
loss 
Normal BC thresholds and average air-bone gap of 15 dB or more for 
0.5, 1, and 2 kHz 
Mixed hearing loss BC threshold greater than 20 dB HL in combination with averaged 
air-bone gap 15 dB or more for 0.5, 1, and 2 kHz 
 
Degree Normal Thresholds were better than 20 dB HL in both ears 
Mild Thresholds were measured between 20-40 dB HL in both ears 
Moderate Thresholds were measured between 40170 dB HL in both ears 
Severe Thresholds were measured between 71-90 dB HL in both ears  
Profound Thresholds were > 90 dB HL in both ears 
*These definitions are derived from BSA (2004) document 
 
3.4 Objective audiometric measures 
 
3.4.1 Clinical measurement of acoustic immittance  
In order to determine how efficiently the middle ear transmits acoustical energy, a 
number of indirect measurements are made based on how efficiently a low frequency tone 
is transmitted. This is called acoustic immittance. The resultant data provides information 
about the „likelihood‟ of a specific condition or can be used as part of a differential 
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diagnosis. Collectively this data can be used to provide invaluable information about the 
middle ear, cochlea, VIIIth CN, brainstem and facial (VIIth) nerve integrity. 
The clinical measurement of acoustic immittance is based on three components: 
static compliance, tympanometry and stapedial reflex thresholds
17
. Because static 
compliance has limited clinical value
18
, only tympanometry and stapedial reflex thresholds 
are described, below. 
Both of these measures were recorded using the same equipment:  a v2 GSI-33
 
Middle Ear Analyzer (Guymark, UK).  Using the manufacturer supplied test cavity, the 
calibration of the ml/mmho meter and graphic display at 0.5cc, 2.0cc and 5.0cc was 
performed at the start of each day. A qualitative check of each test mode using the 
ipsilateral and contralateral probe was also completed daily. The middle ear analyser was 
calibrated annually
 
by an independent contractor (EMIS).   
 
3.4.1.1 Tympanometry  
Tympanometry is an objective technique for determining how the compliance of the 
middle ear system changes in variation to the air pressure on the tympanic membrane. A 
probe tone is introduced into a hermetically sealed ear canal by means of a loudspeaker 
located with the probe box. The probe tone selected is age-dependent – in subjects older 
than 6 months a low probe tone of 226 Hz is selected because the normal middle ear system 
                                               
17
 In the literature, the acoustic reflex threshold (ART) has also been called the middle ear muscle reflex, or 
the stapedial reflex threshold. In this thesis we will refer to it as the acoustic reflex threshold (ART). 
18 Static compliance is considered a weak component of the immittance test battery because of the wide range 
of variability shown in normal individuals. 
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is a „stiffness dominated‟ system (Meyer et al., 1997). The intensity of the probe tone is 
monitored via a microphone, also located within the probe box.  
The measurement is carried out by introducing controlled degrees of both positive 
and negative air pressure into the closed cavity of the external ear canal. As the pressure 
within the ear canal is varied, the tympanic membrane is subjected to varying degrees of 
stress which alters its mobility. Maximum mobility occurs when the pressure on both sides 
of the tympanic membrane are equal. Changes in tympanic membrane mobility (e.g. otitis 
media or „glue ear‟) will result in a change in the probe tone level within the ear canal.  
The tympanogram is a graphical representation of the relationship of air pressure in 
the ear canal to impedance (resistance to movement) of the ear drum and middle ear 
system. This is plotted on calibrated x- and y-axes; where the x-axis represents the change 
in differential pressure across the tympanic membrane and the y-axis represents the 
mobility or admittance of the middle ear system. The shape of a tympanogram is altered in 
some predictable ways by various ME abnormalities, which are summarised in Table 3.3. 
Tympanograms are classified in one of three ways (Table 3.2). Firstly, it can be 
described according to the shape of the function – whether it is „peaked, flat, rounded etc. 
Secondly, where the location of the compliance peak is obtained and finally according to 
the difference in compliance between the value at +200 (daPa) (or mmH20) and that at the 
peak (static compliance).  
 
Table 3-2 Tympanogram interpretation 
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Jerger Pattern Characteristics Pattern associated with known pathologies 
A Clear peak that occurs at 0 
daPa ± 50 daPa with a base-
peak compliance difference in 
the range of 0.3-1.6 ml 
 
None – normal middle ear status 
As Clear peak that occurs at 0 
daPa ± 50 daPa with a base-
peak compliance difference in 
the range of < 0.3 ml 
Thickened TM 
Adhesions 
Ossicular fixation 
Ad Clear peak that occurs at 0 
daPa ± 50 daPa with a base-
peak compliance difference in 
the range of > 1.6 ml 
Ossicular discontinuity 
Hypermobile TM (usually due to widespread 
atrophic scarring on the TM surface) 
B No clear peak (flat) A number of pathological conditions and 
technical errors can cause this pattern so need to 
consider the shape and the equivalent volume. 
Pathologies that can result in a flat tympanogram 
include: iimpacted cerumen, foreign bodies, 
middle ear effusion, tympanic membrane 
perforation and in-situ and patent grommets 
 
Technical errors include incorrect canal wall 
placement of the probe tip. 
 
C Clear peak  that occurs at > 
100 daPa, with a base-peak 
compliance difference in the 
range of 0.3-1.6 ml 
Eustachian tube dysfunction 
 
Tympanograms were recorded
 
using a 226-Hz probe tone and a positive (+200 
daPa) to negative
 
(–400 daPa) air-pressure sweep using a slow (50 daPa/second) test speed. 
The first test ear was selected at random. The test was repeated if the curve required 
confirmation. Tympanograms were classified according to the British Society of Audiology 
(1992) recommendations (BSA, 1992). 
 
3.4.1.2 Acoustic Reflex Thresholds 
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In a normal healthy ear, middle ear admittance will show a sharp reduction in 
response to a loud acoustic stimulus. This is due to a bilateral contraction of the stapedial 
reflex muscle
19
 which results in an increase in the impedance of the ossicular chain and 
tympanic membrane (Mukerji et al., 2010). The acoustic reflex response depends on 
adequate functioning of the entire reflex arc, including the sensory receptors (cochlea), 
afferent neurons (NVIII), inter-neurons (brainstem – superior olivary complex), efferent 
neurons (NVII) and effector organ (stapedius muscle).  The function of the stapedial reflex 
is still unclear but it is thought that it may confer some (nominal) protection of the inner ear 
from loud sound and have a role in identifying stimulus in continuous background noise. 
For a more in-depth review of this topic see Mukerji et al., (2010) 
Figure 3.5 shows a block diagram of the ipsilateral (same side) and contralateral 
(opposite side) pathways that are thought to generate the response. It is important to note 
that no response is usually observed when there is a conductive loss or in cases of severe or 
profound sensorineural hearing loss. The known influence of peripheral hearing loss clearly 
underscores the need to accurately measure hearing sensitivity when interpreting the ART. 
Figure has been removed due to copyright restrictions 
 
Figure 3-5 Block 
diagram of the 
stapedial reflex arc  
                                               
19 Two small muscles are attached to the ossicles in the middle ear: the tensor tympani and the stapedius 
muscle. The tensor tympani is attached to the malleus near the tympanic membrane and anchored in the wall 
of the Eustachian tube. It is innervated by the trigeminal (fifth) cranial nerve. The stapedius muscle is attached 
to the posterior side of the neck of the stapes and anchored in the wall of the middle ear cavity. It is innervated 
by the facial (seventh) cranial nerve. In humans, only the stapedius muscle contracts to acoustic stimuli; the 
tensor tympani contracts to non-acoustic stimuli such as touch and pressure.  
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Reflex contraction 
following a loud acoustic 
stimulus causes the 
stapes footplate to swing 
outward and backward 
from the oval window.  
This limits the motion of 
the stapes footplate, 
therefore reducing the 
fluid motion in the inner 
ear. This results in an 
increase in resistance 
with which acoustic 
energy can be conducted 
through the auditory 
pathway. Figure adapted 
from Katz (1994). 
 
The acoustic reflex response has a relatively small magnitude, typically resulting in 
a decrease in mobility of >0.02ml when a low frequency probe tone has been used (e.g. 226 
Hz). Because the stapedial muscle contracts bilaterally, stapedial reflex measurements can 
be obtained either ipsilaterally (i.e. the stimulus is presented to the same ear where the 
measurements are made) or contralaterally (i.e. the measurements are made with the probe 
in one ear while the stimulus is presented to the opposite ear through a transducer).  
In this thesis, the acoustic reflex threshold was measured both ipsilateral and 
contralateral to the stimulated ear, with pure-tone stimuli from 500 Hz to 4000 Hz and 
using the GSI33 Middle Ear Analyser (Guymark, UK). For ipsilateral measurements, a 
pulsed tone was used and a steady tone was used for contralateral measurements (Mellott, 
1992).   
ARTs were elicited with pure tones in the following order: 1, 2, 4 and 0.5 kHz. 
Intensity was started at 70 dB and increased in 5 dB steps until a reflex threshold was 
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observed. The intensity of the tone was increased by a further 5 dB in order to observe 
growth of the reflex and then decreased in steps of 5 dB until the reflex disappeared. The 
acoustic threshold was taken as lowest level reflex observed on descending run. The reflex 
threshold was judged subjectively by shape and looking for growth, although a reduction in 
compliance of 0.02ml or more was usually observed (BSA, 1992). 
The reflex was considered elevated for responses > 100 dB HL or abnormal if they 
exceeded 105 dB HL at two or more frequencies or if the inter-aural threshold difference 
exceeded 10 dB on at least two frequencies (Cohen and Prasher, 1988).  Acoustic reflexes 
at 4kHz were not considered as they are frequently absent. The patterns interpreted as 
indicating brainstem lesions were vertical (abnormal ART by stimulation of one ear only), 
horizontal (ART abnormal by contralateral stimulation of both ears), inverted L (combined 
vertical and horizontal) and „full house‟ (all ipsilateral and contralateral reflexes abnormal) 
(Cohen and Prasher, 1988).  
 
3.4.2 Otoacoustic emissions 
Otoacoustic emissions are low-amplitude acoustic responses associated with 
normally functioning cochlear outer hair cells (OHCs) (Kemp et al., 1990) (see Chapter 2). 
As a result of the active non-linear mechanical feedback, acoustic energy is returned from 
the cochlea into the ear canal which can be recorded if a sufficiently sensitive microphone 
is placed in the ear canal. The exact mechanism for the generation of otoacoustic emissions 
is still not clear but there is overwhelming evidence linking the presence of OAEs to the 
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normal functioning of the OHCs
20
. Furthermore, it seems that the efferent system allows for 
some regulation of this mechanism by the CANS (see e.g. Guinan et al., 2010 and Pickles, 
2008 for a review).  
Otoacoustic emissions can be spontaneous or evoked. Spontaneous otoacoustic 
emissions (SOAEs) occur without external stimulation, whilst evoked otoacoustic 
emissions (EOAEs) can be evoked and recorded depending on the stimulus that is selected. 
For example, transient evoked OAEs (TEOAEs) are evoked using a click (broad frequency 
range) or with a brief duration tone burst stimulus. The click stimulus evokes a wide 
frequency range from a healthy cochlea. Distortion product OAEs (DPOAEs) are evoked 
using a pair of primary tones f1 and f2 with particular intensity and ratio (f1: f2) (Robinette 
and Glattke, 2007). 
We chose to employ TEOAEs over DPOAEs for several reasons, namely: 
sensitivity, frequency resolution and speed. Although DPOAE technology has the 
advantage of superior detection of high frequency OAEs, there are several disadvantages in 
using it. Firstly, it suffers from lower frequency resolution and lower noise immunity at low 
frequencies, relative to TEOAEs. This is an important consideration when measuring OAEs 
in children. A more serious practical drawback is the dependence of DPOAE on the precise 
stimulus configuration (frequency and level ratios); for further discussion and a review of 
this topic see Kemp et al., 1990 or Robinette and Glattke, 2007. 
                                               
20  Evidence for this includes (1) OAEs still recorded even when VIIIth nerve is severed or blocked 
chemically, (2) OAEs reverse in polarity along with the stimulus (unlike neural responses) and are affected by 
stimulus rate (3) OAEs are vulnerable to acoustic trauma, hypoxia, and ototoxic medication which cause 
hearing loss and assoc damage to OHCs 
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3.4.2.1 Transient Evoked Otoacoustic Emissions 
The ILO v6 otoacoustic emission analyser (Otodynamics Ltd) was used to generate 
test stimuli and record the TEOAE responses. The ILO v6 is a dual channel machine which 
allows the presentation of two independent stimuli. Channel A provides for a stimulus 
output and a response input while channel B provides stimulus output only. Standard 
TEOAE probes containing a loudspeaker and a microphone were used in each channel.   
Transient evoked otoacoustic emissions (TEOAEs) were recorded and analysed 
using the method proposed by  Kemp and colleagues (Kemp et al., 1990). During the initial 
insertion of the probe (pre-collection mode), a series of stimuli were presented, and the 
stimulus spectrum was derived. If there was substantive ringing in the waveform, stimulus 
spectrum amplitude was low or uneven across the frequency range, or if the OAE analyser 
warned of poor probe fit, then the probe tip was repositioned or changed prior to retesting 
(Norton and Widen, 1990). The probe was calibrated daily using the manufacturer supplied 
1 cm
3
 calibration cavity and software.  
The emission data were obtained using the preset mode with a low-cut filter and a 
stimulus band width of 500 to 5000 Hz. The stimulus intensity across ears ranges from 75 
to 85 dB peak SPL with 50 clicks per second. This type of click stimulus is ideal for 
clinical investigations and capturing low frequency OAEs. The IL0 v6 system was set in 
nonlinear click mode, in which responses to sets of four clicks are subaveraged and 
alternately sent to two different buffers. The non-linear stimulation and signal processing 
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help eliminate stimulus artifacts from the TEOAE response. After 260 subaverages were 
collected on each buffer, the test was complete and was stopped automatically (Kemp et al., 
1990).  During testing, the stimulus is repeatedly presented to the ear. Recordings of this 
type of OAEs use a system of time-synchronous averaging. As a stimulus is presented to 
the ear, the sound in the ear canal is sampled and with continued presentations, new 
samples are averaged with previous samples so that each OAE response is the same. The 
rationale for this system is to reduce any noise or artefacts which are not related to the ear 
and improve the signal to noise ratio. 
The presence of normal OAEs in the 2.5 to 20ms post stimulus period was 
determined by an overall response amplitude signal-to-noise ratio of at least 3dB and 
waveform reproducibility in at least three octave bands of >75% (Hurley and Musiek, 
1994). At least three of the frequency bands were required to be robust to pass this 
criterion.  
 
3.4.2.2 Medial olivocochlear suppression test (MOCS) 
Medial olivocochlear suppression (MOCS) testing provides a non-invasive window 
to allow the study of the centrifugal pathways in the auditory brainstem (Guinan, 2010). 
Suppression occurs as a result of activity of the medial efferent pathways descending from 
the olivocochlear bundle to the OHCs (Chapter 2). Figure 3.6 is a simplified representation 
of the pathways that are implicated in the MOCS response.  
Figure 3-6 Block diagram showing the olivocochlear reflexes to one frequency region in the right 
cochlea*.  
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Figure has been removed due to copyright restrictions 
 
Abbreviations: Dashed lines indicate pathways that have not been conclusively identified or might contain 
additional unidentified interneurons. Some MOC and LOC collaterals are not shown. OHCs, outer hair cells; 
IHC, inner hair cell; AN, auditory nerve; LOC, lateral efferents; MOC, medial efferents.* Figure reproduced 
from Guinan et al., (2006). 
MOCS is measured clinically by comparing OAEs obtained with and without 
introduction of a suppressor stimulus. The suppressor stimulus can be presented 
ipsilaterally, binaurally or more commonly as shown in Figure 3.7, in the ear contralateral 
to the OAE stimulus.   
The suppression of OAEs refers to the reduction of amplitude of acoustic output 
measured at the tympanic membrane (Figure 3.7). The reduction in amplitude is typically 
small – usually between 1-4 dB SPL (Ceranic et al., 1998). It is usually seen soon after 
introduction of the suppressing stimulus and will last as long as the stimulus is present, 
disappearing with the removal of the suppressor.  
Figure 3-7 A simplified representation of MOCS application and analysis* 
In order to accurately measure MOCS, hearing must be greater than 30-35 dB HL with normal ME 
function.*Figure reproduced from www.otoacoustic emissions.com   
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Figure has been removed due to copyright restrictions 
 
 
The functional role and clinical relevance of the efferent auditory system remains 
largely unknown, but current theories include: enhancement of frequency-resolving 
capacity and the vowel discrimination, especially in a background of noisy environment  
and  the optimization of interaural intensity differences for high frequency stimuli (Pickles, 
2008). 
The MOCS is not used routinely in a clinical setting but a number of studies have 
applied it in clinical populations and have found that it is abnormal in auditory neuropathy 
(Starr et al., 1991, Starr et al., 1996, Starr et al., 2001, Hood et al., 2003); e.g.,. in cases of 
acoustic neuroma (Prasher et al., 1994), vestibular neurectomy (Williams et al., 1994), in 
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children diagnosed with auditory processing disorders (Kumar and Vanaja, 2004) and 
tinnitus (Ceranic et al., 1998). Of particular interest to this thesis, is recent work in children 
with hyperacusis that has shown an increased or „hyperactive‟ MOCS response (Veuillet et 
al., 1999, Attias et al., 2008). A similar finding has also been shown in neurodevelopmental 
disorders such as autism (Khalfa et al., 2001, Hitoglou et al., 2010) and musicians 
(Brashears et al., 2003). 
We recorded and analysed the MOCS using the method proposed by (Ceranic et al., 
1998). Briefly, a dual channel otoacoustic emission analyser (Otodynamics) was used, one 
channel (A) for ipsilateral and the other (B) for contralateral acoustic stimulation. For 
ipsilateral stimulation, a linear click at 60 (SD 3 dB) SPL intensity, and for the 
contralateral, broad band noise (0.50-6 kHz) at 40 dB sensation level (SL), were used, 
applying an alternating technique, a "difference B on/off" mode, from the ILO92 software. 
This allows alternating recording of TEOAE responses with and without contralateral 
stimulation. A total of 600 sweeps were recorded, in 10 groups of 60 sweeps. The average 
responses were directly computed and the difference, obtained by their subtraction, 
represented the suppression effect. 
 
3.5 Click evoked Auditory Brainstem Response Measurement 
3.5.1 The generic ABR 
 Earlier in Chapter 2, we introduced the ABR and provided a detailed background 
regarding the neural substrates that generate each of the waveform components (Chapter 2). 
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We considered at some length the effects of maturation on the ABR waveform and then we 
systematically reviewed the scientific literature to explore the relationship between the 
ABR and two atypical eye movement disorders: slow saccades and opsoclonus.  
However, the ABR is strongly dependent on a wide range of stimulus and 
acquisition manipulations, and non-pathological (subject) factors. To accurately measure 
and interpret the ABR depends on an appreciation of how each of these factors interacts 
(for more in-depth treatments of each of these factors see (Suzuki and Yamane, 1982, 
Gorga and Thornton, 1989, Don et al., 1996, Hall, 2007).  
 
3.5.1.1 Stimulus factors 
In order to successfully generate an ABR, a suitable acoustic stimulus must be 
selected. Several acoustic stimuli have been used to record the ABR including clicks, 
chirps, tone bursts and more recently syllable‟s (Dhar et al., 2009, Hornickel et al., 2009a). 
Here we focus our attention on the most commonly used stimulus for ABR measurement – 
the click stimulus.  
Traditionally, the ABR is considered to be an „onset‟ response. As such it is best 
generated when recorded with a very brief acoustic (transient) stimulus (i.e. a stimulus with 
a fast rise and fall time). This rapid onset ensures neural synchronicity. A click stimulus is 
produced by passing a brief square wave through an earphone. This results in a broad 
frequency spectrum with null value at frequencies that are dependent on the duration of the 
square wave. The flatness and upper frequency cut-off of the spectrum are determined by 
the transfer function of the transducer. 
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A myriad of studies have shown that the properties of the click stimulus – such as 
frequency, duration, intensity, rate and polarity – exert a profound and often inter-related 
effect on the ABR. A summary of each of these factors and their effects on the ABR is 
presented in Table 3.3. 
For the majority of our experimental work (see Chapters 4-6), the ABR data was 
collected using an electrical click of about 100μS; with alternating polarity to minimise 
stimulus artefact (the effects of stimulus polarity on the ABR recording are considered in 
more depth in Chapter 7). Stimuli were presented at rate of 11.1 per second. This rate of 
stimulus presentation was selected for two reasons. Firstly, to ensure clarity of the 
waveform, which is paramount in our interpretation of the ABR. Secondly, because the 
waveform definition in our study population may be compromised by the presence of 
brainstem disease; a slower rate helps to recruit the greatest aggregate of VIIIth nerve 
fibres, improving neural synchrony.  
Click stimuli were generated by 100µs rectangular voltage pulses delivered 
monaurally through an insert earphone (EAR-3A). The duration of this stimulus was 
selected because some studies have shown that stimuli with shorter durations can result in a 
reduction in intensity, by as much as 13 dB (Gorga and Thornton, 1989).   Insert earphones 
were  
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Table 3-3 Summary of selected stimulus factors that influence the ABR 
*The definitions presented in this table have been compiled from Hall (2007) 
 
Text has been removed due to copyright issues. 
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used where possible (unless indicated otherwise) for a number of reasons including 
increased interaural attenuation, increased patient comfort and an overall reduction in 
transducer ringing. 
Overall, we were not concerned with using the ABR as a marker of hearing 
thresholds – these were measured using a number of other hearing tests previously, as 
described in sections 3.3 and 3.4.  Therefore, stimulus intensity levels presented for air 
conduction were 80 and 90 dB nHL. These suprathreshold intensity levels were selected in 
order that the ABR would reflect maximal synchronous discharge (i.e. so that, where 
possible, all waveform components would be elicited, reflecting optimal auditory ability, 
see Table 3.3).  
Stimulus intensities were calibrated relative to the averaged behavioural threshold 
of 20 normal hearing adults following the recommended procedure outlined by (Sininger, 
1992). A broadband masking noise of 35-45 dB nHL was applied to the non-test ear to 
prevent a response from the non-test ear due to possible stimulus cross-over from the test 
ear. This was an important consideration in our study given the high stimulus intensities 
that were used to evoke the ABR (Burkard and Hecox, 1983, Burkard et al., 1990a, 1990b).  
 
3.5.1.2 Recording (acquisition) factors 
To measure ABR, a series of stimuli are presented to the ear at a constant rate by a 
transducer. The electrodes pick up the neural response, which is amplified, filtered and then 
averaged by a computer. Continuous recording information recorded at the scalp needs to 
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be converted into a non-continuous digital format. This is achieved by using an analogue-
to-digital converter. The data can then be manipulated using digital filtering and/or artefact 
rejection (elimination of responses if too noisy). A typical ABR experimental set up is 
schematically represented in Figure 3.8.  
 
Figure has been removed due to copyright 
restrictions 
 
 
Figure 3-8 Typical ABR 
experimental set up. 
 
 
 
The greatest challenge when recording the ABR is improving the signal to noise 
ratio. Typically the ABR signal is small – between 0.5 and 50 µV. In contrast, interference 
from noise (either physiological or non-physiological sources) is at least 50 µV. There are 
two possible sources of noise that can contaminate the ABR: physiological noise 
(bioelectrical activity including spontaneous EEG, muscle potentials, cardiac potentials, 
electro-ocular potentials, electrodermal potentials) and non-physiological noise 
(electromagnetic, electrostatic and instrumentation noise). It is not possible to eliminate all 
of these sources of noise from the signal of interest but we can overcome many of these 
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problems by manipulating different acquisition factors during the recording process (see 
Hall, 2007 for a review).  
Detecting the ABR response is also influenced by electrode placement. An electrode 
is a device that makes contact with the body and conducts bioelectrical activity from a wire 
lead to the recording device. The electrodes used in the present study were disposable. 
These were chosen for ease of use and hygiene. Placement of electrodes is usually based on 
the 10-20 system (Hall, 2007). 
For most of the experimental studies (see chapters 4-6), the ABR was recorded 
differentially from four electrodes: subject's forehead (Fpz) as ground; vertex (Cz) (non-
inverting electrode); and both mastoid processes (Ml, M2) as the inverting electrode. A 
single recording channel (vertex and ipsilateral mastoid) was used in all ABR tests. 
Disposable electrodes were used, following skin exfoliation with Nu-Prep. Electrode 
impedances were maintained below 5000 Ω and inter-electrode impedances were balanced 
to within 2000 Ω in order to maximise rejection of common mode signals. 
The EEG inputs were amplified by 100,000 and band-pass filtered from 150 to 3000 
Hz (12 dB per octave roll-off) using a Nicolet Spirit system (Nicolet Biomedical Ltd). In 
order to maintain good resolution, an averaging window of 20ms and an artefact-rejection 
feature (a simple amplitude cut-off, or amplitude limiting, where the noise has a larger 
envelope than signal), set at 25 µV peak to peak, was selected.  
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3.5.1.3  Non-pathologic factors 
In Chapter 2, we examined the influence of maturation and age on the ABR. 
However, a number of non-pathological subject characteristics can also significantly 
influence the outcome of the ABR recording. For example, distinct differences in ABR 
latency and amplitude have been reported for female versus male adults. Females have been 
shown to have shorter peak latency and larger waveform amplitudes (Jerger and Johnson, 
1988, Dehan and Jerger, 1990). This is thought to be due to a combination of head size and 
hormonal influences. When interpreting the ABR, other „human‟ factors that must be 
accounted for include age, hearing sensitivity, body temperature and medication. Table 3.4 
presents a summary of the non-pathological factors that may impact on the ABR.  
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Table 3-4 Summary of selected non-pathologic factors that are known to influence the ABR 
Non-pathologic factors Effect on the ABR Reference 
Age 
Older adults show an increase in ABR peak and interpeak latencies and a 
decrease in amplitudes despite considerable variability in hearing thresholds. 
Jerger et al., (1988); Psatta et al., 
(1988) 
 
Gender 
Significant differences in latency reported for males and females. Males have 
been shown to have longer peak and inter-peak latencies and smaller 
amplitudes than females. 
Dehan et al., (1990); Keith et al., (1987) 
Hearing sensitivity 
With increasing hearing loss, ABR components have been shown to increase 
in latency and decrease in amplitude. This finding is further complicated by 
an interaction between aging and gender. 
Jerger et al., (1988);  
Body temperature 
Latencies of ABRs increase and amplitudes decrease with lower 
temperatures. The opposite is observed in cases of hyperthermia. 
Hall et al., (1988); Koshi et al., (1990); 
Rodriguez et al., (1995); 
Rodriguez et al., (1999) 
Drugs/medications 
Few drugs have been reported to have any effect on the ABR. Some drugs 
used for anaesthesia or as a sedative have been reported to effect ABR 
latency. Ototoxic drugs (e.g) chemotherapy agents, alcohol etc can result in 
hearing loss, particularly a high frequency hearing loss and should always be 
checked prior to undertaking an ABR. 
Hall (2007) 
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3.5.1.4 Interpreting the click-evoked ABR 
To record the ABR, all participants reclined comfortably in an acoustically and 
electrically shielded booth. In order to help minimise the effects of any myogenic noise 
on the ABR, participants were instructed to relax fully, paying particular attention to 
their neck, shoulder and jaw muscles. They were advised that they could sleep if desired 
and to tell the tester should any of the test signals become uncomfortably loud. No 
sedatives were administered during any of the recordings. Two averages were made at 
each test signal and the presence of reproducible components was defined. A third 
replication was carried out if there was any uncertainty in the result.  
Three measures are commonly used when interpreting the ABR – latency, 
amplitude and morphology. These measures are defined and quantified as follows:   
 Latency refers to the length of time (usually specified in ms) between the 
introduction of the stimulus and the elicitation of the response. In this thesis, 
we report two measures of latency: absolute latency and interpeak latency.  
 Amplitude refers to the magnitude (usually specified in µV) of each 
waveform component. In this these we report the absolute peak amplitude. 
  Morphology refers to the overall appearance, shape and reproducibility of a 
waveform.  
Each waveform response represents an average of 2048 stimulus presentations 
over a 20-ms analysis window. A normal ABR was determined by the examination of 
absolute latencies of waves I, III and V, and inter-wave latencies of I-III, III-V and I-V. 
The amplitude of waves I, III and IV/V (measured from the most positive peak of the 
fused IV/V complex to the vertex negative peak after wave V) were also measured. 
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4 Chapter 4 
Characterising the ‘audiological phenotype’ in children diagnosed 
with Gaucher Disease 
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4.1 Introduction  
Lysosomal storage diseases (LSD) are a group of rare disorders characterised by 
a deficiency in a single lysosomal enzyme or essential cofactor. This deficiency results 
in the abnormal accumulation of one (or more) natural compounds within the lysosome. 
Although individually rare, these „orphan‟ diseases collectively represent a group of 
more than 40 inheritable disorders – affecting as many as 1 in 5000 births (Meikle et al., 
1999). As a consequence, the LSD are the commonest cause of paediatric 
neurodegenerative disease (Aerts et al., 2003).  
The most prevalent subgroup of LSD‟s are the glycosphingolipidoses (GSLs). 
These are inherited disorders that are characterised by excessive accumulation of one or 
multiple (glyco)sphingolipids. This group includes gangliosidosis, Niemann-Pick 
disease types A and B, Gaucher‟s disease, Farbers disease, Fabry‟s disease, 
metachromatic leukodystrophy, multiple sulphatase deficiency, Krabbe‟s disease,  and 
sphingolipid activator protein deficiency. With one exception (Fabry disease, which is 
X-linked) all GSLs have an autosomal recessive inheritance pattern (Meikle et al., 
2006). 
These disorders pose a major challenge to the clinician – most become manifest 
during early infancy or childhood and present with a wide array of neurological signs 
and symptoms. These signs and symptoms can include seizures, respiratory distress, 
hypotonia, loss of motor skills, regression in developmental milestones, disturbed vision 
and impaired oculomotor function and deafness. Many of these signs occur as a direct 
result of neurological damage to brainstem circuits in the auditory and oculomotor 
centres, for example, the exaggerated startle response (beginning between ages 3-6 
months) observed in Tay-Sachs disease (Kaback and Desnick, 1993) or the abnormal 
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vertical saccades, which is the hallmark of Niemann-Pick type C disease (Higgins et al., 
1992, Patterson et al., 2007).  
Diagnosis is particularly challenging in these disorders – because the same 
disease can have many different presentations (phenotypes) depending to some extent 
on the age of onset and the stage of development of the child‟s nervous system. The 
clinical picture is further complicated by our incomplete understanding of the 
pathophysiological processes which trigger many of these diseases.  
While there have been significant advances in treatments for this group of 
diseases, our lack of suitable, quantitative tests to measure the neurological status in 
many of these patients remains a significant barrier to the early detection and diagnosis 
in many cases (Whitfield et al., 2005, Cachon-Gonzalez et al., 2006, Cox, 2010a). We 
will revisit this issue later in this chapter (see section 4.4) and again in Chapter 5.  
In Chapter 1 of this thesis, we proposed that combined multimodal measures 
(eye movements and audiological tests) had a wide application in baseline diagnostic 
assessment and longitudinal monitoring of patients in clinical trials or on treatment for 
many neurodegenerative disorders. In this chapter, we begin to develop this argument 
by reviewing recent work on eye movement and audiological investigations in Gaucher 
disease (GD).  
Gaucher disease (GD) is the prototypical GSL caused by a deficiency in the 
enzyme, glucocerebrosidase. This rare disease is characterised by the accumulation of 
the substrate glucocerebroside (glucosylceramide, ceramide β-glucoside) in 
macrophages (Gaucher cells) in the spleen, liver, bone, lungs and brain. Phenotypical 
features are markedly varied, but symptomatic GD patients typically manifest an array 
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of systemic signs including hepatosplenomegaly, anaemia, thrombocytopenia, growth 
retardation, lung and bone disease (Grabowski et al., 2004, Vellodi et al., 2009).  
The majority of patients‟ exhibit only systemic signs (non-neuronopathic) and 
are usually classified as having Type 1 disease (GD1). However, approximately 5% of 
all GD cases will exhibit additional primary neurological signs (neuronopathic disease). 
These signs include eye movement abnormalities, auditory abnormalities, myoclonus, 
abnormal EEG/ seizures, cognitive impairment and progressive bulbar palsy (Harris et 
al., 1999, Goker-Alpan et al., 2003, Goker-Alpan et al., 2005, Goker-Alpan et al., 
2008). The clinical features of GD are displayed in Table 4.1. 
Table 4-1 Summary of the clinical features reported in GD. 
Abbreviations: OMIM = Online Mendelian Inheritance in Man; PME = progressive myoclonic epilepsy; 
SIF = saccade initiation failure; + signs refer to the degree of involvement; - lack of involvement 
 
Why have we chosen to study GD? There are two reasons. Firstly, the abnormal 
eye movements seen in nGD are considered by many clinicians to be the universal 
indicator of the neurological (neuronopathic) subtypes (nGD). Audiological 
abnormalities have also been described in nGD (Dreborg et al., 1980, Bamiou et al., 
2001, Grasso et al., 2006), although there is little agreement as to whether audiological 
Phenotype OMIM Primary CNS 
Involvement 
Bone 
Disease 
Other 
Type 1 
(Non-neuronopathic) 
230800 
Parkinsons Disease? 
Cognitive impairment? 
+ 
Splenomegaly 
Hepatomegaly 
Cytopenia 
Pulmonary Disease 
Type 2  
(Acute or infantile) 
230900 
Bulbar signs 
Cognitive impairment 
Pyramidal signs 
_ 
Splenomegaly 
Hepatomegaly 
Cytopenia 
Pulmonary Disease 
Dermatological 
changes 
Type 3 
(Neuronopathic; Subacute; 
Juvenile) 
231000 
SIF 
PME 
Seizures 
Cognitive impairment 
+ 
Splenomegaly 
Hepatomegaly 
Cytopenia 
Pulmonary Disease 
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investigations could be considered reliable tests of neurological involvement in GD 
(Benko et al., 2011). Clearly further studies examining the potential role of auditory 
studies, particularly those that test the integrity of brainstem pathways are required. 
Secondly, GD has been hailed as a disease with “totemic significance for the 
development of orphan drugs” (Cox, 2010, p 299). Clearly, any novel insights in this 
rare neurodegenerative disorder may be directly applicable to the multitude of other 
„orphan‟ diseases. 
We begin this chapter by providing a detailed clinical description of GD, paying 
particular attention to the abnormal eye movements which are considered a hallmark of 
the neuronopathic subtypes (Harris et al., 1996, Harris et al., 1999). We then outline 
what is known experimentally about the use of eye movement and audiological 
techniques from the published literature relating to the diagnosis of GD, and draw 
attention to those results most relevant to the thesis, before introducing our empirical 
data. 
We consider two issues in this chapter:  
1. Firstly, we ask whether audiological tests when coupled with eye movement 
studies, can be used to provide reliable subclinical and pre-symptomatic tests of 
neurological involvement in GD? The inclusion of such studies may provide 
important clues in understanding the pathophysiology in GD. 
2. Secondly, we ask whether the use of these combined tests will enable us to 
correctly distinguish between phenotypes. If the tests are sensitive enough, can 
they help reduce the phenotype-genotype discordancy that has been extensively 
described in this disease?  
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4.2 Gaucher Disease – clinical phenotypes 
Historically, GD has been subdivided into one of three possible phenotypes – 
based upon the age of presentation and whether or not any primary neurological signs 
were observed (Table 4.1). This resulted in GD being classified as either: type-1 (GD1) 
without primary neurological involvement; type-2 (GD2) with severe neuronopathic 
disease leading to death by the 3rd year; or type-3 (GD3) with less severe and more 
variable neurological involvement (Table 4.1).  
Since one of the objectives of this chapter is to determine whether the 
application of auditory testing can be used to improve phenotypic identification (section 
4.1), we now expand upon each of these phenotypes in more detail to provide context 
for our later discussion. 
 
4.2.1 Type 1 Gaucher disease (GD1)  
Type 1 Gaucher disease (GD1)
21
 is the most common type of GD with an 
estimated prevalence of  1:200,000 (Weinreb et al., 2008). It is relatively common 
across all ethnic groups but several studies have shown an increased incidence in the 
Ashkenazim Jewish population (Diaz et al., 2000, Koprivica et al., 2000). Studies in this 
population have estimated an increased frequency of  1 in 5000  with a carrier frequency 
as high as approximately 1 in 10 (Cox et al., 2008).  
GD1 is highly variable in onset and severity. Some patients may show 
symptoms in infancy, while others may be asymptomatic and only come to medical 
                                               
21 This phenotype has been variously referred to in the literature as „adult‟ GD, non-neuronopathic GD 
and type 1 GD. See Table 4.1 for a description of the clinical features of this phenotype. To avoid any 
confusion, we shall refer to this subtype as GD1. 
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attention because of affected relatives (Lachmann et al., 2004, Cox et al., 2008, Cherin 
et al., 2010). For this reason, the reported frequency of GD1 is probably underestimated 
(Cox et al., 2008).  
Typically this phenotype will only have systemic disease (or rarely secondary 
neurological problems). The most common systemic signs include splenomegaly, 
thrombocytopenia, hepatomegaly and bone disease (Table 4.1). Atypical bone pain, 
pathological fractures, avascular necrosis and bone crisis are frequently reported 
(Grabowski et al., 2004). Secondary neurological signs including sciatica, paraesthesia, 
muscle weakness, cramps and tremor have also been widely reported in GD1 patients 
(Pastores et al., 2003). 
The traditional view of this phenotype, as one without primary neurological 
involvement, has recently been challenged. CNS signs have been reported in GD1 
patients, often later in adult life (Miller et al., 1973, Neudorfer et al., 1996, Tayebi et al., 
2001, Guimaraes et al., 2003, Cherin et al., 2010, Giraldo et al., 2011). Neurological 
signs in this „adult-onset form‟ (or late-onset neuronopathic subtype), have been 
reported to manifest anywhere from 17 – 55 years of age (Tayebi et al., 2001, 
Guimaraes et al., 2003).  
Atypical Parkinson symptoms (PD) have also been widely described in the 
literature (Alfonso et al., 2007, Biegstraaten et al., 2008, Alonso-Canovas et al., 2010, 
Cherin et al., 2010, Giraldo et al., 2011).  This „akinetic-rigid syndrome‟ was reported 
as co-existing with other neurological signs including cognitive impairment in 19/60 
cases; myoclonus in 2/60 cases, dementia and abnormal horizontal eye movements in 
3/60 cases. A crucial assumption underlying each of these studies is that patients were 
correctly phenotyped (i.e. correctly identified as having non-neuronopathic disease). As 
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we will show later in this chapter (See section 4.4.4.2), it is possible that many of these 
studies, in the absence of formal eye movement studies, had failed to correctly 
distinguish the GD1 patient from the GD3 patient (Harris et al., 1999). 
 
4.2.2 Type 2 Gaucher disease (GD2) 
Type 2 Gaucher disease (GD2)
22
 is a significantly less common but more severe 
form of the disease. Estimates of the frequency of classic GD2 disease in the general 
population have ranged widely from 1 in 100,000 to 1 in 500,000 births (Grabowski, 
1993). The onset of the disease is usually in the first year of life and the affected infant 
typically presents with severe systemic disease and extensive neurological impairment, 
particularly in the brainstem. GD2 patients are usually seen clinically as an infant who 
is failing to thrive and recurrent infections. Hypertonicity, organomegaly, and bulbar 
palsy are common clinical findings (Table 4.1). The complications arising from the 
relentless brainstem deterioration usually results in early demise, typically by the age of 
two years.  
More recently, a lethal perinatal phenotype associated with ichthyosis or 
collodion skin and hydrops fetalis has been found (Church et al., 2004). This group of 
infants have little, if any, detectable β-glucocerebrosidase activity and survival is not 
tenable (Finn et al., 2000, Stone et al., 2000). The mechanisms contributing to the 
devastating neurological manifestations seen in GD2 remain unknown. However, 
auditory electrophysiological abnormalities have been reported in an infant as young as 
7 weeks old (Lacey and Terplan, 1984). It therefore seems plausible that neurological 
                                               
22 This subtype has also been called infantile‟ or „acute‟ GD. The more severe neonatal form characterised 
by foetal hydrops and ichthyosis has been called the Collodion baby. In this thesis, we shall refer to this 
severe phenotype as GD2. 
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damage may be present prenatally in these cases. This is supported by the recognition of 
a prenatal lethal form of the disorder (Finn et al., 2000).  
 
4.2.3  Type 3 Gaucher disease (GD3) 
Type 3 Gaucher disease (GD3)
23
 is neuronopathic disease that is less severe than 
GD2. Systemic disease is always present, but it is often more severe than systemic signs 
seen in GD1 and is usually evident in early infancy. Typically the neurological 
progression seen in GD3 is much slower than in GD2 but the degree of neurological 
involvement is highly variable (Table 4.1). For example, neurological signs may 
initially be absent or not recognised for years, and progression may be very slow and 
insidious, resulting in psychometric decline, oculomotor deficits, ataxia, myoclonus, 
epilepsy and dementia (Dreborg et al., 1980, Beutler and Grabowski, 1995).  
 
4.2.4 Distinct phenotypes or part of a continuum? 
“These observations raise an important question: Why is there such vast phenotypic 
variation in this presumably single gene disorder” (Sidransky, 2004, p7) 
More recently, these phenotypic distinctions have been extended and blurred in 
the neuronopathic subtypes, (Abrahamov et al., 1995, Stone et al., 2000, Goker-Alpan et 
al., 2003). Figure 4.1 shows a highly simplified representation of the clinical subtypes 
and the spectrum of varying phenotypical signs and symptoms that have been reported.  
 
                                               
23 This neuronopathic subtype has also been referred to as „juvenile‟ or sub-acute‟ GD. GD3 has been 
further subtyped into GD3a, GD3b and GD3c. For a detailed review of these different subdivisions see 
Abrahomov et al., (1995) or Patterson et al., (1993). Throughout this thesis, we shall simply refer to this 
phenotype as GD3.  
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Figure 4-1 Proposed model of phenotypical traits across GD 
 
Figure has been removed due to copyright restrictions 
 
Clearly, the question arises as to whether there is a similar continuum between 
neuronopathic and non-neuronopathic disease (Biegstraaten et al., 2008). Systemic 
disease tends to be more severe in the neuronopathic subtypes than in non-
neuronopathic phenotype, implying that GD1 patients may have very mild and 
undetected neurology (Cherin et al., 2010, Giraldo et al., 2011). This is supported by 
recent audiological electrophysiological studies in GD1 (Perretti et al., 2005, Grasso et 
al., 2006). Unfortunately, these studies fail to mention how the initial phenotype 
diagnosis of type-1 disease was reached, other than on „clinical grounds‟ (Perretti et al., 
2005, Grasso et al., 2006).  
One of our core aims in this chapter is to examine whether the use of combined 
eye movement and audiological investigations can improve the phenotype/genotype 
discordancy that has been previously described in this disease. 
 
4.3 Genotypes 
In the previous section, we described a wide variation in the different 
phenotypes that have been reported in GD. However, we have discussed little, if 
anything at all, about the corresponding genotype. We begin to address this matter in 
this section. 
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The glucocerebrosidase gene was mapped to a large gene on chromosome 1 q21-
23 in 1985 (Ginns et al., 1985). Since then more than 200 different disease-causing 
mutations have been identified (Grabowski and Horowitz, 1997, Koprivica et al., 2000). 
However, it is still not possible to make the diagnosis of GD by genotyping alone.  
Most alleles are rare. However four mutations – N370S, L444P, 84insG and 
IVS2 have been frequently identified and account for the majority of cases, but there are 
wide ethnic variations (Grabowski and Horowitz, 1997). For example, the N370S and 
84GG alleles account for over 80% of GD in the Ashkenazi Jewish population, 
permitting screening for the disorder in this group (see Koprivica et al., 2000 for a 
review), but less than 45% in German, Spanish, Portuguese and British non-Jewish 
populations (le Coutre et al., 1997). In Japanese patients these alleles appear to be 
absent (Ida et al., 1995).  
In contrast, the L444P mutation accounts for about 3% of mutant alleles in 
Ashkenazi Jewish populations, but about 25% in non-Jewish Caucasian populations and 
44% in Japanese patients (Ida et al., 1999). In the genetically isolated region of 
Norrbottnian in Sweden all patients are homozygotic for the L444P allele. These ethnic 
distributions probably reflect founder effects.  
The relationship between genotype and phenotype is surprisingly discordant for 
reasons that are unclear, but it is clear that the extensive heterogeneity observed 
between patients cannot be explained by a mutation in the glucocerebrosidase gene 
alone. Genetic background and other environmental factors must also play an important 
role. Figure 4.2 presents a summary of these factors.  
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Figure 4-2 Schematic showing the proposed relationship between phenotypic expression and other 
factors that may influence disease expression in GD 
 
Figure has been removed due to copyright restrictions 
 
4.3.1 Genotype-Phenotype correlation? 
 
The remarkable variability seen in phenotype expression has severely impeded 
the diagnostic and prognostic value of genotyping. Nevertheless, some broad 
generalisations can be made based on the literature. For example, several studies have 
shown that the N370S allele is highly correlated with a mild form of the disease. Both 
heterozygotes and homozygotes appear to be free from neuronopathic signs and 
symptoms (Grabowski and Horowitz, 1997). As such, it is thought that even a single 
copy of this allele may confer some degree of „neurological protection‟. Other 
mutations such as R463C and R496H have also been associated with „mild‟ disease. 
In direct contrast, the L444P allele is strongly associated with neuronopathic 
disease. Studies have shown that 68% of GD3 and 48% of GD2 mutant alleles are 
L444P (L444P/N370S appears to be non-neuronopathic). Other mutations such as 
V394L and D409H have also been observed in cases of GD with more severe 
phenotypes.  
However, the relationship between genotype and phenotype in the majority of 
GD patients is imperfect. For example, although the majority of L444P homozygotes 
demonstrate neuronopathic disease, some apparent type 1 phenotypes have been 
reported (Kawame et al., 1993, Sidransky et al., 1994, Ida et al., 1995, Beutler and 
Gelbart, 1996, Hatton et al., 1997). It is possible that some patients may have been 
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incorrectly identified as L444P/L444P due to failure to detect a recombination with the 
pseudogene. However, even with more elaborate genotyping techniques, some papers 
have reported some L444P homozygotes as having non-neuronopathic phenotype 
(Germain et al., 1998).  
This picture is further complicated, not only by inaccurate genotyping, but by 
the persistent failure to correctly establish the phenotype in the first instance (Harris et 
al., 1999). This is supported by recent epidemiological work which estimates that only a 
small proportion of GD patients (10-20%) are correctly diagnosed and treated (Niederau 
et al., 2001). Clearly, it is imperative to develop sensitive quantitative measures that are 
able to detect subtle neurological abnormalities before irreversible overt signs appear. In 
this thesis, we propose that combined eye movement and auditory testing may offer a 
solution to this long-standing dilemma.  
 
4.4  Diagnosis of GD 
Throughout this chapter, we have made mention of the diagnostic challenges 
that face clinicians working with these rare orphan diseases. Until now, we have 
concentrated our discussion solely on the varying genotype and phenotypes that have 
been described in the literature. At this point in the thesis, we must consider in more 
detail how GD is diagnosed and, of more relevance to this thesis, we must address the 
question – how do we diagnose neuronopathic GD?   
Until recently, diagnosis was based primarily on a clinical examination and an 
invasive bone marrow biopsy (Brady and Schiffmann, 2004). The presence of Gaucher 
cells in the biopsied sample, was considered confirmatory of the disease. Misdiagnosis 
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was frequent, as cells masquerading as Gaucher cells (pseudo-Gaucher cells), were also 
reported in a number of other conditions (Bain and Lee, 2010).
24
  
The definitive diagnosis of GD is now made using relatively non-invasive blood 
tests measuring levels of glucocerebrosidase activity in leucocytes or alternatively from 
skin fibroblasts (Grabowski et al., 2004, Vellodi et al., 2009). Lowered 
glucocerebrosidase activity (between 0 and 30% of normal values) is considered 
diagnostic of GD. Other testing (e.g. DNA testing) is also routinely measured in 
asymptomatic homozygotes and carriers in close relatives of affected individuals 
(Vellodi et al., 2009).  
 
4.4.1 Diagnosing neuronopathic disease 
Although a simple blood test is now all that is required in order to diagnose GD, 
there is no evidence to show that this biomarker is able to differentiate between non-
neuronopathic and neuronopathic phenotypes (Vellodi et al., 2009). Identifying the 
correct phenotype is based partially on genotype and partially on phenotype but as we 
have already remarked upon earlier in this chapter, there is limited value in this 
approach.  
The clinical hallmark of neuronopathic disease is early brainstem disease (Table 
4.1). Signs of brainstem involvement can include oculomotor abnormalities, dysphagia 
resulting in feeding problems, apnoeic episodes, laryngeal stridor due to bulbar palsy 
and abnormal auditory brainstem responses (Schiffmann et al., 1997, Goker-Alpan et 
al., 2005, Vellodi et al., 2009). The most widely accepted phenotypic indication of 
                                               
24 Pseudo-Gaucher cells have also been described in sickle cell anaemia, chronic granulocytic lymphoma, 
and Hodgkin‟s disease. 
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neurological involvement is the presence of specific eye movement abnormalities 
(Schiffmann et al., 1997). However, as Harris and colleagues (1999) have shown, it is 
all too common for eye movement abnormalities to remain undetected, resulting in 
patients with GD3 being erroneously labelled as having GD1. The long term 
consequences of these misdiagnoses are as yet unknown
25
.  
 
4.4.2 The importance of correct phenotyping in GD 
Major advances have been made in developing treatments for GD. As a result of 
this remarkable progress, GD has become a prototype for treatments for a number of 
related orphan diseases (Elstein, 2011). Figure 4.3 presents a summary of the currently 
available therapies that have been developed or are currently undergoing clinical trials. 
The introduction of enzyme replacement therapy (ERT) (Cerezyme®) – a recombinant 
human glucocerebrosidase expressed in genetically engineered Chinese hamster ovary 
cells – was at the forefront of this revolution. Prior to the availability of ERT in the 
early 1990s, no specific or curative treatments were available for GD.  
Figure 4-3 A summary of current treatments that have been developed or are in development for 
use in GD. 
                                               
25 There is a substantial literature that has recently been published following the contamination of one of 
the sites responsible for manufacturing ERT. This dramatic event saw world-wide rationing of ERT. It is 
possible that these studies may allow us a „window‟ to examine this issue further (see e.g. Cox et al., 
2010; Hollak et al., 2010 for a review). 
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Hailed as a „pharmaceutical blockbuster‟ by many investigators, ERT has been 
shown to clearly reverse many of the systemic manifestations of GD, but its therapeutic 
effect on the neurological component is much less certain (Cox and Schofield, 1997). In 
vitro studies have shown that the exogenous enzyme should work, but there is limited 
human data to support this (Pelled et al., 2000). A more recent therapeutic development 
is substrate depletion using N-butyldeoxynojirimycin (OGT 918; Zavesca®; (Platt et al., 
1994, Platt and Jeyakumar, 2008). Clinical trials of Zavesca® have shown significant 
amelioration of hepatosplenomegaly and haematological manifestations in GD1 patients 
(Cox et al., 2000). It is still not known whether it can reverse the neurological deficits in 
nGD. We will address this issue in more depth in our next chapter (Chapter 5). 
Current therapeutic 
developments  
in GD 
Enzyme augmentation  
(e.g. aglucerase) 
Genetically engineered 
enzyme augmentation  
(e.g. imiglucerase) 
Biosimilar protein 
agents 
Velaglucerase-alfa 
Taliglucerase 
Substrate depletion 
(inhibitor) therapy 
Miglustat 
Eligustat tartrate 
Pharmacological 
chaperone therapy 
Gene therapy 
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The development of these new treatments
26
 has also placed an imperative on the 
early distinction between different phenotypes (non-neuronopathic and neuronopathic 
disease) to allow the appropriate treatment to commence as soon as possible. Patients 
with neuronopathic disease require a higher dose of ERT to slow down the neurological 
progression of the disease (Vellodi et al., 2001, Vellodi et al., 2009). 
Treatments for GD are prohibitively expensive. As a result, it is estimated that 
only a minority of GD patients (10% or currently 5000 patients world-wide) have access 
to treatment (Cox, 2010b). The extreme cost also precludes high-dose treatment for all 
GD patients, making it absolutely essential to correctly identify the phenotype
27
. 
Scientific investment in the development of objective markers, such as saccadic and 
auditory measures, that allow the early accurate identification of the neuronopathic 
phenotype are urgently required. In the following sections, we consider these two 
objective assessments in more detail and critically evaluate their current utility in the 
diagnosis of GD. 
 
4.4.3 Eye movement signs in neuronopathic GD 
Patients diagnosed with nGD demonstrate specific saccadic eye movement 
abnormalities. These were first described by Reiss and Kato in 1932
28
. Since then a 
                                               
26 The development of new enzymatic preparations, velaglucerase alfa (VPRIV™) and taliglucerase alfa 
(UPLYSO™), as well as alternative treatments substrate reduction and pharmacological chaperones, are 
important additions to the management portfolio of this disease. A review of the therapies in GD is 
beyond the scope of this thesis but a number of excellent reviews are available (see Cox 2010). 
 
27 Annual average costs to treat an adult Gaucher patient with ERT is of the order of £100,000 and in the 
early debulking phases of the illness, about £200,000 per annum (Cox, 2010). 
 
28 Reiss and Kato described abnormal gaze (abduction defect or 6th N palsy) in two cases of GD. 
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variety of eye movement abnormalities in neuronopathic GD have been described in the 
literature (Herrlin and Hillborg, 1962, Kraoua et al., 2011). These include: 
 Horizontal SIF (hSIF) (Schiffmann et al., 1997, Harris et al., 1999, Altarescu 
et al., 2001b) 
 Slow horizontal saccades (Harris et al., 1999, Park et al., 2003, Goker-Alpan 
et al., 2005) 
 Vertical SIF (especially downward) (Miller et al., 1973, Cogan et al., 1981, 
Garbutt and Harris, 2000) 
 Slow vertical saccades (especially downward) (Miller et al., 1973, Cogan et 
al., 1981, Garbutt and Harris, 2000) 
 Abnormal vestibulo-ocular reflex (Miller et al., 1973, Dreborg et al., 1980)  
 Strabismus  (Dreborg et al., 1980, Erikson and Wahlberg, 1985, Vivian et 
al., 1993, Bembi et al., 1994, Harris et al., 1999) 
 6th N paresis (Miller et al., 1973, Winkelman et al., 1983, Erikson and 
Wahlberg, 1985, Vivian et al., 1993)  
The combination of SIF and slow saccades are widely accepted to be a 
diagnostic sign of neuronopathic disease in a patient already diagnosed with GD. The 
onset of saccade abnormalities in unknown – in GD2, the onset is probably in utero 
(Stone et al., 1999, Tayebi et al., 1999, Finn et al., 2000, Stone et al., 2000, Gupta et al., 
2010). The onset in GD3 is also unclear, although it appears to be very early (Cox-
Brinkman et al., 2008).  Clearly the earlier the onset of the disease, the more difficult it 
will be to accurately diagnose without the use of objective, non-invasive measures.  
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A number of studies have also reported that atypical eye movements are often 
„precocious‟, preceding other neurological signs, often by many years (Harris et al., 
1999, Garbutt and Harris, 2000, Accardo et al., 2010). Interestingly, ABR abnormalities 
have also been reported in very young nGD patients (as young as 7 weeks old in GD2; 
and 5/12 in GD3) (Lacey and Terplan, 1984, Cox-Brinkman et al., 2008). This makes 
oculomotor (and potentially auditory) testing a very useful diagnostic tool, but it also 
raises the important question as to why these irreplaceable brainstem circuits are so 
vulnerable to GD neurotoxicity.  
The major abnormalities in nGD are difficulties in triggering horizontal and 
vertical (especially downward) saccades and a consistently severe degree of saccadic 
slowing. Harris et al., (1999) has argued that this combination of abnormalities almost 
certainly reflects brainstem dysfunction, consistent with post-mortem studies (Kaga et 
al., 1982, Kaga et al., 1998) and the other obvious brainstem signs seen in advanced 
cases of nGD (Akdag et al., Conradi et al., 1991, Patterson et al., 1993, Cox and 
Schofield, 1997, Michelakakis et al., 2002, Goker-Alpan et al., 2003, Gupta et al., 2010, 
Kraoua et al., 2011).  
At this juncture in the thesis, we will limit our discussion and focus only on the 
most common eye movement abnormalities in GD – saccade initiation failure (SIF) and 
slowing of saccadic eye movements which we have discussed extensively, earlier in 
Chapter 2. 
4.4.3.1 Saccade Initiation Failure (“ocular motor apraxia”) in GD 
Saccade initiation failure (SIF) is a difficulty in triggering or generating a 
saccade (Vivian et al., 1993, Harris et al., 1996, Harris et al., 1999, Cassidy et al., 
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2000a). This rare defect has been referred to in the literature as „ocular motor apraxia‟, 
„supranuclear gaze palsy‟, „looping‟, or „saccade initiation failure‟ (SIF) (Harris et al., 
1996, Harris et al., 1999).  
In neuronopathic subtypes, the triggering mechanism responsible for initiating 
horizontal eye movements (h-SIF) appear to be preferentially affected, making it 
extremely difficult for the child to shift their gaze along the horizontal plane (i.e.) from 
left and right. Although the horizontal and vertical saccade centres are anatomically 
remote from each other, a number of studies have also shown that vertical eye 
movements (particularly downward SIF) can also be impaired in nGD (Miller et al., 
1973, Garbutt and Harris, 2000). This usually occurs in the more advanced stages of the 
disease (Benko et al., 2011), but there have been no systematic studies examining this 
issue.  
Two adaptive strategies have evolved to compensate for this defect in gaze: a 
hypermetric head movement (head-thrust)
29
 and synkinetic blinking
30
 (Harris et al., 
1999). These overt signs are strongly suggestive of neuronopathic disease in a child 
already diagnosed with GD. These adaptive strategies are not pathognomonic of h-SIF 
but a number of clinicians incorrectly attributed these signs as evidence of 
neuronopathic disease (Harris et al., 1999). One study that clearly underscores the need 
for objective measurement in nGD is outlined in Harris et al., (1999). They recorded eye 
movements in a group of 8 enzymatically diagnosed GD children. They found SIF in 6 
                                               
29 In a head-thrust the patient rotates the head rapidly in the direction of the peripheral visual target. These 
very large head movements drive the eyes to the mechanical limit of gaze (lock-up) and allow them to 
drag gaze over to the target. Once the target is foveated the head is then returned to the straight-ahead 
position while the VOR keeps the eyes on target. For an excellent review of this topic see Cassidy et al., 
(2000) or Harris et al., (1999). 
 
30 Synkinetic blinking (SB) is a compensatory mechanism in which the child is able to initiate a saccade 
by a blink. SB is difficult to detect and the underlying mechanism is unclear. See Rottach et al., 1998 for 
a review on the effects of blinking on the saccadic system. 
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cases – leading to the diagnosis of GD3 in 2 young children who were too ill for reliable 
clinical examination, and a revision of diagnosis from GD1 to GD3 in 3 cases.  
The pathophysiology of SIF is still unknown although there is a substantial 
literature implicating a number of CNS structures including the brainstem (Shawkat et 
al., 1995). This topic is reviewed extensively in Harris et al., (1999).  
 
4.4.3.2 Saccade Slowing 
Although SIF has considerable diagnostic value when properly assessed, it is 
difficult to use as a longitudinal quantitative measure.  An alternative measure that is 
more suited for monitoring purposes is saccade slowing. When saccades can be 
generated, most neuronopathic patients will also exhibit slow horizontal saccades 
(Harris et al., 1999, Park et al., 2003, Goker-Alpan et al., 2005). In advanced cases of 
GD2, no saccades are made, so it is impossible to measure their speeds (Vivian et al., 
1993).  
Few studies have successively managed to record saccades in uncooperative 
patients or in children younger than 6 to 7 years of age. As we will show later in this 
chapter, there is a paucity of saccadic data, particularly in children (Stowens et al., 
1982, Grafe et al., 1988, Gross-Tsur et al., 1989, Harris et al., 1996, Garbutt and Harris, 
2000) and even fewer quantitative examinations (Harris et al., 1999, Garbutt and Harris, 
2000, Cohen CS, 2001, Garbutt et al., 2001). One study has shown that the saccades are 
grossly slow in four children diagnosed with GD3. Interestingly, horizontal saccades 
were of a normal speed in the single GD1 case (Harris et al., 1999). We have 
summarised the available quantitative studies of GD in Table 4.2. 
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We highlighted earlier in Chapter 2 of this thesis that measurement of saccade 
speed is very difficult to detect by simple clinical observation alone. This view is 
endorsed by a retrospective case study review of 32 L444P homozygote patients 
outlined in Goker-Aplan et al., (2005). They reported that slowed horizontal saccades 
were a common finding in these patients but were not always documented at the time of 
diagnosis. For example, in two cases, slow horizontal saccades were detected several 
years (11 years in one case and 27 years in another) after the initial diagnosis.   
There are two possible explanations for this finding. Either abnormal eye 
movements are not always adversely affected in neuronopathic disease or more likely – 
as we show later in this chapter – that in the early stages of the disease, it is not easy to 
clinically differentiate between GD1 and GD3. This is because neurological signs in 
GD3, particularly abnormal eye movements are subtle and easy to miss without precise 
measurement. 
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Table 4-2 Summary of previous studies that have formally assessed eye movements in GD. 
Author Year N= 
Age 
(yr) 
Sex 
Study 
design 
Genotype Phenotype Treatment? EM Summary of key findings 
    M F       
Cogan et al.   1981 4 5/12 
– 1 
3 1 CR - GD3 SPL AB ¾ cases had eye movements that „simulated‟ congenital 
OMA. Similar age of onset. Headthrusts routinely 
observed. Vertical movements relatively spared. In one 
case eye movements were the presenting sign of GD (at 
5 months). 
Vivian et al.    1993 1 40884 1 - CR - GD2 - AB HSIF and VSIF reported. The presence of a functional 
sensory visual pathway was indicated by the presence of 
flash ERGs and pattern reversal EPs. 
Harris et al.    1996 1 NR -  CS NR GD2 NR AB Investigated a wide group of children with OMA using 
objective eye movement studies. The infant diagnosed 
with infantile GD never exhibited any saccades or quick 
phases. 
Harris et al.   1999 8 - -  CS L444P. GD1 and 
GD3 
ERT AB Measured EOG and video – revised GD diagnosis for 
patients with GD1. 
Garbutt and 
Harris  
2000 7 - - 7 CS NR 1 GD1, 1 
GD2, 5 
GD3 
NR AB Vertical saccade initiation failure (in either direction, 
up/down, or both). 
Garbutt et al.   2001 1 NR NR NR CR NR GD3 NR AB OKN quick phases had a longer duration and lower peak 
velocity compared with the age matched control  
OKN quick phases may be a simple means for 
approximating the main sequence and thus a useful 
clinical tool for identifying brainstem pathology.  
Accardo et 
al.   
2005a 1 3.5 - 1 CR L444P/F213I Initially 
diagnosed 
as GD1 – 
revised to 
GD3 
ERT AB Record and quantify the saccadic eye movements in the 
case of a 3.5-year old cooperative child who was 
affected by GD. 
Accardo et 
al.   
2005b 15 19694 NR NR CS (?) NR GD1 ERT N* Main sequence and saccade latency were WNL in all 
GD1 cases. *But authors report anomalies in number of 
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Author Year N= 
Age 
(yr) 
Sex 
Study 
design 
Genotype Phenotype Treatment? EM Summary of key findings 
oscillations in the velocity profile in 8/5 cases. 2/8 cases 
later developed seizure activity but no clinical details 
given.  
Capablo et 
al.   
2007 1 5 1 - CR L444P/E326K+, 
N188S 
Initially 
diagnosed 
as GD1 – 
revised to 
GD3 
1o ERT but 
followed with 
comb 
ERT/SRT 
N? Neurological signs first seen at age 23 years – seizures. 
No „oculomotor paralysis‟ observed clinically Combined 
therapy resulted in progressive improvement of his 
neurologic picture was observed. Walking a short 
distance (20 m) with aid became possible again. 
Cox-
Brinkman et 
al.   
2008 3 
sib 
Birth- 
1.5 
1 2 CR L444P 
homozyg. 
GD3 1
o
 ERT but 
followed with 
comb 
ERT/SRT; 
One case has 
only had comb 
therapy 
AB in 
all 
cases# 
#Diagnosed with „partial OMA‟ initially in one case 
(this later deteriorated and h-SIF and v-SIF recorded); 
one case had no observable OMA until age 15 mo which 
also deteriorated. The final case also had slow saccades 
and „partial OMA‟. Authors report neurological signs 
stabilised in all 3 cases following combined therapy. 
Accardo et 
al.   
2010 2 - - 2 CR R353G 
homozyg. 
GD3? Miglustat AB Quantitative measure of miglustat in GD by estimating 
the characteristic parameters of saccadic main sequence. 
Miglustat treatment effective and resolved SEM.   
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4.4.4 Are abnormal eye movements truly diagnostic of neuronopathic disease?  
Several investigators have also recently questioned whether there is value in 
distinguishing between the phenotypes – arguing that the division between the three 
phenotypes is no longer valid, particularly with emerging evidence that patients with 
GD1 may have neurological disease – albeit with a later onset in many cases (Cherin et 
al., 2010, Giraldo et al., 2011).  
More importantly with regards to this thesis, a number of studies have also 
asserted that eye movements are also abnormal in some patients with non-
neuronopathic disease (Miller et al., 1973, King, 1975, Harris et al., 1999, Ida et al., 
1999, Garbutt and Harris, 2000, Tayebi et al., 2001, Tayebi et al., 2003, Varkonyi et al., 
2003, Goker-Alpan et al., 2004, Wong et al., 2004, Accardo et al., 2005a, Accardo et 
al., 2005b, Alfonso et al., 2007, Capablo et al., 2008, Goker-Alpan et al., 2008, Accardo 
et al., 2010, Alonso-Canovas et al., 2010).  
These studies clearly contradict those investigators who have made the claim
31
, 
that SIF (and by association, slow saccades) are an „obligatory feature‟ or a „universal 
finding‟ in patients diagnosed with neuronopathic disease (Schiffmann et al., 1997, 
Altarescu et al., 2001b, Frei and Schiffmann, 2002, Goker-Alpan et al., 2003, Vellodi et 
al., 2009, Benko et al., 2011).  
This discrepancy is highly disconcerting – particularly as we have already 
clearly emphasised in Section 4.4.2, that the nosology of nGD is determined by the 
presence or absence of abnormal eye movements. Clarification of this issue is 
particularly important as classification of patients with GD as one type or another is 
                                               
31 It could be argued that this claim is based on opinion and/or clinical experience alone and is therefore 
unsupported. At the time of writing, there is no published study which has systematically evaluated the 
evidence for this statement. 
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used to predict the outcome or response to treatment and more importantly, the correct 
level of dose.  
In the following sections, we examine the available scientific literature to see 
whether there is any evidence to support the theory that GD1 and GD3 are not distinct 
phenotypes on the basis of eye movement studies.     
 
4.4.4.1 Do non-neuronopathic GD patients have abnormal eye movements? 
We undertook a systematic review of the available literature, using the electronic 
database PUBMED. The search strategy, inclusion and exclusion criteria are shown 
separately in Appendix 2. Sixty-five papers published across a 40-year period (from 
1970-2010) reported eye movement abnormalities in GD (Appendix 2). Of these, a total 
of 17 studies (26%) reported atypical eye movements in patients diagnosed with GD1. 
We present the key findings from each of these studies in Table 4.3.  
The data provided four possible interpretations – each of which may explain 
why abnormal eye movements are reported in GD1. These include: a) application of 
outdated phenotype classifications b) incorrect phenotyping and lack of qualitative 
measurements resulting in misdiagnosis; c) co-morbidity and d) late-onset disease 
associated with PD. We now provide a discussion on each of these below. 
 
4.4.4.1.1 Application of outdated phenotype classification  
Historically, GD3 was considered to be restricted to children and adolescents, 
i.e. GD was categorised on the basis on age of disease onset, hence the terms „infantile‟ 
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and „juvenile‟. However, over time it has been recognized that neurological 
involvement in GD3 sometimes emerges in adulthood. Before this recognition, several 
case reports have described patients with GD1 disease and adult-onset neurological 
manifestations (Miller et al., 1973, King, 1975, Tayebi et al., 2001) who could better be 
classified as late-onset GD3. 
 
4.4.4.1.2 Incorrect phenotyping and lack of qualitative measurements 
resulting in misdiagnosis 
A number of studies shown in Table 4.4 have published case reports in which 
patients originally thought to be GD1 were misdiagnosed and which required revision to 
GD3 (Harris et al., 1999, Ida et al., 1999, Tayebi et al., 2001, Accardo et al., 2005a, 
Accardo et al., 2005b, Capablo et al., 2008, Accardo et al., 2010). Furthermore, several 
studies have regrettably published little (if any) detail regarding how they obtained their 
eye movement results. For example, Alfonso et al., (2007) reported eye movement 
disorders in 3 cases but failed to provide any specific details about the type of 
abnormalities or how these were measured.  Furthermore it is not clear whether these 
patients had a revised diagnosis (from GD1 to GD3) or what their neurological course 
was.  
  
4.4.4.1.3 Co-morbidity known to be associated with nervous system diseases 
A third explanation for the abnormal eye movements seen in Table 4.4 is the 
existence of co-morbid neurological disease (Garbutt and Harris, 2000, Accardo et al., 
2010). For example, Accardo et al., (2010) describe atypical eye movements in two 
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patients with epilepsy. The seizure activity was initially considered „casual‟ in both 
cases but led to a revised diagnosis, from GD1 to GD3, in one case
32
. Garbutt and 
Harris (2000) reported vSIF in a child diagnosed with GD1 who had normal horizontal 
OKN responses. An MRI scan in this child revealed a lesion in the rostral midbrain with 
the appearance of an old haemorrhage. This presumably was the cause of the vSIF. Both 
of these examples lend strong support for our argument in this thesis for the 
development and application of additional tests in phenotype identification.  
 
4.4.4.1.4 Late-onset disease associated with PD. 
A relatively new obstacle that may impede correct phenotypic classification is 
the case of the GD1 patient who develops Parkinsonism and abnormal horizontal 
saccadic eye movements (Tayebi et al., 2001, Tayebi et al., 2003, Varkonyi et al., 2003, 
Alonso-Canovas et al., 2010); see our earlier discussion in section 4.2.1. Eye movement 
abnormalities especially in the saccadic eye movements, are also associated with 
Parkinsonism, although they usually develop when the disease progresses (Zee, 1986, 
Leigh and Zee, 1999a). Unfortunately, it is unclear whether the abnormal eye movement 
signs seen in this small group of GD1 patients are present before the onset of 
Parkinsonism or whether they are developed in the course of Parkinsonism. This most 
likely reflects the lack of precise quantitative eye measurements. This is clearly 
illustrated in a study described by Tayebi et al.  (2001).  
                                               
32  It is of interest that the treatment for seizures (barbituates) used in one of these cases may have 
accounted for the slow saccades in one case but it is not clear whether the authors of this study accounted 
for the potential side-effects of this treatment. 
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Here the authors report what they describe are the initial signs of neurological 
involvement (Parkinson-like neurological signs) in a 42 year old woman with GD1.  
They say that  
“…we were not able to establish whether the oculomotor abnormality preceded 
the parkinsonian symptoms, although the patient always had to move a book in order to 
read” (p319).  
It is not clear whether these sporadic cases should still be classified as GD1 in 
the presence of neurological symptoms such as Parkinsons. Biegstraaten et al. (2008) 
has argued that while  
“the term non-neuronopathic Gaucher disease does not seem to be an 
appropriate characterization of type I Gaucher disease. However, the neurological 
signs and symptoms in type I Gaucher disease are of a totally different kind from and, in 
the majority of cases, of much less severity than the signs and symptoms associated with 
types II and III disease” (p337). 
Clearly, clarification of this issue and a world-wide consensus on correct 
phenotyping, using precise quantitative procedures, is urgently required to prevent 
further confusion in this area. 
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Author Year N= Genotype Phenotype Treatment? 
Eye 
movements 
Recording 
method 
Summary of key findings 
         
Miller et al.    1973 2 - GD1 - AB C First report of oculomotor disturbances in GD in adult siblings. First 
neurological signs observed were seizures and deterioration in IQ. 
King 1975 1 - GD1 - AB NR PME – first sign of neurological involvement. Saccadic eye movements 
„slow‟ in all directions. Authors concluded that this case was evidence 
for neurological involvement in the „adult‟ phenotype of GD. 
Harris et al.  , 1999 8 L444P MIX ERT AB O Revised diagnosis in 2 cases 
Ida et al.   1999 15 MIX MIX NR AB in 4/15  C No significant details available other than evidence of abn eye 
movments 
Garbutt and 
Harris  
2000 7 NR 1 GD1, 
1 GD2, 
5 GD3 
NR AB O Vertical saccade initiation failure (in either direction, up/down, or 
both). 
Tayebi et al.   2001 1 L444P/ 
D409H 
GD1 SPL 
ERT 
 
AB C First neurological signs were PD at age 42 yrs.  
Her eyes could fix and follow, but she had difficulty initiating 
movements and had almost no horizontal saccadic eye movements. 
Pursuit was only possible with a great deal of blinking.  
„We were not able to establish whether the oculomotor abnormality 
preceded the parkinsonian symptoms, although the patient always had 
to move a book in order to read. This distinction is relevant because the 
longevity of children and adolescents with type 3 Gaucher disease and 
oculomotor abnormalities is now increased due to enzyme replacement  
therapy and it will be important to closely monitor these patients for 
movement disorders.‟ (p319) 
Accardo et al.   2005
a 
1 L444P/ 
F213I 
Initially 
diagnosed 
as GD1 – 
revised to 
GD3 
ERT AB O Record and quantify the saccadic eye movements in the case of a 3.5-
year old cooperative child who was affected by GD. 
Accardo et al.   2005
b 
15 NR GD1 ERT N* O Main sequence and saccade latency were WNL in all GD1 cases. *But 
authors report anomalies in number of oscillations in the velocity 
profile in 8/15 cases. 2/8 cases later developed seizure activity but no 
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Table 4-3 Selected  eye movement studies that have reported that GD1 patients with abnormal oculomotor signs. 
 
clinical details given.  
Alfonso et al.   2007 19
3 
 178 GD1 
7/193 GD2 
8/193 GD3 
NR AB in 3/178 
GD1 
 
NR characterise the GBA mutations and analyze 
genotype/phenotype relationships in 193 unrelated patients from the 
Spanish GD Registry 
Capablo et al.   2007 1 L444P/ 
E326K+ 
N188S 
Initially 
diagnosed 
as GD1 – 
revised to 
GD3 
1o ERT but 
followed 
with comb 
ERT/SRT 
Norm O Neurological signs first seen at age 23 years – seizures.No „oculomotor 
paralysis‟ observed clinically but they note bilateral blepharospasm. 
During the following 12 months of combination therapy,a progressive 
improvement of his neurologic picture was observed; visceral and 
laboratory parameters of the disease remained stable or improved , 
myoclonic epilepsy improved, and tonic–clonic seizures decreased. 
Sleep, speech, and swallowing, as well as social interaction, also 
improved markedly. Walking a short distance (20 m), with aid, became 
possible again. 
Accardo et al.   2010 2 R353G  
homozyg. 
GD1 
initially 
but this 
was 
revised in 
1 case to 
GD3 
following 
onset of 
EM 
abnorm. 
ERT 
initially but 
followed 
with SRT 
alone 
AB O Serial eye movement recordings made using limbus eye tracker. 
Normal control data also presented. Both cases  had seizures in 
adolescence but this was considered 'casual' . One case showed no 
further neurological signs later in life and EM studies were always 
normal. The second case however showed a deterioration in EM on the 
main sequence but this improved after 2 years of SRT. 
Alonso-
Canovas et al.   
2010 1 N370S/ 
L444P 
GD1 ERT AB Check video 
[C] 
Authors report a case of atypical parkinsonism with apraxia and 
supranuclear gaze abnormalities in GD1. There was difficulty in 
initiating eye movements and a supranuclear gaze abnormality with 
restriction and hypometric saccades, especially in the vertical plane. 
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4.4.4.2 Do neuronopathic GD patients have normal eye movements? 
Only four studies (6%) that we included in this review actually reported that 
patients diagnosed with GD3 had normal eye movements (Chabas et al., 1995, Erikson 
et al., 1995, Ida et al., 1999, Suwannarat et al., 2007). We have presented a summary of 
these studies in Table 4.4.  
The data from this small group of studies was plagued by inconsistent reporting 
and a lack of any formal eye movement measurement. For example, the patient 
described by Suwarannet et al., (2007) with „normal‟ eye movements was the youngest 
in a series of four GD3 patients. The same patient (who presented at 0.65 years) and was 
described as „asymptomatic‟ and „appeared normal‟ on the physical exam was later 
described in the same publication as showing signs of „devastating neurological 
regression‟ (p349). Regrettably, no further details are made available33 (Suwannarat et 
al., 2007). In another study, undertaken in a series of 8 patients diagnosed with GD3 
L444P homozgygotes, the authors describe gaze abnormalities in 7/8 cases. They note 
that the single case that had no eye movement abnormalities had in their opinion „type 1 
disease‟ (p 204) as she did not display any other neurological signs except a general 
slowing on her EEG (Erikson et al., 1995).  
None of these studies have objectively measured the eye movements in their 
patients despite incontrovertible evidence to show that it is easy to miss abnormal eye 
movements based on purely clinical observation. There is insufficient evidence from 
these studies to conclude that neuronopathic GD patients (at this time) have normal eye 
movements.  
                                               
33 The information regarding this patient is limited and the authors report that the patient developed 
seizures at 11 months. No further mention is made regarding eye movements or how they are measured.  
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Table 4-4 Previous eye movement studies that have reported normal eye movements in GD3 cases. 
 
Author Year Genotype Phenotype Treatment? Summary of key findings 
      
Chabas et al.   1995 D409H GD3  Three sisters suffering from an unusual form of Gaucher's disease are described. 
These patients had cardiovascular abnormalities consisting of calcification of the 
ascending aorta and of the aortic and mitral valves. Neurological findings included 
ophthalmoplegia and saccadic eye movements in two patients, and tonic-clonic 
seizures in the third. The three patients died, two of them after having undergone 
aortic valve replacement. Tissue was obtained from one of the sibs and fibroblast 
and liver beta-glucocerebrosidase activity was reduced to 4% and 11% of mean 
normal values. Genotype analysis indicated that the patient was homozygous for the 
D409H mutation.  
Erikson et al.   1995 L444P GD3 NR Reported 1 case as having normal eye movements although some speculation 
regarding neurology 
Ida et al.   1999 MIX Varied NR Normal eye movements in some cases, although no clear discussion of how SEM 
measured 
Suwarannet 
et al.   
2007 F2131 in 3 
cases  and 
various 
mutations 
AB in 3 
cases of 
GD3 
NR Report SIF in 3 cases and normal eye movements in one case classed as GD3 who 
was asymptomatic at initial diagnosis (later developed seizures). 
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4.4.5 Auditory signs in GD 
There are comparatively fewer studies that have investigated the auditory system 
in GD. The majority of these studies have used the ABR to investigate brainstem 
involvement in GD. We have constructed a series of tables that summarise these studies 
across the three different GD phenotypes (see Table 4.5 for ABR studies in GD1; Table 
4.6 for ABR studies in GD2 patients and Table 4.7 for ABRs performed in GD3 
patients). 
As we discussed previously in Chapter 2, the ABR is a well-validated measure 
for testing the integrity of auditory brainstem pathways which has been available since 
the early 1970s as a clinical tool. However, we could find only five studies that have 
measured the ABR in GD1 patients (Ida et al., 1999, Accardo et al., 2005a, Pensiero et 
al., 2005, Grasso et al., 2006, Accardo et al., 2010); seven studies in GD2 patients 
(Kaga et al., 1982, Lacey and Terplan, 1984, Vivian et al., 1993, Kaga et al., 1998, Ida 
et al., 1999, Grasso et al., 2006, Miyata et al., 2006) and eight studies in GD3 patients 
(Abrahamov et al., 1995, Schiffmann et al., 1997, Altarescu et al., 2001a, Aoki et al., 
2001, Bamiou et al., 2001, Goker-Alpan et al., 2005, Grasso et al., 2006, Cox-Brinkman 
et al., 2008). 
All of the ABRs recorded in GD2 have been reported as abnormal (Kaga et al., 
1982, Lacey and Terplan, 1984, Kaga et al., 1990, Kaga et al., 1998), corresponding to 
histopathological abnormalities of loss of neuronal cells and gliosis in the CN and SOC 
(Lacey and Terplan, 1984, Kaga et al., 1998).  
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Table 4-5 A comparison of previous studies investigating the ABR in GD1 patients 
 
Author Year 
N= 
 
Age 
(onset) 
Yrs 
Sex Genotype Treatment SIF? Hearing Recording method Conclusions 
    
M F     Stim Rate 
 
Intensity 
 
Waveforms 
shown? 
 
Ida et al.   
 
1999 4 
1 - 5 yrs 
and 3/12 
3 1 
L444P 
homozyg. 
ERT (11/12) 
 
BMT (1/12) 
N 
(4/12) 
 
 
Hearing loss 
in 2/12 
cases 
 
? normal in 
other cases 
NR NR NR N 
12 cases originally diagnosed as 
GD1 – of these, 9/12 cases later 
developed neurological signs. 
ABRs recorded only in 4/12 cases 
and was abnormal in the 2 cases 
which later developed additional 
neurological signs.  
No detail given regarding 
abnormalities seen. 
Accardo 
et al.   
 
2005a 1 3.5 - 1 
L444P/ 
F213I 
ERT Y NR NR NR NR N 
Initially diagnosed as GD1 – 
revised to GD3. ABR showed 
abnormal morphology with poor 
repeatability and increased 
latencies. 
No details about abnormalities. 
Perretti 
et al.    
(2005) 
 
2005 16 
3yr -48 
yr 
6 10 various NR N NR Click 11/s 
65 dB 
SL 
Y 
ABR recorded in 16 cases (11 
adults and 5 children)  
5/16 ABRs abnormal 
Peak latencies and amplitudes not 
reported. 
Grasso et 
al.    
2006 54 NR 26 28 NR NR NR 
HL reported 
in 13/54 
cases of GD1  
Click 11.1/s 
≥90 dB 
nHL 
Y 
ABR abnormal in 1/54 and 
elongated in 8/54 GD1 cases 
Peak latencies and amplitudes not 
reported. 
Accardo 
et al.   
2010 2 
16-22 
yrs 
- 2 
R353G/ 
R353G 
ERT & 
comb SRT 
Y  NR NR NR NR N Normal 
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Author Year 
N= 
 
Age 
(onset) 
Yrs 
Sex Genotype Treatment SIF? Hearing Recording method Conclusions 
    
M F     Stimuli Rate Intensity 
Waveforms 
shown? 
 
Kaga et al.   1982 1 6/12 1 - NR None Y NR 
Click 
 
10/s 
NR 
 
Y 
Delayed waveforms and loss of 
waves III-V. 
Lacey and 
Terplan  
1984 1 Birth 1 - NR None Y NR 
Click 
 
10/s 
65, 80, 
88 dB 
N 
Wave I-II present; wave III only 
present at intensity of 88 dB. 
Vivian et 
al.   
 
1993 1 7/12 1 - NR None Y NR NR NR NR N 
Report a “major disturbance of 
function in aud. pathways 
through the upper part of the 
brainstem” 
No other details reported 
Kaga et al.   
 
1998 1 Birth - 1 NR None Y 
„poor  
response‟ 
NR NR NR Y 
Wave I-II present at normal 
latencies and loss of waves III- 
V. 
Ida et al.   1999 3 
3/12 – 
5/12 
1 2 
L444P/ 
L444P 
NR Y NR NR NR N N 
Abnormal ABR in 1 case; ABR 
not examined in the other 2 cases 
Miyata et 
al.   
 
2006 
1 
 
18/12 - 1 ? NR Y NR NR NR NR N 
Abnormal ABR 
Lesions in CN 
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Table 4-6 A comparison of previous studies investigating the ABR in GD2 patients 
 
Grasso et 
al.    
2006 5 NR 4 1 NR NR NR NT Click 
11.1
/s 
≥90 dB 
nHL 
Y 
ABR abnormal in all cases with 
absent IV-V bilaterally. As the 
disease progressed the ABR 
showed a gradual loss of waves 
II and III. 
Peak latencies and amplitudes 
not reported. 
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The picture is less clear in GD1 and GD3 patient groups. For example, several 
investigators have compared the ABR findings in GD3 and while some degree of 
similarity has been identified, several inconsistencies have also been reported. Patients 
with GD3 may have normal ABR waveforms or delayed/absent waves II-V and ERT 
may stabilise the ABR findings in some cases (Schiffmann et al., 1997), although they 
have not been thoroughly investigated. We explore the utility of the ABR as a marker of 
treatment efficacy in our next chapter. 
The discrepancies seen in the GD1 and GD3 literature may reflect 
methodological differences (different stimuli, intensity, stimulation rates, polarity) or 
different recording techniques (montages) may have lead to different conclusions. 
Generally the recording method is never reported (Table 4.5 and 4.7) and a description 
of waveform analysis is typically missing. Furthermore other essential auditory 
investigations are often not performed. For example, many of these studies have never 
established that the peripheral hearing mechanism required to generate an ABR is 
normal (Schiffmann et al., 1997, Altarescu et al., 2001b, Perretti et al., 2005). 
More recently, it has been claimed that patients with GD1 have sub-clinical 
neurological signs as indicated by audiological measurements (Perretti et al., 2005, 
Grasso et al., 2006). Clearly, as we mentioned earlier in Section 4.4.4, the finding of 
neurological abnormality in non-neuronopathic disease (similar to those seen in GD3 
disease) is highly significant. However, before we can accept these data, two important 
issues need to be carefully clarified: a) the questionable diagnosis of neuronopathic 
disease in this study and b) the dubious interpretation of their ABR and other 
electrophysiological data. We begin to address these questions later in this chapter. 
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Author Year N= 
Age 
(onset) 
Yrs 
Sex Genotype Treatment SIF? 
Normal 
Hearing 
Recording method Conclusions 
    
M F     Stimuli Rate 
 
Intensity 
 
Waveforms 
shown? 
 
Abrahamov 
et al.    
1995 12 2-20 7 5 
D409H/ 
D409H 
NR Y NR NR NR NR N 
ABRs all normal but no data 
presented 
Schiffman et 
al.    
1997 5 3 – 8 4 1 
L444P/ 
L444P in 
3/5, 
D409V/ 
RecNciI in 
1/5 and 
U in 1/5 
3/5 partial 
SPL 
ERT 
Y NR NR NR NR N 
3/5 children had normal ABRs;  
1/5 had wave I only;  
1/5 had delayed latencies and 
developed hyperacusis. 
Altarescu et 
al.   
2001 21 
8/12 – 
35 yrs 
12 9 various ERT Y NR NR NR NR N 
ABRs recorded in all 21 cases: 
11/21 patients were reported with 
normal ABRs, of which only 2 
showed deterioration. Of the 
remaining 10 with abnormal 
ABRs, there was no deterioration, 
and 2 even showed improvement 
with ERT. 
No details about abnormalities 
Aoki et al.   2001 1 8/12 1 - 
L444P 
homozyg. 
ERT Y  NR NR NR NR N 
Wave I only present at baseline  
After 12 months waves, I-II, IV-V 
on one side and wave V on other 
ear were observed. 
Bamiou et al.    
 
2001 
9 
 
3.3 – 
11.7 
1 8 
L444P 
homozyg. 
in 8 cases, 
Pending in 
1/9 
ERT 
BMT (2) 
Y 
Normal in 
all 9 cases 
 
Click 
 
11.1/s 
90 - 100 
dB nHL 
N 
ABR abnormal in 6/9 cases 
Abnormalities incl delayed 
waveforms and absent waves 
from II-V. 
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Table 4-7 A comparison of previous studies investigating the ABR in GD3 patients 
Goker-Alpan 
et al.   (2005) 
2005 32 
2/12-
2.5 
 
15 17 
L444P 
homozyg. 
9/32 SPL 
2/32 BMT 
23/32 ERT 
Y NR NR NR NR N 
ABR abnormal in 9/32 cases; 
normal in 10/32 cases and NA in 
13/32 cases 
 
 
Grasso et al.    2006 8 NR 4 4 NR NR NR 
HL 
reported in 
1/8 GD3 
case 
Click 11.1/s 
Min 
intensity 
of 90 dB 
nHL 
Y 
ABR abnormal in 3/8 cases of 
GD3 cases 
Peak latencies and amplitudes not 
reported. 
Cox-
Brinkmann 
et al.    
2008 
3 
sib 
Birth- 
1.5 
 
1 2 
L444P 
homozyg. 
1o ERT but 
followed with 
comb 
ERT/SRT 
One case has 
only had 
comb therapy 
Y NR NR NR NR N 
Serial ABRs undertaken. 
In case 1  - initially a normal 
ABR reported which became abn 
(absent wave IV/V and prolonged 
I-III); 
Case 2 – report a „grossly 
abnormal ABR‟ – waves I and V 
only 
Case 3 – mildly prolonged 
waveforms which were later 
reported as normal following 
comb therapy. 
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What is clear from the data presented across Tables 4.5 and 4.7 is that there is 
still no agreement as to whether audiological investigations could be a sensitive marker 
of disease burden with some studies reporting a wide range of latency abnormalities 
(Schiffmann et al., 1997) and other reporting normal ABRs in GD3 patients (Altarescu 
et al., 2001b). Despite these differences, there are common trends in the data that 
appear. It would seem from the limited data that the ABR is always abnormal in severe 
neuronopathic disease (GD2). Furthermore, it would seem that the ABR may be able to 
detect even subtle neurological changes in the less severe neurological subtypes. More 
importantly, the potential role of the ABR as an outcome measure for monitoring 
neurological disease is also unclear. We will examine this issue later in Chapter 5 of this 
thesis.  
A number of other auditory abnormalities have been reported in the scientific 
literature. These include: 
 Sporadic reports of hearing loss (conductive and sensorineural) in some cases 
(Dreborg et al., 1980, Grasso et al., 2006, Alfonso et al., 2007) 
 Middle ear reflexes are absent or elevated (Bamiou et al., 2001, Grasso et al., 
2006) 
 Suppressed or absent medial olivocochlear suppression (Bamiou et al., 2001) 
 Hyperacusis has also been reported (Schiffmann et al., 1997) 
In summary, much of the published literature which has investigated auditory 
function in GD is characterised by a poor description of experimental paradigms, often 
providing limited data regarding data processing methods and criteria. Clearly, there is a 
need to undertake a more systematic approach. In this first experimental chapter, we 
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begin to address this issue by undertaking a systematic assessment of auditory function 
by carrying out investigations on a wide range of GD patients, with known eye 
movement status
34
. Our primary aim in this study is to construct a fuller, more complete 
„audiological profile‟ of the possible effects of GD on auditory pathways. 
 
4.5 Methodology 
4.5.1 Subjects 
Twenty five cases diagnosed with GD were identified from referrals to the 
Metabolic unit at Great Ormond Street Hospital. Diagnosis of GD had been previously 
made by demonstration of deficient β-glucosidase activity either in peripheral 
leucocytes or fibroblasts (See section 4.4 for a description of this process). Table 4.8 
summarises the clinical features of each of the patients.  
Subjects were classified into 3 phenotypic groups based on enzymatic or DNA 
analyses in conjunction with a thorough history and physical examination and a 
complete oculomotor assessment by an experienced clinician.  Group 1 (cases 1-7; n=7) 
consisted of seven non-neuronopathic (GD1) patients (age range 6-17 years, 5 females). 
Group 2 consisted of neuronopathic patients (cases 8-21, n = 18) and included two GD2 
patients (cases 8-9, 2 females) and twelve GD3 patients (cases 10-21; 8 females). The 
data presented was collected over a four year interval from 2002 to 2006. 
An equal number of age (within 6 months) and gender-matched children (n=25, 
15 females, 18month – 17 years; mean age – 8 years) with normal hearing threshold 
levels (normal pure tone audiogram and tympanometry) with no known predisposing 
                                               
34 Some of the discussion presented in this chapter has appeared in two papers (Campbell et al., 2003; 
2004). 
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factors for hearing loss were used as controls (Appendix 2). Control subjects were 
initially recruited using convenience sampling, (e.g. posters and emails with information 
about the project were sent to co-workers and colleagues known to the investigators). In 
the latter stages of the study, controls were recruited using snowballing techniques.  
Ethical Committee approval was obtained for the study and informed consent was 
obtained from the parents of the younger children and from the older subjects 
themselves. 
A history of ear disease was reported in 7/25 cases of GD. All of the 7 cases who 
identified a hearing loss in the case history were categorised as neuronopathic GD 
(n=2/7 GD2; n=5/7 GD3). Both cases with the GD2 phenotype were reported as having 
fluctuating problems with their hearing, although it was unclear whether the hearing 
problems were the result of intermittent middle ear infections or difficulty accurately 
recording hearing thresholds as a result of tracheostomy in both cases. In the remaining 
5 cases, only case 11 had been fitted with binaural hearing aids. The other 4 cases had a 
history of middle ear disease which would resolve spontaneously or required treatment 
with antibiotics. None of these cases had ever required surgical intervention (i.e. 
grommets).  
Interestingly, case 17 reported having been diagnosed as profoundly deaf and 
was fitted with hearing aids. The hearing aids were later withdrawn, when it was noted 
that the hearing aids were causing discomfort and hearing was later discovered to be 
within the normal range. 
The modified listening profile is a 36-item checklist, typically administered by 
the parents and/or teachers and is designed to identify possible listening difficulties in 
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children. It does this by asking the observer (parent or educator) to compare the child to 
a reference population of other children of similar age and background. The profile 
concentrates on six different listening conditions (noisy, quiet, ideal, multiple inputs, 
auditory memory/sequencing, and auditory attention span) described in Appendix 3. 
Parents (or educators working directly with the child) were asked to judge 
whether or not the child had „more‟ difficulty than other children in each listening 
condition using a five point scale (i.e.) did they feel that their child had 1) less 
difficulty, 2) same amount of difficulty, 3) more difficulty, 4) considerably more 
difficulty or 5) doesn‟t function at all when compared to children of similar age and 
background. The overall responses for each child are summarised in Table 4.8.   
The questionnaire was completed and returned in 17/21 cases. The questionnaire 
was not administered to four families (cases 8, 9, 15 and 24) simply because the child 
involved was too young.
35
 The questionnaire was not returned in four other cases (cases 
4, 10, 11 and 21).  
All children diagnosed with non-neuronopathic GD children reported either 
having „less difficulty‟ or „the same amount of difficulty‟ in each of the six listening 
conditions (n=6) (Table 4.8). Interestingly, several concerns were identified using the 
                                               
35 The questionnaire requires that the parent or teacher compare the listening behaviour with their peers. 
Four of the cases enrolled in the study were too young and were not attending nursery or school, therefore 
any comparison of their listening behaviour would not have been possible. 
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Table 4-8 Summary of patient clinical characteristics 
If a parent or educator indicated that the child had „less difficulty‟ or „same amount of difficulty‟ then listening in that condition was not considered to be concern. However, if 
parents or educators ticked the boxes showing either „more difficulty‟, „considerably more difficulty‟ or „doesn‟t function at all‟, then that was considered a concern. Abbreviations: 
BMT – Bone marrow transplant, ERT – enzyme replacement therapy, F- female, HL – hearing loss, M- male, N – No, Norm – normal, NR – no response, SIF – saccade initiation 
failure, Y – Yes.  
Case 
Age 
(yrs) 
Sex 
Neurological 
Signs 
Genotype Phenotype Treatment 
Ear 
problems? 
Problems/Concerns reported in the listening profile?  
       
 Noise Quiet Ideal Multiple 
inputs 
Auditory 
memory/sequencing 
Auditory 
attention span 
1 6 M None N370S/U 1 ERT N N N N N N N 
2 8 F None N370S/U 1 ERT N N N N N N N 
3 14 M None L444P/R463C 1 ERT N N N N N N N 
4 15 F None U/U 1 ERT N NR NR NR NR NR NR 
5 12 F None U/U 1 ERT N N N N N N N 
6 7 F None R463T/53bp del 1 ERT N N N N N N N 
7 17 F None N370s/84gg 1 ERT N N N N N N N 
8 2 F SIF L444P/c1263del55 2 ERT Y NR NR NR NR NR NR 
9 1.5 F SIF L444P/U 2 ERT Y NR NR NR NR NR NR 
10 4 M SIF, epilepsy L444P/L444P 3 ERT N NR NR NR NR NR NR 
11 10 M SIF V15L/S339L 3 ERT HL NR NR NR NR NR NR 
12 10 F SIF, ataxia L444P/L444P 3 BMT N Y N N Y Y Y 
13 5 F SIF L444P/L444P 3 ERT Y - Ear 
infections 
Y N N Y Y Y 
14 4 F SIF L444P/L444P 3 ERT N N N N N N N 
15 2 M SIF U/U 3 ERT Ear 
infections 
NR NR NR NR NR NR 
16 5 F SIF L444P/L444P 3 ERT Y Y N N N N N 
17 8 M SIF, Tourettes L444P/L444P 3 ERT N Y Y Y Y Y Y 
18 6 F SIF L444P/L444P 3 ERT N N N N N N N 
19 12 F SIF L444P/L444P 3 ERT Y Y Y Y Y Y Y 
20 15 F SIF L444P/L444P 3 BMT N Y Y Y Y Y Y 
21 12 F SIF L444P/L444P 3 ERT N NR NR NR NR NR NR 
22 4 F SIF, ataxia L444P/L444P 3 ERT N N N N N Y Y 
23 9 F SIF L444P/L444P 3 ERT N Y N N N N Y 
24 2 M SIF L444P/L444P 3 ERT N NR NR NR NR NR NR 
25 6 F SIF L444P/L444P 3 ERT N N N N N N N 
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listening profile within the neuronopathic GD group (Table 4.8). Three children 
diagnosed with neuronopathic disease reported no problems in any of the listening 
conditions (cases 14, 18 and 25). Unsurprisingly, there were fewer auditory difficulties 
reported when the listening conditions were described as either „quiet‟ or „ideal‟ 
(n=8/11), although 3 cases consistent reported experiencing „more difficulty‟ than their 
peer group even in an optimal listening environment. The listening conditions identified 
by the questionnaire as the more challenging in the neuronopathic GD group were 
„noisy‟ environments (n=7/11 children) and at times when the children need to attend to 
multiple auditory inputs (n=6/11) or when recalling auditory information (n=7/11). 
 
4.5.2 Procedure 
All subjects had standard baseline audiological assessment as previously 
described in Chapter 3. The presence of hearing loss in GD subjects as assessed by 
abnormal audiometric and impedance audiometry tests was a criterion of exclusion from 
the study. This criterion was essential in view of the known influence of the 
transmission properties of the middle ear on otoacoustic emissions, acoustic reflexes 
and the ABR.  
Audiometric results were obtained from all subjects in the same session in which 
electrophysiological tests were performed. The ABRs were recorded to clicks (100 s in 
duration) of alternating polarity presented at a rate of 11.1/s at an intensity of 90 dB 
nHL using TDH-49 headphones.  
Clinical examinations were carried out by a neurologist and/or ophthalmologist 
using techniques previously outlined in Table 2.7. Once the initial clinical assessment 
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had been completed, a more detailed assessment was undertaken by an experienced eye 
movement specialist using DC-coupled electro-oculography (EOG) and simultaneous 
video (Harris et al., 1992, Jacobs et al., 1992).  
EOG recording was bitemporal, with disposable electrodes placed on the outer 
canthi with reference electrode in the mid-forehead. Infants sat on their parent‟s lap. GD 
subjects were also examined for locking up during optokinetic nystagmus elicited by 
horizontal moving stripes using a full field system high-contrast coloured curtain rotated 
about the infant at 25 and 50 degrees per second. For this test, eye movements were 
recorded with EOG only. Subsequent assessments were by bedside video only. 
Saccades were recorded and analysed off-line. Duration and peak velocity of saccades 
were measured using a standard computer algorithm previously described in Harris et 
al., (1999). The findings are summarised in Table 4.14 
 
4.5.3 Data analysis 
The following summary statistics were presented for continuous variables: 
number of values, mean, standard deviation (SD), median, minimum, and maximum. 
For categorical data, frequencies and percentages were to be presented. Distribution 
normality and equality of variance between groups were assessed by one-sample 
Kolmogorov--Smirnov test (with Lilliefors correction) and Levene‟s tests, respectively.  
Because of the small sample size, performance on audiological measures in the 
GD patients was compared with that of control participants using the nonparametric 
Mann-Whitney U test or the Wilcoxon Rank Sum Test. Two-tailed statistics were used 
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throughout, and p< 0.05 was considered significant. All statistics were computed with 
SPSS (v14) statistical software (SPSS, Chicago, IL). 
 
4.6 Results 
4.6.1 Baseline Audiometric Tests 
 
4.6.1.1 Pure tone audiometry 
Pure tone audiometry was measured in 24/25 (96%) of all cases. We were 
unable to measure behavioural thresholds in one subject (case 15) because of poor co-
operation. Results of air conduction audiometry across, confirmed normal hearing in 
23/25 (92%) of GD subjects (95CI=73.97-99.02). A bilateral moderate mixed hearing 
loss was recorded in one subject (case 11) and was excluded from the remainder of the 
study. Overall mean thresholds are plotted in dB HL for the three different phenotypes 
and the age matched control group in Figure 4.4.  
 
Hearing thresholds were comparable across the groups and the control subjects 
for both ears. Differences between the groups were tested for significance using the 
Wilcoxon signed-rank test which showed that pure tone thresholds did not differ 
significantly between the control group and the Gaucher group, except at 2 kHz on the 
left ear (z = -2.974, p< .05, r = - .44).  
However, the hearing thresholds were elevated at 0.5, 1 and 2 kHz for the two 
infants in the GD2 group when compared with the other GD phenotypes. This is not an 
unexpected finding. It has been well documented in the literature that younger children 
typically require a higher level of auditory stimulus than older children when 
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performing audiometry – although the reason for the variability is still unclear (Trehub 
et al., 1989). But it is commonly attributed to either the maturation of auditory 
sensitivity with increasing age or may simply reflect the maturation of the child in terms 
of improved attention or listening skills. Mean threshold levels across frequencies 0.25 
to 8 kHz are shown below in Table 4.9.  
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Figure 4-4 Mean ( SEM) hearing threshold levels for the right and left ears. 
Data is shown for the right and left ears in the conventional for the control group and in three GD phenotypes (n=23) in dB HL; error bars show the 95% confidence interval of the 
mean at each frequency.  
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Table 4-9 Mean air conduction thresholds.  
Data is shown across both ears, for GD1 (neuronopathic subgroup); NGD (neuronopathic subgroup which includes the GD2 and GD3 subtypes) and for age-and-
gender matched normal control subjects.  
   
Group   Rt 
0.25 kHz 
Rt 
0.5 kHz 
Rt  
1 kHz 
Rt  
2 kHz  
Rt  
4 kHz 
Rt  
8 kHz 
Lt  
0.25 kHz  
Lt  
0.5 kHz 
Lt  
1 kHz 
Lt  
2 kHz  
Lt  
4 kHz 
Lt  
8 kHz 
GD1 Mean 7.14 2.86 3.57 0.00 5.71 5.00 7.86 4.29 .00 -1.43 4.29 5.00 
  N 7 7 7 7 7 7 7 7 7 7 7 7 
  Std. Dev. 4.88 2.67 5.56 5.77 6.07 2.89 3.93 5.35 2.89 2.44 3.45 5.77 
  SEM 1.84 1.01 2.10 2.18 2.30 1.09 1.49 2.02 1.09 0.92 1.30 2.18 
  Median 5.00 5.00 5.00 0.00 5.00 5.00 5.00 5.00 0.00 0.00 5.00 5.00 
NGD Mean 9.23 5.00 3.44 4.69 6.56 5.00 7.70 5.63 3.12 0.94 4.38 6.92 
  N 13 16 16 16 16 13 13 16 16 16 16 13 
  Std. Dev 4.00 5.16 5.69 6.44 6.25 2.04 3.30 5.44 5.12 4.17 3.10 5.22 
  SEM 1.11 1.29 1.42 1.61 1.56 0.57 0.92 1.36 1.28 1.04 0.77 1.45 
  Median 10.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 0.00 0.00 5.00 5.00 
Control Mean 7.40 4.20 1.20 2.40 7.20 5.60 8.00 5.40 1.60 3.60 5.00 6.40 
  N 25 25 25 25 25 25 25 25 25 25 25 25 
  Std. Dev 5.23 4.00 4.85 5.42 7.23 6.66 5.40 5.58 4.94 3.07 4.79 7.00 
  SEM 1.05 .80 .97 1.08 1.45 1.33 1.08 1.12 0.99 0.61 0.96 1.40 
  Median 5.00 5.00 0.00 0.00 5.00 5.00 10.00 5.00 0.00 5.00 5.00 5.00 
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4.6.1.2 Tympanometry 
All 25 GD subjects had normal middle ear function as determined by 
tympanometry on the day of testing and the middle ear pressure was comparable 
between the groups. Table 4.10 shows the mean and standard deviation of the middle 
ear analysis for the right and left ear across the Gaucher phenotypes and the age-and-
gender matched controls. The ear canal volume was noticeably smaller in the GD2 
group but this most likely reflects the age of the participants. 
 
Table 4-10 Mean tympanometric values in normal controls and in patients with GD. 
SD is shown in brackets. Abbreviations: ECV – ear canal volume 
 
 RIGHT EAR LEFT EAR 
 ECV 
(ml) 
Compliance 
(ml) 
Pressure 
(daPa) 
ECV 
(ml) 
Compliance 
(ml) 
Pressure 
(daPa) 
Control 
(n=25) 
0.90 (0.19) 0.70 (0.60) 7.00 (30.83) 0.89 (0.21) 0.72 (0.58) -4.38 (32.41) 
GD1 
(n=7) 
1.03 (0.43) 0.59 (0.19) -9.29 (39.63) 1.09 (0.42) 0.66 (0.47) 0.71 (25.73) 
GD2 
(n=2) 
0.48 (0.21) 0.60 (0.57) -17.5 (45.96) 0.55 (0.21) 0.45 (0.21) -20.1 (44.18) 
GD3 
(n=16) 
0.87 (0.09) 0.60 (0.44) -36.3 (31.67) 0.93 (0.14) 0.58 (0.38) -28 (35.71) 
 
4.6.1.3 Transient evoked otoacoustic emissions 
Transient evoked otoacoustic emissions were recorded in all 24 GD subjects. 
The mean TEOAE amplitudes in the non-neuronopathic group was 13.4 ± 2.4 dB SPL 
for the right ear and 12.5 ± 1.35 dB SPL on the left ear compared with 14.6 ± 3.6 dB 
SPL for the right ear and 12.5 ± 4.9 dB SPL for the control group. In contrast, a smaller 
mean amplitude was observed in both ears for the neuronopathic group (10.9 ± 2.2 dB 
SPL for the right ear and 10.2 ± 1.8 dB SPL for the left ear).  
Figure 4.5 shows the 95% confidence intervals (95% CIs) for the means of each 
of the GD subgroups. The TEOAE amplitude responses are comparable across right and   
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Figure 4-5 Box-plots illustrating transient evoked otoacoustic emissions (TEOAE) amplitudes 
across the different GD phenotypes and in the age-and-gender matched controls. Amplitude 
response (dB SPL) for the right ear is shown in (A) and amplitude response data for the left ear is 
shown in (B). 
 
A. 
 
 
 
 
B. 
 
 
 
left ears. The GD2 subgroup was too small (n=2) to perform any meaningful statistical 
analysis. However, when compared to the other two GD groups, the magnitude of the 
OAE amplitude response is greater in the two GD cases. TEOAEs are widely reported 
  
216 
 
as being larger in younger age groups compared with older age groups. For example, 
clinically normal adult ears have been reported to have a weaker response of < 3 dB 
SPL with little or no response at higher frequency bands. This decrease in cochlear 
response associated with the ageing process is thought to reflect the sensitivity of the 
OAE to damage (e.g. ototoxic damage, noise exposure) (Kemp et al., 1990, Hurley and 
Musiek, 1994, Oghalai, 2004, Robinette and Glattke, 2007). 
Interestingly, there is a marked difference in variability between the left and 
right ears for GD2 cases. (i.e.) there is little variability on the left ear (13.4 dB SPL in 
case 1 and 13.2 dB SPL in case 2) compared with the OAE measurement on the right 
side (12.5 dB SPL in case 1 and 16.5 dB SPL in case 2). TEOAE measurement is highly 
sensitive to physiologic and ambient noise levels (Kemp et al., 1990, Norton and 
Widen, 1990, Hurley and Musiek, 1994, Robinette and Glattke, 2007) and the greater 
response on the right side of case 2 is due to an improved signal-noise ratio during 
recording (i.e. the infant was asleep and required no suctioning of the tracheostomy tube 
as a result).  
Because there were no observable differences between ears, we combined the 
data from both ears to perform statistical analysis. The mean TEOAE amplitude was 
significantly different across the groups (H(2) = 17.80, p<.05). Mann-Whitney tests 
were used to follow up this finding.  A Bonferroni correction was applied and so all 
effects are reported at a 0.0167 level of significance. It appeared that the TEOAE 
amplitude was not significantly different between the GD1 phenotype and the control 
group (U = 297, r = - 0.08). However, TEOAE amplitude was significantly lower in the 
GD3 phenotype when compared to normal age and gender matched controls (U = 434, r 
= -0.40) and when compared with the GD1 phenotype (U = 69, r = -0.53). 
 
  
217 
 
4.6.2 Brainstem tests 
4.6.2.1 Acoustic reflex thresholds 
We were unable to record the acoustic reflex threshold in 8/24 (33%) cases, 
because of poor co-operation (cases 8 – 10, 12, 22 – 25). In one case (case 17) acoustic 
reflex thresholds could not be obtained due to the patient's oversensitivity to the 
acoustic stimuli. ARTs were normal with ipsi-and-contralateral stimulation in 7 cases 
(cases 1-7) (range 80 – 100 dB) but abnormal (elevated or absent) in the remaining 
cases (cases, 13-16, 18-21).  
 
4.6.2.2 Medial olivocochlear suppression 
The suppression effect of the medial olivocochlear system was obtained by 
subtraction of the TEOAE responses under contralateral stimulation from those without 
contralateral stimulation. Medial olivocochlear suppression with contralateral 
stimulation was measured in 15/24 GD patients. We were unable to record MOCS in the 
remaining nine cases because the subjects were unable to accurately report 40 dB SL 
required to complete the test in 6/9 cases and because of poor co-operation in the 
remaining 3 cases.  
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Figure 4-6 Box-plots showing the medial olivocochlear suppression in patients diagnosed as GD1 
and GD3 compared with control group. 
 
The mean MOC suppression in the non-neuronopathic group was 2.8 ± 0.8 dB 
for the right ear (range: 1.9 – 4.2 dB, n=7) and 2.3 ± 0.8 dB on the left ear (range: 1.6 – 
3.9 dB, n=15) compared with 2.9 ± 1.2 dB for the right ear (range: 1.4 – 4.6, n=15) and 
2.4 ± 1.1 dB for the left ear (range: 0.8 – 4.6, n=15) for the control group. In contrast, in 
the neuronopathic group, suppression was found to be reduced or absent in both ears 
(0.7 ± 0.3 dB, range: 0.3 – 1.1 dB, n=8, right ear and 0.6 ± 0.2 dB, range: 0.4 – 0.9, n=8, 
left ear). Figure 4.6 shows a box and whisker plot of the GD phenotypes and the control 
group. Only 2/16 ears (12.5%) of GD3 subjects (95CI = 1.55-38.35) had normal 
suppression values greater than 1 dB.  
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Differences between the groups were tested for significance using the Kruskall-
Wallis test. MOC suppression was significantly different across the groups (H(2) = 
33.68, p<.05). Mann-Whitney tests were used to follow up this finding.  A Bonferroni 
correction was applied and so all effects are reported at a 0.0167 level of significance. 
MOC suppression was not significantly different between the GD1 phenotype and the 
control group (U = 199, r = - 0.04). However, suppression was significantly lower in the 
GD3 phenotype when compared to normal age and gender matched controls (U = 5.5, r 
= -0.79) and when compared with the GD1 phenotype (U = 0, r = -0.81). 
 
4.6.2.3 Auditory Brainstem Responses 
The ABR was measured in all subjects across both ears. ABR waveforms, 
latencies and interpeak latencies were normal in 7/20 (cases 1-7) and abnormal in 13/20 
cases (cases 8-10, 12-25). ABR waveforms, morphology and latencies were normal in 
all of the non-neuronopathic subjects (cases 1-7) but the ABRs in the neuronopathic 
group had a wide range of abnormalities including absent waveforms, delayed peak and 
interpeak waveform latencies in all subjects. The absolute latencies of waves I, III, and 
V and the interpeak intervals I-III, III-V, and I-V for each individual case are shown in 
Table 4.11 
In the neuronopathic group, only wave I was identifiable all subjects although it 
was delayed in 1/17 (case 15). Wave III was normal only in 3 of the 17 cases studied 
(absent in 12/17; delayed in 2/17) on the right ear and normal in 6 of the 17 (absent in 
9/17 cases and delayed in 2/17) for both ears. Wave V was abnormal on the right ear for 
all of the neuronopathic subjects (absent in 12/17; delayed in 5/17) and normal only in 1 
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Table 4-11 Individual ABR data for peak latencies.  
Latencies are grand mean averages of two or more traces. Each ABR was recorded at an intensity level of 90 dB nHL. Abbreviations: AB – absent; NT – not tested 
Case Right Ear Left Ear 
 Wave I Wave III Wave V Interpeak 
I-III 
Interpeak 
III-V 
Interpeak 
I-V 
Wave I Wave III Wave V Interpeak 
I-III 
Interpeak 
III-V 
Interpeak 
I-V 
1 1.56 3.74 5.66 2.18 1.92 4.10 1.56 3.67 5.45 2.11 1.78 3.89 
2 1.49 3.60 5.33 2.11 1.73 3.84 1.49 3.50 5.47 2.01 1.97 3.98 
3 1.51 3.50 5.40 1.99 1.90 3.89 1.51 3.54 5.44 2.03 1.90 3.93 
4 1.63 3.65 5.35 2.02 1.70 3.72 1.49 3.60 5.46 2.11 1.86 3.97 
5 1.68 3.60 5.28 1.92 1.68 3.60 1.59 3.66 5.37 2.07 1.71 3.78 
6 1.54 3.49 5.45 1.95 1.96 3.91 1.50 3.53 5.50 2.03 1.97 4.00 
7 1.49 3.52 5.43 2.03 1.91 3.94 1.52 3.49 5.37 1.97 1.88 3.85 
8 1.75 4.2? AB 2.45? - - 1.69 AB AB - - - 
9 1.78 AB AB - - - 1.83 AB AB - - - 
10 1.61 AB AB - - - 1.59 AB AB - - - 
11 NT NT NT NT NT NT NT NT NT NT NT NT 
12 1.43 AB AB - - - 1.51 3.93 AB 2.42 - - 
13 1.64 4.40 6.32 2.76 1.92 4.68 1.58 3.80 6.18 2.22 2.38 4.60 
14 1.50 AB 5.90 2.07 2.33 4.50 1.47 3.54 5.79 2.07 2.25 4.32 
15 2.2 AB AB - - - 2.14 AB AB - - - 
16 1.56 4.18 6.40 2.62 2.22 4.84 1.51 3.97 6.25 2.46 2.28 4.74 
17 1.79 AB AB - - - 1.73 AB AB - - - 
18 1.46 3.52 5.94 2.06 2.42 4.48 1.51 3.43 5.91 1.92 2.48 4.40 
19 1.45 AB AB - - - 1.48 AB AB - - - 
20 1.64 AB AB - - - 1.52 AB AB - - - 
21 1.59 AB AB - - - 1.52 AB AB - - - 
22 1.67 AB AB - - - 1.73 3.67 AB 1.94 - - 
23 1.78 AB AB - - - 1.70 AB AB - - - 
24 1.73 3.5 AB 1.77 - - 1.80 3.67 6.72 1.87 3.05 4.92 
25 1.51 3.55 5.83 2.04 2.28 4.32 1.58 3.50 5.66 1.92 2.16 4.08 
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of the 17 cases (case 25) on the left ear (absent in 11/17; delayed in 5/17).  Table 4.12 
displays the peak latencies for each phenotype. 
Amplitudes were measured for all peak waveforms. A nominal value of 0 µV 
was allocated when no waveform was evident. For illustrative purposes we also 
constructed a series of whisker and box plots of the amplitudes for the control group and 
across the different GD subgroups (Figure 4.8).  Typically, the wave V amplitude is 
larger than other peak waveforms in the GD1 and control group. In contrast, in the GD3 
group, wave I is the largest (range: 0.09-0.56 µV, right ear; 0.12-0.76 µV, left ear). 
Table 4-12 Mean peak latency data presented for each GD phenotype.  
Abbreviations: R – right ear; L – left ear 
PHENOTYPE LATENCY (MS) 
 Ear Wave I Wave III Wave V 
Non-neuronopathic 
(GD1)  
R 1.56 (0.07) 3.59 (0.09) 5.41 (0.12) 
L 1.52 (0.04) 3.57 (0.07) 5.44 (0.50) 
Neuronopathic 
(GD2) 
R 1.77 (0.02) - - 
L 1.76 (0.10) - - 
Neuronopathic 
(GD3) 
R 1.64 (0.19) 3.83 (0.43) 5.69 (0.20) 
L 1.62 (0.18) 3.69 (0.20) 6.09 (0.38) 
 
There were no observable differences between any of the groups for wave I 
amplitude, however the greatest decrease in amplitude for waves III and V was seen in 
the neuronopathic subtypes (GD2 and GD3) when compared to the control group and 
the non-neuronopathic GD subtype. 
To compare the amplitude of each peak waveform for the GD groups and 
control subjects statistically we performed the non-parametric Kruskall-Wallis test. This 
showed highly significant differences between the groups and peak amplitude for wave 
III and wave V on the right ear and for all of the peak waveforms on the left ear  
(p<0.05). Post-hoc analysis showed that the peak amplitude was not significantly 
different between the GD1 phenotype and the control group (U = 297, r = - 0.08). 
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However, amplitude was significantly lower in the GD3 phenotype when compared to 
normal age and gender matched controls (U = 434, r = -0.40) and when compared with 
GD1 patients (U = 69, r = -0.53). 
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  Figure 4-7 ABR amplitudes for peak waveforms (I, III and V) in patients diagnosed as GD1 and GD3 compared with an age-and-gender matched control group
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4.6.3 Comparison of audiological findings and oculomotor signs 
A summary table of oculomotor signs and auditory assessments for all of the 
subjects is shown in Table 4.14. Subjects clustered into two distinct groups. One group 
(n=7) had normal eye movements and normal auditory investigations (cases 1-7). The 
other group (n=18) exhibited SIF and or slow saccades, absent waveforms and poor 
morphology on the ABR, absent or elevated ARTs, abnormal MOCs and normal 
peripheral hearing (cases 8-9, 11-21). Table 4.13 shows a contingency table of eye 
movement and audiology test results. There was a 100% concordance between 
oculomotor and auditory findings and there is no gradation between the two groups. 
 
Table 4-13 A 2x2 Contingency table of auditory and oculomotor tests in GD. 
 
 
 
 
 
  EYE MOVEMENTS 
  Abnormal Normal 
A
U
D
IT
O
R
Y
 
Normal 
 
0 7 
Abnormal 
 
18 0 
  
225 
 
Table 4-14 Summary of oculomotor and auditory tests (n=25) during the present study. 
Abbreviations: ARTs = Acoustic reflex thresholds (dB), HL = Hearing loss (dB HL), MOCS = medial olivocochlear suppression test (dB), N/A = test not applicable due to the 
presence of a conductive hearing loss, N/T = not tested due to poor co-operation, OAEs = Otoacoustic emissions, PTA = Pure tone audiometry, TEOAE = Transient evoked 
otoacoustic emissions, TYMP = Tympanometry. 
Case Age Sex Phenotype Eye Movements Audiology 
    OKN Saccades PTA TYMP ARTs OAEs ABR 
         TEOAEs MOCS  
1 5 M 1 N NT N N N N N N 
2 8 F 1 N N N N N N N N 
3 14 M 1 N N N N N N N N 
4 15 F 1 N N N N N N N N 
5 12 F 1 N N N N N N N N 
6 7 F 1 N NT N N N N N N 
7 17 F 1 N N N N N N N N 
8 2 F 2 SIF NT N N NT N NT AB 
9 1.5 F 2 SIF NT N N NT N NT AB 
10 4 M 3 SIF NT N N NT N AB AB 
11 10 M 3 SIF Slow L, R AB AB NT NT NT NT 
12 10 F 3 SIF Slow L, R, D N N NT N AB AB 
13 4 F 3 SIF NT N N AB N AB AB 
14 3 F 3 SIF NT N N AB N AB AB 
15 1 M 3 SIF NT N N AB N NT AB 
16 4 F 3 SIF NT N N AB N AB AB 
17 7 M 3 SIF NT N N NT N NT AB 
18 5 F 3 SIF Slow L, R, D N N AB N AB AB 
19 11 F 3 SIF Slow L, R, D N N AB N AB AB 
20 14 F 3 SIF Slow L, R N N AB N AB AB 
21 11 F 3 SIF Slow L, R N N AB N AB AB 
22 4 F 3 SIF NT N N NT N NT AB 
23 9 F 3 SIF NT N N NT N AB AB 
24 2 M 3 SIF NT N N NT N NT AB 
25 6 F 3 SIF NT N N NT N NT AB 
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4.7 Discussion 
4.7.1 Baseline audiometry measures 
Pure tone audiometry revealed normal hearing in 23/24 GD participants. Only 
one child (case 11) was found to have a bilateral moderate mixed hearing loss.  We 
found no statistically significant difference in the hearing thresholds across the different 
phenotypes.  
To the best of our knowledge this is the first study to have formally assessed the 
peripheral hearing in the acute neuronopathic subtype (GD2) despite previous studies 
providing vague behavioural descriptions (e.g. “unresponsiveness” (Lacey and Terplan, 
1984) or a “poor response” (Kaga et al., 1998). It is surprising that this is the first time 
that any formal assessment of peripheral hearing has been undertaken in GD2; 
particularly as precise interpretation of all auditory measures, particularly the ABR 
depends upon establishing accurate levels of hearing. 
There are sporadic reports of hearing loss scattered throughout the GD literature, 
although details provided in these publications are often ambiguous or lacking in detail 
(Dreborg et al., 1980, Schiffmann et al., 1997, Alfonso et al., 2007). The incidence of 
hearing loss reported in these papers varies widely from 4% report by Alfonso et al., 
(2007) to as high as 21% in Grasso et al., (2006). Moreover, the type of hearing loss 
also differs across studies. For example, one study describes „neurogenic‟ loss in one 
case and a „slight conduction impairment‟ in three GD patients (Dreborg et al., 1980).  
The largest audiological study in GD showed that hearing was normal in 48/62 
cases (41 GD1, 7GD3); abnormal in 13 GD1 patients and in 1 GD3 case (Grasso et al., 
2006). This high incidence of hearing loss is alarming and potentially has wide 
implications for patients diagnosed with GD.  
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The authors highlight this concern in their study, arguing that “…the prevalence 
of hearing loss among the general population is 10%. In our study, hearing loss is 
present in the 24% of subjects with GD1”  (Grasso et al., 2006, p70).   
Our findings are very different. We found only one case of hearing loss in GD3 
and no discernible hearing loss in any patient diagnosed with GD1. Indeed our TEOAE 
data were within normal limits for all GD1. Interestingly, the mean TEOAE amplitude 
data for the GD3 group was significantly below the GD1 and age matched control 
groups. This finding may indicate that there is subtle subclinical damage in the cochlea 
of these patients which has not been detected on the audiogram. This finding may 
reflect subclinical microvascular damage within the cochlea which may be due to 
abnormal blood flow, altered blood vessel properties or abnormal blood composition.  
The reason for the discrepancy between our results and previously published 
studies is not clear. One possibility is that there are significant differences between 
patient groups; age differences, stage of the disease and treatment parameters. For 
instance, our sample are much younger (age range 1-17 years) than those described in 
the Grasso et al., (2006) study (age range of 5 months – 50 years; median 32 years). 
Furthermore, many of the children in our sample were on high-dose ERT which may 
have slowed or halted any potential degeneration (Vellodi et al., 2009).  
Unfortunately, Grasso et al., (2006) have only published the degree of hearing 
loss (mild loss in 12 GD1 and profound in 1 GD1). In view of their normal 
tympanometry results – a finding consistent with our own study – it is unlikely that the 
hearing loss reported in their series of GD1 patients is conductive. Regrettably, they 
also failed to publish any individual frequency or ear specific data.  Without more 
detailed information regarding their age range and onset of hearing loss we can draw no 
further conclusions. 
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Whether hearing loss is seen in patients with GD1 and/or GD3 at a later onset 
has still to be determined but because of the discrepancy between our audiometric 
findings and those reported by Grasso et al., (2006), we would recommend that all 
children diagnosed with GD undergo serial auditory evaluation regardless of phenotype. 
We will revisit the issue of the value of serial audiometric measures again in Chapter 5. 
 
 
4.7.2 Brainstem auditory tests 
 
4.7.2.1 Acoustic reflex thresholds  
In our study, we found that acoustic reflexes thresholds were normal in all GD1 
patients and abnormal in 8 cases of GD3. We were unable to reliably record the ART in 
10/25 cases (40%) because of poor co-operation and hypersensitivity to loud sound in 
one case. In spite of this limitation, our data still lead us to conservatively conclude that 
acoustic reflexes are elevated or absent in at least 50% (8/16) of GD3 children.  
This data is consistent with those previously reported by Bamiou et al., (2001) 
but differs significantly from those results reported in Grasso et al., (2006). They 
reported normal ARTs in 94% (51/54) of GD1 patients and normal ARTs in 87% (7/8) 
GD3 patients. It is conceivable that the differences between our studies may simply be a 
result of different testing techniques and interpretation. For example, Grasso et al., 
(2006) applied a stricter criterion (compliance change > 0.03ml), while we adopted the 
UK recommendations of >0.02ml (BSA, 1992).  
The presence of both ipsilateral and contralateral abnormalities in the 8 cases of 
neuronopathic disease usually indicates central disease, localised to the cochlear nuclei 
and the olivary nuclei. These findings could reflect involvement of the facial nucleus or 
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its fascicle. In GD2 disease, 6th N palsies are common. The lengthy 7th fascicle 
proceeds dorsomedially and bends around the 6th nucleus at its genu and returns 
ventrolaterally before exiting the brainstem. Thus, it is conceivable that a midline lesion 
near the genu could affect both fascicles to give a bilateral lesion and also affect the 
horizontal saccade centres in the PPRF.  
The functional role of the ART is unclear. It is thought to be important in 
protecting the inner ear from damage by continuous loud sound, but it is also thought to 
play an important role in improving speech perception particularly in noisy background 
environments. It is thought to achieve this by attenuating low frequency noise that can 
cause the upward spread of masking of the high frequency sounds. Our findings that the 
ART is impaired in GD3 patients results may indicate increased listening difficulty in 
an acoustically challenging background or an increased sensitivity to sound as described 
by a number of individual GD3 cases (Table 4.8). 
Several post-mortem studies have previously implicated the central auditory 
nervous system in nGD (Winkelman et al., 1983, Erikson, 1986). However, because of a 
lack of studies in this area we cannot judge what the functional implications might be. 
Clearly future studies should consider including well-defined psychoacoustic studies 
and other behavioural measures of central auditory pathways as a logical and necessary 
development in this new area of research. 
 
4.7.2.2 Medial olivocochlear suppression  
In our study, we have clearly shown that patients diagnosed with GD3 
demonstrated a significantly reduced suppression of TEOAEs when compared to both 
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the control group and GD1 patients.  These findings are consistent with data previously 
reported in Bamiou et al., (2001). We could find no evidence to show that the MoCB 
was impaired in patients with GD1. As far as we are aware, this is the first time that 
MOCs has been reported in patients diagnosed as GD1.  
It is difficult to interpret these findings because of the complexity of the 
anatomical pathways that are responsible for generating the response. The lack of 
suppression in the GD3 patients could reflect either (a) abnormal MOCS feedback or (b) 
may be due to inability to access efferent system via a dysfunctional afferent auditory 
pathway. Evidence from cases of unilateral auditory neuropathy would seem to indicate 
that impaired efferent suppression is due to poor synchrony in the afferent pathways. 
The pathway involves the projection from olivocochlear neurons mostly in the 
medial region of the superior olivary complex (SOC) to the contralateral cochlea. 
Crossing olivocochlear axons pass the midline in the dorsal brainstem near the floor of 
the 4th ventricle passing under the genu of the facial nerve. Thus, it is plausible that 
lesions affecting the horizontal saccades could also compromise contralateral 
suppression.  
The functional role of the efferent auditory system remains largely unknown. 
Moreover, the clinical significance of these findings is equally unclear. Evidence from 
animal and human studies has suggested that the efferent pathway enhances the 
frequency resolving capacity of the auditory system, particularly in the presence of 
competing acoustic signals or degraded acoustic signals (Kumar and Vanaja, 2004, 
Guinan, 2006, 2010).  
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Abnormal MOC suppression has been reported in a number of clinical 
populations including acoustic neuroma (Prasher et al., 1994), vestibular neurectomy 
(Williams et al., 1994), auditory neuropathy (Starr et al., 1996), patients with tinnitus 
(Ceranic et al., 1998), and in children with auditory processing disorder (Kumar and 
Vanaja, 2004).  
Although our sample size is small, these results taken together with our ARTs 
data suggest extensive abnormalities within the auditory brainstem in GD3. These 
abnormalities could result in significant encoding and processing deficits. Further study 
is needed to clarify the extent of these abnormalities and their clinical relevance.  
 
4.7.2.3 Auditory brainstem response 
We found normal ABRs in the non-neuronopathic group and abnormal ABRs in 
all of the neuronopathic GD subjects. The severity of abnormalities in the nGD group 
were diverse and ranged from delayed waveforms, poor or absent wave III-V and in 
many cases with only one peak waveform (typically wave I) being identifiable in many 
cases. Our findings are unequivocal: we have shown no evidence for any auditory 
abnormalities in children with non-neuronopathic GD. We have also clearly shown that 
children with neuronopathic GD have a number of widespread auditory brainstem 
abnormalities.  
We have previously shown in this chapter that the existing literature that has 
investigated the ABR in GD is baffling and difficult to interpret, because of a clear lack 
of control data and other methodological issues (See section 4.4.5). We do not wish to 
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add to this confusion, so in the following sections, we will compare our findings 
directly with the previously published studies for each phenotype. 
 
4.7.2.3.1 Comparison of our findings with previous ABR studies in GD1  
In our study, we could find no evidence of any ABR abnormality or on any of 
our other audiological measures in children with the GD1 subtype. Our finding is 
consistent with those reported in Accardo et al., (2005).  Only five studies (n=77; 35 
male, 42 females) that have used the ABR as a core index test have been reported in the 
literature (Ida et al., 1999, Accardo et al., 2005a, Perretti et al., 2005, Grasso et al., 
2006, Accardo et al., 2010). We have summarised these studies and presented their key 
findings in Table 4.5.  
The ABR findings across these studies were inconclusive – the ABR was 
reported as normal in 60/77 cases and abnormal in 17/77 cases; however two of the 
studies that had initially reported their patients here as „type 1‟ later revised this 
diagnosis to „type 3‟ (3 cases) (Ida et al., 1999, Accardo et al., 2005a). Eye movement 
data across these studies – which we have established is essential in establishing the 
correct phenotype – was limited, (Ida et al., 1999, Perretti et al., 2005) and in some 
cases, absent (Grasso et al., 2006).  Without objective phenotyping with eye movement 
recording, the data presented by Grasso et al., (2006), Perretti et al., (2005) or Ida et al 
(1999) cannot be taken as evidence for significant abnormalities in type 1 disease.  
Furthermore, it is not clear whether the abnormalities seen in some of the ABRs 
were due to peripheral hearing loss.  Peripheral hearing was measured only in two 
studies (Ida et al., 1999, Grasso et al., 2006) and hearing loss was identified in 15 
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patients. However, it is not entirely clear whether hearing was actually measured in all 
of the patients described in the Ida et al., (1999) study. It is not possible to determine 
whether the prolonged latencies reported occurred as a result of the hearing loss 
(typically high frequency) or whether the ABR reflected an impairment in auditory 
pathways as a result of the disease process. An example of this is outlined in Grasso et 
al., (2006). They report a high incidence of hearing loss in the GD1 population (in 13/54 
or 24%) which was a mild high frequency hearing loss in 12 cases and profound hearing 
loss in 1 case. Obviously we would not expect to see any ABR trace in a patient who for 
whom the stimulus was not audible. Unfortunately, audiometric data and ABR data for 
individual patients are not presented so we are unable to draw any further conclusions 
about whether hearing loss may explain the elongation in I-V. Further audiometric 
studies including pure tone audiometry, stapedial reflexes and tympanometry would be 
needed to clarify the origins of these abnormalities 
Furthermore, none of the studies reported here presented any quantitative 
latency or amplitude data. Three studies failed to report any technical details regarding 
the ABR recording and did not publish their waveforms so we are unable to draw any 
conclusions (Schiffmann et al., 1997). The ABR waveform presented in the Perretti et 
al., (2005) study is from a L444P homozygote and typically expected in GD3 disease 
showing prolonged I-III interval and poor morphology. In the absence of definitive eye 
movement recording, we cannot accept these data as evidence of neurological 
involvement in GD1. 
Control data was also limited across these studies. The question of abnormal 
electrophysiological findings is usually based on the standard deviation of in-laboratory 
control data. In the absence of control data, it would seem that several studies have 
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made independent decisions on each individual test in each individual. This is highly 
questionable as it will almost certainly lead to false positive claims.  
 
4.7.2.3.2 Comparison of our findings with previous ABR studies in GD2  
In contrast with the data presented for the GD1 patients, our findings in GD2 are 
extremely consistent with previously reported studies in this phenotype. Seven studies 
have previously reported ABR data in 11 GD2 (6M, 5F) (Kaga et al., 1982, Lacey and 
Terplan, 1984, Vivian et al., 1993, Kaga et al., 1998, Ida et al., 1999, Grasso et al., 
2006, Miyata et al., 2006). The age of onset of these cases was variable, but most of the 
patients were diagnosed at birth or early in infancy; only one study measured the ABR 
in the latter stages (at 18/12 months; (Miyata et al.   2006)). SIF was reported in all of 
the cases with the exception of the Grasso et al., (2006) study which failed to report any 
other clinical details other than the audiological data. 
In all of these cases, the ABR was abnormal, although none of the studies 
examined the peripheral mechanism to ensure normal hearing. All of the studies 
concluded that the ABR was abnormal in the 11 cases, with many of the studies 
identifying a progressive loss of components waves (Table 4.6). In each case, the patient 
died before their 2nd birthday. Abnormalities were very similar and all of the studies 
reported a loss of wave V and in some papers a loss of wave III was also observed. 
Generally the earlier ABR components (waves I and II) were preserved.  
The technical data presented in each of the studies was limited. For example, 
click stimuli was used to elicit the ABR in 3 studies but was unreported in four studies; 
intensity levels used to elicit a response was reported in two studies (Lacey and Terplan, 
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1984, Grasso et al., 2006). Representative ABR waveforms were shown in only in 3 
studies (Kaga et al., 1982, Kaga et al., 1998, Grasso et al., 2006).  
 
4.7.2.3.3 Comparison of our findings with previous ABR studies in GD3  
 
Our results in this study clearly showed that the ABR was markedly abnormal in 
all GD3 patients, without exception. Over the last 3 decades, only 8 studies have been 
undertaken in GD3 patients using the ABR (Abrahamov et al., 1995, Schiffmann et al., 
1997, Altarescu et al., 2001b, Aoki et al., 2001, Bamiou et al., 2001, Goker-Alpan et al., 
2005, Grasso et al., 2006, Cox-Brinkman et al., 2008) (Table 4.7). These studies 
represent the results from a total of 78 individual GD3 subjects. Collectively, the ABR 
was reported as being „normal‟ in 56% of reported cases with GD3 and abnormal in 
44% of the reported cases. We found that the ABR was abnormal in 100% of our 
patients. Eye movement abnormalities were a common finding across the other 7 
studies, with one exception – one patient reported in Altarescu et al., (2001) showed no 
clinical signs of hSIF at the time enrolment into a clinical trial investigating ERT in 
GD3. Interestingly, they developed „mild‟ hSIF during the initial treatment phase. 
Why is there such a discrepancy between our data and previously reported 
studies? One possibility is the technical differences in experimental paradigms, 
standards, data processing methods and criteria used across studies, e.g. the 
implementation of different experimental conditions, type of stimulus used, etc. We 
have summarised these in Table 4.8. Another concern is the lack of multivariate 
statistical comparison to a control group. In the majority of the studies presented, 
limited descriptive analysis (e.g. ABR is normal or abnormal) is presented. In a number 
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of studies, no control data is shown. Furthermore, although the ABR is a quantitative 
measure of brainstem function - none of the studies included here have published any 
quantifiable latency and/or amplitude measures. This is the first study to present 
quantitative data not just descriptive analysis. 
Alternatively, it is likely that there are group differences in treatment, 
particularly dose; genotype and age of the patients investigated which may explain the 
variation. Most of the patients enrolled in these studies were on ERT. Only two studies 
fail to mention whether their patients are receiving treatment (Abrahamov et al., 1995, 
Grasso et al., 2006).  
Clearly the greatest barrier to using the ABR as a measure of brainstem 
dysfunction in GD is the lack of standardised testing and interpretation. If the ABR is to 
be used as a routine application in this area, then investigators in this area urgently need 
to reach some consensus.  
 
4.7.3 Pathophysiology 
At the beginning of this thesis (Section 4.1) we asked whether audiological tests 
when coupled with eye movement studies, can be used to provide reliable subclinical 
and pre-symptomatic tests of neurological involvement in GD? We believe that we have 
clearly demonstrated the sensitivity of the ABR as a marker of subclinical deterioration 
in nGD patients. In this section, we ask what the results of the ABR (and other 
audiological tests) tell us about the pathophysiology disease mechanisms in nGD. 
The ABR test assesses whether auditory information reaches the brainstem in a 
synchronised manner or not (Hall, 2007) and does not provide any information on 
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clinical auditory correlates. The precise anatomical correlates of abnormal ABRs are 
uncertain and the ABR test is frequently considered as a whole rather than with separate 
analysis of its anatomically distinct generators. Waves I and II are thought to denote 
activation of its distal and proximal extra-axial portion of the 8th nerve, and waves III–
V activation of more central relays in the brain stem, from the region of the dorsal 
cochlear nucleus to that of the inferior colliculus, although waves III–V will be affected 
secondarily when waves I and II are impaired or absent. If the cell body was the primary 
site of pathology in nGD then the inevitable outcome would be prompt death of its 
afferent dendrites and efferent axon and myelin sheath (Wallerian degeneration). This 
would have resulted in a loss of waves I-II on the ABR even in the presence of 
functional OHCs. However we have clearly shown that wave I was always evident in 
nGD. 
However, it may be misleading to focus on the absence of specific waves 
because in all the nGD patients, the ABR morphology, with the exception of wave I, 
was extremely poor. The morphological abnormalities seen could be explained by 
problems in timing disparity. The ABR occurs within a few milliseconds of stimulation 
therefore volleys must be precisely timed to be recordable with surface averaging 
techniques. Poor synchronization results in abnormal waveform morphology and 
plummeting of the ABR amplitude (Starr et al., 2001). Minor jitter in timing within the 
auditory nerve can also interfere with precise phonemic decoding and, consequently, 
with the perception of speech sounds and other auditory tasks particularly in 
background noise (Starr et al., 1991, Berlin et al., 1994, Starr et al., 1996, Starr et al., 
2001). It is tempting to postulate that part of the progressive intellectual decline as 
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reported in various studies in GD could be accounted for by specific central auditory 
deficits. 
To our knowledge no systematic studies of auditory processing in GD have been 
undertaken although neuropathological studies have implicated several central auditory 
structures in GD including cerebral and cerebellar Purkinje cells, neuronophagia in the 
cerebral cortex, brainstem and other areas (Winkelman et al., 1983, Erikson, 1986). 
Further research is urgently needed to clarify these issues. 
The combined findings of normal evoked otoacoustic emissions (TEOAE) and 
absent or markedly disturbed auditory evoked potentials from the brainstem are 
reminiscent of „auditory neuropathy‟ (Starr et al., 1996). A set of salient features 
defining auditory neuropathy include elevated auditory thresholds to pure tone stimuli, 
absent to severely abnormal ABRs to high level stimuli, the presence of otoacoustic 
emissions (that do not suppress with contralateral noise stimulation), absent acoustic 
reflexes to both ipsilateral and contralateral tones and word recognition ability poorer 
than expected from the audiogram. 
The pathology underlying auditory neuropathy is unknown, but can be caused 
by disruption in neural synchrony or by patchy damage to inner hair cells in the cochlea. 
Harrison (1998) developed an animal model of selective IHC loss resulting in many of 
the characteristics of auditory neuropathy (Harrison, 1998). We propose that the 
„paradoxical‟ pattern of auditory abnormalities that we have seen in neuronopathic GD 
could reflect preferential damage to the IHC pathways with preservation of normal or 
near-normal OHC pathways. Following IHC degeneration there is associated loss of 
type I afferent fibres (Takeno et al., 1998) (which constitute 90-95% of the auditory 
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nerve) and that more central neurons (at least to the mid-brain) will also show some 
degeneration. Thus, central involvement is not precluded by this hypothesis (Salvi et al., 
1999). Further audiometric studies including middle latency and cortical evoked 
responses are urgently needed to clarify the origins of these abnormalities. 
 
4.7.3.1  Is there a link between auditory signs and eye movement signs? 
It is not clear why either the auditory and saccadic systems appear to be 
preferentially affected in neuronopathic disease. Our data suggests that there may be a 
link between the eye movement and auditory abnormalities in neuronopathic GD. One 
possibility is that these pathways are more vulnerable as a result of some direct (or 
indirect) neurotoxic event. The unusual pattern of audiological and oculomotor 
abnormalities is consistent with an excitotoxic mechanism predisposing nerve cells to 
glucocerebroside toxicity, which is further exacerbated by high average neuronal firing 
rates. Recent animal studies have identified a possible candidate as glutamate, an 
excitatory amino acid that may be responsible (Korkotian et al., 1999, Pelled et al., 
2000).  
Recent studies have shown that neuronal cell cultures treated with 
glucocerebrosidase inhibitor have been found show an increased sensitivity toward 
glutamate and other metabolic inhibitors, suggesting compromised neuronal function. A 
release of intracellular Ca2+ appears to be related to this increased sensitivity, resulting in 
neuronal cell death (at least in neurons with elevated glucocerebroside levels) 
(Korkotian et al., 1999, Pelled et al., 2000). Therefore, GD neurotoxicity might be 
directly attributed to accumulation of the substrate itself. The addition of 
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glucocerebrosidase to the cultured cells prevents neuronal cell death. However, 
contributions to raised intracellular Ca2+ from other toxic agents, such as 
glucosylsphingosine, cannot be excluded (Nilsson and Svennerholm, 1982, Conradi et 
al., 1984, Orvisky et al., 2000).  
Glutamate is known to have neurotoxic properties when released in large 
amounts or when incompletely recycled. In the cochlea, this „excitotoxicity‟ leads to  
neuronal death in the spiral ganglion (Pujol and Puel, 1999).  
Glutamate is also an important neurotransmitter in the supranuclear control of 
saccades. It is the dominant neurotransmitter for excitatory burst units (EBNs) (Leigh 
and Zee, 1999a), which provide the intense phasic pulse that drives the eyes at high 
speed during saccades. Dysfunction of these very active cells would lead to slow 
saccades. In addition, excitatory afferents of omnipause neurons (OPN) have been 
shown to be glutamanergic, possibly reflecting signals from the superior colliculus. 
OPNs are cells that fire continuously at high rates except during saccades. Dysfunction 
of these cells can also cause saccade slowing but could also interfere with saccade 
triggering. 
Further elucidation of these mechanisms in GD is clearly needed, but we raise 
the hope that pharmacological agents directed at the neurotoxic process itself may halt 
or even reverse neurological progression. 
 
4.7.4 Implications for correct phenotyping in GD 
One of the aims of this chapter was to determine whether the combined use of 
ocular motor and auditory tests, could help improve phenotypic identification in GD. In 
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this study, we have clearly shown, for the first time, two distinct phenotypes with one 
group exhibiting normal eye movements and no audiological abnormalities that we 
could detect. A second group had uniformly abnormal saccadic eye movements and 
ABRs. Remarkably there were no exceptions in spite of a range of severity of disease. 
Our findings lead us to conclude that GD1 and neuronopathic GD (GD2 and GD3) 
phenotypes are distinct based on these tests. 
These results are exciting and the application of audiological testing may offer 
an inexpensive solution to the dilemma that we are now seeing in patients diagnosed 
with GD1 but who are presenting with additional PD signs.  
 
4.8 Conclusions 
In this chapter, we systematically investigated the audiological function in 25 
children with enzymatically diagnosed GD using a series of tests that measured the 
integrity of overlapping but not identical efferent and afferent pathways and brainstem 
structures in the auditory system. All of the children enrolled in this study had 
undergone formal eye movement studies. The data from our study has clearly shown a) 
that combined auditory and oculomotor studies can be used to better delineate the 
underlying neurological deficits in nGD and b) GD1 and GD3 are really distinct 
phenotypes based on auditory and eye movement testing. 
We could find no indication of gradations between the two groups, consistent 
with the notion of two distinct phenotypes –neuronopathic and non-neuronopathic. 
Although our sample size is small, the data also suggests that audiological abnormalities 
are more commonplace than previous electrophysiological studies have shown. This 
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novel finding has important implications for the habilitation of children diagnosed with 
nGD. 
We believe that these findings provide sufficient evidence to warrant the 
inclusion of audiological testing as part of the standard assessment of newly diagnosed 
GD patients and recommend that they undergo these tests prior to commencing 
treatment. Furthermore, these tests may have a wider application as longitudinal 
outcome measures for use in clinical trials or as markers of neurological burden in GD. 
We examine this in more detail in the next chapter. 
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5 Chapter 5 
The utility of the ABR as a longitudinal measure in neuronopathic 
Gaucher disease 
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5.1 Introduction 
“The development of valid clinical instruments for appraising each LSD and its 
effects on key life outcomes is but a science in the earliest period of embryonic 
development” (Cox, 2009, p2) 
 
The general outlook for patients with GD (and related orphan diseases), for 
which new treatments have been introduced, has infinitely improved (Goker-Alpan et 
al., 2008, Benko et al., 2011). However, in the race to develop these „extremely 
profitable‟ new treatments, some researchers have criticised the lack of scientific 
investment in developing outcome measures for monitoring brainstem dysfunction in 
these patients and for use in clinical trials. They have forcefully argued that resources 
have been focussed solely on developing (or modifying) drug therapies, to the exclusion 
of developing tools to monitor the progression (or remission) of neurological 
involvement in GD (Cox, 2010b, Elstein, 2011).  
These philosophical arguments – concerning the ethics of orphan drug 
treatments – are highly contentious and scientifically laudable, but they have also 
inadvertently unveiled a parallel concern, highlighted in Miekle and Hopwood (2003):  
“the effectiveness of these therapies, particularly for those LSD involving CNS 
and bone pathologies, will rely heavily upon the early diagnosis and treatment of the 
disorder, before the onset of irreversible pathology” (S36).  
 
Our ability to test the neurological efficacy of new therapies is very limited, if 
not absent, for the young or cognitively impaired child. What tools or techniques can we 
use to determine the success of these different therapies that are tasked with halting (and 
ideally reversing) the neurological component and meet an unprecedented demand for 
early diagnosis and longitudinal monitoring of disease status in these conditions.  
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In our previous chapter, we showed that combined auditory and oculomotor 
studies could be used reliably to detect the presence of neuronopathic disease before 
overt neurological signs and symptoms become manifest. As such these tests have the 
potential to provide a means for preclinical diagnosis of brainstem disease in nGD in the 
very young child. In this chapter, we build on these results and ask whether the auditory 
tests could be used to measure the disease burden for those patients on treatment.  
Two key questions arise: 
(3) Can the ABR be used for long term monitoring of any neurological progression 
in GD? Little is known about the fluctuations in the ABR over time and if we 
hope to exploit the full potential of the ABR for longitudinal monitoring, then it 
is imperative that we address this issue.  
(4) If the ABR is shown to be a sensitive and reliable longitudinal measure of 
subclinical neurological disease burden, then can the ABR be used to capture 
any drug efficacy over the limited time frame of clinical trials?  
 
In this Chapter, we present two empirical studies. Our first study is concerned 
with our question of whether the ABR can be used to reliably measure the disease 
burden in the neuronopathic subtypes of GD. We present data for the first time of serial 
ABR recordings in type 2 and type 3 GD. In our second study, we take an in-depth look 
at an emerging and promising treatment, i.e., substrate reduction therapy (SRT), an 
alternative approach to the current enzyme replacement therapy. We then present our 
data on use of the ABR as a secondary outcome measure in the substrate restriction 
therapy GD3 trial.  
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5.2 Experiment 1: The utility of the ABR in monitoring the disease burden 
in nGD 
5.2.1 Introduction 
Biomarkers are objective, biological measurements that are used to aid in the 
diagnosis of disease and to monitor disease progression. However it is clear that not all 
biomarkers that have great value for diagnosis are suitable when it comes to monitoring 
disease progression. Indeed, some offer little value in this regard. This is particularly 
true in the study of GD where the application of systemic biomarkers do not necessarily 
reflect the neurological component of the metabolic disease.   
Let‟s consider one example relating to the diagnosis of GD. At present, the 
definitive diagnosis of GD is based on the activity level of the enzyme 
glucocerebrosidase. In individuals with GD, the enzyme activity is significantly lower 
than in individuals without GD. However, as we have previously argued in Chapter 4, 
there is no evidence to show that this biomarker is able to differentiate between non-
neuronopathic and neuronopathic phenotypes (Pentchev et al., 1983). Furthermore, it 
has no value in predicting the rate of neurological progression or severity (Beutler and 
Gelbart, 1996, Cox, 2010b, Elstein, 2011).  
In order to monitor neurological progression in GD, we need to look for a 
different set of markers that specifically serve this purpose – suitable neurological 
markers that can detect change in neurological function. Several neurological 
biomarkers have been proposed as having a potential utility as a biological marker of 
disease burden in nGD. These putative biomarkers include the clinical evaluation of a 
subset of neurological symptoms, (e.g. assessing mental state, cranial nerves, motor 
skills, and other neurological symptoms; (Schiffmann et al., 1997, Altarescu et al., 
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2001b)), somatosensory evoked potentials (Garvey et al., 2001) and a series of 
neuropsychological assessments (such as Purdue Peg Board test, Wechsler Scale, 
Benton visual retention test, Rey auditory verbal learning test, d2 test of attention, 
continuous performance test, and Trail Making Test  (Benko et al., 2011).  
However, many of these routine clinical markers have no quantitative data and 
their use in monitoring response to therapy is poorly defined. Furthermore, many of 
these assessments are critically dependent upon a considerable degree of co-operation 
and communication.  
An alternative approach, which has been used to document neurological 
involvement in GD, has involved the use of a questionnaire-based severity scoring 
measurement. Two scales are routinely used to assess the severity of involvement for 
patients with GD (Zimran et al., 1992, Di Rocco et al., 2008). Of note, these scales 
calculate all neurological involvement in one domain only, and are not sensitive enough 
to track neurological changes seen over time. More recently, Davies et al. (2007) 
developed a list of clinical signs and symptoms, along with a severity-scoring system, 
for patients with nGD. Unfortunately during the development of this tool, authors 
excluded reports of type-2 patients, and focused only on the severity and progression of 
symptoms in patients with GD3 (Davies et al., 2007). 
One attempt to address this gap in our clinical knowledge resulted in the 
establishment of a specialist (European-wide) Task Force on nGD. They were tasked 
with developing guidelines for the assessment and monitoring the neurological aspects 
of GD (Vellodi et al., 2001). These guidelines recommended a comprehensive clinical 
examination at the initial assessment to include formal eye movement studies (where 
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possible), audiometry, neuro-ophthalmology assessment, brain imaging (MRI or CT), 
electrophysiological measures (EEG and ABR) and psychometric testing to establish 
the distribution and types of neurological abnormalities that may be present. Table 5.1 
shows a summary of the serial measures and schedule that are recommended, following 
the initial clinical assessment.  
How well these guidelines were received or more importantly, how well they 
were implemented remains unclear. In the following sections, we consider the evidence 
to support the application of the ABR as a longitudinal measure in normal hearing 
subjects and in patients diagnosed with GD. 
Table 5-1 Minimum clinical protocols for longitudinal monitoring neurological involvement in GD.  
Follow up assessment Time Frame (mo) Other information 
3 6 9 12 O  
Clinical examination Neurological exam 
 
X X X X  In year 1, a neurological 
exam should be 
undertaken every 3 
months and then every 
6 months after. 
Eye movement 
examination (preferably 
formal) 
 X     
Neuro-ophthalmological 
investigation 
 
   X   
Measurement of 
peripheral hearing 
   X   
Brain imaging MRI (or CT if MRI not 
available) 
    X Only if clinically 
indicated 
Neurophysiology EEG     X Only if clinically 
indicated (eg) seizures. 
ABR    X   
Neuropyschometry IQ tests    X  Recommend widely 
available tests (eg) 
WISC-III 
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5.2.1.1 The longitudinal study of the ABR in normal human subjects and in 
neurological cases 
Previously in Chapter 1, we argued that the ABR test had the potential to 
objectively track changes in the status of the auditory brainstem pathways. The 
literature offers a number of examples of this attribute, including documentation of the 
natural fluctuations in ABR activities that occur in normal human subjects (Chiappa et 
al., 1979, Edwards et al., 1982, Tusa et al., 1994). Longitudinal studies of the ABR have 
also been used to assess changes in brainstem function in patients diagnosed with MS 
and head trauma (Robinson and Rudge, 1978, Aminoff et al., 1984, Nuwer et al., 1987, 
Schoenhuber et al., 1987).  
One the earliest studies to assess the reliability of the ABR, as a longitudinal 
measure, was reported by Chiappa et al., (1979). They measured the ABR in a small 
group of normal hearing participants (n=8), over an interval spanning 2 – 9 months. 
Their study showed no statistically significant changes in ABR latency or amplitude, 
suggesting that the ABR is a robust technique for serial application (Chiappa et al., 
1979). Similar findings were also reported in Edwards et al., (1982) and Robinson and 
Rudge (1978).   
Repeated ABR measurements were also examined in a larger sample (n= 87 
normal hearing subjects) over a longer time frame (2 years). Although the ABR was 
shown to have an increased variability in latency and amplitude compared to previous 
studies, it was not considered clinically significant. The authors concluded that the ABR 
was a „stable‟ electrophysiological measure, that could be used longitudinally to capture 
changes (if any) in auditory brainstem disease (Tusa et al., 1994). 
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Serial ABRs have also been used to assess the integrity of brainstem pathways in 
a number of neurological disorders, particularly in MS. In contrast to the studies in 
normal hearing participants, studies that have used the ABR as a longitudinal measure 
in neurological disease have reported wide variation in the latency and amplitude of the 
ABR component (Robinson and Rudge, 1978). One study reported that the ABR was an 
extremely reliable measure in control subjects and in clinically stable MS patients over 
2.5 years. However, the ABR in some patients who had clinical relapses during the 
study showed significant fluctuations in both the latency and amplitude parameters 
(Robinson and Rudge, 1978). This finding was supported by another study in 12 
patients diagnosed with MS, that also showed excessive variability between test 
sessions even when the clinical deficit was stable (Aminoff et al., 1984). In contrast, 
Nuwer et al., (1987) described the ABR as a „sensitive and objective measurement‟ 
based on recordings that took place over a 3 year double-blind, placebo-controlled drug 
trial in MS (Nuwer et al., 1987).  
The reason for the discrepancy between these studies is not clear. One 
possibility may reflect different technical applications of the ABR, or a heterogeneous 
MS population with varying expression of symptoms and ages. Clearly, the role of the 
ABR in monitoring disease progression requires further study.  
 
5.2.1.2 The longitudinal study of the ABR in GD 
Six studies have recorded serial ABR measures, since the introduction of the 
European guidelines more than a decade ago (Altarescu et al., 2001a, Aoki et al., 2001, 
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Cox-Brinkman et al., 2008, Benko et al., 2011). These longitudinal studies are 
summarised in Table 5.2.  
Two studies have monitored the ABR in GD2 infants. Both documented a clear 
deterioration in the ABR over a very short time interval (1-2 months). Moreover, they 
identified that ABR abnormalities were present at a very young age (age 7 weeks) 
(Lacey and Terplan, 1984). Because of the relentless neurological progression observed 
in GD2, treatment is usually palliative. There have been no studies investigating 
whether ERT (or any other treatment options) can modify the ABR in GD2.  
The picture in GD3 is more confusing and the potential for the ABR to be used 
as an outcome measure for monitoring neurological disease remains unclear. One study 
has recently claimed that it is:  
“possible to study the longitudinal course of a complex neurometabolic disorder such 
as GD3 with objective neurological, neurophysiological and neuropsychological 
endpoints” (Benko, 2011, p.8). 
 
However, from the limited data presented in this study, it is not entirely clear 
how well the ABR fulfils that role. From the small number of studies conducted, it is 
clear that although a few investigators have recorded ABRs in GD, there is still no 
agreement as to whether audiological investigations could be a sensitive longitudinal 
marker of disease burden. Our goal in this experiment was to determine whether the 
ABR could be used to provide objective evidence of the time course of neurological 
involvement (progression or remission) in patients diagnosed with nGD who were 
undergoing high dose ERT.   
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Table 5-2 Summary of longitudinal ABR studies previously reported. 
Author Year n Phenotype Treatment ABR Baseline Follow 
up (yrs) 
ABR Final 
Kaga et al. 1982 1 GD2 None 
Abnormal – waves I,II and III 
present but prolonged  
 
2/12 
Abnormal – waves I and II present but 
delayed. Wave III present but prolonged 
on left ear only 
Lacey and 
Terplan 
1984 1 GD2 None 
Abnormal – waves I, II and III 
present in both ears 
1.5/12 Abnormal – only waves I and II present  
Altarescu 2001 21 GD3 ERT 
Normal ABR in 11 cases; 
Abnormal ABR in 10 cases 
2 – 8 
 
11 patients were reported with normal 
ABRs, of which only 2 showed 
deterioration.  
Of the remaining 10 with abnormal 
ABRs, there was no deterioration, and 2 
even showed improvement 
Aoki 2001 1 GD3 ERT Only wave I was present in both ears 1 
ABR improved following treatment with 
ERT - waves, I-II, IV-V on one side and 
wave V on other ear were observed. 
Cox-
Brinkmann 
2008 3 GD3 
Cases 1 and 2 were on ERT only but 
followed with 12 mo. Of comb ERT/SRT 
 
Case 3 has only had comb therapy 
Case 1 - normal ABR reported 
 
Case 2- report a „grossly abnormal 
ABR‟ – waves I and V only 
 
Case3 - mildly prolonged waveforms 
3 – 7 
Case 1  - ABR deteriorated (absent wave 
IV/V and prolonged I-III) 
 
Case 2 – no change 
 
Case 3 – ABR normalised following 
comb therapy. 
Benko et al. 2011 15 GD3 
All patients except one 
were on enzyme replacement therapy 
(ERT) years, while patient 14 was 
successfully treated with hematopoietic 
stem cell transplantation. 10 patients 
„temporarily‟ received investigative SRT  
as part of a clinical trial 
4/15 had normal ABRs, varying 
degrees of ABR abnormalities were 
reported in the other 11 patients.   
2 – 4 
Of the 15 cases presented, only 12 had 
serial measures. 
9/12 cases had an abnormal ABR on the 
right ear and 8/12 had an abnormal ABR 
on the left. 
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Here we present our serial ABR findings in a group of GD3 children who were 
receiving high-dose ERT and in two infants diagnosed with GD2 (pre and post ERT 
treatment). A preliminary account of this work has appeared in two papers (Campbell et 
al., 2003, Campbell et al., 2004). 
 
5.2.2 Methodology 
5.2.2.1 Subjects  
Out of a pool of 14 potential patients with nGD, 10 patients underwent serial 
ABR testing. The remaining 4 cases were not included in this study: two children had 
received bone marrow transplants (cases 12, 20) and were not receiving ERT. One case 
had a mixed moderate hearing loss and has since died (case 11). We were unable to 
complete ABR testing in one child (case 10) as they were no longer resident in the UK.  
All of the remaining 10 patients (2 males) had been enzymatically diagnosed 
with GD and subsequently genotyped – 17/20 alleles were the L444P mutation, 1/20 
alleles were D409H, 1/20 c1263del55 and 1/20 unknown. A summary of individual 
clinical characteristics and treatments is presented in Table 5.3. All of the GD3 patients 
had been receiving high-dose ERT (120 IU/kg/2weeks) for 1- 3 years. Each of the 
patients had a significant improvement in their overall systemic response with no overt 
neurological changes observed during this study.  
 
5.2.2.2 Procedures 
All subjects had standard baseline audiological assessment as described in detail 
in Chapter 3. All of the patients described in this chapter had established SIF (Table 5.3) 
as confirmed by an experienced clinician. Other oculomotor abnormalities were 
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identified in cases 8 and 9 following clinical examination. These are described in detail 
in the Section 5.2.3.1 below.  
The ABRs were recorded to clicks (100 s in duration) of alternating polarity 
presented at a rate of 11.1/s at an intensity of 90 dB nHL using TDH-49 headphones as 
previously described in Chapter 3 (section 3.5). 
Table 5-3 Summary of clinical characteristics and treatments 
Case Sex Neurological signs Genotype Phenotype Treatment 
8 F * L444P/c1263del55 2 ERT 
9 F * L444P/U 2 ERT 
13 F SIF L444P/D409H 3 ERT 
14 F SIF L444P/L444P 3 ERT 
15 M SIF L444P/L444P 3 ERT 
16 F SIF L444P/L444P 3 ERT 
17 M SIF, Tourette-like 
Symptoms 
L444P/L444P 3 ERT 
18 F SIF L444P/L444P 3 ERT 
19 F SIF L444P/L444P 3 ERT 
21 F SIF L444P/L444P 3 ERT 
Abbreviations: U- unknown, ERT – enzyme replacement therapy, SIF = saccade initiation failure.  
* Neurological features for cases 8 and 9 are described in further detail in section 3.2.3.1. 
 
 
For cases 8 & 9, the initial ABR test and audiometry were carried out before 
commencement of ERT; thus the follow-up studies, in these two infants, described ABR, 
post-ERT treatment. We discuss cases 8 & 9 individually in section 5.2.3.1, below and 
present a comparison of the two cases who were not receiving any treatment at baseline.  
The ABR data presented in Section 5.2.3.2, describes the remaining 8 cases of 
GD3 (cases 13-19, 21; 2 males), which was undertaken in GD3 patients who were 
already receiving ERT; as such no pre-and-post ERT data was available for comparison. 
The follow-up ABR test and audiometry were carried out 1 to 3 years later. Ethical 
Committee approval was obtained for the study and informed consent was obtained 
from the parents of the younger children and from the older subjects themselves. 
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5.2.3 Results 
5.2.3.1 Clinical course and audiological findings in GD2 
5.2.3.1.1 Case 8 
This female child was born at 37 weeks to healthy unrelated parents following 
an uncomplicated pregnancy. She was admitted to the special care baby unit because of 
meconium aspiration. At this time she was also noted to have conjugated 
hyperbilirubinaemia and thrombocytopenia, which resolved spontaneously, and she was 
discharged at one month of age. Hepatosplenomegaly was noted prior to discharge. She 
was re-admitted at 6 months for poor feeding and failure-to-thrive. At 7 months she was 
cachectic, with weight and head circumference below the 3
rd
 centile. Head control was 
poor and there was generalised hypotonia with mildly increased reflexes. She had 
marked hepatosplenomegaly. At 7 months, oculomotor testing revealed full ocular 
motor range, and Doll‟s head manoeuvre was normal. No strabismus was seen.  
There was a complete absence of horizontal saccades, and horizontal headthrusts 
were evident although head control was generally poor. Optokinetic stimulation showed 
an absence of downward saccades, but some upward saccades could be elicited. White 
cell enzymes showed a low level of beta-glucosidase and elevated plasma 
chitotriosidase. Mutational analysis demonstrated compound heterozygocity for the 
L444P and c1263 del 55 mutations, confirming the diagnosis of Gaucher disease. Brain 
MRI and EEG were normal. EMG showed clear evidence of neurogenic change in the 
genioglossal and minor changes in the two facial muscles with masseter possibly 
showing some neurogenic change, consistent with a bulbar palsy. Video fluoroscopy 
demonstrated moderate oral phase dysphagia.  
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Initial audiological investigations were carried out at 7½ months. Visual 
reinforcement audiometry showed normal responses to stimuli between 0.25 and 4.0 
kHz consistent with normal peripheral hearing in at least one ear. Tympanometry was 
normal indicating normal middle ear function. Transient evoked otoacoustic emissions 
(TEOAEs) were normal with amplitudes of 12.5 dB on the right ear and 13.4 dB for the 
left ear. The ABR was abnormal with waves I – III being recorded at normal peak 
latencies and wave V absent. An emergency tracheostomy was performed following 
frequent laryngospasms and upper airway obstruction.  She was commenced at 8 
months on high dose infusions of macrophage-targeted placental glucocerebrosidase 
(Ceredase) at 120 IU/kg administrated every two weeks.  
She responded systemically to ERT over the next 1-2 months however, her 
neurological signs deteriorated. Table 5.4 shows the biomarkers commonly used to 
assess the efficacy of systemic responses to treatment. At 8½ months a gastrostomy was 
performed due to aspiration.  
Table 5-4 Systemic response to ERT at the commencement of treatment and at follow-up. 
Parameter Normal Range Case 8 Case 9 
  Baseline Final Baseline Final 
Dose  120 120 120 120 
Haemoglobin 
(g/dl) 
10.5 - 13.5 10 13.8 9 13.8 
White cell 
count (l)  
6 - 18 (x 109) 
12.7 14.56 5.43 12.15 
Neutrophils (l) 
2 - 8.5 (x 10
9
) 
4.44 6.11 2.33 8.91 
Platelets (l) 150 - 450  
(x 109) 
99 617 94 251 
Chitotriosidase 
(nmol/hr/ml)  
0-150 
21008 2992 10164 3903 
 
Subsequent ABRs carried out at 9 months showed increased latencies of waves 
I, II and III. At 11 ½ months myoclonic seizures occurred. Repeat ABR performed at 
this stage showed only wave I. Pre-and-post ERT ABR recordings are shown for both 
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infants in Figure 5.1. At 16 months she succumbed to an overwhelming chest infection. 
Post mortem was not carried out.  
5.2.3.1.2 Case 9 
This female infant was born by normal delivery to healthy non-consanguineous 
parents at 41 weeks following an uneventful pregnancy. There were no neonatal 
concerns, but feeding difficulties, recurrent vomiting and failure-to-thrive emerged. By 
4 months there was uncoordinated swallowing and abdominal distension. Hypotonia 
and a bilateral convergent strabismus had developed by 6 months, and she was referred 
to our tertiary referral centre at 7 months. Examination revealed loss of motor skills, 
strabismus, respiratory difficulties, abnormal oesophageal motility and 
hepatosplenomegaly. Oculomotor examination revealed some limitation of up and down 
gaze, full adduction and limited abduction of each eye. A vestibulo-ocular reflex was 
present to Doll‟s head manoeuvre.  
Optokinetic testing revealed a tonic deviation in the direction curtain rotation, 
with a complete absence of horizontal and vertical saccades, and headthrusts and 
synkinetic blinks were occasionally observed. Supranuclear brainstem lesions and 
probable bilateral abducent nerve palsy were indicated, and GD2 was suspected. Other 
ophthalmic investigations were unremarkable. EEG, motor and sensory nerve 
conduction studies were normal. White cell enzymes showed a low level of beta-
glucosidase and elevated plasma chitotriosidase. Molecular genetic analysis 
demonstrated that she was a compound heterozygote for the L444P and an unknown 
mutation, confirming the diagnosis of GD.  
Initial audiological investigations were carried out at 8 months. Air conduction 
thresholds measured between 0.25 and 4.0 kHz were normal, consistent with normal 
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peripheral hearing in at least one ear. Tympanometry was within normal limits 
indicating normal middle ear function. Transient evoked otoacoustic emissions 
(TEOAEs) were normal with the response amplitude signal-to-noise ratio of at least 
4dB and waveform reproducibility in at least three octave bands of >75%. TEOAE 
amplitudes were 16.5 dB right ear and 13.2 dB left ear. The initial ABR measured 
before the commencement of high dose ERT. All recordings were abnormal with waves 
I – IV being recorded at normal peak latencies and wave V absent. 
At 9 months, she was commenced on high-dose infusions of macrophage-
targeted placental glucocerebrosidase (Cerezyme®) at 120 IU/kg administrated every 
two weeks. Over the next 3-4 months, there was a systemic response, with decreased 
chitotriosidase levels and haematological improvement (Table 5.4). However, 
neurological signs did not improve. Serial ABRs (at 9, 10 months) showed a gradual 
increase in latencies of waves I, II, and III, and by 11 months only wave I and II could 
be detected (Figure 5.1).  
At 10 months a tracheostomy was performed following life threatening 
laryngospasm. At 13 months, oculomotor responses deteriorated with reduce vertical 
motility, and facial nerve palsy emerged. A gastrostomy was performed at 15 months 
for swallowing difficulties. By 18 months there were myoclonic seizures and dystonic 
posturing. She was unable to sit unsupported, and head control was poor. ERT was 
discontinued at 19 months At 20 months there were uncontrolled seizures and EEG 
revealed an excess of slow background frequencies and frequent inter-ictal epileptiform 
discharges. Respiratory distress with probable central apnoeic episodes emerged, and 
she died at 25 months from hypostatic pneumonia. A postmortem was not performed.  
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Figure 5-1 A: ABR in case 1 showing traces at baseline (before commencement of ERT) and final 
recording (after commencement of ERT). B: shows the ABR recorded from case 2. 
 
Figure has been removed due to copyright restrictions 
 
5.2.3.2 Audiological monitoring in GD3 children 
 Pure tone audiometry, tympanometry, otoacoustic emissions were normal in all 
subjects. A representative audiogram of the most severely affected case (case 18) is 
shown in Figure 5.2. The audiogram shown in Figure 5.2 shows no change in hearing 
levels‟ (i.e.) hearing is normal on both sides when measured at baseline and at the final 
measurement (Table 3.1), despite deterioration in the ABR, over the same 18 month 
interval (Appendix 2, section 9.2.6). Clearly, in the case, the change in ABR cannot be 
attributed to deterioration in the peripheral auditory system. 
ABR findings revealed diverse results including prolonged peak and inter-peak 
latencies for waves I-V and generally dysmorphic wave formation. ABRs had normal 
latencies for waves I-V in 3 patients (cases 15, 19, 21) and prolonged or absent waves in 
5 cases (cases 13-14, 16-18).  
At a stimulus intensity of 90 dB nHL, wave I was identifiable in 8/8 cases. Wave 
III was recorded in all of the cases but was delayed in 1/8 cases (case 16). Wave V 
showed the greatest abnormalities and was absent in 2/8 of all the cases (cases 13, 18) 
and delayed in 3/8 cases (cases 14, 16, 17). The morphology was abnormal in all 
patients, with markedly reduced peak-to-peak amplitudes and wave V/I amplitude ratio 
reversal (Figure 5.3). 
  
Figure 5-2 The pure tone audiogram of the most severe ABR abnormality (case 18) is shown at the 
commencement of the study and at follow-up (18 months later). 
 
  
260 
 
 
 
 
 ABRs recorded after 1-3 years showed a clear deterioration in all cases, with 
worsening morphology leading to extinction of waves, and where discernible, waves III 
and V became delayed. Wave I was still present in all 8 cases, wave III was absent in 
5/8 cases (cases 13, 16-18, 21) and wave V absent in 4/8 cases (cases 13, 16-18). We 
have summarised the ABR findings over the 1-3 years interval in Table 5.5 below and 
presented the individual waveforms for each subject in Figure 5.3. 
 
Figure 5-3 The initial (baseline) and final ABR measurements are shown for each GD3 case. 
Initial and final ABRs for cases 1-8 are shown. Each trace is the average of with two or three separate 
trials (1024 clicks, rate 11.1/s). The active electrode was positioned at Cz with the reference electrode 
positioned at the mastoid contralateral to ear stimulated and a ground electrode placed at Fz. Data was 
collected with a bandwidth of 150-3000 Hz, 12 dB per octave roll-off, and analysed employing an epoch 
of 0-20ms. In all cases two runs were carried out to check for replicability. Latencies were measured for 
waves I, III, and V and for the inter-peak intervals I-III, III-V and I-V. A normal ABR recorded from a 
child (age 12 years) with characteristically normal peak and interpeak latencies is shown for comparison. 
 
 
 
Figure has been removed due to copyright restrictions 
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Table 5-5 Summary of the patient’s clinical characteristics and ABR findings over a 3 year period.  
 
Case 
Age 
(yrs) 
Sex Neurology ABR Baseline 
Follow-up 
(years) 
ABR Final 
13 1 M SIF 
Absent wave 
V 
1 
All waves absent 
except I and II 
14 4 F SIF Delayed V 3 Delayed III/V 
15 4 F SIF Normal 3 Delayed wave V 
16 9 M 
SIF, Tourette-
like 
Symptoms 
Delayed III/V 1 All waves absent except I 
17 13 F SIF Delayed V 1.5 
All waves absent 
except I 
18 12 F SIF 
Absent wave 
V 
1.5 
All waves absent 
except I 
19 5 F SIF Normal 2 Delayed wave V 
21 3 F SIF Normal 3 
Delayed wave V, 
absent wave III 
 
5.2.4 Discussion  
5.2.4.1 Monitoring neurological progression in GD2  
To our knowledge, this is the first report of the use of serial objective 
audiological testing to monitor the neurological progression in acute neuronopathic 
Gaucher disease (GD2). For cases 8 & 9, both patients responded to the ERT 
systemically, as measured haematologically and by chitotriosidase activity although 
complete correction was not achieved as has been reported previously (Erikson et al., 
1993). Despite this improvement, both infants continued to deteriorate neurologically.  
Both infants exhibited audiological progression, as indicated by abnormal ABRs with 
absence of waves IV and V, and a gradual loss of waves II and III during the course of 
their illness, with preservation of wave I.  
Our findings of rapid deterioration in later ABR waveform components are 
consistent with the previously reported studies in GD2 (Kaga et al., 1982, Lacey and 
Terplan, 1984, Kaga et al., 1998). Interestingly, the remarkable changes in the ABR 
reported by Kaga et al., (1982) preceded any pathological changes. Kaga and colleagues 
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(1982) reported a “relative preservation of the nuclei and tracts of the auditory pathways 
in the brainstem” (p210).  
Only one other study has reported serial ABR measures and post-mortem data in 
an infant with GD2 (Lacey and Terplan, 1984).  ABR measurements were abnormal at 
the initial baseline recording (age 7 weeks), with only the earlier components being 
spared (waves IV, V were absent). By age 12 weeks, only waves I and II were evident. 
The infant died at age 13 weeks. In contrast to the post-mortem findings reported by 
Kaga et al., (1982), there was a complete neuronal absence in the cochlear nuclei 
(bilaterally), hypoplastic superior olivary complex, a complete neuronal loss in the 
vestibular nuclei and scattered neuronal loss and gliosis throughout the inferior olives. 
Although the ABR „signature‟ is comparable in both cases – clearly the 
histopathological findings are very different. This is not surprising and may simply 
reflect the different rates of neurological progression in each case reported here. Neither 
of our cases underwent post-mortem examination so we cannot draw any further 
conclusions regarding this aspect. 
 
5.2.4.2 ERT does not halt neurological progression in GD2  
The GD2 patients previously reported in these studies were not undergoing ERT 
(Table 5.2). Thus, as far as we are aware, this is the first objective evidence for 
progressive neurological involvement, despite ERT, which has included measurements 
pre-and post enzyme treatment. Our conclusion is inescapable – ERT does not halt 
neurological progression in this severe form of the disease.  
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The reason for this failure is not clear. In vitro studies of rat hippocampal cells 
have shown that delivery of imiglucerase (glucocerebrosidase) can reverse the effects of 
glucosylthioceramide (an inhibitor of glucocerebrosidase) (Pelled et al., 2000). Thus, 
the failure to halt neurological progression may reflect the known poor permeability of 
the blood-brain barrier to imiglucerase or rapid CNS turnover of this enzyme or other 
contributory toxic substances, such as glucosylsphingosine (Orvisky et al., 2000).  
One attempt to overcome the difficulties posed by the blood-brain barrier has 
been to infuse „therapeutic‟ levels of glucocerebrosidase directly into the brain. Human 
studies in GD2 have been undertaken (Lonser et al., 2007).  Infusions to the right 
paramedian frontal lobe, and brainstem regions (region of the right facial and abducens 
nuclei) were given. Despite this more aggressive approach, there was no evidence to 
support a change in the neurological status of the patient. In the absence of any therapy 
to halt, slow down or stabilise the rate of neurological deterioration in these patients, 
recent studies argue that treating the GD2 patient with ERT may merely result in the 
prolongation of pain and suffering (Vellodi et al., 2009). Our data emphasize the urgent 
need to understand the neurotoxic mechanisms in neuronopathic GD in order to develop 
effective treatments for application in this devastating phenotype.  
 
5.2.4.3 Monitoring neurological progression in GD3 
In this study, we have shown that the ABR deteriorated in all 8 children 
diagnosed with GD3 who were receiving high-dose ERT. Our data lead us to conclude 
that high-dose ERT does not prevent the deterioration of ABRs in children with GD3.  
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Although our sample is small, the data presented here is significantly different 
from data reported previously, as shown in Table 5.2. For example, Altarescu and 
colleagues (2001) showed that of 21 GD3 patients (8 months - 35 years) undergoing 
ERT, 11 patients were reported with normal ABRs, of which only 2 showed 
deterioration. Of the remaining 10 with abnormal ABRs, there was no deterioration, and 
2 even showed improvement, leading to the conclusion that most patients did not 
deteriorate neurologically under ERT. This study was supported by a claim of 
improvement, including ABR, in a 20-year-old GD3 male following 1 year of ERT 
therapy (Aoki et al., 2001).  
The reason for the discrepancy between our finding and Altarescu et al. (2001) 
study is not clear. One possibility may reflect different testing techniques and 
interpretation. Unfortunately, previous studies (Schiffmann et al., 1997, Altarescu et al., 
2001a, Aoki et al., 2001) have not published ABR waveforms or recording techniques, 
so we cannot draw further conclusions. 
Another possibility is that there are significant differences between patient 
groups. In our patients 15/16 alleles were the L444P mutation, which is the most 
common type-3 mutant allele. In the Altarescu study, 13 out of 21 patients were of  the 
L444P homozygote, 1/21 were the L444P heterozygote and 7/21 were unknown.  
The waveforms in the ABR reflect the synchronous neural activity in the 
brainstem auditory pathways, including the 8
th
 cranial nerve, cochlear nucleus, superior 
olivary complex, lateral lemniscus and/or the inferior colliculus (Chapter 2, section 2.4). 
However, because the exact generator sites of the ABR are not known, the 
pathophysiology of abnormalities is speculative, but we suggest that multiple factors 
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could be involved including axonal and neuronal loss and demyelination. 
Neuronopathic GD is known to involve brainstem (Lacey and Terplan, 1984, Harris et 
al., 1999, Bamiou et al., 2001) thus it seems most likely that the progressive 
deterioration in ABRs reflects underlying sub-clinical brainstem degeneration in our 
patients.  
We cannot exclude the possibility that some GD3 patients may have a more 
positive response to ERT, but caution is needed as lack of ABR deterioration may 
simply reflect slower neurological progression in some patients. The insidious nature of 
the neurological disease may mean that outcome measures of the efficacy of ERT or any 
other treatment for neuronopathic disease may require years of follow-up.  
 
5.3 Experiment 2 - The ABR as a ‘Neuromarker’ for Neuronopathic 
Gaucher Disease 
5.3.1 Introduction 
There is no doubt that ERT is very successful in the treatment of systemic GD 
(Kauli et al., 2000), but its therapeutic effect on the neurological component is much 
less certain (Kraoua et al., 2011). We have shown that in our earlier experiment that 
ERT is not beneficial in GD2. It is possible that the overwhelming severity of the 
infantile condition and/or irreversible foetal damage may be insurmountable with post-
natal treatment. However, even in GD3, our results from auditory studies are not 
encouraging. 
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In vitro studies have shown that exogenous enzyme should work, however the 
difficulty in delivering sufficient enzyme to nerve cells remains a significant challenge 
for researchers in this field (Pelled et al., 2000).  
An alternative strategy that has been proposed in a number of centres is to 
combine ERT with concomitant substrate depletion therapy, Miglustat (N-
butyldeoxynojirimycin)
 
(Cox et al., 2000). Clinical trials in GD1 patients have shown 
that Miglustat has a number of beneficial effects on the systemic component of the 
disease (Cox et al., 2000, Zimran and Elstein, 2003, Elstein et al., 2004). Preclinical 
studies in animal models have also indirectly shown that it crosses the blood-brain 
barrier raising hopes that this treatment could potentially enter the brain and reduce the 
neuronal burden of this lipid, thus improving the function of the CNS (Platt et al., 1994, 
Platt et al., 1997a, Platt et al., 1997b, Jeyakumar et al., 1999, Platt et al., 2001, Platt and 
Jeyakumar, 2008) .  
Preliminary ABR data has been optimistic and has indicated that combined 
therapy with Miglustat may improve neurological manifestations in GD3 (Table 5.2) 
(Cox-Brinkman et al., 2008). One study describes a marked improvement in the ABR in 
one case. Initially the ABR in the youngest sibling was reported abnormal with 
prolonged latencies. However, by the age of 3 years, the ABR had normalised.  
Our aim in this study was to evaluate the potential for clinical improvement of 
the neurological aspects of 13 children diagnosed with GD3 who were undergoing a 
clinical trial to evaluate the efficacy and safety of Miglustat. Here we report the 
longitudinal ABR data from a 24 month clinical trial that used the ABR as a secondary 
outcome measure. 
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5.3.2 Methods 
5.3.2.1 Study design including the choice of control groups 
This was a randomized, controlled study in patients with GD3. This study aimed 
to evaluate up to 30 patients diagnosed clinically with neuronopathic Gaucher disease 
who, if receiving ERT, had been stable on ERT for at least 6 months, or had 
successfully undergone a bone marrow transplant (BMT) at least 1 year prior to study 
entry. The original study took place across two centres: the UK and the US. The data we 
present in this chapter is from the UK centre only (n=13).  
Patients were required to meet all of the following inclusion criteria shown in 
Table 5.6, and none of the exclusion criteria shown in Table 5.7, in order to be recruited 
into the original 12-month treatment period. 
Table 5-6. Inclusion criterion  
Inclusion criteria Patients must meet the clinical diagnoses for nGD 
Be stable on ERT for at least 6 months or had a successful BMT at least 1 year 
prior to study entry 
Able to swallow a capsule 
 
Once it had been determined that a patient was eligible for the study, he or she 
was to be randomly allocated to either the OGT 918 group or the No Treatment group. 
The randomization schedule was to yield an overall ratio of 2:1. To randomize a patient, 
sequentially numbered scratch cards were used by the Clinical Project Manager to 
reveal the individual patient assignment. The Clinical Project Manager (central 
randomization) confirmed recruitment and the treatment group to which the patient had 
been randomized, and allocated the next patient number by faxed reply. The 
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randomization sequence used a block size of six within each stratum (splenectomy 
status), and was generated by Quintiles UK, Biometrics department. 
Randomization was stratified based on whether the patient had undergone a 
splenectomy. The rationale behind this decision was based on data from previous 
studies which have shown that splenectomised GD3 patients have a greater 
accumulation of glucosylceramide in liver and brain compared to non-splenectomized 
patients
36
.  
Table 5-7. Exclusion criterion 
Exclusion criteria Patients < 18 yrs who were unable to give informed assent or whose legal 
guardian was unable to provide informed consent. 
Patients > 18+ yrs who could not provide informed consent or whose legal 
guardian was unable to provide witnessed informed consent. 
Fertile patients who, at the time of the study, were sexually active and did not 
agree to use adequate contraception throughout the study and for 3 months 
after cessation of OGT-918 treatment. 
Patients who could not tolerate the study procedures or were unable to travel to 
the study center as required by this protocol. 
Concurrent therapy which may interfere with gastrointestinal absorption or 
motility. 
Clinically significant diarrhoea without definable cause within 3 months of 
screening visit, or who had a history of significant gastrointestinal disorders. 
Intercurrent medical conditions that rendered them unsuitable for the study 
e.g., human immunodeficiency virus (HIV), hepatitis infection. 
Creatinine clearance of less than 70 ml/min/1.73m2 (crcl  70). 
 
On completion of the 12-month treatment period, patients randomized to no 
treatment were to have the option of receiving Migustat as part of the Extension study, a 
further option to enter a 12-month Extended Use study, and on completion of Month 36 
(study end) an option of continued therapy with Miglustat was to be provided.  
                                               
36 Partially splenectomized patients were grouped with patients with an intact spleen. 
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A placebo control group was not chosen for this study because of known side 
effects of the Miglustat treatment
37
 and the well documented swallowing problems that 
have been seen in patients with GD3. 
38
 
 
5.3.2.2 Subjects 
Thirteen subjects (2 male; age range 2-19 years, mean age 8.4 years) diagnosed 
as having GD3 were recruited into the clinical trial, after informed consent had been 
obtained. The subjects were recruited from a larger multicentre study evaluating the 
efficacy and safety of Miglustat in GD3 in adult, juvenile and paediatric patients, with 
particular emphasis on changes in neurological and systemic parameters.  
Table 5-8. Demographic and baseline characteristics 
Group Age Gender Current treatment 
Treatment (TX)  
TX 1 7 F ERT 
TX 2 3 F ERT 
TX 3 2 M ERT 
TX 4 16 F ERT 
TX 5 19 F BMT 
TX 6 7 F ERT 
No-treatment (NTX) 
NTX 1 8 F ERT 
NTX 2 5 F ERT 
NTX 3 6 F ERT 
NTX 4 8 F ERT 
NTX 5 9 F ERT 
NTX 6 11 M ERT 
NTX 7 8 F ERT 
 
                                               
37  Diarrhoea is strongly associated with OGT 918 treatment (with onset occurring shortly after the 
treatment commences), no benefit would be obtained by using placebo to blind the treatment groups.  
38 Patients with NGD have swallowing difficulties, it was considered unethical to administer placebo for a 
continuous 12-month period with no potential benefit, in view of the likely discomfort patients would 
experience swallowing placebo.  
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At baseline, the 13 patients were to be randomized in to either a Treatment 
group (n=7) or a No Treatment group (n=6). The No Treatment group (n=6) received 
their normal clinical care.
39
 Table 5.8 shows the individual subject characteristics for the 
two groups. Subjects were all allocated a unique patient identifier number and the local 
assessors were blinded to the treatment. The CONSORT diagram in Figure 5.5 shows 
the flow of participants through each stage of the clinical trial. 
 
5.3.2.3 Procedure 
All patients were to complete a follow-up visit 4 weeks after either completion 
of the 12-month study or withdrawal from the 12-month study (Figure 5.4). An analysis 
of the 12-month data was planned to be carried out to compare treatment with Miglustat 
(TX) to no treatment (NTX). All patients in the study were given the option to continue 
in the Extension study for an additional 12 months (total of 24 months) as long as no 
safety reasons prohibited this. All patients were to receive Miglustat in the Extension 
study, and the Extension study was performed to collect safety and efficacy data.  
To avoid any confusion however, we will simply to refer to the groups as 
„treatment‟ (TX) or „no treatment‟ (NTX) and highlight the length of time each group 
has participated within the trial as either baseline (t=0); month 12 (t=12) and month 24 
(t=24). 
 
                                               
39 A No Treatment control group was chosen as an alternative to placebo. Patients randomized to the No 
Treatment group received the standard clinical care that would normally have been available. These 
patients continued to receive concomitant ERT throughout the study, and provided data from which a 
natural history for this disease could be built.  
 
  
271 
 
Figure 5-4 CONSORT diagram  
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ERT) 
(n=1 post-BMT) 
TREATMENT 
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(Miglustat) 
(n=6) 
Withdrawn 
(n=1) 
Entered extension 
phase (n=5) 
Completed 24 
months of 
Miglustat (n=5) 
NO 
TREATMENT 
GROUP 
(n=7) 
Withdrawn 
(n=1) 
Entered extension 
phase (n=6) 
Completed 12 
months of 
Migulstat (n=6) 
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Serial audiological assessments were performed at baseline (t=0); month 12 
(t=12) and month 24 (t=24). These included pure tone audiometry and auditory 
brainstem responses which we have previously described in detail in Chapter 3. Where 
participants were unable to perform audiometry, we have used additional screening tests 
(e.g.) otoacoustic emissions or free-field audiometry as previously described in Chapter 
3. The equipment that was used to measure each of these assessments was the same for 
each subject and did not require significant recalibration at any of the annual 
maintenance checks. 
 
5.3.2.4 Statistical Analysis 
The following summary statistics were presented for continuous variables: 
number of values, mean, standard deviation (SD), median, minimum, and maximum. 
Distribution normality and equality of variance between groups were assessed by one-
sample Kolmogorov--Smirnov test (with Lilliefors correction) and Levene‟s tests, 
respectively.  
The data is examined as group data and on a case-by-case basis to determine the 
trajectory of change. Unfortunately we were only able to perform limited inferential 
statistical testing on the ABR amplitude trial data. This is due in part to the 
heterogeneity of the groups, small sample sizes and number of missing data values
40
 . 
We were also unable to combine the audiometric data in any meaningful statistical 
analysis because of the small number of participants; particularly following the 
withdrawal of some patients and failure to complete the test by others which resulted in 
                                               
40 There are several missing data sets from the trial data, particularly latency data. This is due to the 
effects of the neurological component of the disease and ABR and not due to the ABR itself. 
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heterogeneous samples within the two groups over the 24 month interval, so a 
descriptive analysis of PTA measures was undertaken instead. 
Performance on continuous ABR amplitude data measures (waves I, III and V) 
in the treatment group was compared with that of the non-treatment group at 24 months 
using the nonparametric Mann-Whitney U test or the Wilcoxon Rank Sum Test. A 
descry All statistics were computed with SPSS (v16) statistical software (SPSS, 
Chicago, IL).  
 
5.3.3 Results 
Thirteen patients (12 on ERT, one post-BMT) were randomized to receive either 
Miglustat (n = 6) or „no treatment‟ (n = 7) for 12 months. All patients completed the 
first 12 months. Eleven patients (85%) entered the 12-month extension. Two patients 
withdrew: one from the TX group (1 female) and one from the NTX group (1 male) so 
that 5 patients completed 12 months of extension treatment with Miglustat (i.e. 5 
received combined therapy for a total of 24 months) (Figure 5.4). 
 
5.3.3.1 Pure tone audiometry 
Pure tone audiometry was completed by 10 GD3 (76.9%) subjects at all 
frequencies (0.25-8.0 kHz). Three patients (cases TX 2, TX3 and NTX 6) were unable 
to complete audiometry because of poor co-operation.  
Of the 10 cases that were able to perform audiometry at baseline, 4 cases were in 
the treatment group (TX 1, TX4, TX5 and TX 6) and 6 cases in the no-treatment group 
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(NTX 1-5 and NTX 7). Patient NTX5 had no measureable hearing on the left ear and 
this data was excluded from all further analysis.  
Audiometry (or screening audiometry) in the treatment group revealed normal 
hearing thresholds in 3 cases; a mild unilateral sensorineural hearing loss on the right in 
one case, a mild bilateral sensorineural hearing loss in one case and a case with a 
bilateral sensorineural hearing loss which was moderate-severe in the high frequencies 
(Table 3.1, Appendix 2, section 9.1). 
Table 5-9 Mean ( SEM) hearing threshold levels measured at baseline (t=0) for the right and left 
ears in dB HL 
Group Frequency 
(kHz) 
Right  Ear Left Ear 
  Mean Std.Err. Mean Std. Err. 
Treatment 
(n=4) 
0.25 16.7 4.4 13.3 1.7 
0.50 15.0 5.0 16.7 1.7 
1 18.3 6.7 20.0 2.9 
2 23.3 11.7 30.0 12.6 
4 13.3 6.0 20.0 10.0 
8 8.3 4.4 40.0 15.0 
No treatment 
(n=6) 
0.25 20.0 5.7 18.0 4.6 
0.50 19.0 5.6 20.0 3.9 
1 15.0 3.2 18.0 5.6 
2 11.0 3.7 12.0 2.5 
4 11.0 2.4 15.0 3.5 
8 8.0 4.1 15.0 5.0 
 
At baseline in the no-treatment group, 4 cases had normal hearing bilaterally, 
one had a mild unilateral conductive hearing loss on the right ear, another case had a 
bilateral mild moderate conductive loss and one case had a profound sensorineural 
hearing loss on the left ear (Table 3.1, Appendix 2, section 9.1). In summary, in the no-
treatment group, 3/7 cases had a hearing loss and 3/6 had a hearing loss in the treatment 
group. The mean hearing thresholds (in dB HL) as measured at baseline are compared 
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in Table 5.9 for both groups. For illustrative purposes we have also constructed 
individual audiometric profiles for each participant. The right and left ear data for the 
treatment group are shown in Figure 5.5 and the data for the non-treatment group are 
shown in Figure 5.6.   
Of the 10 cases that were able to perform audiometry at month 12, 4 cases were 
in the treatment group (TX 1, TX4, TX5 and TX 6) and 6 cases in the no-treatment 
group (NTX 1-5 and NTX 7). Mean hearing thresholds (in dB HL) as measured at 
month 12 are compared below in Table 5.10 for both groups.  
There was very little change in audiometric hearing thresholds in either group. 
In the treatment group, one case showed a remarkable improvement of 10 dB. This 
meant that the sensorineural hearing loss „recovered‟ slightly on the right side. Another 
case that had previously shown a conductive hearing loss also improved and was within 
normal levels (Table 3.1, Appendix 2, section 9.1). 
Table 5-10 Mean ( SEM) hearing threshold levels measured at month 12 (t=1) for the right and 
left ears in dB HL (n=10). 
Group Frequency 
(kHz) 
Right  Ear Left Ear 
  Mean Std. Err. Mean Std. Err. 
Treatment 
(n=4) 
0.25 15.0 5.0 13.8 4.3 
0.50 12.5 1.4 16.3 5.2 
1 13.8 4.3 15.0 5.0 
2 15.0 7.4 18.8 12.1 
4 10.0 6.1 15.0 10.0 
8 11.3 4.3 22.5 12.0 
„No treatment‟ 
(n=6) 
0.25 18.3 5.7 16.7 5.1 
0.50 16.7 4.9 17.5 5.6 
1 15.0 3.4 15.0 4.5 
2 10.8 1.5 12.5 1.2 
4 9.2 2.0 10.8 1.5 
8 6.7 2.1 14.2 2.7 
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Only 9 cases underwent audiometry at month 24: one case withdrew from the 
treatment group (TX 4) so that the data presented in Table 5.11 represents hearing 
threshold levels from three participants only (n=3). Six cases remained in the no-
treatment group (NTX 1-5 and NTX 7).  
Table 5-11 Mean ( SEM) hearing threshold levels measured at month 24 (T=2) for the right and 
left ears in dB HL (n=10). 
Group Frequency 
(kHz) 
Right  Ear Left Ear 
  Mean Std.Err. Mean Std. Err. 
Treatment 
(n=3) 
0.25 15.0 7.6 13.3 8.8 
0.50 13.3 6.0 16.7 7.3 
1 8.3 4.4 10.0 2.9 
2 6.7 1.7 8.3 4.4 
4 8.3 1.7 18.3 13.3 
8 10.0 2.9 23.3 18.3 
No treatment* 
(n=6) 
0.25 19.0 3.7 29.0 5.1 
0.50 18.0 5.1 25.0 4.5 
1 16.0 4.0 21.0 2.9 
2 14.0 2.9 16.0 1.9 
4 17.0 4.6 16.0 2.9 
8 13.0 4.4 15.0 4.2 
*On combined therapy for 12 months only as part of the extension study. 
If we examine the data from the treatment group (as presented in Figure 5.5) on 
a case-by-case basis, we see that there is a wide range of hearing thresholds for each 
case. Audiometry performed on patient TX1, in Figure 5.5, revealed a mild bilateral 
SNHL (bone conduction levels not shown) at baseline. By month 12, there was a 
clinically significant improvement in the overall hearing threshold levels, with both 
sides now within normal limits. By month 24, there was little change in the overall 
hearing thresholds and hearing was normal bilaterally (Table 3.1, Appendix 2, section 
9.1). 
The audiometric data for patients TX 2 and TX 3 is not shown in Figure 5.5. 
These were the two youngest participants in the clinical trial and were unable to 
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complete a full audiogram. Both participants had their hearing screened using 
otoacoustic emissions (See Chapter 3). These data showed the presence of OAEs 
bilaterally, consistent with normal cochlear outer hair cell function. This is consistent 
with hearing thresholds with normal-near normal hearing thresholds (<35 dB HL). 
There was no observable change in peripheral hearing sensitivity in either case when at 
follow up.  
Patient TX 4 withdrew from the clinical trial after month 12 – therefore no data 
is available for month 24. The audiometric profile of this participant is shown in Figure 
5.5. At baseline, a mild-moderate high frequency SNHL was recorded bilaterally. This 
showed a small improvement of 10 dB at 2 kHz only on the right ear (Table 3.1, 
Appendix 2, section 9.1). 
Pure tone audiometry revealed a mild low frequency hearing loss on the right ear 
in patient TX 5 at baseline. This is shown in Figure 5.5.  A moderate-severe high 
frequency SNHL was recorded on the left. At month 12, hearing threshold levels had 
decreased by 10 dB. At month 24, this participant showed deterioration in hearing 
thresholds on both sides (Table 3.1, Appendix 2, section 9.1). 
We were unable to record audiometry at baseline (t=0) in patient (TX6). 
However hearing was screened using a hand-held warbler system and conditioned play 
audiometry performed in the sound field (dashed blue line) in Figure 5.5. Hearing 
thresholds were within normal limits, at least for one ear (Table 3.1, Appendix 2, 
section 9.1). No change in hearing thresholds was seen at either the month 12 or month 
24 follow-up. 
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Figure 5-5 Individual audiometric data from treatment group shown as measured at three time 
points (baseline, month 12 and month 24). Normative PTA data is shown in Appendix 2, Section 
9.2.1 for comparison. 
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TX6 
 
 
By 24 months, the total number of participants with a hearing loss (in at least 
one ear) had increased from 6/13 at baseline to 8/11 (72%) of all GD3 participants. 
However, the hearing loss in the majority of these of these cases was the result of a 
conductive impairment such as impacted wax or otitis media. 
If we examine the data from the no-treatment group (as presented below in 
Figure 5.6) on a case-by-case basis across the 24 month interval, we see that there is a 
wide variation in the hearing thresholds for each participant but there is no obvious 
effect of treatment or no-treatment. 
Figure 5-6 Individual audiometric data from the non-treatment group shown as measured at three 
time points (baseline, month 12 and month 24). Normative PTA data is shown in Appendix 2, 
Section 9.2.1 for comparison. 
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NTX 2 
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NTX 5 
 
NTX 7 
 
  
For example, patient (NTX1) had a mild conductive hearing loss on the right ear 
only (bone conduction thresholds are not shown) at baseline. The hearing thresholds are 
within normal limits for the left side (Table 3.1, Appendix 2, section 9.1). At month 12 
(t=12), we observe a small improvement of 10 dB at 2 kHz on the right ear only but no 
change on the left side. At month 24 (t=24), the hearing on the right ear has normalised 
but the left ear has a mild low frequency hearing loss.  
Two cases (NTX2 and NTX3) had normal hearing thresholds for the right ear 
over the entire 24 month period. However, the hearing thresholds in their left ears 
showed some fluctuation over the same time scale (Table 3.1, Appendix 2, section 9.1). 
Patient (NTX4) had normal hearing thresholds bilaterally at baseline which showed 
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little change at month 12 (Table 3.1, Appendix 2, section 9.1). However, by month 24, 
there was a marked deterioration in hearing thresholds, particularly in the low 
frequencies on the left. 
Patient (NTX5) had a profound sensorineural hearing loss on the left but normal 
hearing thresholds on the right (Table 3.1, Appendix 2, section 9.1). There was little 
change in the overall hearing during the clinical trial. The data for case NTX6 is limited 
and is not shown in Figure 5.6. This patient withdrew from the trial after month 12. 
Hearing thresholds were screened and shown to be within normal limits for this case.  
The final participant (NTX7) had a mild-moderate mixed hearing loss 
bilaterally. A slight decline in hearing thresholds of 10 dB at 0.5 kHz and a slight 
improvement in the high frequencies by 10 dB on the left ear was seen at month 12. 
There was no observable change in these thresholds on the right side. By month 24, the 
hearing had shown some improvement but the high frequencies still showed a mild loss 
bilaterally (Figure 5.6) (Table 3.1, Appendix 2, section 9.1). 
 
5.3.3.2 Brainstem auditory evoked potentials 
We present the absolute latencies and amplitudes for the ABR for each patient in 
the treatment group in Tables 5.12 and 5.13 respectively. An arbitrary value of 0 was 
assigned as an amplitude value when a waveform was absent.  A summary of the 
presence or absence of waves (I, III and V) for individuals in the „treatment‟ group is 
presented in Table 5.14. There is no clear pattern across the group particularly when we 
examine individual patients‟ performances at baseline, month 12 and month 24.  
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At baseline, only wave I was seen on both ears for patient TX 1. However at 
month 12, there was a remarkable improvement in ABR morphology and amplitude 
with waves III on the right ear and wave V clearly identifiable on the left ear. A small 
decrease in amplitude in both ears for wave I was seen at 12 months (Table 5.13). 
However, at month 24, only wave I was recordable on both ears (Table 5.12). 
 
Table 5-12 Individual latency data for the treatment group   
Subject 
Timepoint 
(t) 
Latency (ms) 
Right Ear 
Latency (ms) 
Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
TX1 
0 
1.78 - - 1.7 - - 
12 
1.73 3.82 - 1.8 - 5.4 
24 
1.8 - - 1.63 - - 
TX2 
0 
1.68 - - 1.73 - - 
12 
1.68 - - 1.73 - - 
24 
1.66 3.41 5.88 1.8 - - 
TX3 
0 
1.73 3.5 - 1.8 3.67 - 
12 
1.61 3.43 - 1.63 3.67 - 
24 
1.7 3.48 - 1.78 - - 
TX4 
0 
1.58 - - - - - 
12 
1.58 - - - - - 
24 
W W W W W W 
TX5 
0 
1.51 - - - - - 
12 
1.58 - 5.4 - - - 
24 
1.66 - 5.3 1.58 4.61 - 
TX 6 
0 
- - 5.98 1.82 4.06 5.86 
12 
1.82 - 5.66 1.8 - 5.81 
24 
1.54 3.82 5.47 1.56 3.55 5.57 
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Table 5-13 Individual amplitude data for the treatment group 
Note: Amplitude values recorded in μV, where a wave is absent a value of 0 has been inserted. 
Subject 
Timepoint 
(t) 
Amplitude (µV) 
Right Ear 
Amplitude (µV) 
Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
TX1 
0 
0.18 0 0 0.25 0 0 
12 
0.17 0.22 0 0.12 0 0.35 
24 
0.23 0 0 0.31 0 0 
TX2 
0 
0.45 0 0 0.27 0 0 
12 
0.35 0 0 0.27 0 0 
24 
0.65 0.15 0.17 0.21 0 0 
TX3 
0 
0.34 0.17 0 0.24 0.04 0 
12 
0.35 0.23 0 0.41 0.31 0 
24 
0.48 0.32 0 0.31 0 0 
TX4 
0 
0.4 0 0 0 0 0 
12 
0.33 0 0 0 0 0 
24 
W W W W W W 
TX5 
0 
0.3 0 0 0 0 0 
12 
0.21 0 0.31 0 0 0 
24 
0.25 0 0.36 0.08 0.08 0 
TX 6 
0 
0 0 0.45 0.14 0.06 0.23 
12 
0.29 0 0.47 0.24 0.24 0.37 
24 
0.19 0.07 0.28 0.24 0.04 0.28 
 
Only wave I was identifiable on the right and left side in Patient TX 2 at baseline 
(Table 5.14). At 12 months, there was little change in the ABR except for a small 
decrease in wave I amplitude on the right (Table 5.13). At month 24, there was a 
marked improvement on the right side, with all waveforms now visible but on the left, 
only wave I was evident at a prolonged latency (Table 5.12).   
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Table 5-14 Presence/absence ABR data for the treatment group 
Subject 
Timepoint 
(t) 
Right Ear Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
TX1 
0 N AB AB N AB AB 
12 N N AB N AB N 
24 N AB AB N AB AB 
TX2 
0 
N AB AB N AB AB 
12 
N AB AB N AB AB 
24 N N N N AB AB 
TX3 
0 
N N AB N N AB 
12 
N N AB N N AB 
24 N N AB N AB AB 
TX4 
0 
N AB AB AB AB AB 
12 
N AB AB AB AB AB 
24 W W W W W W 
TX5 
0 
N AB AB AB AB AB 
12 
N AB N AB AB AB 
24 N AB N N N AB 
TX6 
0 
AB AB D N D D 
12 
N AB N N N D* 
24 
N N N N N N 
Abbreviations: N – normal (present at normal peak latency); D– delayed (waveform is present but 
delayed latency); AB – absent (waveform is absent); W – withdrew from clinical trial (*) Waveform is 
delayed but the delay has improved compared with baseline latency measurement (ms) 
 
Waves I and III were present bilaterally at baseline for patient TX 3. Wave V 
was absent on both ears at this time. By month 12, there were no major changes in the 
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ABR morphology for either side, except a mild improvement in peak waveform 
amplitude on the left (Table 5.13). At month 24, a similar pattern emerged on the right, 
with no change in the overall ABR – waves I and III were still present. However, the 
left ear had shown some deterioration by month 24 and only wave I was evident (Table 
5.14).  
The ABR for Patient TX 4, at baseline, only demonstrated wave I in the right ear 
and there was little change by month 12. Only a small decrease in amplitude was 
observed (Table 5.13). This patient withdrew from the clinical trial so no data was 
available for month 24. 
Patient TX 5 was the oldest participant recruited onto this trial and the only 
patient to have received BMT. Only wave I was identifiable on the right side of the 
ABR. There was no clear observable waveform on the left side. This may be a reflection 
of the high frequency SNHL that was measured on this ear (Figure 5.5). By month 12, a 
significant improvement in the ABR was evident, with a clear wave V. Significant 
improvement in the ABR with wave V clearly identifiable on the right ear. At the final 
measurement, month 24, waves I and V were present on the right side and wave I and 
III were seen on the left.  
The final patient enrolled in the treatment group, patient TX 6, showed wave V 
only on the right but all ABR waves were present on the left ear. An overall 
improvement in the ABR was seen at month 12, with wave I clearly identifiable on the 
right ear. There are also improvements in the absolute latencies in waves V on the right 
ear and waves III and V on the left (Table 5.13). At month 24, the ABR was normal on 
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both sides, with all waveforms showing a remarkable improvement in latency (Table 
5.12).   
Table 5-15 Individual latency data for the NO-treatment group  
Subject 
Timepoint 
(t) 
Latency (ms) 
Right Ear 
Latency (ms) 
Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
NTX1 
0 
1.68 - - 1.82 3.79 5.66 
12 
1.66 3.6 5.69 1.79 3.72 - 
24 
1.63 3.5 - 1.68 - - 
NTX2 
0 
1.54 - 5.47 1.54 3.12 5.42 
12 
1.58 3.65 5.57 1.61 3.34 5.47 
24 
1.61 - 5.47 1.54 - 5.5 
NTX3 
0 
1.51 3.55 5.83 1.58 3.5 5.66 
12 
1.58 - 5.69 1.63 3.36 5.54 
24 
1.56 3.74 5.81 1.61 - 5.47 
NTX4 
0 
1.63 3.65 5.76 1.63 - 5.81 
12 
1.73 3.67 6 1.54 - 5.81 
24 
1.68 3.67 6.02 1.66 3.98 5.93 
NTX5 
0 
1.82 3.94 - - - - 
12 
- - - - - - 
24 
1.66 - 5.54 - - - 
NTX 6 
0 
- - - - - - 
12 
- - - - - - 
24 
W W W W W W 
NTX7 
0 
- - - 1.8 - - 
12 
- - - 1.8 - - 
24 
1.9 3.22 6.05 1.73 - 5.76 
 
We present the absolute latencies and amplitudes for the ABR for each patient in 
the no-treatment group in Tables 5.15 and 5.16 respectively. An arbitrary value of 0 was 
assigned as an amplitude value when a waveform was absent. A summary of the 
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presence or absence of waves (I, III and V) for individuals in the „treatment‟ group is 
presented in Table 5.17. Visual inspection of the data shows no clear pattern across the 
group particularly when we examine individual patients‟ performances at baseline, 
month 12 and month 24. 
When we compare the wave amplitudes for the treatment group with the non-
treatment group at 24 months, we find no evidence to support a difference in the ABR 
amplitude for wave I (U=13, n.s, z= -0.365), wave III (U=13.5, n.s, z= -0.281), or wave 
V  (U=10, n.s, z=-0.921) for the right ear. There was no significant difference in the 
amplitude between the treatment groups for wave I (U=5, n.s, z= -1.834), wave III 
(U=12, n.s, z= -0.699), or wave V (U=13, n.s, z= -1.409) on the left side.  
A summary of the presence or absence of waves (I, III and V) for individuals in 
the „no-treatment‟ group is presented in Table 5.17. There is no clear pattern across the 
group particularly when we examine individual patients‟ performances at baseline, 
month 12 and month 24.  
For patient NTX 1 only wave I was present on the right ear but all waveforms 
were present on the left side. At 12 months, a marked improvement was observed for 
waves III and V on the right ear, but deterioration in wave V on the left ear. At month 
24, waves I and III were identifiable but there was marked deterioration in the overall 
morphology of the ABR on the left side and only wave I was observed (Table 5.17). 
Patient NTX 2 had a normal ABR bilaterally at baseline. At the 12 month 
follow-up, a small decrease in amplitude of wave I on both ears was evident (Table 
5.16). A worsening in waveform amplitude morphology in wave III and V on the right 
side was also seen (Table 5.16). The deterioration is independent of the peripheral 
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hearing, which has remained essentially normal. A mild improvement in wave III 
amplitude on the left ear was also seen at month 12 but at month 24 wave III was absent 
again (Table 5.17).  
 
Table 5-16 Individual amplitude data for the NO-treatment group 
Subject 
Timepoint 
(t) 
Amplitude ( µV) 
Right Ear 
Amplitude ( µV) 
Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
NTX1 
0 
0.41 0 0 0.77 0.08 0.28 
12 
0.42 0.12 0.23 0.49 0.2 0 
24 
0.21 0.32 0 0.44 0 0 
NTX2 
0 
0.5 0 0.41 0.2 0.35 0.56 
12 
0.39 0.05 0.36 0.62 0.36 0.44 
24 
0.1 0 0.32 0.34 0 0.18 
NTX3 
0 
0.39 0.19 0.42 0.41 0.08 0.28 
12 
0.36 0 0.14 0.31 0.22 0.28 
24 
0.52 0.04 0.66 0.66 0 0.29 
NTX4 
0 
0.33 0.2 0.44 0.35 0 0.44 
12 
0.18 0.12 0.32 0.31 0 0.35 
24 
0.62 0.06 0.24 0.39 0.08 0.28 
NTX5 
0 
0.25 0.22 0 0 0 0 
12 
0 0 0 0 0 0 
24 
0.46 0 0.23 0 0 0 
NTX 6 
0 
0 0 0 0 0 0 
12 
0 0 0 0 0 0 
24 
W W W W W W 
NTX7 
0 
0 0 0 0.31 0 0 
12 
0 0 0 0.33 0 0 
24 
0.2 0.09 0.29 0.34 0 0.28 
 
 
 
  
290 
 
Table 5-17 Presence/absence ABR data for the NO-treatment group 
Subject 
Timepoint 
(t) 
Right Ear Left Ear 
  Wave I Wave III Wave V Wave I Wave III Wave V 
NTX1 
0 
N AB AB N N N 
12 
N N N N N AB 
24 
N N AB N AB AB 
NTX2 
0 
N N N N N N 
12 
N AB N N N N 
24 N N N N AB N 
NTX3 
0 
N AB N N N N 
12 
N N N N N N 
24 
N N N N AB N 
NTX4 
0 
N D AB AB AB AB 
12 
AB AB AB AB AB AB 
24 
N N N N N N 
NTX5 
0 
N N N N AB D 
12 
N N D N AB D 
24 
N AB N AB AB AB 
NTX 6 
0 
AB AB AB AB AB AB 
12 
AB AB AB AB AB AB 
24 
W W W W W W 
NTX7 
0 
AB AB AB N AB AB 
12 
AB AB AB N AB AB 
24 
N N N N AB AB 
 
Patient NTX 3 had a normal ABR on the left and only wave III was absent on 
the right side. A significant improvement for waves III on the right ear was observed at 
month 12 but wave I and wave V showed a small decrease in absolute amplitude at this 
time (Table 5.16). There was a marked improvement in waveform amplitude 
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morphology in wave I on the left side. At the 24 month follow-up, wave I and V were 
present on both sides and wave III was absent bilaterally (Table 5.17).  
At baseline, on the ABR only waves I and III were identifiable in patient NTX 4. 
At the 12 month follow-up, a small decrease in amplitude of wave I on the right ear was 
evident (Table 5.16). Interestingly, at month 24 on the right ear, wave I and V were 
recorded and wave III was absent (Table 5.17). The ABR was not recorded on the left 
ear in this patient because of the presence of a profound SNHL that was measured on 
audiometry. 
The ABR for patient NTX 5 was normal on the right ear and only wave III was 
absent on the left. No change in the ABR was seen on the left ear at the follow up, 12 
months later but an increase in the absolute waveform latency of wave V on the right 
side was evident (Table 5.15). The deterioration is independent of the peripheral hearing 
which has remained normal. A small decrease in waveform amplitude and overall 
morphology was also seen in both ears (Table 5.16). At month 24, all waves were 
present on both ears, although wave V was prolonged on the right side (Table 5.15).  
The ABR was only measured at month 12 and at baseline in patient NTX 6 
because they withdrew from the clinical trial. At baseline, there were no observable 
responses in the ABR for either ear. There was no change in the ABR at month 12 
(Table 5.17).  
At baseline, there were no clear waveform components on the ABR for the right 
ear and only wave I was seen on the left in patient NTX 7[214]. No change in the ABR 
was seen at the 12 month follow up, except for slight improvement in the amplitude of 
wave I (Table 5.16). At month 24, all waveforms were seen on the right side, although 
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the latency of wave V was prolonged (Table 5.15). On the left ear, wave I and V were 
seen (Table 5.17). 
Table 5.18 presents a table summarising the overall results of the ABR. We 
compared the ABR waveform data at baseline with that at month 24. We considered an 
improvement in the ABR had occurred if a wave is not present at baseline and is now 
present. Conversely, we defined a deterioration is said to have occurred if a wave is 
present at baseline and is now absent. No change is said to have occurred if a wave is 
absent at both baseline and at month 24. 
Table 5-18 Summary of the changes in the ABR based on the presence/absence of the ABR for each 
group.  
 Treatment (TX) group No-treatment (NTX) group 
 Right Left Right Left 
 I III V I III V I III V I III V 
Improved 1 2 3 2 2 1 1 4 2 1 1 1 
No change 4 3 2 3 2 3 5 1 4 4 2 3 
Deteriorating 0 0 0 0 1 1 0 1 0 1 3 2 
N 5 5 5 5 5 5 6 6 6 6 6 6 
 
No notable differences were observed between the two treatment groups for the 
presence or absence data when we compared the groups from baseline to month 24. The 
most striking feature of the data was the variability in the ABR, which was not evident 
in our longitudinal studies using the ABR in patients receiving ERT alone. 
 
5.3.4 Discussion 
5.3.4.1 Baseline audiometry 
Our application of pure tone audiometry in this clinical trial has revealed two 
important findings. First our data constitutes the first longitudinal study of pure tone 
audiometry in children with neuronopathic disease. Our data over the 24 months has 
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shown that peripheral hearing loss is more common in these children than previously 
thought and may emerge as a concern later in this condition. We found at baseline that 
6/13 cases had a hearing loss. Four of these cases (31%) had a sensorineural hearing 
loss, consistent with damage to the cochlea. None of these cases had previously shown 
any hearing loss. By 24 months, the total number of participants with a hearing loss had 
increased to 8/11 cases (2 withdrawals). More than half of these cases were the result of 
a conductive impairment such as impacted wax or otitis media. 
The unveiling of hearing loss in GD may have been signalled earlier in our 
studies in Chapter 4, as evidenced by the lower amplitude TEOAEs in the GD3 group. 
This finding may reflect a subclinical cochlear lesion and not be detected on routine 
audiometry. Several studies have shown that normal audiograms can have „hidden 
hearing loss‟ or cochlear „dead‟ regions. Indeed, studies have shown that up to 30% of 
the OHC population may be damaged before there is any audiometric evidence in the 
quarter octaves pure tone audiometry from 0.125 kHz to 16 kHz. (Ceranic et al., 1998).  
Such findings could reflect widespread loss of afferent nerve terminals and 
degeneration of the cochlear nerve, which may also provide a partial explanation of the 
variability seen in our ABR studies (see 5.3.2.2). Damage to these inner ear structures, 
can result in perceptual abnormalities such as the speech-in-noise difficulties („noisy‟) 
as described on the listening profile by 7/11 GD3 patients (Table 4.8). Future drug trials 
should consider the inclusion of more fine-grained audiometric assessments including 
TEOAEs or the TEN HL test.
41
 
                                               
41 The TEN HL test is a simple audiometric test recently developed to measure cochlear dead regions in 
the inner ear. 
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Hearing loss is prevalent in a number of other related LSD such as Fabry‟s 
disease (Brady and Schiffmann, 2004, Desnick, 2004, Whitfield et al., 2005) and 
Niemann-Pick type C (Aisen et al., 1985, Pikus, 1991, Higgins et al., 1992, Lossos et 
al., 1997, Patterson et al., 2007). This suggests that these storage disorders may be more 
predisposed to developing cochlear hearing loss or VIIIth nerve damage (see Chapter 4, 
section 4.7.1 for further discussion of this topic).  
The data further underscores the importance of measuring hearing thresholds in 
all children, particularly those undergoing ABRs as a part of monitoring the disease 
process. There are few studies that have investigated the hearing loss in older adults 
with GD and it may be that hearing loss becomes more prevalent with age (Schiffmann 
et al., 1997, Bamiou et al., 2001, Grasso et al., 2006). Alternatively, in the era of new 
therapies, which have extended the life expectancy in these conditions, it is entirely 
conceivable that we are beginning to see the emergence of manifestations that were not 
observed prior to the introduction of these treatments. Clearly this is an area that 
warrants further study as only GD has been thoroughly investigated to date.  
  Our second finding is related to the application of pure tone audiometry in 
clinical trials. We encountered a number of difficulties in implementing this behavioural 
measure in such a young population and, in interpreting the data for a clinical trial, this 
test presented a number of challenges. For example, what can be considered a clinically 
significant improvement or deterioration in audiometric thresholds? Perhaps the greatest 
barrier lies in the lack of any standardised method of reporting hearing loss. For 
example, there are no international guidelines for describing the configuration or degree 
of hearing impairment. 
  Our studies throughout this thesis, have clearly flagged the importance of 
correctly measuring peripheral hearing. In the absence of this data, interpretation of 
  
295 
 
other audiological measures such as the ABR is less meaningful. Future studies urgently 
need to consider the importance of accurately reporting this often overlooked but vital 
test data.  
 
5.3.4.2 ABR findings 
Over the 24-month study period there was remarkable diversity in the BAEP 
responses at both recordings including absent waves I, III and/or V. When present, 
latencies were prolonged in many, but not all, cases. The majority of patients in each 
group (treatment vs non-treatment) showed no little or no change from baseline to last 
value with respect to the presence or absence in the right ear and left ear of waves I, III 
and V.  
Comparison between baseline and month 24 in the treatment revealed no change 
in the overall ABR in the majority of waveform components (17/30); an improvement 
in 11/30 waveform parameters and deterioration in only 2/30 peak waveforms. In the 
no-treatment group, comparison between baseline and month 24 ABR parameters 
reveals a similar trend with the majority of patients showing no evidence for change 
(19/36), deterioration in 7/36 and 10/36 an overall improvement in their ABR. We 
found no significant difference in the waveform amplitude (I, III or V) between the 
treatment and non-treatment participants.  
It is difficult to account for the reversal in ABR abnormalities in some cases of 
GD3, especially in the absence of a placebo group (i.e. a group not receiving any 
treatment). The improved ABR morphology was evident in some cases in both groups 
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but it is important to remember that by month 24, both groups had received some degree 
of combination therapy.  
Interpretation of the data is further complicated by the possible irreversible 
nature of the neurological deficits in GD3. For example, if the critical cells (and/or 
neural circuits) involved in generating a synchronous onset ABR response have suffered 
irreparable damage during the disease process, then the best outcome we would expect 
is that treatment would prevent further progression and the ABR parameters would 
remain stable over time or show no change at all. The improvement in the ABR data in 
some cases suggests partial or incomplete damage to auditory brainstem circuits.  
To the best of our knowledge, only 6 studies have undertaken serial ABR 
measures (Table 5.2). Two of these studies (n=16) have examined the effect of 
combined therapy on the ABR. Interestingly, the uncharacteristic variability that we 
observed in the treatment and non-treatment groups is not restricted to our study. 
Similar data has recently been published in Benko et al., (2011).  
They reported serial ABR data from 12 cases diagnosed with GD3. The ABR 
showed remarkable variability, even within the same subject, similar to our own 
findings. For example, 3/12 showed an improved ABR, 4/12 deterioration and 5/12 
reported no change in the ABR on the right ear. Similar data was presented for the left 
ear (3/12 improvement in the ABR; 2/12 deterioration on one or more ABR parameters 
and no change in 7/12). Unfortunately, latency and amplitude data was not shown and it 
is entirely unclear which patients were on combined treatment (ERT and Miglustat) 
although the authors comment that 10 of the patients had received combination therapy 
during the study interval (4 years).  
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Such variation in the ABR is not typical in studies of normal hearing controls 
(Robinson and Rudge, 1978, Chiappa et al., 1979, Tusa et al., 1994). Indeed, ABR peak 
latencies and inter-peak latencies have been shown to be highly reproducible, even 
when measured over a 2 year interval (see Section 5.2.2.1 for further discussion). Nor 
was this variability evident in our longitudinal ABR studies of ERT in GD2 and GD3.  
Studies in MS have reported a highly variable ABR in „active‟ disease but not in 
healthy controls or „clinically stable‟ patients (Robinson and Rudge, 1978). These 
studies point to a number of possible causes for fluctuations in the ABR conduction 
velocity. For example, it might be due to the sensitivity of the ABR to extrinsic factors 
such as small changes in temperature, or non-pathologic characteristics such as hormone 
fluctuations or altered calcium/phosphate levels in patients, an important consideration 
in GD patients or methodological issues such as sampling rate of patient testing (i.e. 
how often were patients tested, time of day assessed etc) (Table 3.7) (Hall et al., 1988, 
Jerger and Johnson, 1988, Dehan and Jerger, 1990, Rodriguez et al., 1995, Rodriguez et 
al., 1999, Hall, 2007).  These data could also be explained by sub-clinical changes in the 
peripheral auditory system (see earlier in section 5.4.3.1). Further study exploring the 
potential influence of each of these factors is essential. 
Alternatively, we could attribute the variability to the disease state, but the 
neural origin is unknown (i.e) due to the natural history of the disease. Or it may simply 
be the case that some individuals have a more positive response to treatment. 
We could not clearly show evidence that Miglustat had an influence on the 
progression of ABR abnormalities, in part because there was little change in ABR 
parameters over the observed period. These results differ significantly from previously 
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reported case studies (Cox-Brinkman et al., 2008) (Table 5.2). The failure to detect 
treatment effects on the ABR may have resulted from multiple factors. For example, our 
trial may have been too short and lacked statistical power to detect any significance. 
Tusa et al., (1994) has suggested a minimum of 7 patients in each group (control and 
treatment) to detect a statistically significant difference of 0.20ms in the I-III and III-V 
IPL and a minimum sample size of 10 to detect a statistically significant change in the I-
V IPL
42
 (Tusa et al., 1994).  Other possibilities that could explain the lack of an effect 
include a marginal inhibitory effect on glucosylceramide synthesis of Miglustat 
compared with the concentration in the brain.  
In summary, the 24-month trial of Miglustat – the first randomised, controlled 
study of a drug treatment in patients with GD3 – did not show significant differences on 
the ABR. These results must be interpreted cautiously because of the design of the study 
including a small sample with widely different baseline characteristics and a lack of a 
placebo control. Our findings also indicate that the ABR may provide important 
diagnostic information; but their role in monitoring disease progression has not been 
established. Larger scale trials, with rigorous methodology and systematic test 
application need to be undertaken.  
 
5.3.4.3 Comparison of audiological assessment in other treatment trials 
A number of clinical studies have advocated the use of eye movements and/or 
auditory studies as biological markers for monitoring GD (Harris et al., 1999, Vellodi et 
al., 2001, Baldellou et al., 2004, Grabowski et al., 2004, Accardo et al., 2005a, Pensiero 
                                               
42 The sample size is calculated on two measures in each subject, a power of 80% and a two-tailed α = 
0.05. 
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et al., 2005, Cox-Brinkman et al., 2008, Vellodi et al., 2009, Accardo et al., 2010) and 
in other LSD (Bembi et al., 2006, Patterson et al., 2007).  
One study that systematically measured SEM in siblings diagnosed with GD3, 
showed that that quantitative eye movement studies were able to identify subtle 
neurological changes in these patients. Moreover, they documented an improvement in 
SEMs in one case (Accardo et al., 2010). The ABR has also been shown to be a useful 
marker in studies of neuronopathic GD (Cox-Brinkman et al., 2008, Accardo et al., 
2010, Benko et al., 2011). More recently, Benko et al., (2011) reported a significant 
correlation between saccadic eye movements and ABR latency in nGD. 
However, the use of eye movements has also been strongly criticised. Kraoua et 
al. (2011) measured eye movements in 6 patients with neuronopathic GD. They 
observed that the eye movement deficits occurred early in the disease process in nGD 
but argued that eye movements were not a sensitive outcome measure for monitoring 
disease progression in GD. They argued that the presence or absence of atypical eye 
movement signs was as 
“erratic in treated patients as in untreated patients making it a poorly reliable 
marker of the efficacy of ERT on other neurological signs of the condition” (p1).  
Eye movement studies in clinical trials have also been heavily criticised for 
selecting inappropriate saccadic measures. One small study of children with Tay Sachs 
disease (and other GM2) showed that saccadic latency was a more robust and sensitive 
serial measure in LSD (Roos et al., 2011). The authors strongly condemn earlier clinical 
trials (Patterson et al., 2007, Schiffmann et al., 2008, Benko et al., 2011) that have used 
markers such as duration, amplitude and peak velocity to quantify neurological 
impairment.  
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Remarkably, the use of audiology and eye movement studies in clinical trials has 
also received criticism for failing to measure cortical function. Roos et al., (2011) 
argued that these markers of brainstem function fail to reveal anything about global 
cortical function or produce any data that could be used to measure therapeutic efficacy. 
The censure of these measures simply because they are not measures of cortical 
function is unreasonable. These measures are selected because they do measure 
brainstem disease. 
So what are the characteristics of an ideal marker of neurological disease? Cox 
(2009) argues that these markers need to be simple, quick to administer, inexpensive 
and sensitive. The techniques that we have advocated in this thesis, meet many of these 
requirements. However, we do not believe that the application of these techniques, 
particularly the audiological measures have demonstrated sufficient sensitivity for GD 
to use as a „stand-alone‟ or as a „primary outcome measure‟. There is a wide variation in 
the ABR – across parameters – as demonstrated by our application in a clinical trial. 
Outcome measures of the efficacy of any treatment for neuronopathic disease 
may require years of follow-up. Thus, there is an urgent need to find means of 
monitoring the disease burden. It is possible that ocular movements and auditory testing 
may provide such a way. However, too few patients and lack of standardised measures 
represent significant hurdles that need to be overcome. 
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5.4 Conclusions 
In the first experiment of this chapter we showed that the ABR in neuronopathic 
GD patients continues to deteriorate even during treatment with ERT, suggesting that 
ERT therapy alone does not halt the decline in the neurological manifestations of GD. 
In the second experiment of this chapter we examined whether the ABR can be a 
useful both as a longitudinal biomarker of disease progression and as a tool for 
objectively assessing the efficacy of new drug treatments for GD. We recorded the ABR 
in patients participating in a clinical trial for a new therapy for GD – Miglustat. We 
found that, over a 24 month period, the ABR varied in its abnormality within and 
between subjects but found no significant difference between the treatment and non-
treatment groups. We believe that the ABR has most application when considered as 
part of a battery tests to assess brainstem function and neurological deficits. 
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6 Chapter 6 
Audiological profile of Dancing Eye Syndrome 
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6.1 Introduction 
In the preceding experimental chapters, we investigated the use of combined 
audiological and oculomotor assessment in GD, a neurodegenerative disorder that is 
characterised by SIF and slow saccades. We identified a number of auditory 
abnormalities, originating within the auditory brainstem pathways. These findings raise 
an interesting question – if the auditory brainstem system is impaired in disorders with 
slow saccadic function, is it also impaired in disorders seen at the other end of the eye 
movement spectrum? For example, is there evidence of auditory dysfunction in 
disorders with hyper-excitable eye movements, such as opsoclonus, one of the 
distinguishing features of Dancing Eye Syndrome (DES)?  
DES is an extremely rare disorder that is characterised by a jerky ataxia, 
shivering movements (myoclonus), and „chaotic‟ saccadic oscillations (opsoclonus). In 
the majority of cases, initial signs and symptoms appear in very young children, 
typically aged between 10 months and 3 years, who have never displayed any evidence 
of neurological disease. While a number of the acute neurological signs that are 
characteristic of this disease resolve quickly, approximately 80% of all cases are left 
with residual neurological deficits (Wilson, 2006, Klein et al., 2007, Brunklaus et al., 
2011b).  
Many unanswered questions remain about which brain structures are involved in 
DES. Previous eye movement and auditory studies have implicated both the cerebellum 
(Mezey and Harris, 2002) and the brainstem (Horikawa et al., 1993) as probable 
candidates. Whatever the underlying cause, it is crucial that we identify which parts of 
the brain are affected by the disease. 
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In this chapter, we apply all that we have previously learned from chapters 4 and 
5, and investigate the utility of auditory measures in advancing our understanding of 
pathophysiology in DES. It is possible that application of the ABR (in addition to eye 
movement studies) could provide valuable new insights into the neuroanatomical 
structures that may be involved in DES. Furthermore if we can show that these studies 
are sensitive markers of any brainstem abnormalities in DES, they may offer a unique 
opportunity to facilitate earlier diagnosis, identify neural structures involved in the 
disease process and could potentially prove useful as longitudinal (prognostic) tests.  
Auditory studies in DES could also be particularly important in the acute phase because 
many of the tests used require no overt responses. 
We begin this chapter by presenting a synopsis of the signs and symptoms that 
are seen in DES. We then present a summary of previous eye movement and auditory 
studies that are pertinent to this thesis.  
 
6.2 Dancing eye syndrome  
Dancing Eye Syndrome (DES) was initially reported by Kinsbourne (1962), who 
described a striking combination of symptoms in six children. These signs included 
opsoclonus, myoclonus, ataxia and extreme irritability (Kinsbourne, 1962). Since then, 
a number of publications have described the same disorder – albeit with a wide variety 
of different names. We have summarised these various synonyms in Table 6.1. In order 
to avoid confusion we will use the term DES throughout the remainder of this thesis. 
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Table 6-1 A summary of the various names by which DES is known in the scientific literature* 
Description Reference 
Myoclonic encephalopathy of infants (or 
childhood) 
(Martin and Griffith, 1971, Leonidas et al., 1972, 
Senelick et al., 1973, Brandt et al., 1974, Delalieux 
et al., 1975) 
Dancing eyes (Chiba et al., 1970, Kalmanchey and Veres, 1988, 
Matthay et al., 2005) 
Dancing feet (Dyken and Kolar, 1968, Imtiaz and Vora, 1999, 
Senanayake and Sumanasena, 2004, Badaki and 
Schapiro, 2007) 
Infantile polymyoclonia or polymyoclonus 
syndrome 
(Dyken and Kolar, 1968, Moe and Nellhaus, 1970, 
Manson, 1973, Fowler, 1976, Kumta et al., 1976, 
Sugie et al., 1992, Horikawa et al., 1993) 
Kinsbourne syndrome (Corrias et al., 1985, Papini et al., 1992, Rodriguez-
Barrionuevo et al., 1998) 
Opsoclonus, body tremulousness and benign 
encephalitis 
(Cogan, 1968, Aikawa et al., 1984) 
Syndrome of ocular oscillations and truncal 
myoclonus 
(Baringer et al., 1968, Bhatt et al., 1982) 
Encephalopathy associated with occult 
neuroblastoma 
(Berg et al., 1974) 
Opsomyoclonus (Nickerson and Hutter, 1979, Warrier et al., 1984, 
Warrier et al., 1985, Hiyama et al., 1994, Tejeda 
and Kaplan, 1994, Honnorat et al., 1997) 
Opsoclonus-myoclonus (Battaglia et al., Leder, 1981, Rosenberg, 1984, 
Araki et al., 1989, Bataller et al., 2003, Armstrong 
et al., 2005, Koul et al., 2007, Burke and Cohn, 
2008, Brunklaus et al., 2011b) 
Opsoclonic cerebellopathy (Nausieda et al., 1981, Bachman, 1982) 
Acute cerebellar encephalopathy (Bray et al., 1969, Bray, 1972, Telander et al., 
1989, Liebling et al., 1993) 
Syndrome of rapid irregular movements of eyes 
and limbs in childhood 
(Pampiglione and Maia, 1972) 
*Adapted from Pranzatelli (1992) 
DES has been reported in both children (Korfei et al., 2005, Badaki and 
Schapiro, 2007, Klein et al., 2007, Krasenbrink et al., 2007, Catsman-Berrevoets et al., 
2009, Brunklaus et al., 2011b, a) and adults (Anderson et al., 1988, Garg et al., 1996, 
Baets et al., 2006, Brunklaus et al., 2011b, Groiss et al., 2011). The disease is often 
observed following an apparent viral infection or with neuroblastoma in children (Sheth 
et al., 1995, Turkel et al., 2006, Rothenberg et al., 2009, Sakuma et al., 2010, Brunklaus 
et al., 2011a). In adults, this constellation of symptoms exists much more rarely in 
association with carcinoma (Scholz et al., 1994, De Luca et al., 2002, Baets et al., 2006) 
or viral infection (Markakis et al., 2008, Scott et al., 2009).  
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DES is extremely rare, with prevalence estimates of 10 new cases diagnosed in 
the UK each year (Dale, 2003)
43
. Males and females appear to be equally affected 
(Boltshauser et al., 1979, Pohl et al., 1996, Tate et al., 2005) with most cases typically 
presenting before a child‟s third birthday (Dale, 2003). 
 
6.3  Clinical signs and symptoms in DES 
Clinical signs and symptoms seen in DES have two phases: acute and chronic. 
Symptoms observed in the acute phase are typically more intense. For example, at the 
peak of the illness, an affected child will have difficulty sitting or standing. They may 
have trouble speaking clearly and sleep patterns are also frequently disturbed. Many 
children will experience extreme bouts of disruptive behaviour, e.g.rage attacks, and 
extreme irritability. Others demonstrate a desperate need to be held, almost constantly 
(Mitchell et al., 2002, Turkel et al., 2006). Table 6.2 presents a summary of the more 
common signs and symptoms reported in DES.   
Table 6-2 Common presenting signs and symptoms of DES 
Signs and Symptoms 
Primary CNS involvement Other 
Opsoclonus 
Myoclonus 
Ataxia 
Dysphasia 
Neuroblastoma  
Learning difficulties and cognitive impairment 
Lethargy  
Irritability 
Sleep disturbances 
Developmental sequelae are common including 
motor, speech and language deficits 
 
 
Neuroblastoma is common in DES, although its reported prevalence is highly 
variable across studies, ranging from 40% (Brunklaus et al., 2011b, a) to 85% (Mitchell 
                                               
43 Other studies have reported a much lower incidence of 0.18 cases per million total population per year 
Pang KK, de Sousa C, Lang B, Pike MG (2010) A prospective study of the presentation and management 
of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 
14:156-161.. 
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et al., 2005). Such variability may reflect an improvement in imaging methods. 
However, others have argued that a low-grade neuroblastoma is present in all cases with 
DES but may have spontaneously regressed before detection (Pranzatelli, 1992).  
Relapses are common. The acute neurological symptoms often return during 
periods of illness, fever, stress or discontinuation of immunotherapy. Interestingly, those 
cases who experience a monophasic disease course, appear more likely to recover 
without residual cognitive and motor deficits (Mitchell et al., 2005).  
 
6.3.1 Acute neurological signs 
In this section, we describe the acute neurological signs and symptoms that are 
generally seen over a relatively short time frame, typically a few days or weeks (Klein 
et al., 2007). These include opsoclonus, myoclonus, ataxia and a disruption to normal 
behaviour patterns. We have summarised typical and atypical features in Figure 6.1. 
Opsoclonus consists of a series of involuntary, arrhythmic, chaotic, 
multidirectional saccades, with horizontal, vertical, and torsional components. We have 
previously described the features of opsoclonus earlier in Chapter 2. These 
characteristic eye movements often occur in „spells‟ or „bursts of activity‟ in DES. 
Several studies have reported that opsoclonus is occasionally seen within the two days 
of the onset of the disease (Pranzatelli, 1992, Mitchell et al., 2002, Dale, 2003, Matthay 
et al., 2005, Mitchell et al., 2005, Pang et al., 2010). It has also been reported as  
 
Figure 6-1 Flow chart summarising the distinctive motor and behavioural characteristics that are 
seen in DES.  
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Figure has been removed due to copyright restrictions 
 
appearing later in the course of the disease – after the onset of motor symptoms such as 
ataxia (Chiba et al., 1970). We will discuss the eye movement signs in DES later in this 
chapter (section 6.4.2). 
Children with DES also experience profound dysfunction in other movement 
systems (i.e.) myoclonus and ataxia. The degree of myoclonus seen in DES is highly 
variable – ranging from tremulous polymyoclonia to coarse multi-focal jerks (Baringer 
et al., 1968, Bhatt et al., 1982). These shaky movements are usually exacerbated when a 
child is trying to move or because of increased emotional distress. The cause of the 
myoclonus is unclear but EMG studies have implicated the brainstem (Gwinn and 
Caviness, 1997). This finding is also supported by sporadic case studies that describe 
exaggerated startle responses to unexpected auditory stimuli during myoclonic episodes 
(Maeoka and Maegaki, 1998, Yonekawa et al., 2011). These studies suggest that the 
pontine brainstem may be involved in DES.  
The ataxia observed in DES can have an acute or sub-acute onset. In most cases, 
the child shows signs of significant motor regression – they are often no longer able to 
walk independently or sit unsupported (Pang et al., 2010). Speech and language abilities 
are also critically impaired in children with DES but systematic studies examining this 
aspect of the disease are sorely lacking (Brunklaus et al., 2011b). 
DES is also characterised by abrupt changes in mood and behaviour. Turkel and 
colleagues (2006) describe a wide range of psychiatric symptoms including disruptive 
behaviour, affective dysregulation, severe irritability, impulsivity, cognitive impairment, 
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and poor attention
44
. However, other children with DES may present with malaise, 
apathy, a loss of social interaction and a general unwillingness to engage in age-
appropriate play (Turkel et al., 2006). 
6.3.2 Chronic neurological signs 
Longitudinal studies have shown that DES is a chronic debilitating illness. Many 
affected children experience lifelong neurologic sequelae that impair motor, cognitive, 
language, and behavioural development (Mezey and Harris, 2002, Dale, 2003, 
Brunklaus et al., 2011b). A recent retrospective review of 101 cases reported residual 
motor problems in 60% cases; atypical speech patterns in 66% cases, learning disability 
in 51%, and behaviour problems in 46% (Brunklaus et al., 2011b).  
Although there is mounting evidence that indicates that both humoral and cell 
mediated immune mechanisms are involved in DES, treatment options remain limited. 
Surgical resection of the neuroblastoma has failed to resolve many of the neurological 
symptoms (Tate et al., 2005). Short term, high dose steroid therapy is generally the most 
commonly reported treatment used but with mixed results, particularly in view of the 
associated side effects (Pranzatelli, 1992, Burke and Cohn, 2008, Catsman-Berrevoets et 
al., 2009). Figure 6.2 is a presents a summary of commonly used therapies used to treat 
DES.  
A number of different treatment strategies have been advocated in the literature. 
However, the efficacy of these individual therapies is questionable as there is little data 
                                               
44 Affective dysregulation describes a severe and persistent inability to control one‟s mood states. These 
children will demonstrate an impaired ability to filter and process the sensory information presented to 
them. This is often accompanied by explosive and unpredictable episodes of out of control behaviour. 
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Figure 6-2 A summary of the different possible treatments that are currently used in DES.  
Abbreviations: ACTH – Adrenocorticotropic hormone; IVIG – intravenous immunoglobulin 
 
 
Treatments  used 
in DES 
ACTH Corticosteroids IVIG 
Immuno-
suppresive drugs 
Treatment for 
the 
neuroblastoma 
Chemotherapy 
Surgery 
Plasmapharesis Rituximab 
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available from randomised clinical trials. Further discussion of treatments is beyond the 
scope of this thesis but see (Battaglia et al., Oguma et al., Pranzatelli, 1992, 1996, 
Veneselli et al., 1998, Yiu et al., 2001, Armstrong et al., 2005, Matthay et al., 2005, 
Mitchell et al., 2005, Pranzatelli et al., 2005b, Bartos, 2006, Blaes et al., 2008, Burke 
and Cohn, 2008, Ertle et al., 2008, Wilken et al., 2008, Pang et al., 2010) for an 
excellent review of this topic. 
 
6.3.3 Immunopathogenesis 
Earlier in Chapter 2, we stated that while opsoclonus and myoclonus can occur 
separately, the combination of both signs is extremely rare. These specific clinical signs 
signal the possibility of a tumour or a viral infection (Pranzatelli, 1992). Indeed, the 
well-documented presence of a tumour (typically a neuroblastoma) and/or infection in 
so many cases of DES has given rise to a number of theories which have attempted to 
reconcile how a tumour or a viral infection could manifest as opsoclonus or myoclonus.   
The most widely accepted theory is that DES is an auto-immune disorder in 
which the brain is, 
“an innocent bystander which is caught in the cross-fire between the immune 
system and the tumour or virus, which it is trying to destroy” (Pranzatelli, 1992, p 187).  
This hypothesis has received significant support from clinical studies that have 
shown marked improvement in symptoms following treatment with immune modulating 
therapies (Dale, 2003, Glatz et al., 2003, Armstrong et al., 2005, Kirsten et al., 2007, 
Fuhlhuber et al., 2009, Gorman, 2010). However, the exact immunopathogenesis of the 
disease is not known and no common antibody–antigen complexes have been 
consistently identified (Antunes et al., 2000).  
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6.4 Diagnosis of DES  
Diagnosing DES is fraught with difficulty – particularly as many of the clinical 
features of DES have an early onset. Furthermore, recent data suggests that children 
with a severe initial presentation, particularly in those who are very young at disease 
onset, and those who are untreated are more likely to develop long-term sequelae 
(Brunklaus et al., 2011b).  
Misdiagnosis is common. Tate and colleagues reported an average delay to 
correct diagnosis of almost 3 months, with a maximum delay of 26 months. Another 
study has shown that children are erroneously diagnosed with post-infectious acute 
cerebellar ataxia of childhood (Tate et al., 2005, Pang et al., 2010). In fact, until 
opsoclonus appears, the conditions are clinically similar, and acute cerebellar ataxia of 
childhood is far more common. Other misdiagnoses have included common childhood 
illnesses such as otitis media or more infrequently labyrinthitis, and Guillain-Barre 
syndrome. 
The difficulty in accurately diagnosing DES is further compounded by a lack of 
any objective marker of this disease. Conventional neuroimaging studies such as MRI 
or CT have provided little evidence of abnormalities or overt damage.  Two case reports 
have described focal inflammatory lesions in the pons and cerebellar vermis (Araki et 
al., 1989). Conversely, Dale and colleagues (2007) found no evidence of any anomalies 
in the brain MRI of 10 cases of DES children. Other studies such as EEG have also been 
reported as normal (Mukherjee and Chakrabarty, 2004, Aguilera Albesa et al., 2009).  
These problems underscore the need for early diagnosis and treatment. Clearly 
novel techniques are urgently required to facilitate timely diagnosis (Gorman, 2010). 
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Throughout this thesis, we have argued that audiology and oculomotor studies may 
offer a way forward. In the following sections, we begin to review the application of 
these tests in DES. 
 
6.4.1 Eye movement signs in DES 
We discussed the aetiology and possible pathophysiological mechanisms of 
opsoclonus at some length, earlier in Chapter 2. Here we briefly review the relevant 
studies that have examined opsoclonus in DES. Opsoclonus is evident when the 
saccadic system becomes „unstable‟. This rare pattern is the hallmark of DES, although 
the onset in the acute phase of the disease is highly variable with some studies reporting 
the onset of opsoclonus as late as 18 months after the start of other clinical signs (e.g. 
ataxia) (Pang et al., 2010).  
Although opsoclonus is a dramatic condition in which the eyes appear to „jump 
wildly‟, misdiagnosis is frequent, particularly as the abnormal eye movements can be 
fleeting or incorrectly diagnosed as nystagmus (Cassidy et al., 2000a). Formal eye 
movement recording is essential and can be used to differentiate between the two 
abnormal eye movements
45
. However measuring eye movements in the acute phase of 
the disease is challenging and quantitative data remains limited (Pranzatelli, 1992).  
Ocular flutter has also been widely reported in DES, particularly in patients with 
resolved DES (Pranzatelli, 1992, Mezey and Harris, 2002, Matthay et al., 2005). Ocular 
flutter consists of back-to-back saccades which are confined to the horizontal plane. 
                                               
45 Formal eye movement recordings will show burst of back-to-back saccades with no inter-saccadic 
interval if opsoclonus is present. It will not show the rhythm or slow phases of nystagmus (see Cassidy et 
al., 2000 for a review). 
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Both of these saccadic abnormalities can result in significant visual disturbance 
including oscillopsia, although systematic study examining the potential effects of these 
secondary disturbances has not been undertaken (Leigh and Zee, 1999b, Leigh and 
Kennard, 2004, Matthay et al., 2005, Ramat et al., 2005). 
An important consideration is whether opsoclonus truly resolves. Opsoclonus 
can reappear – even after apparent complete resolution – during a relapse or if 
medication is altered or reduced. One study suggests that that minimal opsoclonus can 
still be elicited on clinical examination
46
 (Matthay et al., 2005). Even in the absence of 
opsoclonus, abnormalities of smooth pursuit eye movements and hypometric saccades 
are commonly seen even years after treatment (Shawkat et al., 1993, Mezey and Harris, 
2002, Mitchell et al., 2002).  
Interestingly, one study that formally examined eye movements in 6 children 
diagnosed with DES reported that smooth pursuit was more adversely affected than the 
saccadic eye movements. They also reported that vertical saccades were more impaired 
than the horizontal saccades but that vertical saccadic function showed some degree of 
improvement when the target stimuli was slower (Mitchell et al., 2002).  
In direct contrast, Shawkat et al (1993) reported normal smooth pursuit and 
OKN in 5 children with DES, when they measured their eye movements using EOG. 
The most consistent finding in each case was overshoot dysmetria which lead the 
authors to propose that the origin of the eye movement deficit was in the cerebellar 
fastigial nuclei.  
                                               
46 Matthay et al., (2005) describes a series of clinical exams in which the child is asked to repeatedly re-
fixate from near to far, or asking a child to partially squeeze their eye-lids shut, then the clinician partly 
opens them.  
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There is considerable controversy surrounding the possible neuroanatomical 
structures that are involved in DES and the combined symptoms of opsoclonus and 
ataxia suggest a regional involvement of the brainstem and cerebellum neural circuits 
(Shawkat et al., 1993, Mezey and Harris, 2002, Helmchen et al., 2003a, Helmchen et al., 
2003b, Helmchen et al., 2003c).  
In the following section, we examine the scientific literature to determine 
whether auditory studies, particularly the ABR, show any evidence for brainstem 
involvement in DES.  
 
6.4.2 Auditory signs in DES 
There is limited evidence of auditory involvement in DES. Peripheral hearing 
loss is described in a single adult case study (Rosenberg, 1984) however it is not clear 
whether the hearing loss was the result of ototoxic treatment (i.e. chemotherapy regime) 
or whether it constituted part of the natural history of the disease.  
Only six studies have measured the ABR in patients diagnosed with DES.  
These studies have shown auditory electrophysiological abnormalities in children 
(Kalmanchey and Veres, 1988, Horikawa et al., 1993, Maeoka and Maegaki, 1998, 
Sakuma et al., 2010) and adults (Araki et al., 1989, Bartos, 2006). We have summarised 
these studies in Table 6.3. Of the 10 cases that have been reported, 5 have shown 
abnormalities on the ABR (4 children and 1 adult). Delayed wave III and V, and 
prolonged inter-peak intervals I–III and III–V were the most commonly reported 
findings. These data suggest
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Table 6-3 Summary of all previous studies comparing the ABR in DES in the last 30 years. 
Author Age at time of 
assessment  
Age on 
onset 
Disease 
course 
Treatment Hearing Recording method Comments 
      Stimulus Intensity(d
B) 
Polarity Rate 
(sec) 
Filters 
(Hz) 
Control 
Data? 
 
Kalamanchey & 
Veres (1988) 
 
Serial ABRs
 
recorded in 3 cases
1
 
15month old 
female; 
21month old 
female; 
48 month old 
female 
Relapsing 
Corticosteroids 
ACTH 
 
NR Click 
 
60 & 80 
 
NR 12.8 
150-
3600 
Y 
ABR abnormalities worse in 
acute stage of disease; less 
marked in remission. 
Prolonged III-V interval in 1 
case and I-III interval in 2/3 
cases 
Araki et al. 
(1989) 
 
ABR recorded in a 
single case. Age of 
subject at assess NR 
41 yr old 
female; 
 
Monophasic NR NR NR NR NR NR NR Y 
Prolonged I-III interval 
Horikawa et al. 
(1993) 
Serial ABRs 
recorded in a single 
case
2
 
15month old 
male 
Relapsing 
Prednisolone 
ACTH 
NR Clicks 80 dB Alt 10 NR Y 
Prolonged I-III interval 
bilaterally 
Maeoka and 
Maegaki (1998) 
 
ABR recorded in a 
single case. Age of 
subject at assess NR 
13 month old 
female* 
Relapsing Tumour resection NR NR NR NR NR NR NR 
ABR normal 
Bartos (2006) ABRs recorded in 1 
adult case. Age of 
subject at assess NR 
29 yr old female Relapsing 
Prednisolone 
ACTH 
Clonazepam 
NR NR NR NR NR NR NR 
ABR normal 
Sakuma et al. 
2010 
ABR recorded in 3 
cases. Age of 
subject at assess NR 
23 month old 
male; 
8 month old 
male; 
21 month old 
male 
Relapsing 
IVIG 
Prednisolone 
NR Click 70 NR 10 NR NR 
ABR normal in all cases – 
data not shown in the study 
Abbreviations: *neuroblastoma associated, ** ganglioneuroma associated. Age at time of assessment: Serial –1ABR measured at  2ABR measured at month intervals 
(15,16,17,18,19,20,21,22,23,25,28,32,39 months), Disease course: monophasic: symptom control within 5 months, no relapses; rl: multiple relapses; >14, 24 months, 
respectively: no remission of opsoclonus and myoclonus during that time on various medications.NT – not tested.
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that the auditory brainstem may be impaired in DES although it is not clear why some 
cases have normal ABR responses and others show abnormalities.  
Other studies have described abnormalities in the auditory startle reflex circuit. 
Yonekawa and colleagues described an exaggerated startle response to unexpected 
auditory stimuli during an episode of myoclonic status in a 3 year old male. Similar 
findings have also been reported in adults with DES (Wirtz et al., 2002). These studies 
lend support to the theory that the pons is damaged in DES. Other reports of auditory 
hypersensitivity have also been described. One parent described their daughter‟s 
behaviour as, 
 “…..very distressed when around loud noises and sudden movements. Moving 
traffic and car journeys made her even worse” (Caunter, 2010, p29).  
Clearly further systematic studies investigating the involvement of auditory 
brainstem pathways are needed. 
We now turn to our experimental data and present two studies. In our first study, 
we present our preliminary findings from a parental questionnaire that was administered 
to families of DES throughout the UK. Our core goal in this experiment was to 
determine whether the hyper-excitability expressed in the eye movement system, as 
opsoclonus, is mirrored in the auditory system, i.e. do children diagnosed with DES 
demonstrate an unusual hypersensitivity to sound?  
In our second study, we present for the first time a systematic audiological 
evaluation of DES. Here, we were chiefly interested in identifying whether children 
with DES have auditory deficits, and if so, whether there is any evidence of longer-term 
brainstem disease, particularly in the absence of any overt eye movement abnormalities. 
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6.5 Experiment 1: Do children with DES have hyperacusis? 
6.5.1 Introduction 
Several studies have argued that DES is the result of hyper-excitable neural 
activity in independent but neighbouring structures within the pontine tegmentum 
(Hattori et al., 1988, Araki et al., 1989, Maeoka and Maegaki, 1998, Yonekawa et al., 
2011). This hyper-excitability is evident in both the motor (opsoclonus and myoclonus) 
and behavioural responses (e.g. irritability, lack of sleep). This theory is supported by 
the apparent efficiency of ACTH in reducing some of the cardinal symptoms in DES 
symptoms, consistent with the role of ACTH in reducing cerebral blood flow and thus 
neuronal excitability.  If this „pontine‟ hypothesis is correct, then we could speculate 
that the hyper-excitability displayed in other sensory domains could have an 
audiological analogue, i.e. hyperacusis, which presents as an unusual hypersensitivity to 
acoustic stimuli.  
Hyperacusis is a subjective phenomenon that is used to describe an unusual 
hypersensitivity or discomfort induced by exposure to sound (Baguley, 2003). 
Hyperacusis may be due to either peripheral or central causes and is well documented in 
patients with Williams‟s syndrome (WS) (see Baguley, 2003 for an in-depth review). 
Central excitability, increased central gain and the failure of the nervous system to 
habituate to the startle response are all theories regarding the mechanism by which 
hyperacusis is thought to be produced (Baguley, 2003). Interestingly, a few case studies 
have described an exaggerated startle response in both children (Maeoka and Maegaki, 
1998, Yonekawa et al., 2011)  and adults (Wirtz et al., 2002). 
Measuring hyperacusis is problematic – there are no tests that are able to verify 
or quantify hyperacusis. As such, measurement of hyperacusis relies solely on self-
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reported assessment and questionnaires (Klein et al., 1990, Anari et al., 1999). 
However, evaluating the prevalence of hyperacusis in children is difficult as few 
questionnaires have been specifically developed for use in a younger population 
(Baguley, 2003), although it is clear from the limited published data that hyperacusis is 
relatively common in young children (Klein et al., 1990, Oen et al., 1997, Rosenhall et 
al., 1999, Khalfa et al., 2004, Coelho et al., 2007). For example, one study of 506 
children (aged 5-12 years) reported that the prevalence of hyperacusis was 3.2% in this 
group and that 42% were „bothered by sounds‟. Phonophobia, defined as a fear of 
sound, was experienced by 9% of the children (Coelho et al., 2007). Table 6.4 
summarises the studies that have examined the issue of hyperacusis in children. 
 
Table 6-4 Studies that have been used to assess the prevalence of hyperacusis in children.  
Author Questionnaire detail Key findings 
Klein et al., 
(1990) 
Parental questionnaire to families of children with 
Williams syndrome (WS) (n=65). Control group 
(n=65). 
Prevalence of 95% hyperacusis 
in WS; 12% in control group. 
Oen et al., 
(1997) 
Oral interview and parental questionnaire to families 
of children diagnosed with spina bifida (n=50). 
Control group (n=19) 
Prevalence of 50% hyperacusis 
in spina bifida; 10.5% in 
control group. 
Rosenhall et 
al., (1999) 
Hyperacusis was defined as intolerance to broadband 
click at 80 dB HL. Study was undertaken in a group of 
children diagnosed with autism (n=111). Control 
group (n=57) 
Prevalence of 95% hyperacusis 
in ASD; 12% in control group. 
Khalfa et al., 
(2004) 
Hyperacusis was defined as LDL < 80 dB HL. Study 
was undertaken in a group of children diagnosed with 
autism  (n=11). Control group (n=11) 
Prevalence of 18% hyperacusis 
in ASD; 0% in control group. 
Coelho et al., 
(2007) 
Hyperacusis was defined as lowered LDL associated 
with an abnormal annoyance to sound. Questionnaires 
for parents and children, interviews and estimates of 
LDLs were used in 506 school-aged children aged 
between 5 and 12 years old. 
Prevalence of 3.2% 
hyperacusis in school aged-
children. 
Abbreviations: ASD – Autistic spectrum disorder; LDL – Loudness discomfort levels; WS – Williams Syndrome 
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In this study we present our preliminary findings from a parental questionnaire 
that was administered to families of DES throughout the UK. Our goals in this study 
were (a) to determine the prevalence of hyperacusis and (b) to determine if we could 
better understand DES by investigating whether the „hyper-excitability‟ of DES has an 
audiological analogue, such as hyperacusis? 
 
6.5.2 Methodology 
6.5.2.1 Subjects  
An invitation letter explaining the study and a hyperacusis questionnaire (see 
6.5.2.2) was sent to parents (or guardians) who were all members of the UK DES 
association. A copy of the invitation letter is shown in Appendix 3. Of the initial 87 
postal questionnaires that were sent, 50 questionnaires (58%) were completed and 
returned by post. However, 2/87 (2%) were returned „addressee unknown‟ and 4/87 
(4%) were received after the data analysis was completed and were not used. The 
remaining 31/87 (36%) did not respond for unknown reasons.  
The returned questionnaires represent data from 31 females and 19 males, with 
an age range of 2.5 to 21 years (mean 9.5 years). Table 6.5 presents the individual 
responses for each participant to the medical and treatment segment of the 
questionnaire. An equal number of age-and-gender matched children (n=50; 31 female, 
age range 2-22 years, mean 10 years) recruited using convenience sampling techniques 
and with no known predisposing factors for hearing loss were used as controls (n=50). 
Local ethical committee approval was obtained for the study and informed consent was 
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obtained from the parents of the younger children and from the older subjects 
themselves. 
6.5.2.2  Hyperacusis Questionnaire 
The questionnaire was adapted from Klein et al., (1990). This questionnaire was 
originally designed to obtain prevalence data of hyperacusis and otitis media
 
with 
effusion (OME) in Williams Syndrome (WS) (Klein et al., 1990). The questionnaire 
consists of eight questions relating to the occurrence of hyperacusis, the nature and 
characteristics of the sounds that are considered offensive, the reaction of the child to 
these offensive sounds, previous counselling on hyperacusis and the occurrence of otitis 
media and hearing loss. The complete questionnaire is shown in full in Appendix 3. 
Figure 6.3 shows a summary of the key points of the questionnaire and self-assessment 
questions that were asked. The same questionnaire was administered to the control 
group. Parents were also asked to provide additional information regarding the history 
of their child‟s illness including treatment and outcome. 
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Figure 6-3 Flow diagram summarising the key characteristics of the hyperacusis questionnaire 
used. 
 
 
 
6.5.2.3 Data analysis 
The following descriptive statistics were presented for continuous variables: 
number of values, mean, standard deviation (SD), median, minimum, and maximum. 
For categorical data, frequencies and percentages were to be presented. Associations 
between categorical variables were evaluated using Pearson χ2 or Fisher exact tests as 
appropriate. For all correlations, Spearman‟s correlation coefficient was used due to 
non-normality of the DES data. Two-tailed statistics were used throughout, and p< 0.05 
was considered significant. All statistics were computed with SPSS (version 14) 
statistical software (SPSS, Chicago, IL). 
Patient  
data 
• Age, gender, date 
of diagnosis 
• Neuroblastoma? 
• Past treatment 
• Current treatment 
Ear 
infections 
• Constantly 
• Several 
• Rarely 
• Never 
List of 
possible 
offensive 
sounds 
• Never a problem 
• Past problem 
• Current problem 
Reactions 
to sound 
• Behavioural 
• Verbal 
• Other responses 
Sound 
„triggers‟ 
• Loudness 
• Low frequency 
• High frequency 
• Sudden onset 
• Other 
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Table 6-5 Summary of the medical, diagnostic and treatment regimes for individual respondents of the hyperacusis questionnaire (n=50) 
Patient Sex Age 
(yr) 
Age  at 
presentation 
(months) 
Neuroblastoma Past treatment Current 
treatment 
DES 
Improved? 
Improved at what 
age? (years) 
Hyperacusis 
1 F 2.5 7 Y SURG,CHEMO Viagram Y 2 Y 
2 F 2.5 28 Y 
(ganglioneuroblastoma) 
SURG , IV IMG N Y 2.7 Y 
3 F 2.5 22 Y (Adrenal gland) SURG Pred Y (slow) 3 Y 
4 F 3 U U U U U U Y 
5 F 3 13 Y (Adrenal gland) None N Y 2 Y 
6 M 3 U U U U U U Y 
7 F 3 18 N ACTH Steroids Y U Y 
8 F 3.5 24 Y(Adrenal gland) CHEMO, STEROIDS, 
SURG 
Pred Y 3 Y 
9 F 3.5 12 Y SURG, STEROIDS Pred Y (slow) - Y 
10 F 3.5 11.5 Y (Thoracic) SURG, STEROIDS N Y 3 Y 
11 F 3.5 11 Y SURG,CHEMO Pred, IMG 
infusion 
Y 4.25 Y 
12 F 3.5 U U U U U U N 
13 M 3.5 U U U U U U N 
14 F 4 12 Y (Left kidney) SURG,CHEMO Pred, IMG 
infusion 
Y 2 Y 
15 M 5 18 N N/A N Y 1.8 Y 
16 F 5 U U U U U U Y 
17 M 5 23 N STEROIDS N Y 5 Y 
18 M 5 18 Y SURG, STEROIDS N Y 4.5 Y 
19 F 5 23 Y SURG Pred, 
Azathioprine 
Y 5 N 
20 F 6 21 N STEROIDS N Y 6.2 Y 
21 M 6 U U U U U U Y 
22 M 6 21 N STEROIDS N Y 5 Y 
23 F 6.5 2 N N/A N Y 6 Y 
24 F 8 18 Y (Adrenal gland) SURG, STEROIDS N Y 4 Y 
25 M 8 28 N STEROIDS N Y 7.5 Y 
26 F 8 23 N N/A N N - Y 
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Patient Sex Age 
(yr) 
Age  at 
presentation 
(months) 
Neuroblastoma Past treatment Current 
treatment 
DES 
Improved? 
Improved at what 
age? (years) 
Hyperacusis 
27 F 8 16 N STEROIDS 
(2.5 yrs) 
N Y 4 N 
28 M 8 U U U U U U UNCLEAR 
29 M 9 18 N N/A N Y 3 Y 
30 F 10 13 N N/A N Y 5 UNCLEAR 
31 F 12 U U U U U U Y 
32 F 12 U U U U U U Y 
33 F 12 13 N ACTH N Y 7 Y 
34 F 13 18 Y SURG, STEROIDS N Y 3 N 
35 M 13 U N N N N - N 
36 M 14 21 N ACTH N Y 8 Y 
37 F 14 U U U U U U Y 
38 M 15 U U U U U U Y 
39 M 15 U U U U U U Y 
40 F 15 18 Y SURG, STEROIDS N Y (slow) - N 
41 F 16 13 N STEROIDS N Y 14 Y 
42 M 16 U U U U U U N 
43 F 17 17 N STEROIDS N Y (slow) - Y 
44 M 17 24 N STEROIDS N Y 5 N 
45 F 18 U U U U U U N 
46 F 19 U U U U U U N 
47 M 20 15 N N/A N Y 8 Y 
48 M 20 20 N NONE N Y 8 N 
49 F 20 20 Y (Adrenal) STEROIDS N Y (slow) - UNCLEAR 
50 M 21 U U U U U U Y 
Abbreviations: ACTH - , F – female, IMG – Immunoglobulin treatments, M – male, N – No, N/A – Not Applicable, Pred – Prednisolone, SURG – Surgery, U 
– unknown, Y - Yes 
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6.5.3  Results 
6.5.3.1 Study characteristics 
The mean age of the children at the time of this questionnaire was 11 years for 
males (n=19) and 8.4 years for females (n=31). The average age of onset of the disease 
was 18 months (range 7 – 28 months; n=33). Disease onset was not reported in 17 
cases. The majority of respondents reported that they had never been diagnosed with a 
neuroblastoma (n=19, 10 males). Fifteen respondents (1 male) reported that they 
had been previously diagnosed with a neuroblastoma. A significant association between 
gender and the presence of neuroblastoma was seen in our study. Neuroblastoma was 
more significantly more common in females than males in our study population (χ2, p < 
0.01) however this finding should be interpreted with caution as data was unavailable in 
16 cases (8 male). 
Several respondents reported a significant delay in the diagnosis of DES. The 
initial diagnosis was often reported as an inner ear infection (18%) or ataxia (24%). 
Medical, diagnostic and treatment information is summarised in Table 6.6.  
Thirty six percent of respondents received immunosuppressant medication, in 
various dosages, schedules and combinations. The most commonly prescribed 
immunotherapies were ACTH or prednisolone. Other treatments included surgery, 
chemotherapy or a combination (Table 6.6). Sixty four percent of our sample reported a 
significant improvement in the signs and symptoms of DES. Only 3 cases (case 5, 35 
and 48) reported receiving no treatment. Interestingly, two of these cases reported a 
significant improvement in their overall symptoms. At the time of completing this 
survey, 8 cases (16%) were still receiving treatment.  Only 4% cases reported no overall 
improvement in the disease course (Table 6.6).  
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Table 6-6 Summary of the diagnostic and treatments in the study population (n=50) 
  Males 
(n=19) 
Females 
(n=31) 
Mean age (years) 
 
 11 8.4 
Mean length of time with DES 
(years) 
 
 9.4 6.1 
Mean age DES first diagnosed 
(months) 
 
 19 17 
Neuroblastoma reported? 
 
Yes 1 14 
No 10 9 
Unknown 8 8 
    
Past treatments 
 
None 2 1 
Steroids only 9 9 
Surgery and 
chemotherapy 
0 1 
Chemotherapy and 
steroids 
0 2 
Surgery and Steroids 1 10 
Unknown 7 8 
    
Currently receiving treatment? 
 
Yes 0 8 
No 11 15 
Unknown 8 8 
    
DES improved? 
 
Yes 10 22 
No 1 1 
Unknown 8 8 
    
Hyperacusis? 
 
No 6 9 
Past problem? 8 8 
Current problem? 5 14 
 
6.5.3.2 Hyperacusis  
Of the 50 questionnaires returned, 35 (70%) respondents described having 
difficulties with hypersensitivity to sound. Of the 35 respondents who reported 
hyperacusis, 19 (5 males) reported this as a current problem (5 males) despite most 
parents reporting a marked improvement of DES symptoms (Table 6.6). Sixteen 
respondents reported that although hyperacusis had been a problem, it was no longer a 
concern (8 males). There was no significant difference between the percentage of males 
and females with hypersensitivity (χ2, p > 0.05). Thirty percent (15/50) reported that 
they had never been frightened or bothered by certain sounds. In the age-and gender 
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matched control group, only 4% (2/50) reported a problem with hyperacusis (χ2, p > 
0.05). We could find no evidence to suggest a significant relationship between those 
reporting hyperacusis and those children diagnosed with neuroblastoma (χ2, p > 0.05). 
Despite the high occurrence of hyperacusis, only one parent (2.5%) reported ever 
having received counselling by a professional about dealing with the hypersensitivity 
problem. They were advised to “avoid loud noises”. 
Respondents were asked to indicate which sounds disturbed their child (if any). 
Figure 6.5 shows the sounds that parents considered most offensive to their children. 
The types of sounds that provoked the discomfort were variable in intensity and 
frequency. Sounds that children found most disturbing were fire crackers in 80% cases; 
electric drills in 66% and motor cycles in 63%.  
The prevalence of hyperacusis in our control population was 4%, which 
compares favourably with the data published in Coelho et al., (2007) but is slightly 
lower than control groups reported in previous studies (see Table 6.4) (Klein et al., 
1990, Oen et al., 1997, Rosenhall et al., 1999, Khalfa et al., 2004).  
Parents were also asked to describe their child‟s reactions to „offending‟ sounds 
and the general type of sound that triggers the adverse reaction. Of the 70% of DES 
children who indicated that they had hyperacusis, 80% reported problems with sudden 
sounds and 71% with loudness (71%). Figure 6.6 shows a graphical representation of 
the data across gender. Regardless of the sound characteristic, females consistently 
showed more distressed responses across all categories. This was particularly evident 
when the sound was considered as having a sudden onset or was more intense (louder). 
Low frequency sounds, were reported to be the least disturbing (3%) in the DES group 
and not at all a concern in males.  
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Behavioural responses to these sounds are shown graphically in Figure 6.6. The 
most commonly reported reactions were verbal responses (51 % reporting „I don‟t like 
it‟) and the most common behavioural response was children covering their ears with 
their hands  in 69 % or cringing in 54%. 
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Figure 6-4 Stacked bar chart showing the total percentage of respondents who indicated that the sound was offensive to their child (n=35). 
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Figure 6-5 Stacked bar chart showing the sound characteristics that triggered an adverse reaction (%) in children with DES (n=35). 
 
 
 
Sudden Onset Loud High Freq Low Freq Other
0
10
20
30
40
50
60
70
80
90
100
Offensive sound characteristic
%
 R
e
sp
o
n
se
 
 
Male Female
 331 
 
Figure 6-6 Stacked bar chart showing the reaction (behavioural and verbal) to sounds offensive to the DES respondents (n=35). 
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6.5.3.3 Otitis Media 
Episodes of otitis media were reported as „never or rare‟ in 90% of females and 
68% in males. There was no significant difference between males and females for 
episodes of OME in the DES children (χ2, p > 0.05). Only one case was diagnosed with 
a unilateral sensorineural hearing loss following chemotherapy. 
Each participant was assigned an overall hyperacusis rating (OHR), which was a 
number from 0 to 3 (0 - never a problem to 3 – severe problem). A 0 was assigned to 
those who had never had problems with hypersensitivity to sound; a rating of 1 („mild‟) 
was given to those children who had a „mild‟ problem with sound as indicated by 
reacting to 1-7 offensive sounds; a rating of 2 („moderate‟) was given to those children 
who had a „moderate‟ problem with sound as indicated by reacting to 8-14 offensive 
sounds and a rating of 3 („severe‟) was given to those children who had a „severe‟ 
problem with sound as indicated by reacting to at least >14 offensive sounds. Figure 6.7 
shows the percentage of children with DES and controls with reported number of 
episodes of OME. The Spearman rank correlation coefficient between frequency of 
otitis media and OHR was not significant (rs = 0.022, p < 0.44). 
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Figure 6-7 Stacked bar chart showing the reported episodes of otitis media in the DES group and in controls.  
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6.5.4 Discussion  
In this study, we have shown for the first time, that hyperacusis is a common 
problem in children diagnosed with DES. Seventy percent of parents who responded to 
this study, reported an abnormal sensitivity to ordinary environmental sounds in their 
children. Furthermore, of the 35 respondents who described hyperacusis as a problem, 
19 cases (54%) described this as an on-going concern.  
A number of caveats need to be noted regarding the present study. Firstly, 
although the overall response rate was satisfactory (50/81), 31 parents/guardians failed 
to return the questionnaire, raising the problem of responder bias. It is possible that 
those who returned the questionnaire had different profile characteristics than those who 
did not. Because invitations were sent by an intermediate party, in this case, the DES 
UK support trust, we do not have any information about the non-responders. However, 
our data still lead us to conservatively conclude that hyperacusis is present in at least 
43% (35/81) of children diagnosed with DES.  
Another limitation of our study is the poor completion of some categories of 
questions. The reason for this is not clear. One possibility is the complicated therapeutic 
regime that many of the children receive. This was particularly the case where 
respondents had to indicate whether or not their child had been diagnosed with a 
tumour. Our study found that significantly more females with DES were diagnosed with 
neuroblastoma. Other studies fail to report any significant gender differences (Tate et 
al., 2005). We could find no significant relationship between the presence of a tumour 
and hyperacusis. However, because of the high levels of missing data we must interpret 
these results with caution.  
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Finally, our study could be criticised for being too simplistic. We did not re-
validate the original questionnaire tool, a study design error common to a number of 
earlier studies published in this area (Klein et al., 1990). Studies investigating 
hyperacusis in children are hampered by a lack of well-validated instruments and a non-
uniform description of hyperacusis (see Table 6.4) (Baguley, 2003). It is essential that 
future work in this area in undertaken to overcome these measurement difficulties.  
The high prevalence of hyperacusis documented in other neurological diseases, 
such as Williams syndrome (WS) has led to the suggestion that the abnormal auditory 
sensitivity
 
could be the result of a higher incidence of OME and the associated 
conductive hearing loss in these populations (Klein et al., 1990, Marriage and Barnes, 
1995, Katzenell and Segal, 2001). However, episodes of otitis media were reported as 
rare or infrequent in the majority of our study population and we could find no evidence 
to support a relationship between hyperacusis and otitis media. 
The pathophysiology of hyperacusis is poorly understood (Baguley, 2003). At 
present, the causes of hyperacusis are typically divided into: 1) clinical conditions 
which affect the peripheral auditory system (e.g. Bell‟s palsy, stapedectomy, Ramsay 
Hunt syndrome, and noise induced hearing loss); 2) conditions involving the CNS (e.g. 
depression, headache, head injury, learning disabilities, temporal lobe lesions and WS); 
and 3) hormonal and infectious diseases such as Addison‟s disease or Lyme disease. In 
many cases, no underlying cause has been identified (Katzenell and Segal, 2001).  
Several studies have speculated that hyperacusis may be the result of altered 
serotonin function (i.e) reduced serotonin levels within the CANS. (Marriage and 
Barnes, 1995, Katzenell and Segal, 2001, Attri and Nagarkar, 2010, Mazurek et al., 
2010a, Mazurek et al., 2010b). Although Marriage et al., (1995) has also provided 
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marginal evidence to show that excessive serotonin has also been linked to hyperacusis. 
Further experimental support for this theory has been reported in rats investigating the 
role of 5-HT in sensory modulation (specifically auditory startle) (Davis, 1980, Davis et 
al., 1980a, Davis et al., 1980b). These animal studies examined whether there was a 
specific association between sensory oversensitivity and 5-HT using the behavioural 
acoustic startle response in rats. They demonstrated that the normal startle response to 
90 ms burst of white noise at 115 dB is modified by changes in serotonin levels. The 
startle response is depressed when serotonin levels in the forebrain are raised and 
showed that serotonin inhibits auditory input in the forebrain. 
Interestingly, an exaggerated startle reflex to has been reported in an adult 
patient (Wirtz et al., 2002) and in children with DES (Yonekawa et al., 2011). In these 
studies these abnormal „hyper-excitable‟ responses were elicited using unexpected and 
intense stimuli; both characteristics identified as „offensive‟ in 80% and 71% 
respectively in our study.  
Serotonin abnormalities have also been closely linked to a number of human 
myoclonic disorders (Pranzatelli, 1994) and in cases of opsoclonus (Pranzatelli, 1992). 
Altered serotonin activity has also been report in DES (Pranzatelli, 1992, Pranzatelli et 
al., 1995, Pranzatelli et al., 2005a). Abnormal levels of serotonin metabolites were 
reported in the CSF in DES patients. Concentrations were 30-40% lower in patients 
with DES compared to control subjects. Patients with the lowest values were less than 4 
years old, and a subgroup had extremely low levels. His data suggests a disturbance and 
possible altered ontogeny of serotonin or dopamine neurotransmission in a 
subpopulation of children DES (Pranzatelli et al., 1995). Based on these findings, they 
speculated about the possibility of different „phenotypes‟ based on biochemical data. 
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Such studies are interesting and may be used to predict longer term outcomes and also 
explain why some cases are more „pre-disposed‟ to neurological sequelae.  
An alternative view is that the hyperacusis results from a failure of the CNS to 
inhibit the non-classical auditory pathways. As we mentioned previously in Chapter 2, 
auditory information ascends through the brainstem to the cortex in two parallel 
pathways, known as the classical and the non-classical ascending auditory pathways. 
The importance of the non-classical auditory pathway for hearing in humans is 
unknown but recent data has underscored the functional importance of these pathways 
in loudness perception in children, but not in adults (Moller and Rollins, 2002). 
The non-classical pathways have a number of important anatomical and 
functional links between the subcortical auditory system and the limbic structures which 
are thought to have an important modulatory role in hyperacusis. The limbic system, 
which regulates instinctive behaviour and emotions, is linked to the auditory system via 
the medial geniculate body (amygdala). The hypothalamus, which is the integrative 
centre of the endocrine and autonomic systems, is linked to the auditory system via the 
inferior colliculus. The reticular system, which is focused on the behaviour pattern of 
attention and excitement, projects serotonergic fibres to all pathways of the auditory 
system, ranging from the cochlea to the auditory cortex (Mazurek et al., 2010a). 
It is plausible then that damage to this pathway could provide an explanation of 
the behavioural disturbances (irritability, needing to be held all the time) experienced 
during the acute phase in DES.  However, it is also possible that the irritability and 
desire to be held arise because the child's balance and visual world are so unstable and 
further studies are required to assess the vestibular and proprioceptive input in DES.  
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Several studies have shown that hyperacusis can have a detrimental effect on an 
individual's lifestyle, as a result of decreased sociability and inability to spend time with 
family and friends due to sound intolerance. Our results from the behavioural reactions 
of our respondents certainly support earlier studies, although we could find no clear 
pattern regarding which acoustic feature evoked a negative response. Previous studies 
have also failed to identify any common acoustic features that evoke an adverse reaction 
in children with hyperacusis (Klein et al., 1990, Baguley, 2003). 
One issue that emerges from our novel finding is whether therapy, either 
modified tinnitus retraining or cognitive behavioural therapy (Jastreboff, 1990, Mattox 
et al., 1997) (Andersson & Lyttkens, 1999), would be beneficial in children diagnosed 
with DES. Other treatments that could be considered include the fitting of noise 
generators or even a hearing aid, in more severe cases. The role of some drugs involved 
in the metabolism of the serotonin, for example, serotonin reuptake inhibitors may also 
offer the potential for a new treatment approach.  
In conclusion, the results of this research support the idea that hyperacusis is 
prevalent in DES. These preliminary data suggest that the auditory pathways, in 
particular, the auditory brainstem may be involved in DES. However, we cannot 
exclude the possibility that there may be other lesions in the cerebellum, cochlea or the 
VIIth nerve that may cause hyperacusis (Marriage and Barnes, 1995). However, we 
believe that our preliminary findings provide sufficient ground to examine this issue 
further. In the following experiment we will undertake detailed experimental 
investigation to further clarify the anatomical origins of these abnormalities. 
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6.6 Experiment 2 – The audiometric profile of children diagnosed with 
DES 
6.6.1 Introduction 
The distinctive dyskinesia pattern that characterises DES strongly suggests 
neural dysfunction in cerebellar and brainstem circuits. However, a more accurate 
neuroanatomical localisation has not been possible, because of the lack of post-mortem 
studies. One approach that has been used to investigate possible brainstem involvement 
in children and adults diagnosed with DES is the ABR. The literature examining this 
issue is sparse. A systematic review of the literature found only six studies published 
over a 30 year period (see Section 6.5.3 and Table 6.3 for a summary of these studies). 
These studies represent the results from a total of 10 individual subjects (2 adults; 8 
children; 6 female). Collectively, these studies have described abnormalities in the ABR 
in half of the cases studied (Table 6.3). 
The first report documenting the utility of the ABR in DES measured the ABR 
at different phases of the disease (in the acute, chronic and remission stages) in 3 
children. All of the cases had abnormal ABRs. The degree of abnormality was 
dependent on the phase of the disease – ABR abnormalities were worse in the acute 
stages. Interestingly, mild pontine abnormalities were still evident even when the 
disease was in remission (Kalmanchey and Veres, 1988).  
Another study measured the ABR longitudinally over a two year interval in a 
single case (Horikawa et al., 1993). Despite the improvement in the opsoclonus and 
other clinical symptoms, serial ABR measurements showed that the I-III interval 
remained prolonged and showed no evidence of physiological shortening with 
maturation (Horikawa et al., 1993).  
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This limited research into the ABR and DES is also full of inconsistencies. 
Three studies have shown ABR abnormalities in all of their cases, most notably in the I-
III interval (Kalmanchey and Veres, 1988, Araki et al., 1989, Horikawa et al., 1993). 
This is thought to reflect the conduction time from the intracanalicular segment of the 
VIIIth nerve across the subarachnoid space through the VCN to the caudal pontine 
tegmentum. Conversely, three studies have reported no abnormalities on the ABR 
(Maeoka and Maegaki, 1998, Bartos, 2006, Sakuma et al., 2010). Further study is 
clearly warranted.  
In this study, we systematically measured auditory brainstem function in greater 
detail in a larger group of DES patients. Our aim in this study was to examine whether 
patients with DES have auditory brainstem abnormalities as indexed by the ABR. We 
were chiefly interested in identifying whether children with DES have auditory deficits, 
and if so, whether there was any evidence of longer-term brainstem disease, particularly 
in the absence of any overt eye movement abnormalities.  
 
6.6.2 Methodology 
6.6.2.1 Subjects 
Subjects were ten patients diagnosed with DES (age range 5 – 22 years; mean 
age 10.4 years; 5 males); diagnosis of DES had been previously made by Neurologists 
at the local hospitals. Subjects with DES were recruited through the DES association 
following the success of the questionnaire study. The only criterion for inclusion in the 
study was a definitive diagnosis of DES. Participant numbers were capped at 10 because 
of the limited travel funds available
47
. Table 6.7 shows the clinical characteristics for 
                                               
47 This pilot study was supported by a small pump priming grant awarded by the DES Association, UK. 
The grant met all of the expenses for the DES participants (eg. Travel and accommodation costs etc) 
which is why the participant numbers were capped at 10.   
 341 
 
each of the individuals enrolled in this study. The age of onset of DES ranged from 12-
30 months in this group, which is typical in this disease (Pang et al., 2010). 
Neuroblastoma was reported in 3 of our study group (cases 5 – 6, 9). Seven participants 
complained of hyperacusis, as assessed by our earlier questionnaire study (see Section 
6.5).  
Full-scale IQ data was available only in 5 cases and ranged widely from 54 – 
110 (case 3). This data was not available in the remaining 5 cases. The participants in 
our study group had a number of additional problems including speech difficulties and 
dysarthria in 3 cases; ataxia and poor-co-ordination in 3 cases and behavioural 
difficulties in 3 cases. Learning difficulties were common in our study group (8/10 
cases), with 3 children attending special needs school. Only one case (case 3) showed 
no long term deficits following the onset of DES.  
An equal number of age-matched children were enrolled on the study (age range 
6 – 21 years; mean age 10 years; 4 males). Age was matched to within 9 months of the 
age of individual DES participants. Controls were recruited using convenience sampling 
techniques from a larger normative data study (n=90) which was also being undertaken 
by the author (PC) to determine the normative response to audiometric measures in 
children (Appendix 2, Section 9.2). All controls had normal hearing threshold levels 
(normal pure tone audiogram and tympanometry) with no known predisposing factors 
for hearing loss. Ethical Committee approval was obtained for the study with informed 
consent obtained from each subject.  
 
6.6.2.2 Procedures 
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All subjects had standard baseline audiological assessment as previously 
described in Chapter 3. Audiometric results were obtained from all subjects in the same 
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Table 6-7 Summary of individual clinical characteristics and treatments. 
Case Age at onset of 
disease 
(mo) 
Gender Age at time 
of assessment 
(yr) 
Neuroblastoma Hyperacusis? Full Scale IQ Other 
1 30 M 11 N N NT Dyslexia 
LTM deficits 
Dysarthric 
Learning difficulties 
2 15 M 22 N Y 74 Dysarthric 
Learning difficulties 
Behavioural difficulties 
3 23 M 8 N Y 110 No concerns 
4 13 F 12 N N NT Learning difficulties 
5 14 F 15 Y Y 48 Learning difficulties 
Still unsteady on her feet 
Attends a special needs school 
6 12 F 6 Y Y 73 Learning difficulties 
Attends a mainstream school 
7 18 M 8 N Y NT Learning difficulties 
Still unsteady on her feet 
Attends a special needs school 
8 12 F 5 N Y NT Learning difficulties 
Behavioural difficulties 
Attends a special needs school 
9 13 F 5 Y Y NT Separation anxiety 
Speech delay 
Behavioural difficulties 
10 24 M 6 N N 54 Stroke in the cerebellum 
Ataxic and very clumsy 
Learning difficulties 
Special school: school for learning-disabled children 
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session in which electrophysiological tests were performed. The ABRs were recorded to 
clicks (100 s in duration) of alternating polarity presented at a rate of 11.1/s at an 
intensity of 80 dB nHL using TDH-49 headphones. Eye movements were examined 
clinically by an experienced clinician. The findings are summarised in Table 6.8. It was 
not possible to perform a clinical exam in 3 cases (cases 1, 9 – 10) because of poor co-
operation. In the remaining 7 cases, eye movement abnormalities were observed in 6 
cases – opsoclonus was observed in one case and ocular flutter and/or hypometric 
saccades in 5 cases. The prevalence of eye movement abnormalities is consistent with 
previously reported studies (see Section 6.4.2). 
 
6.6.2.3 Statistical Analysis 
The following descriptive statistics were presented for continuous variables: 
number of values, mean, standard deviation (SD), median, minimum, and maximum. 
For categorical data, frequencies and percentages were to be presented. Distribution 
normality and equality of variance between groups were assessed by one-sample 
Kolmogorov-Smirnov test (with Lilliefors correction) and Levene‟s tests, respectively.  
Differences between groups and among conditions were tested for significance 
using a repeated measure ANOVA using SPSS (version 19.0). Significance tests on 
within factors and interactions were made using the Greenhouse-Geissler correction for 
effects with significant Mauchly test for sphericity. Two-way ANOVAs were used to 
test between groups when a significant interaction was found. In all instances, the 
reported p values were two-tailed since the direction of possible group differences was 
not known. A p value < 0.05 was considered significant. 
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Table 6-8 Clinical eye movements in the study group (n=10) 
Case Pupils EOMs Smooth pursuit Doll‟s head Saccades (H &V) Other 
1 Sluggish Full Normal Normal ?? fast 
Vergence 
Manual spinning – high frequency VN 
2 NT NR NT NT NT Data not available 
3 Normal 
Full – some 
jitter in the 
lateral gaze 
Normal Normal Normal 
Eyes steady under closed lids 
Manual spinning – ok with no observable flutter 
3o left esotropia 
4 Normal Full Normal Normal Normal  
Normal Vergence; 
Downward saccades – hypometric?  
Manual spinning – ok 
No intention tremor 
5 Normal 
Full – endpoint 
nystagmus in 
right gaze 
Horizontal – normal 
Vertical - low gain 
Normal Normal  
Manual spinning – ok with no observable flutter 
Excellent vergence 
Possible flutter observed under closed eye-lids 
6 Normal - Some SP Unable to tolerate Saccades with flutter Right esotropia (from 2yrs old) 
7 Normal Full Normal ?some flutter Normal  - 
8 Normal Full Normal Vigorous 
Saccades present but 
hypometric 
Query opsoclonus with closed lids 
Some vergence but difficult to elicit 
Saccades present but hypometric 
Intention tremor 
9 NT NT NT NT NT Poor co-operation 
10 NT NT NT NT NT 
Not possible to perform a clinical exam. 
When quiet frequent flutter episodes were 
observed. 
Abbreviations: Ab – abnormal; H – horizontal; N – no; Norm – normal; NT – not tested; V – vertical; Y – yes;   
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6.6.3  Results 
6.6.3.1  Baseline Audiometric Tests 
Pure tone audiometry was completed by all the DES subjects at all frequencies 
(0.25-8.0 kHz). Audiometric thresholds were within the normal range for all DES 
participants. Mean hearing thresholds (in dB HL) are compared below in Table 6.9 for 
both groups.  
Table 6-9 Mean ( SEM) hearing threshold levels for the right and left ears in dB HL (n=10). 
Group Frequency 
(kHz) 
Right  Ear Left Ear 
  Mean Std.Err. Mean Std. Err. 
DES 
0.25 16.5 1.5 17.5 1.3 
0.50 17.0 1.9 15.5 0.90 
1 13.0 1.3 12.5 1.3 
2 7.0 1.6 7.5 1.7 
4 8.0 2.0 6.5 1.3 
8 10.5 2.2 9.5 2.0 
Controls 
0.25 9.5 1.8 10.5 1.4 
0.50 8.0 1.5 10.0 2.0 
1 5.5 2.2 6.5 2.0 
2 8.0 1.1 8.0 1.3 
4 11.0 1.8 6.0 1.5 
8 8.0 1.3 8.0 1.3 
 
Overall mean thresholds are plotted in dB HL for the DES group and the control 
subjects (±SD) are shown in two groups in Figure 6.8 (upper panel). Although the 
hearing threshold levels are within the normal range for both groups, plotting these 
separately revealed a distinct trend, with the DES group showing an increase in hearing 
threshold levels in the lower frequency range (0.25, 0.5  and 1.0 kHz) compared with 
the control group. 
When we plot mean audiometric thresholds across all frequencies for DES 
subjects who reported hyperacusis (Figure 6.8 middle panel) compared with DES 
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subjects without hyperacusis, we see that subjects who have had a problem with 
hyperacusis also have worse audiometric thresholds on average, particularly in the right 
ear. However, we observed no difference in audiometric thresholds across gender in the 
DES group (lower panel, Figure 6.8). 
A repeated measure ANOVA was performed to examine whether there were any 
differences within groups. Within subject factors were frequency (levels: 0.25, 0.5, 1, 2, 
4, 8 kHz) and ear (levels: left, right). In the DES group, thresholds were significantly 
different depending on frequency (p<0.001) with a clear U-shaped function; there was 
no significant difference between ears (p=0.49).  
A two-way ANOVA (group x frequency) revealed a significant difference 
between the groups (p<0.01) with a significant interaction between groups and 
frequency (p<0.05). Post-hoc analysis using Tukey‟s least significant difference test 
showed significant differences on hearing threshold levels at 0.25 kHz (p<0.01), 0.5 
kHz (p<0.01) and 1 kHz (p<0.05) for both ears. 
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Figure 6-8 Top panel: Mean ( SD) air conduction thresholds for the right and left ear for the DES and normal control groups (n=10); Middle panel: Mean 
( SD) air conduction thresholds for DES subjects complaining of hyperacusis symptoms (n=7) compared with those reporting no hyperacusis symptoms 
(n=3); Bottom panel: Mean ( SD) air conduction thresholds for male DES subjects (n=5) compared with female DES subjects (n=5). 
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All of the DES subjects underwent tympanometry. Three data measures were 
collected: ear canal volume (ECV); middle ear pressure (MEP) and compliance. Table 
6.10 shows the mean and standard error of the middle ear analysis for the right and left 
ear in the DES group and the control group.  All DES subjects had normal middle ear 
function compared with the BSA (1992) normative data values and ranges (see Table 
3.2 and Appendix 2, section 9.3) and the middle ear pressure was comparable between 
the groups.  
Table 6-10 Mean and standard error of the mean of the tympanometry values in normal control 
subjects and in patients with DES.. Abbreviations: ECV – ear canal volume. 
Group Tympanometry 
measure 
Right  Ear Left Ear 
  Mean Std.Err. Mean Std. Err. 
DES 
ECV 0.94 0.08 0.93 0.06 
MEP -17.00 19.34 -25.00 20.03 
Compliance 0.65 0.05 0.66 0.07 
Controls 
ECV 0.91 0.06 0.90 0.06 
Pressure -15.00 10.80 -32.50 16.52 
Compliance 0.82 0.10 0.89 0.13 
 
6.6.3.2 Transient evoked otoacoustic emissions 
Transient evoked otoacoustic emissions were recorded in all DES participants. 
The TEOAE amplitude responses were comparable across right and left ears, although 
slightly reduced on the left ear in both groups. The mean TEOAE amplitudes (± SD) in 
the DES group was 15.4 ± 4.0 (95CI=12.5-18.3) dB SPL for the right ear and 13.7 ± 5.2 
(95CI=11.1-17.2) dB SPL on the left ear compared with 14.9 ± 3.3 (95CI=10-17.4) dB 
SPL for the right ear and 12.4 ± 2.9 (95CI=10.3-14.5) dB SPL for the control group. An 
independent-t test revealed no significant difference in the TEOAE amplitude between 
the two groups for the right ear (p=0.753) or left ear (p=0.498). 
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6.6.3.3 Acoustic reflex response 
The acoustic reflex response (ARTs) was measured using ipsilaterally at 0.5, 1, 
and 2 kHz for both ears in all of our DES subjects. Table 6.11 shows the mean ART and 
standard error mean values for the DES and the control group. ARTs were normal with 
ipsi-and-contralateral stimulation across 0.5, 1.0 and 2.0 kHz in all DES participants 
(range 80 – 100 dB) (Cohen and Prasher, 1988, 1992) (Appendix 2). Interestingly, our 
control group showed marginally elevated ART responses compared with the DES 
group for both ipsilateral and contralateral stimulation.  
Table 6-11 Mean ( SEM) ART (dB HL) for the right and left ears in dB (n=10). 
Reflex frequency (Hz) GROUP RIGHT EAR LEFT EAR 
  
Mean ART 
(dB HL) 
Std.Err. 
Mean ART 
(dB HL) 
Std.Err. 
Ipsi500 
DES 84.2 2.4 82.5 1.7 
Control 83.8 2.2 87.5 3.2 
Ipsi1k 
DES 85.0 2.8 86.7 2.1 
Control 87.5 3.2 85.0 3.5 
Ipsi2k 
DES 85.0 1.9 81.5 2.2 
Control 90.5 1.4 87.5 4.8 
Contra500 
DES 87.8 4.5 88.3 3.7 
Control 86.8 3.3 93.8 4.2 
Contra1k 
DES 84.2 1.8 89.2 2.0 
Control 87.5 1.4 90.0 2.8 
Contra2k 
DES 84.2 2.1 86.7 3.2 
Control 87.5 2.5 91.2 2.4 
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6.6.3.4 The auditory brainstem response 
The ABR was measured in all subjects across both ears. The absolute latencies 
of waves I, III, and V and the inter-peak intervals I-III, III-V, and I-V for each 
individual case are shown in Table 6.12. All of the peak and interpeak waveform 
components were inspected for each individual case. The ABR was considered 
abnormal when latency or IPL were >2SD outside the normal controls (i.e.) peak 
latency on the ABR was considered abnormal when wave I, III or V latency were 
respectively greater than 1.97 ms, 3.98 ms and 5.86 ms on the right ear and ABR was 
considered abnormal when wave I, III or V latency was greater than 1.96 ms, 3.86 ms 
and 5.81 ms on the left. Table 6.13 shows the mean latency values of wave I, III, and V 
in the DES group and the age-gender matched control group. 
Interpeak latencies were considered abnormal when the I-III, III-V and I-V 
intervals were respectively greater than 2.26 ms, 2.08 ms and 4.17 ms on the right ear 
and 2.18 ms, 2.07 ms and 4.09 ms on the left. Table 6.14 shows the mean latency values 
of wave I, III, and V in the DES group and the age-gender matched control group. 
All peak waveforms were present in the DES group but 9/10 DES children 
(90%) showed abnormal peak latency or inter-peak latency values (Table 6.12). Wave 
III was delayed in 1/10 (case 7) on the left ear and wave V was delayed in 2/10 cases on 
the right ear (cases 4 and 7). The inter-peak intervals showed a greater number of 
abnormalities with a delayed I-III interval in 3/10 cases on the left, a prolonged III-V 
interval in 4/10 cases on the right ear (cases 2, 4, 7 and 9) and in 4/10 cases on the left 
ear (cases 3, 4, 6 and 9). The I-V interval was also delayed in 4/10 cases on the right 
(cases 4, 5, 7 and 9) and in 7/10 cases on the left (cases 3-6, 8-10). Only one subject 
(case 1) showed no evidence of any prolongation of peak and inter-peak latency 
measures.  
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Table 6-12 Individual ABR peak latency data for both ears .*> 2SD above the control mean. 
Case Right Ear Left Ear 
 I III V I-III III-V I-V I III V I-III III-V I-V 
1 1.68 3.82 5.66 2.14 1.85 3.98 1.63 3.79 5.69 2.16 1.90 4.06 
2 1.63 3.65 5.74 2.02 2.09* 4.10 1.68 3.67 5.59 1.99 1.92 3.91 
3 1.61 3.73 5.62 2.12 1.89 4.01 1.59 3.67 5.81 2.08 2.14* 4.22* 
4 1.68 3.62 5.88* 1.94 2.26* 4.20* 1.68 3.62 5.78 1.94 2.16* 4.10* 
5 1.63 3.84 5.86 2.21 2.02 4.23* 1.68 3.72 5.78 2.04 2.06 4.10* 
6 1.56 3.67 5.71 2.11 2.04 4.15 1.56 3.60 5.69 2.04 2.09* 4.13* 
7 1.63 3.82 5.98* 2.18 2.16* 4.34* 1.70 3.96* 5.69 2.26* 1.73 3.98 
8 1.58 3.77 5.66 2.18 1.87 4.06 1.63 3.77 5.74 2.14 1.97 4.10* 
9 1.63 3.67 5.86 2.04 2.19* 4.23* 1.51 3.62 5.74 2.11 2.12* 4.23* 
10 1.78 3.76 5.84 1.98 2.08 4.06 1.61 3.72 5.78 2.11 2.06 4.17* 
For the right ear, the mean peak latency for the DES group was 1.64 ms (95CI= 
1.60-1.69) for wave I; 3.74 ms (95CI= 3.68-3.79) for wave III and 5.78 ms (95CI= 5.70-
5.87) for wave V. For the left ear, the mean peak latency for the DES group was 1.63 
ms (95CI= 1.58-1.67) for wave I; 3.71 ms (95CI= 3.63-3.79) for wave III and 5.73 ms 
(95CI= 5.68-5.78) for wave V (Table 6.13). 
A repeated measure ANOVA was performed to examine whether there were any 
differences within groups using latency in ms units. Within subject factors were latency 
(levels: wave I, wave III and wave V) and ear (levels: left, right). There was no 
significant difference between ears (p=0.63).  
 
Table 6-13 Mean ( SEM) peak latency for the right and left ears in milliseconds (n=10). 
Group Amplitude Right  Ear Left Ear 
  Mean Std.Dev Mean Std.Dev 
DES 
Wave I 1.64 0.02 1.63 .02 
Wave III 3.74 0.03 3.71 .03 
Wave V 5.78 0.04 5.73 .02 
Controls 
Wave I 1.73 0.12 1.76 .10 
Wave III 3.76 0.11 3.74 .06 
Wave V 5.50 0.18 5.51 .15 
 
Because there were no observable differences, we collapsed the latency data 
across both ears. Differences across the two groups were then examined for statistical 
significance by using a two-way ANOVA. There were significant differences between 
the groups (p<0.01). In addition, there was significant interaction between groups and 
waves (p<0.05). To test for group differences at each specific wave, simple main-effect 
comparisons were made using Tukey‟s LSD test. We could find no evidence to support 
any difference between the control group and the DES group for wave I (p=0.51) or 
wave III (p=0.48), but a significant difference was evident for wave V (p<0.05).  
For the right ear, the mean IPL for the DES group was 2.09 ms (95CI= 2.03-
2.16) for wave I-III; 2.05 ms (95CI= 1.94-2.15) for wave III-V and 4.12 ms (95CI= 
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4.03-4.20) for wave I-V. For the left ear, the mean IPL for the DES group was 2.09 ms 
(95CI= 2.02-2.15) for wave I-III; 2.02 ms (95CI= 1.92-2.11) for wave III-V and 4.10 
ms (95CI= 4.03-4.17) for wave I-V. Eight of 10 DES subjects had I-V IPLs longer than 
2 SD above the control mean at 80 dB nHL (Table 6.12). 
Table 6-14 Mean ( SD) interpeak latency for the right and left ears in milliseconds (n=10). 
Group Amplitude Right  Ear Left Ear 
  Mean Std.Dev Mean Std.Dev 
DES 
Wave I-III 2.09 0.09 2.08 0.09 
Wave III-V 2.05 0.14 2.02 0.13 
Wave I-V 4.12 0.12 4.10 0.10 
Controls 
Wave I-III 2.04 0.11 1.98 0.10 
Wave III-V 1.74 0.17 1.77 0.15 
Wave I-V 3.77 0.20 3.75 0.17 
 
As compared with the values of the control group, I-V, and III-V inter-peak 
latency values were significantly prolonged in the DES group (p<0.05). The prolonged 
III-V interval for the DES group is in line with previously reported cases (Kalmanchey 
and Veres, 1988, Horikawa et al., 1993).  
A repeated measure ANOVA was performed to examine whether there were any 
differences within groups using inter-peak latency in ms units. Within subject factors 
were IPL (levels: I-III, III-V and I-V) and ear (levels: left, right). There was no 
significant difference between ears (p=0.47).  
A two-way ANOVA revealed significant differences in IPL between the groups 
(p<0.01). To test for group differences at each specific wave, simple main-effect 
comparisons were made using Tukey‟s LSD test. There was no significant difference 
for the I-III IPL (p=0.62) but there were significant differences was evident for the III-V 
and the I-V IPLs (p<0.05).  
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Figure 6-9 Mean ABR wave I, III and V amplitudes at 80 dB nHL for control and DES subjects 
Vertical bars represent ±2 SEM (n=10) Error bars show the 95% confidence interval of the mean at 
each peak latency.   
 
 
Amplitudes were measured for all peak waveforms. For illustrative purposes we 
also constructed a series of whisker and box plots of the amplitudes which are shown 
above in Figure 6.9.   
A repeated measure ANOVA was performed to examine whether there were any 
differences within groups using amplitude in µV units. Within subject factors were 
wave amplitude (levels: I, III and V) and ear (levels: left, right). There was no 
significant difference in amplitude (p=0.23) or between ears (p=0.06). A two-way 
ANOVA revealed no significant difference in amplitude between the groups (p=0.16).  
One interesting trend that we observe from the amplitude data is that wave III is 
more variable with greater amplitude than seen for the other two components (I and V).  
Previous studies have reported greater wave III amplitudes in patients displaying hyper-
excitable behaviour (Knott et al., 1994). However, in our data, there does not seem to be 
any relationship between the incidence of self-reported hyperacusis and larger wave III 
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amplitude. For example, the mean wave III amplitude in hyperacusis cases (n=7) is 0.42 
µV (range 0.23-0.92 µV) on the right ear and 0.36 µV (range 0.24-0.83 µV) on the left 
which is smaller when compared with the amplitude data from the 3 DES cases who 
reported no hyperacusis (cases 1, 4 and 10) (right ear: mean wave III amplitude of 0.64 
µV; range 0.32-1.13 µV and right ear: mean wave III amplitude of 0.58 µV; range 0.3-
1.15 µV).  
 
6.6.4 Discussion 
6.6.4.1 Peripheral hearing in children with DES 
Our data from this study indicates that peripheral hearing is normal in children 
with DES as measured on pure tone audiometry, tympanometry and otoacoustic 
measures. To the best of our knowledge, there are no other reports of audiometry in 
children with DES. Indeed, we could find only one case report identifying hearing loss 
in an adult case in the literature (Rosenberg, 1984).  This is a surprising finding, 
particularly in view of the extensive chemotherapy treatments that many of these 
children receive.  
Interestingly our group showed significantly poorer hearing thresholds in the 
low frequency range (0.25-1 kHz) compared with an age-and-gender matched control 
group. Hearing thresholds in the low frequency range were also mildly elevated in those 
participants who had complained of hyperacusis compared with those who did not. 
However, these results must be interpreted with caution as our sample size is extremely 
small. 
 
6.6.4.2 Tests of auditory brainstem function in DES 
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We undertook two audiometric tests of brainstem function in children with DES: 
the acoustic reflex threshold and the ABR. The acoustic reflex thresholds were normal 
across a wide frequency range regardless of whether the ipsilateral or contralateral 
pathway was stimulated. We are not aware of any other study that has examined this 
pathway in DES.  
This finding of completely normal ART in all of our patients is interesting. 
Recent studies in children with Williams syndrome (WS), who have well documented 
hyperacusis, reported an absent ART in 62-86% (Attias et al., 2008). However, it is not 
clear whether this result is due to a genuine deficit in the stapedial reflex pathway or is 
an artefact – the result of associated with a high-frequency hearing loss resembling the 
configuration of noise-induced hearing loss. Furthermore, the authors only investigated 
1-4 kHz so we have no information regarding low frequency ART. This is an important 
consideration for future studies.  
We identified a number of mild abnormalities on the ABR although the overall 
morphology of our ABRs was typically unaffected. We were able to record peak and 
interpeak latencies for all the major waveform components – no waveform component 
was absent in any of our recordings. The ABR showed abnormalities on one or more 
latency parameters in 9/10 cases. These slightly prolonged waveforms are still evident 
in children who are in remission from the disease, consistent with one case reported in 
Kalmanchey and Veres (1988). Only one case (case 1) showed no evidence of any 
abnormality. 
This prolongation of peak and interpeak latencies is consistent with a delay in 
the conduction velocity along the auditory brainstem pathways. In our study, three 
parameters were particularly affected: wave V, the III-V IPL and I-V IPL. Our data 
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seems to reflect a delay in conduction between the upper pons and the lower midbrain 
pathways of the auditory brainstem. Our finding is supported by a single case from 
Kalmanchey and Veres (1988) but contradicts other studies that have previously shown 
that investigating the ABR in DES which have shown that the abnormalities are 
typically in the I-III IPL. Previous studies have failed to measure peripheral hearing so 
it is plausible that the abnormal I-III responses are a reflection of hearing loss and 
concomitant disruption in the auditory nerve. 
An alternative explanation for our findings is that the ABR is sensitive to 
learning difficulties.  Numerous studies in the children with learning difficulties 
population have shown that individuals with LD have normal click-ABRs (Mason and 
Mellor, 1984, Jerger et al., 1987, Grontved et al., 1988a, b, Lauter and Wood, 1993, 
Purdy et al., 2002). However, this does not explain the abnormal ABR finding in the 
single case that did not have any learning problems. 
Another interesting finding in our study was the variability shown in the 
amplitude of wave III. Although not statistically significant, wave III amplitude 
reported in this study was highly variable especially when compared with control data. 
The magnitude of wave III amplitudes has also been reported as abnormal in patients 
with behavioural disorders such as panic disorder (Knott et al., 1994). This had led to a 
number of authors hypothesising that this is a marker of brainstem hyper-excitability in 
these patients.  
However, when we examined possible differences in wave III amplitude with 
the incidence of self-reported hyperacusis, we found no evidence to show that wave III 
amplitude was any greater in cases with self-reported hyperacusis compared with the 
group who had no complaint of hyperacusis. Indeed, the mean wave III amplitude was 
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smaller on both ears in the hyperacusis cases. This may be related to poorer neural 
synchrony within the cochlear nucleus complex in DES subjects with hyperacusis but 
such an assertion is purely speculative at this stage. Obviously, these data must be 
interpreted cautiously as our sample size is extremely small but it would be valuable to 
re-examine this issue in a much larger sample. 
It is not clear from our study whether the changes that we have measured 
represent an irreversible alteration to auditory brainstem function or whether it is an 
effect of treatment. It is not clear at present, what role (if any) that treatments such as 
ACTH may play in the measurement of the ABR and we cannot exclude that our results 
may reflect a treatment effect. Such questions can only be answered with longitudinal 
studies with larger sample sizes, strict selection criterion and well-documented 
treatment protocols. 
 
6.6.4.3 Pathophysiology 
The pathophysiological mechanisms of DES are unclear although a number of 
studies have provided conflicting evidence for the involvement of both the brainstem 
and the cerebellum. Our data provides the first systematic audiological study of children 
diagnosed with DES who are in the chronic phase of the disease. Our data clearly shows 
that the brainstem pathways are affected in DES – 9/10 cases had a delay in their ABR 
waveforms.  
These findings support the view that some of the abnormalities seen in DES 
could be consistent with a lesion in the brainstem (Kalmanchey and Veres, 1988, Harris, 
1997).  There is growing support for brainstem involvement in DES including recent 
studies which have described an exaggerated startle response in a patient with DES 
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(Yonekawa et al., 2011). The acoustic startle response is thought to be generated in the 
medial pontine tegmentum although the precise location of the neural substrates in 
humans is not clear (Davis et al., 1980b). The case study reported by Yonekawa et al., 
(2011) argue that the combination of the startle response and the myoclonus are due to 
augmented excitability in the brainstem. They argue that hyperexcitability in co-located 
but independent structures within the pontine tegmentum could explain many of the 
signs and symptoms seen in DES.  
Our findings of hyperacusis and prolonged ABR latency would also lend support 
to these observations, however we cannot rule out damage to the cerebellum, which 
could also explain the abnormal eye movements in DES. These findings in addition to 
the limited literature published in this field, may be useful in providing a framework for 
future study. 
Our findings of an abnormal ABR also raise the possibility that there may be a 
manifestation of a wider 'problem' in the CANS not detected by pure-tone audiometry. 
There is some evidence (Chapter 2) that a deficit in the brainstem could affect the still 
developing pathways in the auditory cortex.  These findings may suggest that the 
aberrant function in auditory brainstem could be partly responsible for some of the 
longer term learning difficulties seen in DES, particularly as the onset of DES occurs 
between 10-36 months when the auditory brainstem is still maturing. This hypothesis 
should be tested in further studies.  
 
6.6.4.4 A link between auditory signs and eye movement signs in DES? 
 
Three main theories have been proposed to explain the striking eye movements 
that characterise DES. These have included: 1) damage to cerebellar circuits could 
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result in disinhibition of the saccadic system from the FN (Wong, 2007); 2) dysfunction 
of the OPN cells in the PPRF, which inhibit the BN that drive ocular motor neurons to 
create saccades (Hattori et al., 1988, Pranzatelli, 1992) and 3) damage to the BN which 
results in increased excitability of these cells in the PPRF (Yonekawa et al., 2011).  
Yonekawa et al., (2011) speculated that the clinical signs observed in DES are 
due to neural hyper-excitability in brainstem pathways. They argued that cerebellar 
lesions due to various aetiologies do not usually alone cause OMS symptoms and that 
the clinical signs seen in DES is a direct result of increased excitability of BN. 
What can our audiological findings contribute to our understanding of the 
abnormal eye movements in DES? Our data from our initial experiment – that some 
children with DES may have hyperacusis – presented here may provide some interesting 
clues which have a direct bearing on the interpretation of the eye movement data.  
The mechanism responsible for hyperacusis is unclear. Several theories have 
been advocated although empirical data supporting each is tenuous (Baguley, 2003). 
One theory is that hyperacusis may reflect a disturbance in serotonin levels (Marriage 
and Barnes, 1995, Katzenell and Segal, 2001). Interestingly, excessive serotonin in the 
brainstem has been shown to inhibit the OPN cells – therefore their inhibition should 
lead to excessive saccadic activity (Schenck et al., 1992, Armitage et al., 1995, Boulos 
et al., 2011). Moreover, there is limited evidence to support a possible serotonergic link 
between opsoclonus in the rat brain and chlordecone (Pranzatelli, 1992). However 
animal data (Boulos et al., 2011) and computational models (Leigh and Kennard, 2004, 
Ramat et al., 2005, 2007) suggest otherwise – showing that dysfunction in OPN results 
in a slowing of saccades – such as we saw for GD earlier in Chapters 4 and 5.  
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Other theories that have been proposed to explain hyperacusis include alterations 
in central gain
48
 and startle reflex – both of these mechanisms explain hyperacusis in 
terms of neural hyperexcitability. Our findings would not exclude either of these 
theories and they could be used to explain the „hyper-excitability‟ seen across a number 
of sensory circuits and behaviours.  
We presented data in our second empirical study which is suggestive of specific 
damage in the pons. We identified that the ABR was abnormal in the majority of the 
cases that we examined, even after the resolution of the primary „acute‟ symptoms 
following disease onset. The prolongation of wave V and delay in interpeak latencies 
(III-V and I-V) are consistent with a deficit auditory processing across multiple levels in 
the auditory brainstem including the cochlear nucleus, SOC, and lateral lemnisical 
pathways. These findings are consistent with the „pontine‟ hypothesis posited by 
Yonekawa et al., (2011) and support earlier studies (Kalmanchey and Veres, 1988, 
Ramat et al., 2005). These data when interpreted alongside the findings of an 
exaggerated startle reflex also seem to strongly suggest that the cochlear nucleus 
complex is involved in DES.  
While our data is not able to differentiate between the potential damage to eye 
movement circuits in the brainstem (i.e.) whether the BN or OPN are affected in DES, it 
does provide strong support for the pontine hypothesis. Our data however, does not 
preclude additional lesions in the cerebellum. It is possible that damage in the pons 
affecting the lateral lemnsicus could also affect ponto-cerebellar connections 
(Kalmanchey and Veres, 1988).  
                                               
48 This alteration in gain has recently been discussed using the thalamocortical dysrhythmia model. This 
model considers the reciprocal circuits between thalamus and cortex to be fundamental to a range of 
positive and negative clinical signs and symptoms (e.g. hyperacusis, tinnitus)  
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The prolonged wave I-V pattern in the ABR that we have reported in DES is 
also evident in a number of cases diagnosed with GD (see Chapter 4 and Chapter 5). 
This would indicate a similar auditory deficit in the auditory brainstem pathways in both 
of these conditions but clearly the eye movements are distinctly different. The delayed 
conduction velocity in the ABR seen GD is mirrored in the „slow‟ saccadic speeds seen 
in the oculomotor system of nGD patients. As such, we could anticipate that the 
auditory abnormalities seen in DES would echo the chaotic back-to-back saccadic 
disturbances evident in opsoclonus (i.e.) we might predict that conduction velocity in 
the ABR would be abnormally „fast‟. So how do we explain these results? At this 
juncture we refer to the limitations of the ABR measurement that we previously 
discussed in Chapter 2 (section 2.4.2.2).  
As a far-field recording, the ABR findings may indicate the level or severity of 
the lesion within the brainstem in these disorders but they do not accurately identify the 
exact site as there is no point by point relationship between the ABR waveforms and the 
anatomical structures (Hall, 2007). Moreover, it is unclear whether ABR activity is 
based on activity from the nerves and fibre tracts or in nuclei. Thus although eye 
movements centres and auditory pathways are undoubtedly affected in both of these 
disorders, the poor correlation between the site of the lesion studies and the ABR, and 
the complexity of the CANS preclude us from drawing any further parallels between the 
two systems. 
 
6.7 Conclusion 
In this chapter we presented data from two studies. In our first study we showed 
that hyperacusis is present in at least 43% of children with DES. Our data lends support 
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to the theory of hyper-excitability in brainstem pathways, specifically within the pontine 
tegmentum area. In our second study, we showed that there were subtle abnormalities in 
the auditory brainstem as shown by the ABR. The most common deficit was seen as a 
prolongation of the wave V, the III-V and I-V interpeak interval. This novel finding, 
even in children with „resolved‟ DES, indicates that the auditory brainstem pathways 
are affected in this disease. 
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7 Chapter 7 
The offset ABR 
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7.1 Introduction 
Our earlier experiments have considered how the onset of a stimulus is 
represented within the auditory brainstem pathways. In this final experimental chapter 
we are concerned with the first stages of understanding the importance of the “offset” of 
sound, i.e. establishing how the brain encodes sound when it disappears. Such study is 
critical in developing our understanding of how the brain identifies the boundaries in 
speech.  
By its very nature, speech is composed of complex sound waves that have rapid 
spectral and temporal changes which are separated by discrete „non-acoustic or silent‟ 
intervals. For example, consider the distinction that the auditory brain is required to 
make between two words – 'stay' and 'say‟ – in which a short, transient difference 
occurs within the syllable of the word.  
Thus, there is significant evidence that the cessation of sound (or „the sound of 
silence‟) is an important acoustic cue in consonant identification (Pind, 1998), 
discriminating sound duration (Schlauch et al., 2001) and in the acoustic startle reflex 
(Ison and Allen, 2003). Furthermore, the existence of offset-type neurons at all levels of 
the auditory tract suggests that detection of stimulus cessation may play an important 
role in central auditory processing (Palmer, 1987, Phillips et al., 2002a, Scholl et al., 
2010). The functional role of these offset-type neurons is still vague, and there has been 
relatively little study of the offset response. Moreover, the origins of the offset response, 
particularly in the auditory brainstem are still controversial (Brinkmann and Scherg, 
1979, Van Campen et al., 1997, Phillips et al., 2002a). 
There is extensive literature supporting the representation of stimulus onsets 
throughout the CANS (see Phillips et al., 2002 or Scholl et al., 2010 for a 
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comprehensive review of this topic). However, the available evidence regarding the 
offset response is extremely limited. „Offset‟ responses have been described in 
electrophysiological studies of the auditory brainstem in humans (Brinkmann and 
Scherg, 1979, Perez-Abalo et al., 1988, Van Campen et al., 1997) and animals (Kodera 
et al., 1977a, Henry, 1985a, b, 1986, Henry and Lewis, 1988).  Cortical responses to 
sound offset have also been reported, using a variety of techniques including auditory 
evoked potentials (Takahashi et al., 2004) and imaging studies (Gutschalk et al., 2002, 
Harms et al., 2005). However, the study of sound offsets is still controversial with some 
researchers arguing that the paucity in offset responses in the CANS reflects the 
functional  
“asymmetry in the neurophysiological and perceptual processing of stimulus 
onsets and offsets: sound onsets have a more elaborate neurophysiological 
representation, and receive a greater perceptual weighting” (p192).  
This view has recently been challenged with new evidence supporting the 
existence of separate auditory pathways for encoding the onset and offset of tones in the 
rat (Scholl et al., 2010). Clearly the study of sound offsets merits closer study as it may 
provide important clues in our understanding of hearing and speech processing.  
One approach that has been used to probe how the brainstem encodes sound 
offsets is the „offset ABR‟ (Kodera et al., 1977a, Henry, 1985a, b, 1986, Henry and 
Lewis, 1988, Van Campen et al., 1997). This component is visualised as a second 
response – with a similar morphology to the onset waveform component – which is 
evoked at stimulus offset. It was first described by Kodera et al., (1977) in both cats and 
humans. Subsequent studies of the offset-ABR have been plagued by a number of 
technical challenges and the origin of the offset ABR as reported in Kodera et al., 
(1977) remains contentious (Brinkmann and Scherg, 1979). 
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In this chapter, we begin by presenting an in-depth review of all „offset-ABR‟ 
studies undertaken in the last 30 years. We then present offset-ABR data from a series 
of different experiments, employing a wide range of frequencies (and rise-fall times) 
and polarity (rarefaction, condensation) in normal hearing participants. This work 
replicates and extends previous studies (Van Campen et al., 1997). Finally, we present, 
for the first time, a clinical application of the offset ABR. This application involves 
recording the offset ABR in our two eye movement disorders (GD and DES) that have 
been the subject of our previous chapters.  
 
7.2  Experiment 1: The offset ABR in normal control subjects 
7.2.1 An overview of the ‘offset’ ABR response 
Since the publication of the seminal study of Kodera et al., (1977), a modest 
number of papers have appeared describing AEPs generated by the offset portion of the 
stimulus in cats (Kodera et al., 1977a, Laukli and Mair, 1985); mice (Henry, 1985a, b, 
1986); gerbils (Henry, 1986);  rats (Henry and Lewis, 1988) and humans (Kodera et al., 
1977b, Brinkmann and Scherg, 1979, Elfner and Barnes, 1983, Perez-Abalo et al., 1988, 
Van Campen et al., 1997). 
These studies have ascribed different functional properties to the onset and 
offset brainstem components. For example in the mouse, these responses differed 
significantly in thresholds, slope intervals of the amplitude-intensity functions and 
tuning curves (Henry, 1985a, b). We have summarised the available literature on the 
offset response in the brainstem undertaken in animals in Table 7.1 and in humans in 
Table 7.2.  
Author Year n Stimulus Key findings 
   Frequency Rise-fall times Intensity Polarity  
Kodera 
et al. 
1977 4 cats 
 
 
1 kHz  Varying durations (1, 3, 5, 10, 
25 and 55 ms) and rise-fall 
times (0.25, 2, 4, 6, 8 & 10 
ms) in cats and rise-fall times 
of 0.25,1, 2.5, 5 and 10 ms in 
humans 
40-90 dB 
peSPL in 
cats 
 
 
A Different morphologies for latency and amplitude responses for the 
offset compared with onset responses. 
Henry 1985 41 mice 4-64 kHz Duration of 10ms. Rise and 
fall time of 200 µs. 
40-100 dB 
SPL 
NR Similar morphology and inter-peak latencies for onset an offset 
responses. Offset responses were present at all frequencies if the 
stimulus was sufficiently long enough (> 7.5 ms). Increased stimulus 
duration resulted in increased latency for offset response but no 
change in the onset ABR was observed. Offset audiogram did not 
parallel the onset ABR audiogram.  
Henry  1985b 10 mice 
in expt. 
1  
 
33 mice 
in expt. 
2 
8 or 32 kHz (in 
the presence of 
cont. masking 
tone) 
ABR TC at 
8,12,16, 20, 24, 
32 & 40 kHz 
Rise and fall times of 0.3 ms 
Plateau – NR 
Masker held 
constant at 
60 dB SPL 
NR At low and high frequencies, onset and offset responses have similar 
thresholds. At mid-frequencies, the offset responses have higher 
thresholds. The offset response was very different from the onset 
response depending on the masking profile applied. Offset response 
at mid-frequencies was more sensitive to continuous masking by 
bands of frequencies above and below the probe stimulus frequency. 
Offset TC response was more resistant to continuous masking at the 
probe stimulus frequency.  Offset TC peak was more finely tuned 
than the tip of the onset TC. 
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Table 7-1 Summary of previous studies investigating the offset responses in animals. 
Abbreviations: A: alternating; D: duration; I-A: intensity-amplitude; I-L: intensity level; NR: not reported; RL: relative to the VDL of the ABR; TC: Tuning curves; VDL: visual 
detection threshold level; WN: white noise. 
  
Laukli 
and 
Mair 
1985 4 cats 0.5-4 kHz 
Masking WN 
Plateau constant at 10 ms. 
Varying rise and fall times of  
0.3, 2, 4 and 8 ms 
10-60 dB RL A Varying plateau lengths (from 5-20ms) resulted in an increase in the 
off-response latency. The waveform morphology and amplitude of 
the offset response was related to the frequency specificity of the 
onset response (greatest for the 4Kz tone and smallest for the WN 
tone burst). Threshold of the 0.5 kHz response was lower than the 
onset response and the amplitude did not increase with increased 
stimulus level. 
Henry  1986 17 mice 
&  
12 
gerbils 
8, 12, 16, 20,24, 
32 & 40 kHz 
Rise and fall times of 0.3 ms 
Varying duration of 5-15ms 
60 dB SPL NR Onset and offset responses were abolished with cochlear lesions 
suggesting a peripheral origin for the offset response. 
Simultaneous masking enhanced offset responses suggesting that the 
cochlea may also encode transients in different ways 
Henry 1988 Rats, 
gerbil, 
guinea 
pig and 
mouse 
8-20 kHz NR 65 dB SPL NR Examined the offset ABR masking tuning curve. Extended previous 
studies across „new animal models‟ and found similar tuning curves 
across all of these species. Also showed that lesions to the 
contralateral ear, OCB or the outer ear do not alter the properties of 
the offset tuning curve. 
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Table 7-2 Summary of previous studies investigating the offset ABR response in humans 
Author Year n Stimulus Key findings 
   
Frequency 
(kHz) 
Rise-plateau-fall time (ms) Intensity 
Polarit
y 
 
Kodera et 
al. 
 
1977 
10 
adults 
 
 
1 kHz 
Varying rise-fall times of 0.25,1, 2.5, 5 and 
10 ms in humans. 
0-60 
dB SL 
 
 
A 
On and offset responses recorded in humans for the first time 
Offset responses were similar to onset responses at lower 
intensity levels; however the I-L and I-A was elevated in 
human subjects at louder intensities. Increased rise times 
resulted in decreased amplitude and a broadening of the offset 
response for the onset response. Offset responses were not seen 
with rise times > 2.5-10ms. 
Brinkmann 
and Scherg 
1979 
3 
adults 
Gated WN 
2kHz gated 
sinusoids 
 
WN gated with Gaussian-shaped 
envelopes of 2ms half-width. 2kHz stimuli 
was  recorded using Gaussian-shaped 
envelopes of 0.2, 1,2,3,4,and 6 HW and 
linear rise times of 0, 1, 2.5, 5 and 10 ms. 
Rise and fall times were kept electrically 
identical within each measurement. 
80-85 dB 
SPL 
Varied 
Offset potentials were only observed at levels > 55 dB SPL 
with smaller amplitudes than those seen in the onset response. 
The polarity of the offset potential was the opposite of the 
onset response to WN stimuli. Systematic decrease in latency 
as a function of increased rise time. Offset potentials amplitude 
increased with shorter fall envelopes and no polarity reversal 
when recorded with 2 kHz tone. 
Elfner and 
Barnes 
1983 
4 
adults 
2 kHz 
1 ms rise-fall time but stimulus duration 
varied 2, 3, 4, 5, 6, 7 and 8 ms which were 
randomly presented 
60 dB SL NR 
Onset potential was reliably recorded for all durations and 
showed little change in latency with increased duration. 
The offset potential varied significantly with duration (i.e an 
increased latency was observed with increasing duration of the 
signal). The offset was not observed with stimulus duration 
<5ms. 
Perez-Abalo 
et al. 
1988 
7 
adults 
0.5 kHz 
 
Rise-fall times of 2 ms with a variable 
plateau of 2, 4, 6 and 8 ms 
 
100 dB 
SPL 
A 
Authors report a linear dependence on plateau time (i.e. 
increased plateau duration showed an increase in latency). The 
offset response less affected by noise compared to onset 
response. 
Van 
Campen et 
al. 
1997 
40 
adults 
0.5 and 2.0 
kHz 
Stimulus duration of 10ms 
Rise and fall times of 0.5, 1, 2.5 and 5 ms 
103 dB 
peSPL 
A 
Offset response reliably recorded in the absence of any 
acoustic ringing. Offset ABR was sensitive to rise and fall 
times and was optimal when recorded using a 500 Hz stimulus. 
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Human studies of the offset ABR have shown that, although the morphology of 
the response is similar to the onset response, the offset response is characterised by a 
number of differences. For example, the threshold of the onset-response was 20 dB SL 
and 30-40 dB SL for the offset response; i.e. the offset response has a higher (or poorer) 
threshold (by 10-20 dB) (Kodera et al., 1977b). A similar finding was reported by 
Brinkmann and Scherg (1979) who observed that the „offset‟ response had smaller 
amplitudes (1/3 to 1/5 smaller compared with the „on‟ response). The authors 
commented that offset thresholds were elevated (55 dB SPL) as they were not easily 
discernible because of the decrement in amplitude. We have summarised the differences 
between the onset and offset ABR, which have been published, in Table 7.3 below. 
Table 7-3 Functional properties of the offset ABR as compared to the onset ABR 
Characteristics of the offset ABR Reference 
Smaller amplitude (Kodera et al., 1977b, Brinkmann and Scherg, 1979, Henry, 
1985a) 
More sensitive to changes in rise-fall 
time 
(Kodera et al., 1977b, Brinkmann and Scherg, 1979, Henry, 
1985a, Laukli and Mair, 1985) 
Responds to intensity changes in a 
non-monotonic pattern 
(Kodera et al., 1977b, Henry, 1985a, Laukli and Mair, 1985) 
Higher threshold (Kodera et al., 1977b, Henry, 1985a, Laukli and Mair, 1985) 
More resistant to effects of masking (Henry, 1985b, 1986, Henry and Lewis, 1988, Perez-Abalo et al., 
1988) 
May be generated from apical 
cochlear areas 
(Henry, 1985b, Henry and Lewis, 1988, Perez-Abalo et al., 1988) 
 
Kodera et al., (1977) also described the effect of changing rise-fall times on both 
the onset and offset ABR. They found that an increase in rise time caused a decrease in 
amplitude and broadened the waveform of the onset response. The increased rise time 
also resulted in an increased latency for onset responses. Rise and fall times also had an 
effect on the offset response: with short rise-fall times of 0.25-1ms offset responses 
were still recorded but not if these were >2.5-10ms.  
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Elfner and Barnes (1983) examined the effect of duration on the onset-offset 
ABR. They reported that duration had little effect on the onset response but that a 
prolongation of the latency and an increase in amplitude was observed in the offset 
response, with increasing stimulus duration. There was no discernible offset for stimuli 
with a shorter duration (<5ms). Collectively, these studies suggest that on and off 
responses may have different generators, however the offset response is often 
overlooked and, as we show in or next section, the origin of the response is fiercely 
debated (Phillips et al., 2002a, Scholl et al., 2010). 
 
7.2.2 The generator of the offset response 
There is little agreement regarding the mechanisms involved in the generation of 
the offset response.  Several studies published after Kodera et al., (1977) have argued 
that what is thought to be an offset response is, in fact, a stimulus artefact, produced by 
acoustic transducer „ringing‟ that follows stimulus onset (Brinkmann and Scherg, 1979, 
Elfner and Barnes, 1983). Support for the „artefact‟ theory came from early work 
published by Brinkman and Scherg (1979) that showed that the offset response 
„reversed‟ in polarity. They argued that the response was elicited by the oscillation of 
the headphone diaphragm which „rings‟ at its resonant frequency, activating neuronal 
activity. Brinkman and Scherg (1979) successfully argued that the offset is really “an 
„onset‟ response evoked by new spectral components occurring at stimulus termination” 
(Van Campen et al., 1997, p36). As a result the offset ABR received little further study. 
The issue of whether the offset response was an authentic neural response or an 
artifact was re-examined by Van Campen et al., (1997). They showed that with careful 
stimulus selection (including stimuli characterised by no ringing artefact) it was 
possible to record a reliable ABR for the offset of tonal stimulation (Van Campen et al., 
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1997) (Van Campen, Hall and Grantham, 1997). Although Van Campen et al., (1997) 
clearly demonstrated reliable offset ABR responses for “all degrees of acoustic ringing” 
(p35), the number of recordable offset responses was much poorer in the no-ringing 
condition (as low as 17% for 2 kHz). The reason for the discrepancy between the two 
conditions is unclear but needs to be explored further. 
One possibility that we explore in our first empirical study is the potential 
adverse effects of polarity on the offset potential. Shifts in wave V latency for low 
frequency ABRs, elicited with rarefaction and condensation onset-phase stimuli, can 
result in partial cancellation of wave V when the responses are combined (Schwartz et 
al., 1990, Orlando and Folsom, 1995, Hall, 2007).  
It is difficult to say whether alternating polarity of stimuli as reported in Van 
Campen et al., (1997) could explain the relative scarcity of responses in the no ringing 
condition – such a study has never been undertaken in the offset potential. However, if 
the offset response behaves in a similar way to the onset response, then alternating 
polarity reduces amplitude, thereby reducing the signal to noise ratio and as a result 
some of the responses may be simply lost in the noise. 
Subsequent studies have proposed three mechanisms which could explain the 
generation of the far-field offset response. One possibility is that the offset response 
reflects the synchronous termination of stimulus evoked neural activity. A second 
possibility is that it reflects a neural response to the offset transient. An alternative view 
is that the offset response is a reflection of synchronous post-stimulus resumption of 
spontaneous discharges. These are illustrated schematically below in Figure 7.1. Similar 
mechanisms have also been proposed at the level of the auditory cortex (Scholl et al., 
2010). 
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Figure 7-1 Schematic showing the three hypotheses that have been proposed to underlie the neural 
response contributing to the far-field recorded offset response. 
 
One possibility is that the 
offset response reflects the 
synchronous termination of 
stimulus evoked neural 
activity (A). A second 
possibility is that it reflects a 
neural response to the offset 
transient (B). A third 
possibility is that it reflects 
synchronous post-stimulus 
resumption of spontaneous 
discharges (C). 
 
Figure has been removed due to copyright restrictions 
 
 
Clearly, more normal descriptive research is needed on the relationship of 
stimulus parameters, such as intensity, duration (rise/fall time, plateau), presentation 
rate, the type of stimulus (noise versus tone burst) and response acquisition parameters 
to offset ABRs.  
Here, we present our offset-ABR data recorded in a normal hearing group of 
adults. We report a series of experiments, employing a wider range of frequencies and 
rise-fall times. This work replicates and extends previous studies published in Van 
Campen et al., (1997). 
 
7.2.3 Methodology 
7.2.3.1 Subjects  
Ten normal hearing young adults (6 females, 18-30 years, mean age of 22.1 
years) with no known predisposing factors for hearing loss participated in the study.  
Study participants were initially recruited through convenience sampling, and 
subsequently through snowball sampling. Ethical Committee approval was obtained for 
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the study with informed consent obtained from each subject. Participants were 
recompensed for their time at all times of measurement. 
All subjects had pure tone audiometric thresholds of 15 dB HL across 0.25-8.0 
kHz. Tympanometry confirmed normal middle ear status in each of the participants. 
Because of the length of testing and the number of stimuli involved, 
electrophysiological testing was performed across 3 sessions (typically 1-2 weeks apart) 
depending upon the availability of each participant. Otoscopy and tympanometry were 
performed at the beginning of each session.  
 
7.2.3.2 Stimuli, recording method and procedures 
All subjects had standard baseline audiological assessment as previously 
described in Chapter 3. The presence of hearing loss as assessed by abnormal 
audiometric and impedance audiometry tests was a criterion of exclusion from the 
study. During each session, participants were instructed to relax on a soft comfortable 
chair in a sound-treated room and encouraged to sleep (if possible). A click evoked 
ABR was undertaken in each participant at the initial electrophysiological session to 
establish a normal baseline measure. These ABRs were recorded in response to clicks 
(100 s in duration) of alternating polarity presented at a rate of 11.1/s at an intensity of 
80 dB nHL using TDH-49 headphones.  
Onset and offset ABR was recorded in response to tone burst stimuli (duration 
10 msec) at 0.25, 0.5, 1, 2, and 4 kHz with varying rise and fall times (from 0.5 to 5 
msec). Table 7.4 summarises the number of conditions and stimuli employed. Because 
the stimulus rate was slower (to avoid overlapping stimuli) the length of testing was 
increased and it was necessary to undertake recording over several sessions.  
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Stimuli were presented monaurally through EAR-3A insert earphones using a 
Biologic NavPro auditory evoked potential measurement system. Tonal stimuli were 
presented at rate of 6.3/s using alternating polarity with an intensity level of 67 dB nHL. 
The presentation order of the different tonal stimuli (n=25) was randomised using a 
modified Latin Square Matrix. Only the right ear of each participant was tested.  
In order to replicate the Van Campen et al., (1997) study as closely as possible, a 
horizontal montage was adopted. The rationale for this selection in Van Campen et al., 
(1997) was based on optimising peak waveform identification. Electrode impedances 
were maintained below 5000 Ω and inter-electrode impedances were balanced to within 
2000 Ω in order to maximise rejection of common mode signals. The EEG inputs were 
amplified by 100,000 and band-pass filtered from 30 to 3000 Hz (12 dB per octave roll-
off) using a NavPro AEP system (Biologic, UK). Each waveform response represents 
an average of 1000 stimulus presentations over a 25-ms analysis window. All responses 
were replicated – in the event of a questionable response a third response was also 
obtained.  
 
7.2.3.3  Data analysis 
Onset and offset ABRs were analysed offline using the visual detection method 
previously described in Van Campen et al., (1997). For the purposes of present study, 
we adopted the same definitions of onset latency and offset latency. Thus, onset latency 
was defined as the time between the start of the rising ramp of the tone burst stimulus 
and the onset of wave V. Offset latency was calculated as the time between the start of 
the falling ramp of the tone burst and the offset V peak. Amplitude for each of these 
measures was measured based on a peak-to-trough calculation as shown in Figure 7.2. 
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A schematic of the method used to calculated onset and offset latency and amplitude is 
shown in Figure 7.2.  
Figure 7-2 Illustration of the method used to calculate onset and offset latency as recommended in 
Van Campen et al. (1997)  
 
 
7.2.3.4 Statistical analysis 
The following descriptive statistics were presented for continuous variables: 
number of values, mean, standard deviation (SD), median, minimum, and maximum. 
We were unable to combine the onset and offset ABR data in any meaningful statistical 
analysis because of the small number of participants which was complicated by the 
varying number of absent waveforms across a number of conditions, so a descriptive 
analysis of ABR measures was undertaken instead. 
 
7.2.4 Results 
7.2.4.1 Descriptive summary of the onset-offset ABR 
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All participants (n=10) had peak and interpeak latencies that fell within clinical 
normative data (± 2SD) for click evoked ABR. Normative ABR data is shown in 
Appendix 2, section 9.2.6. Because of the clear responses obtained across these 
conventional ABRs, we did not seek to routinely record the onset ABR to short tonal 
burst stimuli as previous studies have suggested that the click-evoked ABR, when 
measured at suprathreshold levels, is generated in the apical region of the cochlea (2-4 
kHz) (Hall, 2007). 
The number of onset and offset ABR responses that were recorded varied widely 
across stimuli (n=25). The number of missing data was related to stimulus 
characteristics including frequency and rise-fall time. Generally, the onset was recorded 
in all participants across all frequencies when the rise time was fast (i.e. 0.5 ms). The 
exception for this was at 1000 Hz which was present in 8/10 participants. Interestingly, 
the onset response when recorded with 1000 Hz was highly variable and showed the 
poorest morphology for the onset response (8/10 absent cases) when recorded using a 
rise-fall time of 1ms. Furthermore the onset response was more reliable when recorded 
with high frequency stimuli compared to low frequency stimuli.  
We have summarised the data and also presented the results published in Van 
Campen et al., (1997) for comparison in Table 7.4. Although we can only compare our 
data with Van Campen et al., (1997) at two frequencies (500 and 2000 Hz), our onset 
data that we present here is generally better than that previously reported as evidenced 
by the increased number of missing data at these frequencies.  
The offset ABR had a similar morphology to the onset ABR and consisted 
mostly of wave V. The offset was reliably recorded in most participants for long 
duration, low frequency stimuli particularly when the „fall‟ time was fast (i.e. 0.5ms). 
The offset response varied widely at higher frequencies with missing data ranging from 
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10-80% (Table 7.4). In several cases, the presence of the offset response was obscured 
by a large vertex positive component which appeared at the end of the analysis time 
(Table 7.4). A representative waveform is shown to illustrate this point in Figure 7.3  
Table 7-4 Stimuli employed and the number of recordable onset-offset waveform responses in 10 
normal hearing subjects. Data from a previous study (Van Campen et al., 1997) is shown here for 
comparison. 
 
Frequency Rise-Plateau-
Fall (ms) 
ABR (onset) ABR (offset) 
  
Present study 
(%) 
Van Campen  
et al. 
(%) 
Present study 
(%) 
Van Campen 
et al. 
(%) 
  
 
 
 
Artifact 
(%) 
 
250 Hz 
0.5-9.0-0.5 100 - 100  - 
1.0-8.0-1.0 100 - 90  - 
2.5-5.0-2.5 50 - 30  - 
5.0-0.0-5.0 10 - 30  - 
5.0-4.5-0.5 70 - 100  - 
500 Hz 
0.5-9.0-0.5 100 87 100  60 
1.0-8.0-1.0 70 100 90  72 
2.5-5.0-2.5 90 70 90  62 
5.0-0.0-5.0 70 97 70  70 
5.0-4.5-0.5 90 67 100  55 
1000 Hz 
0.5-9.0-0.5 80  80 10  
1.0-8.0-1.0 20  0 30  
2.5-5.0-2.5 60  60 10  
5.0-0.0-5.0 70  70 30  
5.0-4.5-0.5 80  80 20  
2000 Hz 
0.5-9.0-0.5 100 97 70 20 60 
1.0-8.0-1.0 100 67 60 10 40 
2.5-5.0-2.5 80 85 40 20 17 
5.0-0.0-5.0 70 70 60 10 90 
5.0-4.5-0.5 90 87 80 10 85 
4000 Hz 
0.5-9.0-0.5 100  50 20  
1.0-8.0-1.0 90  40 40  
2.5-5.0-2.5 90  20 30  
5.0-0.0-5.0 100  70 30  
5.0-4.5-0.5 100  90 10  
 
This interference of offset identification may correspond to post-auricular 
muscle activity (PAM) as suggested in Perez-Abalo et al., (1988) or may reflect 
interference from some other  mid-latency response (MLR) activity which has also been 
reported when rise and fall times are very brief (Hall, 2007). This finding may explain 
why the offset response is so variable across previous studies (Elfner and Barnes, 1983, 
Perez-Abalo et al., 1988, Van Campen et al., 1997). 
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Figure 7-3 Top panel: Representative trace showing a large amplitude artifact that commonly 
obscured offset response with 4 kHz tone. Bottom panel: The figure shows two superimposed trials 
of the onset-offset ABR recorded using a 2000 Hz tone (rise-plateau-fall: 2.5-5.0-2.5) from the right 
ear of a normal hearing female.  
 
 
 
. 
 
7.2.4.2 Effects of the rise-fall time on onset and offset ABR 
Previous studies have argued that although the onset and offset ABR 
components may have similar morphology; they have very different functional 
responses. They have cited different responses to rise-fall time of different stimuli as 
evidence to support this claim (Perez-Abalo et al., 1988).  
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In order to examine this in more detail, we investigated the effect of four 
different rise-fall times (0.5, 1, 2.5 and 5 ms) for a wide range of frequencies (0.25, 0.5, 
1, 2 and 4 kHz). We have plotted the data in a series of error bar plots for the latency of 
onset and offset responses in Figure 7.4 and corresponding amplitude data in Figure 7.5.  
Figure 7-4 Error bar graph showing the mean onset (in black) and offset (in blue) wave V latency 
for frequencies plotted as a function of rise-fall times (ms) 
 
We observed several trends in our data. First, the onset and offset ABR showed 
a marked trend of increasing latency with increasing rise-fall time across all 
frequencies.  The slope of the latency rise-fall tie function was less steep for the onset 
ABR. This is in good agreement with data published by Van Campen et al. (1997).  
Second, an increase in frequency correlated with a decrease in latency for both 
components.  
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Figure 7-5 Error bar graph showing the mean onset (in black) and offset (in blue) wave V 
amplitude for frequencies plotted as a function of rise-fall times (ms) 
 
Third, when we compared the amplitudes for both onset and offset components, 
we see that the onset amplitude is generally greater for low frequency stimuli and 
greater than the offset amplitudes recorded at the same frequency. This finding has been 
reported in previous studies (Brinkmann and Scherg, 1979). These earlier studies have 
reported that the amplitude of wave V offset are typically smaller by as much as 1/3
rd
 to 
1/5
th
 (Brinkman and Scherg, 1979) 
 
 
 
0.5 1.0 2.5 5.0
0
0.1
0.2
0.3
0.4
0.5
Rise-Fall Time (ms)
A
m
p
li
tu
d
e 
(m
ic
ro
v
o
lt
s)
250 Hz
0.5 1.0 2.5 5.0
0
0.1
0.2
0.3
0.4
0.5
500 Hz
Rise-Fall Time (ms)
A
m
p
li
tu
d
e 
(m
ic
ro
v
o
lt
s)
0.5 1.0 2.5 5.0
0
0.1
0.2
0.3
0.4
0.5
1000 Hz
Rise-Fall Time (ms)
A
m
p
li
tu
d
e 
(m
ic
ro
v
o
lt
s)
0.5 1.0 2.5 5.0
0
0.1
0.2
0.3
0.4
0.5
2000 Hz
Rise-Fall Time (ms)
A
m
p
li
tu
d
e 
(m
ic
ro
v
o
lt
s)
0.5 1.0 2.5 5.0
0
0.1
0.2
0.3
0.4
0.5
4000 Hz
Rise-Fall Time (ms)
A
m
p
li
tu
d
e 
(m
ic
ro
v
o
lt
s)
 384 
7.2.4.3  The effects of rise-time on the onset-offset ABR 
We examined the onset-offset ABR for two different rise times (0.5 ms an 5.0 
ms) while the fall time was held constant at 0.5ms. We compared the latency and 
amplitude of both components in Figures 7.6 and 7.7 respectively. In general the onset 
latency decreased with an increase in frequency. This finding was mirrored to a lesser 
extent in the offset response. Interestingly, the latency of the onset ABR was more 
sensitive to an increase in the rise time compared with the offset latency. This trend was 
observed across all frequencies but was more noticeable in the lower frequencies.  
Figure 7-6 Error bar graph showing the mean onset (in black) and offset (in blue) wave V latency 
for frequencies (0.25, 0.5, 1, 2 and 4 kHz) plotted as a function of rise time. 
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Figure 7-7 Error bar graph showing the mean onset (in black) and offset (in blue) wave V 
amplitude for frequencies (0.25, 0.5, 1, 2 and 4 kHz) plotted as a function of rise time. 
 
 
 
7.2.4.4 Does polarity have an effect on the recording of the onset-offset ABR?  
Figure 7.8 shows an error bar graph plot of onset ABR latency measured against 
rise-fall time when the stimulus is measured for two conditions: rarefaction and 
condensation. Two trends emerge from the data, when examined, which we have 
already reported earlier. First, onset ABR latency for both condensation and rarefaction 
polarity show an increase in latency with increasing rise-fall time. Second, latency for 
onset ABR is greatest when recorded with low frequency stimuli. Our data suggests 
little, if any, difference between onset latency when measured with rarefaction or 
condensations; i.e. onset latency appears to be insensitive to changes in polarity.  
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Figure 7-8 Error bar graph showing the mean onset V latency responses in milliseconds for 
rarefaction (in black) and condensation (in blue) for frequencies (0.25, 0.5, 1, 2 and 4 kHz) plotted 
as a function of rise-fall time. 
 
 
 Figure 7.9 shows the corresponding data for the offset latency measures for both 
polarity measures. The same trends emerge for the offset data that were seen in Figure 
7.8. Although we observe, a much steeper increase in offset latency with increasing rise-
fall time. This is less obvious at higher frequencies.  
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Figure 7-9 Error bar graph showing the mean offset V latency responses in milliseconds for 
rarefaction (in black) and condensation (in blue) for frequencies (0.25, 0.5, 1, 2 and 4 kHz) plotted 
as a function of rise-fall time.  
No offset ABR data is available when recorded with a 1kHz tone (rise-fall time of 1.0ms). This is due to 
poor morphology of the waveform and a general lack of wave reproducibility which we have attributed to 
PAMR.  
 
  
From the series of error bar plots shown in Figure 7.10, we can make several 
observations regarding the relationship between the onset ABR component and polarity. 
First, the ABR onset amplitude is greater for low frequency stimuli, particularly at 250 
Hz, than when elicited with higher frequency stimuli. Second, onset ABR amplitude is 
sensitive to the rise-fall time. Amplitude is greater with faster rise fall times, although 
this is less obvious at in the onset response recorded with higher frequencies. Third, 
onset amplitude also appears to be influenced by polarity at low frequencies. In general, 
the onset amplitude is greater when recorded with condensation click stimuli compared 
with a rarefaction click. This is seen at 250 Hz and 500 Hz. However, we cannot see any 
evidence for this at higher frequencies. 
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Figure 7-10 Mean onset amplitude for rarefaction (black) and condensation click recordings 
measured in microvolts 
 
 
 
The amplitude data for the offset ABR is plotted for five frequencies (250, 500, 
1000, 2000 and 4000 Hz) for different rise-fall times in Figure 7.10. The data for both 
condensation and rarefaction are shown. The published data concurs with the data we 
present in Figures 7.10 and 7.11 respectively.  
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Figure 7-11 Mean offset amplitude for rarefaction (black) and condensation (blue) click recordings 
measured in microvolts. 
No offset ABR data is available when recorded with a 1kHz tone (rise-fall time of 1.0ms). This is due to 
poor morphology of the waveform and a general lack of wave reproducibility which we have attributed to 
PAMR.  
 
Interestingly, when we examine the offset ABR data plotted in Figure 7.11, we 
can see that the choice of polarity does not appear to influence the amplitude of the 
offset response. Moreover, while the amplitude measures for low frequencies are 
generally larger compared with higher frequency stimuli, this relationship is less clear 
when compared to onset data shown in Figure 7.10.  
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7.2.5 Discussion  
7.2.5.1 Comparison of our data with previous studies 
Our research identified four main findings from the data. First, we showed that 
both components of the onset-offset ABR increased in latency with an increase in the 
rise-fall times, particularly the offset response, which had a more non-linear response to 
increased rise-fall times. This is consistent with previously reported studies for the onset 
response (Fausti et al., 1991, Hall, 2007) and the offset response (Kodera et al., 1977b, 
Perez-Abalo et al., 1988, Van Campen et al., 1997).  
Second, we showed that both of the onset and offset ABR components had 
shorter peak latencies when recorded with progressively higher frequencies. Thus peak 
latencies were longest at 250 Hz compared with 4000 Hz. Once again our results are in 
good agreement with published reports in animal and human studies (Kodera et al., 
1977b, Henry, 1985a, Perez-Abalo et al., 1988, Van Campen et al., 1997). This well-
documented finding has been explained by the delay in the travelling wave such that 
low frequency responses are generated apically and higher frequencies have been 
attributed to more basal regions.   
Van Campen et al., (1997) maintained that this data provides evidence for an 
apical generator site for the offset ABR component. They argued that: 
“the higher frequency stimuli offset wave V latencies were significantly longer 
than onset latencies across stimulus conditions. These results suggest that the high 
frequency stimuli did not optimally stimulate the cochlear partition responsible for 
initiating offset ABR” (p44) 
Perez-Abalo et al., (1988) also argue that the offset ABR comes from a narrow, 
apical region of the basilar membrane. They demonstrated that the offset ABR had 
smaller decreases in amplitude and smaller changes in latency than the onset counterpart 
particularly when the high-pass masking filter was lowered. 
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Third, our data showed that amplitude was smaller for the offset ABR compared 
with its onset counterpart. Interestingly, both components had greater amplitudes when 
recorded with low frequency stimuli compared to higher frequency stimuli. When offset 
responses are reported they are usually described as having smaller amplitudes than the 
onset responses (Antonelli and Grandori, 1984). This differs from the data presented in 
Perez-Abalo et al., (1988) who reported that all of the offset responses were of a similar 
size or greater amplitude compared with the onset response.  
 Finally, we showed that the onset ABR was more sensitive to rise time than the 
offset ABR. This trend was observed across all frequencies but was more noticeable in 
the lower frequencies. We could see no difference in the amplitude for either component 
for the two rise time conditions. This result is not surprising when we consider that only 
the earliest portion of the waveform is important in eliciting a response for the onset, 
thus the transient nature of the ABR favours short rise times and enhanced neural 
synchronicity (Hall, 2007). Our data did not show any evidence to suggest that the 
offset ABR is dependent on rise time. Collectively this supports the idea that these 
components are generated by different mechanisms.  
Our data here differs significantly from Van Campen et al., (1997). They 
reported that the offset ABR had an „enhanced‟ response when measured with a longer 
rise time (5ms) relative to the shorter 0.5 ms rise time. The discrepancy between our 
studies is not clear. Previous studies investigating the effect of rise and fall times on the 
offset ABR postulated that the offset ABR was more sensitive to rise-fall time than 
onset ABR due to subsequent changes in the amplitude of acoustic ringing.  
Alternatively, this may reflect a difference between our recording parameters, for 
example, different gating parameters used to generate our stimuli. Unfortunately they 
did not publish their stimulus waveforms so we cannot judge the degree of ringing in 
each condition and therefore we cannot draw any further conclusions.  
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7.2.5.2  Polarity 
The published data examining the relationship between polarity (or stimulus 
phase) and the ABR is conflicted. There is no consensus on the effects of polarity on the 
ABR. Some studies report very little effect of polarity (Hall, 2007); others report that 
polarity has a significant effect on the ABR (Gorga and Thornton, 1989). Moreover, 
most of these studies have concentrated on the potential influence of polarity on peak 
latency, with less attention given to the influence on wave amplitude (Hall, 2007). 
Here we present the first data from the onset-offset ABR, examining the possible 
effect of polarity on the latency and amplitude of both components. We hypothesised 
that this may provide a partial explanation for the poor response reported in previous 
studies (Van Campen et al., 1997). The use of an alternating polarity click can disrupt 
the phase locking properties of afferent auditory fibres; cancel low frequency phase 
locked components, while summing the input from fibres tuned to high frequencies. 
This can produce responses that are out of phase, which can lead to a poor wave 
morphology or complete absence of the waveform, and in turn this can lead to 
misinterpretation of abnormal brain stem function (Schwartz et al., 1990, Orlando and 
Folsom, 1995)  
Our data showed that the onset ABR is sensitive to polarity but only when 
recorded with lower frequency stimuli. Amplitude was greater when recorded with a 
condensation click compared with the rarefaction click stimulus. This was particularly 
clear at lower frequencies but not obvious at higher frequencies. This result is not 
surprising especially as Gorga and Thornton (1989) maintain that low frequency stimuli 
are separated in time as compared to higher frequency stimuli whose positive and 
negative half-cycles occur closer in time. This would mean that stimulus polarity effects 
are more prominent at low frequencies because of the dependence upon phase-locking 
properties of the cochlear and auditory nerve (Gorga and Thornton, 1989).   
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However, we observed no difference in latency onset to either rarefaction or 
condensation. This differs from empirical data published in Orlando and Folsom (1995) 
that examined the ABR for morphological differences using both polarities and found 
large latency differences between rarefaction and condensation stimuli for low 
frequency stimuli. They argued that this was related to the phase sensitive neural 
responses within the cochlea and auditory nerve (Orlando and Folsom, 1995).  
However, the interpretation of polarity (or stimulus phase) is complicated by several 
factors including the acoustics of the external auditory meatus, stimulus gating 
parameters and stimulus intensity to name but a few (for a review see Hall, 2007). The 
differences between our data and previously published results may just be a reflection of 
different parameters or due to our smaller sample. 
Interestingly, the offset ABR was relatively unaffected by polarity. Indeed, we 
could find no evidence to support a difference in offset ABR amplitude or latency for 
either condition. This may provide evidence for different functional properties of the 
offset ABR compared with the onset response or may simply reflect a difference in the 
neural generators (i.e apical versus basal cochlear mechanics). Although our sample is 
small, we must conclude that polarity does not affect the offset ABR and cannot be used 
to explain the poor responses (i.e. the number of absent measurements that have 
previously been described). A partial explanation for the poorer offset response may lie 
in the choice of electrode montage and the overlapping MLR components. There are a 
number of possible approaches that could be used to try and eliminate the possible 
contributions of myogenic and neurogenic sources such as selecting a different 
electrode montage (to avoid any contribution from the mastoid) or amending the 
stimulus rate.  These should be tested in future studies. 
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7.3 Experiment 2: The offset ABR in a clinical population 
7.3.1 Introduction 
The remarkable ability of humans to reliably identify and categorise phonemes 
with high fidelity – despite considerable natural variation across speakers, and 
distortions brought by noisy and reverberant environments – has been the subject of 
intense study for decades (Anderson and Kraus, Anderson et al., Holt and Lotto, Cacace 
and McFarland, 1998, Griffiths, 1999, Kraus, 1999, Allen et al., 2000, Bellis et al., 
2000, Emanuel, 2002, Fuente and McPherson, 2006, Banai et al., 2007, Hackett, 2011).   
Scientific studies of these phenomena are also strongly driven by our need to 
understand what can cause dysfunction in these critical processes; i.e. states in which 
the brain is unable to accurately represent or process speech as seen, for example, in 
hearing loss, auditory aging or neurological disease. 
One potentially important and related area of research that has received little 
attention is the encoding of sound offsets, particularly in the auditory brainstem. Studies 
of the offset ABR have been strictly limited to normal hearing adults (Palmer, 1987, 
Van Campen et al., 1997).  Study of the offset ABR has never been undertaken in any 
clinical disorders although a number of studies have suggested it may have clinical 
relevance (Van Campen et al., 1997). 
More recently, study of the rat auditory cortex has provided convincing evidence 
supporting the existence of two pathways for auditory processing. This study clearly 
showed that one set of synapses was strongly activated by the onset of tones but a 
different group of synapses responded strongly at the offsets, or the sudden ending of 
the tones. No overlap between the two responding sets of synapses was seen, i.e. the end 
of one tone did not affect the response to a new one (Scholl et al., 2010).  
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Since the anatomical pathways controlling the two responses are thought to be 
different, at least in some respects, it is not unreasonable then to expect that lesions and 
disease processes may differentially affect these functional pathways. Therefore to the 
clinician it may be just as useful to test the offset response as it is to test the onset 
response. Furthermore, knowing how the brain responds to, and organises, sounds could 
lead to better treatment.  
In this chapter, we present our preliminary findings from a small cohort of 
children with atypical saccadic eye movements. A key question that we attempt to 
address is „whether the neural responses of the brainstem in children with oculomotor 
disease is sufficiently rich to support the discrimination of sound offset?  
 
7.3.2 Methodology 
 
7.3.2.1 Subjects  
The study group was composed of 12 children diagnosed with atypical eye 
movements. This group represents a smaller cohort of participants who had taken part in 
our previous studies (as presented in Chapters 4 – 6). Four children were diagnosed with 
neuronopathic GD (4 female, age range 7-19 years; mean age 10.5 yrs) and 8 were 
diagnosed with DES (4 males, age range 4- 15 years; mean age 8.75 years). Table 7.5 
summarises the clinical other features and treatments of the study group. 
An equal number of age and gender-matched children with normal hearing 
threshold levels (normal pure tone audiogram and tympanometry) with no known 
predisposing factors for hearing loss were used as controls. Ethical Committee approval 
was obtained for the study with informed consent was obtained from the parents of the 
younger children and from the older subjects themselves. 
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Table 7-5 Summary of clinical characteristics 
Case 
Age 
(yrs) 
Sex Diagnosis Other neurological signs 
1 8 F GD3 Some difficulties with reading and writing but attends a 
mainstream school. 
2 7 F GD3 No concerns 
3 8 F GD3 No concerns 
4 19 F GD3 Learning difficulties 
5 6 M DES Stroke in the cerebellum; Ataxic and very clumsy; Learning 
difficulties 
6 11 M DES Dyslexia; LTM deficits; Dysarthric; Learning difficulties 
7 4 F DES Learning difficulties 
8 15 F DES Learning difficulties, Still unsteady on her feet; Attends a special 
needs school 
9 8 M DES No concerns 
10 8 M DES Learning difficulties, Still unsteady on his feet; Attends a special 
needs school 
11 6 F DES Learning difficulties but attends a mainstream school 
12 12 F DES Learning difficulties 
Abbreviations: DES – dancing eye syndrome; F- female, GD3 – type 3 Gaucher disease; LM – long term 
memory deficits; M- male, SIF – saccade initiation failure. 
 
7.3.2.2 Recording methods 
 The onset and offset ABR was recorded as previously described in section 7.2.3. 
Tone burst of 0.5 kHz and 2 kHz , with a rise time of 5 ms and a fall time of 0.5ms 
(total duration of 10 ms) were used to obtain the offset ABR. These stimuli were 
selected as our previous studies (and those reported by Van Campen et al. 1997) had 
shown that the offset response was more prominent when recorded with a longer rise 
time and shorter fall time.  
 
7.3.2.3 Data Analysis 
The analysis of each peak component (onset and offset) was undertaken using a 
visual inspection method as previously described in section 7.2.3. Peak waveform 
latency and amplitude data for onset and offset were calculated.  The following 
descriptive statistics were presented for quantitative data: number of values, mean and 
 397 
standard deviation (SD). Because of the small sample size, we have confined ourselves 
to providing a descriptive analysis of our pilot data only.  
 
7.3.3 Results   
7.3.3.1 Comparison of the onset-offset ABR in normal hearing adult and children  
To the best of our knowledge, the offset ABR has not been measured in younger 
participants. Because of the possibility that age may be influence the ABR, we 
compared the onset–offset ABR from two different age groups. All of the participants 
had normal hearing.  
The onset ABR was identifiable in 9/10 older participants for 500 and 2000 Hz. 
The offset ABR was present in all participants for 500 Hz but only present in 8/10 
participants at 2000 Hz. The onset ABR was less reliable in the younger group, and 
present in 8/10 cases when recorded with both 500 Hz and 2000 Hz. The offset response 
was present in 9/10 participants for both 500 Hz and 2000 Hz.  
When we compare our data with that reported in Van Campen et al., (1997) we 
see that our data is similar for both components (87% onset and 85% offset when 
measured with 2000 Hz. However, our onset and offset data at 500 Hz for both younger 
and older subjects was better than previously reported by Van Campen et al., (1997) 
(Table 7.4).  
Table 7.6 shows the mean and SD for ABR latency and amplitude in adults and 
young participants with normal hearing. We could see no evidence from our data to 
support a difference in the latency or amplitude for the onset or offset ABR component 
when measured at 500 Hz or 2000 Hz.  
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Table 7-6 Latency and amplitude data for the onset and offset response to 500 Hz and 2000 Hz for 
normal ‘older’ hearing adults and ‘younger’ children  
Group Stimuli Onset response Offset response 
 
(kHz) 
Latency 
(ms) 
SD 
Amplitude 
(µV) 
SD 
Latency 
(ms) 
SD 
Amplitude 
(µV) 
SD 
Older 0.5  9.93 0.47 0.23 0.09 6.60 0.25 0.29 0.14 
2.0 7.66 0.46 0.21 0.12 5.87 1.57 0.27 0.10 
Younger  
 
0.5  8.89 0.84 0.35 0.24 6.78 1.10 0.26 0.12 
2.0 7.14 0.79 0.28 0.18 6.89 2.45 0.48 0.14 
 
7.3.3.2 The onset-offset ABR in neuronopathic GD 
Of the four children who participated in this study, we were only able to 
successfully complete recording in three cases (1, 3 and 4). We were unable to reliably 
record the onset-offset ABR in case 2 (one of the younger participants) due to poor co-
operation. Their excessive movement during the testing resulted in the need to repeat as 
well as increasing the number of artifacts. Both of these factors increased the total 
length of testing and as a result the testing had to be stopped. 
We were unable to identify any onset or offset waveform component for any of 
these participants for either 500 Hz or 2000 Hz. Figure 7.12 shows a representative 
figure illustrating the response to click stimulus in recorded in the right ear and the 
onset-offset response recorded to 500 Hz.  
Only wave I and III are identifiable on the click ABR recording. There are no 
clear responses for the onset or the offset ABR (Figure 7.12 bottom panel). This was a 
typical response for all of the GD participants across the 500 Hz and 2000 Hz.   
 
7.3.3.3  The onset-offset ABR in DES 
In this study, we were able to successfully measure the onset and offset response 
in 7/8 DES cases. We could not complete testing in case 7 because of poor co-operation. 
In the remaining 7 cases, both components – the onset and offset – were clearly 
discernible. The mean latency and amplitude data for individual DES cases is shown  
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below in Tables 7.7 and 7.8 respectively.  
 
Figure 7-12 Representative onset and offset ABR recordings from one child diagnosed with nGD 
(case 1).  
The top panel shows a traditional onset-ABR recording using a click stimulus, only waves I and III are 
clearly reproducible in the traces. The bottom panel shows two superimposed traces of the onset-offset 
ABR recorded with a 500 Hz stimulus (right ear data only shown). 
 
 
 
The mean onset latency response at 500 Hz was 8.16 ± 0.55 ms (n=7) in children 
diagnosed with DES compared with a mean onset latency of 8.89 ± 0.84 ms in normal 
hearing children (n=9) (Table 7-7). The mean onset amplitude at 500 Hz was 0.41 ± 
0.20 µV (n=7) in children diagnosed with DES compared with a mean onset amplitude 
of 0.35 ± 0.24 µV in normal hearing children (n=9). There were no observable 
differences in onset latency or amplitude between the groups at 500 Hz.  
The mean onset latency response at 2000 Hz was 7.42 ± 0.57 ms (n=7) in 
children diagnosed with DES compared with a mean onset latency of 7.14 ± 0.79 ms in 
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normal hearing children (n=9) (Table 7.7). The mean onset amplitude at 2000 Hz was 
0.53 ± 0.16 µV (n=7) in children diagnosed with DES compared with a mean onset 
amplitude of 0.28 ± 0.18 µV in normal hearing children (n=9). There were no 
observable differences in onset latency or amplitude between the groups at 2000 Hz.  
Table 7-7 Latency and amplitude data for the onset and offset response to 500 Hz for individual 
DES subjects participants. Control data is shown for n =9 cases for onset and n=8 for offset 
response. SD shown in brackets. 
 
Case Onset response Offset response 
 Latency (ms) Amplitude (µV) Latency (ms) Amplitude (µV) 
5 9.2 0.29 7.83 0.31 
6 8.99 0.18 9.60 0.49 
7 NT NT NT NT 
8 8.16 0.81 8.03 0.34 
9 9.72 0.41 7.41 0.50 
10 9.41 0.48 7.58 0.40 
11 8.68 0.32 7.18 0.25 
12 8.47 0.35 7.11 0.40 
Controls 8.89 (0.84) 0.35 (0.24) 6.78 (1.10) 0.26 (0.12) 
 
When we examine the latency data we see that children with DES and the 
younger, normal hearing controls both demonstrate longer latencies for onset and offset 
components when measured with 500 Hz compared to 2000 Hz (Tables 7.7 and 7.8). 
The finding of a frequency-latency dependent relationship for both the onset and offset 
response is similar to that seen in our first empirical study in this chapter and concurs 
with previous published data (Perez-Abalo et al., 1988, Van Campen et al., 1997). 
The mean offset latency response at 500 Hz was 7.82 ± 0.85 ms (n=7) in 
children diagnosed with DES compared with a mean onset latency of 6.78 ± 1.10 ms in 
normal hearing children (n=8) (Table 7.7). The mean offset latency response at 2000 Hz 
was 7.50 ± 0.64 ms (n=7) in children diagnosed with DES compared with a mean onset 
latency of 6.89 ± 2.45 ms in normal hearing children (n=8) (Table 7.8). There were no 
observable differences in onset or offset latencies between the groups at 500 Hz.  
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Table 7-8 Latency and amplitude data for the onset and offset response to 2000 Hz for individual 
DES participants. Control data is shown for n =9 cases for onset and n=8 for offset response. SD 
shown in brackets. 
Case Onset response Offset response 
 Latency (ms) Amplitude (µV) Latency (ms) Amplitude (µV) 
5 8.06 0.38 7.41 0.27 
6 7.33 0.41 7.62 0.76 
7 NT NT NT NT 
8 7.64 0.44 7.76 0.62 
9 6.6 0.56 8.76 0.63 
10 8.16 0.65 6.87 0.45 
11 6.91 0.64 6.99 0.81 
12 7.22 0.62 7.1 0.60 
Controls 7.14 (0.79) 0.28 (0.18) 6.89 (2.45) 0.48 (0.14) 
 
We observed a difference in the offset amplitude data between the two groups at 
500 Hz (Table 7.7). The mean offset amplitude was 0.38 ± 0.09 µV (range 0.25 - 0.5 
µV, n=7) in children diagnosed with DES compared with a mean offset amplitude of 
0.26 ± 0.12 µV in normal hearing children (n=8) (Table 7.7).  
There is no observable difference in the offset amplitude at 2000 Hz in DES 
(0.59 ± 0.18 µV; range 0.27 - 0.81 µV, n=7) compared with normal hearing children   
(0.48 ± 0.14 µV; range 0.27 - 0.81 µV, n=8) (Table 7.8). 
 
7.3.4 Discussion  
 
7.3.4.1 Comparison of the onset-offset ABR in adults and children 
In this study, we investigated whether younger children with normal hearing 
would have a different onset-offset ABR profile compared to an older group of adults 
with normal hearing. Establishing the normal morphological characteristics of the onset-
offset ABR in a younger group – and whether maturation has any overall effect on the 
waveform components or morphology – was an essential undertaking prior to any 
application of this technique in our clinical populations in our later study.    
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We found the onset ABR was a more reliable measure in the adult group 
especially when recorded with low frequency (500 Hz) stimulus as evidenced by the 
fewer number of missing data values. Furthermore, our onset and offset data at 500 Hz 
for both younger and older subjects was better than previously reported by van Campen 
et al., (1997). As stated earlier, this may be due to a technical factor (such as ringing) 
which enhances the offset response in our conditions. Such a response has been reported 
in some studies to result in an increase in amplitude and therefore making it easier to 
discern waveform components (Brinkmann and Scherg, 1979).  
We could find no evidence of any difference in latency or amplitude between the 
two age groups for either the 500 Hz or 2000 Hz stimuli. Such a finding is not 
surprising as there is substantial evidence from click evoked ABR studies to support a 
fully myelinated brainstem and a „mature‟ ABR response from the age of 18 months 
(Moore, 1987a, b, Sininger et al., 1999, Hall, 2007, Moore and Linthicum, 2007). 
However, the age difference between our two groups (mean of 22 years in the older 
group and 9 years in the younger group) was not vast and our sample was very small so 
our results may not give an accurate representation in a wider population. Clearly this 
issue should be re-examined in a much wider age range including neonates and much 
older adults (>65 years) as evidence from the click-evoked ABR would indicate a 
difference in latency (Hall, 2007). While these results need to be validated in future 
studies, pilot studies examining test-retest reliability and the effect of different electrode 
montages, particularly in order to minimise PAMR would also be useful additions in 
this area of research.  
 
7.3.4.2 The onset-offset ABR response in nGD 
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In this study, we present for the first time the onset-offset ABR in 3 children 
diagnosed with nGD. We have previously shown in Chapters 4 and 5 that the click 
evoked ABR in nGD is abnormal, despite normal peripheral hearing. Of the 6 patients 
who participated in this study, we were only able to successfully complete our recording 
in 3 cases. The morphology of the waveforms in each of these 3 cases was grossly 
abnormal – we were unable to identify any onset or offset waveforms – to either the 500 
Hz or 2000 Hz stimuli. 
There are three possible explanations for our data. Firstly, the onset-offset ABR 
is not a wholly reliable measure. We were able to record the onset and offset ABR in 
8/10 children in the first part of our study. It is plausible then that this is an unreliable 
measure of auditory processing and that the cases did have a response but we failed to 
capture or measure it using our current method. Secondly, our stimulus may have been 
„too challenging‟ for the auditory brainstem in these three cases. The stimulus used in 
this study had a very long rise time (5ms) which is a less than optimal for evoking the 
conventional „onset‟ ABR. Previous studies have shown that the onset ABR is highly 
dependent upon the time-locking transient properties of the stimuli. In a disorder – 
characterised by poor neural synchrony – any stimulus that is „suboptimal‟ would 
present a challenge portion not ideal for neural synchrony and eliciting an „onset‟ 
response. Finally, an alternative explanation is that children with nGD don‟t have 
recordable onset-offset responses because of the neurological damage within the 
auditory system. The slower rise time of the tonal stimulus that we used in our study, 
compared to the click we previously used could potentially enhance the effects of poor 
neural synchrony in this group and provide some explanation for the absent responses in 
these patients. 
The origin of the offset ABR is still highly debated in the scientific community. 
Because the conventional ABR is time-locked to stimulus onset, it presumably 
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represents synchronized single unit activity of onset neurons (Moller, 1985). It follows 
then that the offset ABR could reflect single unit activity of offset neurons or a 
synchronized decrease in neural activity. Other studies have concluded that the offset 
ABR could reflect a synchronised „second onset‟ response to stimulus cessation. 
Unfortunately we are unable to draw any conclusions in this regard based on our data. It 
may be of interest to examine the onset-offset ABR in other neurological disorders that 
present with dysynchronous ABRs such as those seen in auditory neuropathy. 
The distinct lack of any „onset‟ response is an important finding and warrants 
future investigation. Onset responses have been shown to have a wide range of 
functional significance including an important in temporal discrimination, music 
perception and loudness perception (Allen et al., 2000, Phillips and Hall, 2002, Phillips 
et al., 2002a, Phillips et al., 2002b, Banai et al., 2005, Abrams et al., 2006, Hornickel et 
al., 2009a, Kraus and Chandrasekaran, 2010). Furthermore, accurate encoding of 
auditory transients is particularly important in speech perception, because both the 
amplitude onset slope and the relative timing of the onsets of energy in different 
frequency bands can be important cues for phonetic identity (Kraus et al., 2000, Phillips 
et al., 2002a). Future studies in children with nGD, or indeed any patient with 
„paradoxical‟ hearing should include a wider range of behavioural and psychoacoustic 
measures of temporal function. Indeed there is emerging evidence of temporal 
asynchrony and perceptual timing deficits in many of these cases (Starr et al., 1996, 
Kraus et al., 2000, Starr et al., 2001). Such studies provide a model for studying the role 
of synchrony in auditory perception and could lead to more effective hearing therapies 
and devices. 
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7.3.4.3  The onset-offset ABR response in DES 
 In this study, we were able to successfully measure the onset and offset response 
in 7/8 DES cases. Both components – the onset and offset – were clearly discernible in 
the DES group. Our latency data was comparable to the normal hearing age-matched 
controls, with longer latencies observed for both onset and offset components when 
elicited with low frequency stimuli (500 Hz) and shorter latencies seen in response to 
2000 Hz. The data supports previously reported studies (Van Campen et al., 1997).  
We could find no evidence to support any differences in onset amplitude data for 
children with DES compared to normal hearing children. However, our data showed a 
difference in the offset amplitude data between the two groups at 500 Hz which was 
significantly greater in children diagnosed with DES. There was no difference in 
amplitude at 2000 Hz. The novel finding – that the offset response is greater in DES, 
particularly at low frequencies – is interesting and may provide a partial explanation for 
the processing difficulties that children report in DES (Table 6.7, Figures 6.4 – 6.6).  
Like the other responses seen in DES this „over-representation‟ of low frequency 
information at stimulus offset may be a reflection of the neural „hyper-excitability‟ seen 
in other aspect of the disease. Our finding suggests that there is an abnormally high 
level of sound induced neuronal activity occurring within auditory brainstem pathways, 
which could be due to abnormal amplification of sound evoked neural signals, 
particularly in low frequencies.  
It is difficult to account for the enhanced offset at 500 Hz in the DES group 
because the actual mechanism by which the offset response is generated is unknown. 
Offset responses could be generated within the cochlea (i.e.) a mechanical transient in 
the basilar membrane caused by the sound offset. Therefore our finding could suggest 
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dysfunction within the cochlear micromechanics, the result of which causes a cascade of 
disordered auditory information, upstream to higher cortical networks. 
Alternatively, the sound offset could be generated by post-inhibitory rebound at 
some point along the auditory hierarchy. Therefore our data could imply that there is a 
distortion in the neural coding of the auditory input that may cause abnormal growth in 
loudness or failure of the central nervous system to habituate the startle response. 
The cause of DES is generally assumed to be related to either antibodies or 
immune cells that are produced, most likely as part of a natural „defense‟ response to the 
neuroblastoma cells. It is plausible then that in DES these antibodies also attack cells in 
key areas in the brain, including cells within the inner ear. These rogue cells could cause 
damage in the inner ear by releasing cytokines (after a delay), resulting in  
additional immune reactions. Alternatively, antibodies or rogue T-cells could cause 
accidental inner ear damage because the ear shares common antigens with a potentially 
harmful substance, virus, or bacteria that the body is fighting off.  
Accurate encoding of sound offsets is important for perceptual grouping and 
auditory scene analysis and there is research that suggests that the auditory system may 
use off responses to „reset‟ itself, at points of rapid amplitude change, in order to update 
the „auditory scene‟. Failure to „reset‟ or accurately integrate fine-grained acoustic cues 
from the temporal envelope could manifest behaviourally as an abnormal perception of 
loudness (or decreased sound tolerance). This finding has been widely reported in other 
conditions associated hyperacusis including patients diagnosed with Autism, Spina 
bifida and Williams syndrome, although we are unaware of any study that has 
investigated the „offset‟ ABR in these cases (Khalfa et al., 2004). 
This finding has important implications for understanding speech, particularly 
when the background environment is challenging (e.g. speech in noise). Speech is 
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composed of complex sound waves and is dependent on rapid spectral and temporal 
changes, which are separated by discrete gaps. The enhanced over-representation of low 
frequency information could mask other important spectral cues, potentially 
compromising speech perception in sub-optimal environments. Evidence supporting this 
finding was recently published by Elsabbagh and colleagues (2011). They examined 
whether hyperacusis interfered with speech processing in children and adults diagnosed 
with WS. They found a significant relationship between the effect of hyperacusis and 
speech discrimination performance (i.e. speech discrimination was worse in cases with 
more severe hyperacusis. They attributed this to auditory and non-auditory factors 
including altered auditory attention and context dependent cues  (Elsabbagh et al., 2011) 
Clearly this is an area which requires further study but our novel finding that suggests 
that the speech offset should also be more closely examined in these studies. 
 
7.3.5 Conclusions  
In this chapter we have presented the preliminary results from the onset-offset 
ABR using simple tonal stimuli. The origin of the onset-offset ABR is controversial and 
research into this potential application has been severely limited. In our first study we 
have shown that with careful recording, an offset potential with a unique set of 
characteristics but similar in morphology to the onset ABR can be recorded. This 
response is highly variable and more sensitive to some changes in the stimulus 
envelope, than its onset counterpart. We have also shown in this study that it is unlikely 
that the use of alternating polarity can explain the discrepancies in identifying the offset 
ABR. It is more likely that the absence of the response is due to stimulus artefact 
obscuring the offset potential waveform.  
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Our second experiment examined the application of the onset-offset ABR in two 
clinical conditions with established brainstem oculomotor disorders. Previous studies of 
these two conditions have shown that the ABR when recorded with simple click is (a) 
absent or significantly dysmorphic in children with nGD and (b) that there is a slight 
prolongation in the children with DES. The onset-offset ABR was significantly different 
from age-matched controls in both groups. Firstly, we were unable to identify any clear 
waveform component (onset or offset) in the nGD group. This may reflect the recording 
parameters used to elicit the response but is more likely to be related to the poor neural 
synchronicity that is evident in the click ABR in this group. Our latency data from the 
DES population was comparable to the normal hearing age-matched controls but the 
amplitude data, particularly at 500 Hz was significantly greater in children diagnosed 
with DES. This data may reflect some of the difficulties that this group report with 
hyperacusis but further psychophysical testing to correlate with our findings are 
required. 
Finally, our studies in clinical setting have identified a number of serious 
concerns with the use of the onset-offset ABR as it is currently measured. Without 
significant investment in basic and applied research studies, any clinical application of 
the onset-offset ABR at this stage would be extremely premature although our data offer 
some very interesting insights that should encourage future work in this area.  
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8 Chapter 8 
General Discussion and Conclusions 
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8.1 Overview 
Firstly, let us look back to the original question that motivated our thesis. We 
asked whether children diagnosed with GD and DES with documented saccadic eye 
movement abnormalities, originating in the brainstem, also have auditory problems.  
Our research was motivated anecdotal patient reports of auditory complaints; previous 
(incomplete) literature and the proximity of the structures. We hypothesized that since 
the neural substrates controlling the oculomotor and auditory systems are anatomically 
co-located within the brainstem then it would be reasonable to expect that auditory 
pathways would also be affected in these two conditions. Moreover, we argued that if 
there is brainstem disease in neighbouring anatomical areas – such as the brainstem 
oculomotor system – then we ought to anticipate some auditory abnormality.  
Our thesis concentrated on two clinical disorders: GD and DES. The hallmark of 
both of these disorders is their abnormal eye movements: slow saccades seen in children 
with neuronopathic GD and opsoclonus as seen in children diagnosed with Dancing Eye 
Syndrome. We selected these conditions as saccadic models of slow saccades and high 
frequency oscillations (opsoclonus) had shown evidence to support that the pons – a 
neural substrate common to both in the oculomotor and auditory brainstem systems – is 
damaged in both of these disorders. 
Our second research question was concerned with the utility of auditory 
electrophysiological measures in the study of eye movement disorders, such as GD and 
DES. Here we asked if the application of the ABR could be used to complement current 
eye movement studies in GD and DES? We argued that the ABR was a potentially 
useful instrument to examine this issue. We maintained that there were several 
advantages in applying this technique including an extensive literature supporting its 
ability to measure the integrity of brainstem pathways and the ability for this non-
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invasive measure to translate successfully from the lab to clinic. We also presented 
literature, albeit limited, suggesting that children with established eye movement 
disorders also have abnormal ABRs. 
Returning to the hypothesis posed at the beginning of this study, it is now 
possible to state that there is ample evidence that the use of audiological assessment in 
children with GD and DES would contribute to clinical practice. Moreover, we believe 
we have presented evidence to support the utility of the ABR alongside eye movement 
studies in a variety of roles.  
In this final chapter, we begin by presenting a summary of our main findings and 
conclusions. We then proceed to outline what we consider are our core contributions 
and discuss their significance and their relevant implications.  Finally, we discuss the 
limitations of the thesis and suggest possible directions for future work.  
 
8.2 Findings and conclusions 
8.2.1 General introduction and background literature 
Our initial chapters were concerned with „setting the scene‟ – providing a 
reasoned argument for our research questions – highlighting the importance of such a 
study in Neuroscience. These studies we argued were of growing import when set 
against the emerging evidence for a „dynamic‟ brainstem: a system that demonstrated 
plasticity and was able to learn.  
We began to develop this argument further in Chapter 2 by outlining the 
saccadic eye movement and auditory brainstem systems. Here we clearly showed the 
close anatomical relationship in the brainstem. We argued that brainstem lesions do not 
respect sensory boundaries and in order to understand the functional implications of any 
disease, that may affect the brainstem, study across sensory modalities was required. 
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Therefore, we argue that a more powerful approach is to combine multimodal 
techniques such that the resultant data measures augment one another. 
We followed this discussion with a brief overview of eye movement techniques 
and audiological techniques that are currently used to examine the brainstem. We had 
previously argued that these techniques are readily available in most Audiology clinics 
– although the routine investigation of eye movement disorders is considered by many 
as beyond the scope of clinical practice.  
Since our thesis was concerned with establishing the central importance of the 
auditory brainstem response (ABR), we asked whether there is any documented 
evidence of auditory abnormalities in other aetiologies associated with slow saccadic 
function or opsoclonus. We explored the scientific literature to see whether both signs 
and symptoms have been reported in conditions. Our findings from the scientific 
literature suggested that, in general, auditory deficits – as indexed by the ABR – were 
commonplace in a number of aetiologies that give rise to slow saccades or opsoclonus. 
However, there was limited multimodal study examining both systems. We believed 
this provided sufficient evidence to warrant further study.  
 
8.2.2 Chapter 4: Audiological profile of Gaucher Disease  
In this chapter, we introduced our first clinical population – Gaucher disease. A 
general assumption made in the clinical literature was that the presence of abnormal eye 
movements – characterized by slow saccades and saccade initiation failure – was a 
universal sign, and therefore diagnostic of the neurological subtype. However, we could 
find no study that categorically supported this assertion. Indeed, we found several 
studies that argued that abnormal eye movements were also present in patients with 
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non-neuronopathic phenotypes. Clearly before we could commence any auditory study 
– we needed to establish the credibility of these claims.  
We undertook a systematic literature review study to examine whether there was 
any evidence to support the theory that GD1 and GD3 are not distinct phenotypes on the 
basis of eye movement studies. Our findings showed that eye movement abnormalities 
in our GD were pathognomonic of neuronopathic disease, at least in children.  
We began the first of our empirical studies in GD. Here we systematically 
investigated the audiological function in 25 children with enzymatically diagnosed GD 
using a series of tests that measured the integrity of the auditory system. We found that 
combined auditory and oculomotor studies can be used to better delineate the 
underlying neurological deficits in nGD. This finding provided our first evidence 
supporting our original hypothesis that children with GD have auditory problems and it 
suggested the possibility of a new role for the ABR and its modification by brainstem 
oculomotor pathology.  
One of the more significant findings to emerge from this first study was that 
GD1 and GD3 are really distinct phenotypes on both measures. There was no indication 
of gradations on either auditory or eye movement tests between the two groups, 
consistent with the notion of two distinct phenotypes –neuronopathic and non-
neuronopathic. The results of this research provide sufficient evidence to warrant the 
inclusion of audiological testing as part of the standard assessment of newly diagnosed 
GD patients. 
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8.2.3 Chapter 5: The use of audiological assessments in the longitudinal 
monitoring of GD  
We began this chapter, by asking whether the ABR could have a wider 
application either as a longitudinal outcome measures for use in clinical trials or value 
as a neurological marker for monitoring disease burden in the brainstem pathways. The 
cost of not developing quantitative measures was extreme: the urgent need to accurately 
diagnose and monitor treatments in these rare diseases – as early as possible – was a 
recurring theme throughout the literature.  
We presented two experimental studies. Our first study was concerned with 
examining whether the ABR could be used to reliably measure the disease burden in the 
neuronopathic subtypes of GD. Here we reported data of serial ABR recordings in type 
2 and type 3 GD. 
We drew two conclusions from the first part of this Chapter. First, our data 
clearly showed that the ABR could be used to provide objective evidence of the time 
course of neurological involvement (progression or remission) in patients diagnosed 
with nGD who were undergoing high dose ERT. Second, we showed, for the first time, 
evidence that high-dose ERT does not prevent the deterioration of ABRs in 
neuronopathic GD. Here we provided empirical evidence to support our second research 
question: if the application of the auditory brainstem response could be used to 
complement eye movement studies? As a result, we proposed that patients should 
undergo these tests prior to commencing treatment to establish a baseline for future 
measures. 
Our second study examined the merit of using the ABR as an outcome measure 
in clinical trials. Only three small case studies had been described in which eye 
movement and auditory assessments were used as outcome measures. All of these 
studies indicated that substrate restriction therapy (Miglustat) could improve 
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neurological manifestations in GD3.  Here we presented our data on use of the ABR as 
a secondary outcome measure in randomized control drug trial of Miglustat in children 
diagnosed with GD3. We could find no evidence to support any improvement in ABR 
waveform components or morphology over a two year interval. Moreover, we found 
that children who had previously had normal peripheral hearing developed hearing loss 
over this short time frame. Our novel finding raised an interesting question – is hearing 
loss is a previously unidentified feature of GD? Such data lent further support to our 
argument for the use of audiological assessment in children diagnosed with GD. 
 
8.2.4 Chapter 6: Audiological profile of Dancing Eye Syndrome 
We began this chapter by introducing our second clinical study group: Dancing 
Eye Syndrome, a rare disorder characterized by remarkable („chaotic‟ or „dancing‟) 
saccadic eye movements. Anecdotal reports painted a picture of extremely distressed 
children when exposed to loud or sudden sounds – reminiscent of hyperacusis. Here, we 
asked whether the hyper-excitability expressed in the eye movement system, as 
opsoclonus, was mirrored in the auditory system, i.e. do children with DES have 
hyperacusis?  Our parental questionnaire provided preliminary evidence to suggest that 
many children with DES did have an abnormal sensitivity to ordinary environmental 
sounds.  
Our second study took up the challenge of establishing whether the auditory 
brainstem was impaired in DES. We highlighted the major gap in our clinical 
knowledge – the inability to accurately identify the site of lesion – in DES. Eye 
movement studies had implicated the brainstem and the cerebellum as possible 
candidates. Here we presented for the first time a systematic audiological evaluation of 
DES. The most obvious finding to emerge from this study was that children with DES 
 416 
had evidence of longer-term brainstem disease, even in the absence of any overt eye 
movement abnormalities. This major finding implicated the auditory brainstem in DES.  
Taken together, these results suggest that children with DES do have auditory 
problems, including an abnormal sensitivity to ordinary environmental sounds. 
Furthermore, these deficits can be reliably measured by the ABR.  
 
8.2.5 Chapter 7: The ‘offset ABR’ in saccadic eye movement disorders  
In our final experimental chapter we presented pilot data for the onset-offset 
ABR. The origin of the onset-offset ABR is controversial and research into this 
potential application has been severely limited. We argued that application of the offset 
ABR merited further investigation in light of new data from animal models. In our first 
study we clearly showed that an offset potential with similar morphology to an onset 
potential can be recorded. This response was highly variable. We showed in this study 
that it is unlikely that the use of alternating polarity can explain the discrepancies alone 
in identifying the offset ABR. It is more likely that the absence of the response is due to 
stimulus artifact obscuring the offset potential waveform.  
Our second experiment examined the application of the onset-offset ABR in two 
clinical conditions with established brainstem oculomotor disorders. Previous studies of 
these two conditions have shown that the ABR when recorded with simple click is (a) 
absent or significantly dysmorphic in children with nGD and (b) that there is a slight 
prolongation in the children with DES. The onset-offset ABR was significantly different 
from age-matched controls in both groups. Firstly, we were unable to identify any clear 
waveform component (onset or offset) in the nGD group. This may reflect the recording 
parameters used to elicit the response but is more likely to be related to the poor neural 
synchronicity that is evident in the click ABR in this group. Our latency data from the 
 417 
DES population was comparable to the normal hearing age-matched controls but the 
amplitude data, particularly at 500 Hz was significantly greater in children diagnosed 
with DES. This data may reflect some of the difficulties that this group report with 
hyperacusis but further psychophysical testing to correlate with our findings is required. 
 
8.3 Research issues examined 
The experiments reported in this thesis present many pieces of an evolving 
puzzle. Moreover the contributions of this thesis also make it clear how little of the 
entire territory has been investigated to date. We now consider the original contributions 
of this thesis concentrating on those research issues we have explored and relating our 
findings back to those questions that motivated our thesis.  
 
8.3.1 Children with GD and DES have audiological abnormalities 
Our ABR investigations, using onset and to a much lesser extent offset stimuli, 
have clearly identified a diverse number of ABR abnormalities in two conditions 
associated with atypical SEM. These findings have not previously been documented. 
The findings from our thesis make several contributions to the current literature which 
we summarized earlier in Chapter 2. 
First, we clarified the usefulness of the ABR as a neurological tool in nGD and 
DES. For example, we presented literature in Chapter 4 to show that the utility of the 
ABR as a clinical measure of neurological dysfunction in GD1 and GD3 was extremely 
confused. Earlier studies in this area had compared the ABR findings in GD and while 
some degree of similarity has been identified, several inconsistencies across studies 
were also reported. Further examination of these studies revealed marked 
methodological heterogeneity and incomplete reporting that limited the interpretation of 
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earlier research in this area. Our study as presented in this thesis was the first to present 
quantitative data and not just a descriptive analysis of ABR waveforms. 
Second, our findings add substantially to our understanding of the 
pathophysiological mechanisms in both of these conditions. The auditory abnormalities 
that we have identified in children with nGD have shown that not only is the ABR a 
sensitive subclinical measure of neurological deterioration in these groups but that the 
peripheral hearing mechanism may also be involved in the latter stages of the disease 
(see 8.3.2 for further discussion). Our data, for the first time, have also clearly 
implicated the auditory brainstem as a site of lesion in DES, even after the oculomotor 
abnormalities resolved. 
In Chapter 4, we also presented a model linking eye movement and audiology 
findings. We argued that the unusual pattern of audiological and oculomotor 
abnormalities identified in our nGD patients suggested an excitotoxic mechanism which 
predisposed nerve cells to glucocerebroside toxicity. In Chapter 6, we discussed the link 
between the eye movement abnormalities in DES and the presence of hyperacusis. Our 
study identified hyperacusis as an undiagnosed concern in at least 43% of children with 
DES. We argued that this finding could be consistent with hypothesis of serotonin 
disturbance in these patients. We showed that this finding is consistent with eye 
movement studies and other biochemical studies in DES. The developments of these 
theories – although speculative – provide strong support for multimodal study that we 
advocated earlier in Chapter 1. 
Third, the this thesis provides additional evidence that auditory tests, such as the 
ABR, in addition to eye movement studies, can improve the phenotype/genotype 
discordancy that has been previously described in this disease. This data has important 
clinical implications in terms of diagnosis and treatment. Major advances have been 
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made in developing treatments for GD and other associated LSD. Given the prohibitive 
costs of many of these treatments, there is an impetus on the early distinction between 
different phenotypes (non-neuronopathic and neuronopathic disease) to allow the 
appropriate treatment to commence as soon as possible.  
Taken together, these findings clearly suggest a role for ABR measurement in 
children with atypical SEM. This research will serve as a basis for future studies. Given 
the exciting developments in learning and plasticity studies of auditory brainstem 
pathways there is a very real possibility for amelioration of some of these deficits and 
auditory rehabilitation in these clinical conditions. 
 
8.3.2 Systematic application of audiological tests provides important clues in 
understanding the pathophysiology in GD 
Our data presented in Chapters 4 and 5 underscored the importance of 
systematically testing the auditory system. By combining standardised audiological tests 
with other tests of overlapping afferent and efferent pathways, including the acoustic 
reflex threshold test, the medial olivocochlear suppression test (MOCS) and the ABR, 
we clearly showed that the auditory system is affected in neuronopathic GD.  
Our multimodal test strategy suggested that the disease affected multiple 
auditory brainstem structures including the cochlear nuclei and the olivary nuclei. We 
argued that a midline lesion near the genu could affect both fascicles to give a bilateral 
lesion and also affect the horizontal saccade centres in the PPRF. Although a number of 
these abnormalities could be accounted for by a solitary lesion located in the 
dorsomedial brainstem (in and around the saccadic eye movement centres), our auditory 
data suggested that it is more likely that there are additional lesions, possibly affecting 
inner hair cell function. 
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Our longitudinal studies, reported in Chapter 5 also showed that the audiological 
abnormalities often mirrored the severity of the phenotype (i.e.) the ABR was more 
impaired in GD2, than GD3. The pathophysiology of these abnormalities is speculative 
but suggests that multiple factors could be involved including segmental demyelination 
and axonal and neuronal loss. Treatment with ERT failed to halt the progression of the 
neurological manifestations and treatment with Miglustat showed no significant 
improvement in ABR abnormalities. 
 Serial auditory studies also revealed that abnormalities within the peripheral 
auditory system. These appear to emerge later in the disease course, suggesting 
subclinical cochlear dysfunction in some cases, and more severe inner ear damage 
(resulting in hearing loss), in others. Because of new and more aggressive treatments, 
which have extended the life expectancy in these rare orphan diseases, we could start to 
see the emergence of other auditory manifestations previously not reported (or 
observed) prior to the introduction of these treatments.  
The site of lesion(s) leading to the auditory abnormalities in neuronopathic GD 
is uncertain.  The neuropathological features of the GD3 phenotype are poorly defined. 
Post-mortem data are limited to a single case report in which the only morphological 
abnormality was infiltration of the Virchow-Robin spaces with lipid-laden 
macrophages. A direct neuronal insult was not found. On the basis of this evidence, we 
must conclude that toxic or metabolic factors extrinsic to the neuron play an important, 
and yet, undefined role in the pathogenesis of GD. 
Based on this new knowledge – gained from auditory and eye movement studies 
– we posited that the unusual pattern of audiological and oculomotor abnormalities was 
consistent with an excitotoxic mechanism. The vulnerability of these neural pathways in 
GD reflects neurotoxicity – induced directly and/or indirectly – by elevated cellular 
cerebroside that potentiates excitotoxicity from excitatory amino acids, possibly 
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glutamate receptors, which is further exacerbated by high average neuronal firing rates. 
Such excitotoxic damage may be amenable to direct therapeutic intervention and 
warrants further study. 
 
8.3.3 The application of the ABR as an outcome measure in clinical trials 
Objective measurement of neurological dysfunction remains a major challenge 
when testing new drugs, especially in young children. The development of suitable 
neurological measures for monitoring the brainstem dysfunction has not kept pace with 
the new drug therapies that are emerging for the treatment of metabolic diseases.  
We presented audiological data that showed the utility of the ABR as a 
longitudinal measure and as an outcome measure in a two year randomized clinical trial. 
Our data clearly showed that audiological investigations could be a sensitive 
longitudinal marker of disease burden. To the best of our knowledge, we presented the 
first data of the use of serial objective audiological testing to monitor the neurological 
progression in acute neuronopathic Gaucher disease (GD2). As far as we are aware this 
was the first objective evidence for progressive neurological involvement, despite ERT, 
that has included measurements pre-and post enzyme treatment. Our data added to an 
emerging literature which showed that ERT does not halt neurological progression in 
this severe form of the disease. Our application of the ABR in children with GD3 who 
were receiving high-dose ERT also showed evidence for the deterioration of the ABR.  
The 24-month trial of Miglustat represented the first randomised, controlled 
study of a drug treatment in patients with GD3. We did not find any significant 
differences on the ABR assessed over 24 months. Indeed, our ABR data showed 
remarkable variability in the degree of abnormality in the ABR. Such variability needs 
to be taken into account when designing clinical trials and it is possible that this time 
 422 
frame was too short to capture any meaningful data regarding the efficacy of the drug. 
Studies regarding treatment efficacy in DES are currently underway – these larger-scale 
randomised controlled trials could provide more definitive evidence about the utility of 
the ABR in this disorder. 
Our findings add to an emerging literature on outcome measures, particularly the 
controversial use of eye movements and auditory tests in clinical trials. The ABR 
certainly meets some of the criteria of an „ideal‟ biomarker. For example, it has been 
argued that a biomarker should be „simple, rapid and inexpensive‟ – and the ABR easily 
fulfils these specifications. However, further study regarding ABR specificity and 
sensitivity are needed before the methods used in this thesis may be applied to other 
clinical trials. Large randomised controlled trials could provide more definitive 
evidence. 
 
8.3.4 The ABR has a wider research and possible clinical role than previously 
indicated. 
The data presented within this thesis both confirms previous findings and 
contributes additional evidence that an atypical „offset‟ ABR response to stimulus 
cessation may account for some of the persistent auditory difficulties that are reported in 
some children with atypical saccadic eye movements. Whilst the study reported in 
Chapter 7 did not confirm the origin of the neural generators of the offset ABR, it did 
partially substantiate the potential usefulness of this technique. However, our studies 
also identified a number of concerns with the use of the onset-offset ABR as it is 
currently measured. Without significant investment in basic and applied research 
studies, any clinical application of the onset-offset ABR at this stage would be 
extremely premature although our data offers some very interesting insights that should 
encourage future work in this area.  
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8.4 Summary of Research Limitations 
Finally, a number of important limitations need to be considered. Although we 
have attempted to address them as they arose, throughout the thesis, a number of 
caveats need to be noted. These can be divided into four main areas including: choice of 
population and sample size; limitations associated with poor source localisation of the 
ABR; lack of correlation to any behavioural measure and, finally, a number of technical 
and methodological issues. 
First, the data applies only to children diagnosed with neuronopathic GD and 
DES. Furthermore, because of the small sample size – a reflection of the rarity of these 
conditions – we urge that caution must be applied when interpreting the data. These 
findings might not be directly transferable to other eye movement disorders presenting 
with slow saccades or opsoclonus. Moreover, we were unable to control for variables 
such as treatments or age effects.  It is not clear from the studies presented here whether 
this is a significant source of variation on the ABR. 
Second, because the exact generator sites of the ABR are not known, the 
pathophysiology of abnormalities seen in both conditions is speculative. The ABR is a 
far-field electrophysiological measure and their generators are complex and dependent 
upon a number of factors that are still not completely understood. Furthermore, 
although exquisitely sensitive to brainstem dysfunction, ABRs do not detect higher 
level (cortical) processing abnormalities. As such, we are unable to draw any 
conclusions about what effect (if any) functional deficits at these levels could have or 
how they may impair the information processing capacity of one, several or all of the 
subserving brain regions. This relationship has yet to be fully explored in healthy as 
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well as in clinical populations and to our knowledge, there have been no studies 
documenting this in children with saccadic eye movement disorders. 
One of the main weaknesses of the studies presented here was the paucity of 
behavioural (or psychophysical) measures of auditory processing or other psychometric 
tests. What is the significance of an abnormal ABR on day to day listening experiences 
in these children? What is the potential usefulness of the ABR in this context? Given 
what we know about the neurological damage seen in these two conditions, it is not 
surprising that ABRs may be disordered in such individuals. However, it is apparent 
from some results that the ABR was normal. It is also unclear whether there are other 
conditions which could produce the same ABR „signature‟. Finally, the ABR‟s 
prognostic usefulness and functional significance is also unclear. Future studies should 
consider working at different levels of analysis, including at the symptom (or 
phenomenological level) and at the neurophysiological level of analysis. Such studies 
are urgently required not only so that we can monitor the neurological problems of 
children with brainstem disease but also so that we can make meaningful rehabilitative 
interventions. 
Finally, we need to mention a number of methodological issues. One source of 
weakness in the studies presented here, which could have affected measurement, was 
the dependence of visual detection for interpretation of the  ABR parameters – although 
this is a much wider issue affecting interpretation of all electrophysiological measures. 
Another limitation is the lack of validity for the questionnaire used in Chapter 6.  At a 
practical level, our findings from Chapter 7 underscore the urgent need to significantly 
redevelop the onset-offset ABR technique before it is implemented clinically or used in 
research studies in a younger and potentially less co-operative population. Indeed, if all 
the patients in these studies were clinically confirmed as having auditory processing 
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deficits and yet only some of them had abnormal ABR then the onset-offset ABR seems 
to be a less reliable test than a clinical history and other findings.  
Another example of a technical issue we faced when recording the onset-offset 
ABR was that we were unable to record from one child simply because of the length of 
testing involved – approximately 25 minutes per frequency – for one ear only. This is a 
significant barrier when considering the merits of incorporating this test into any test 
battery. In addition to examining the optimal recording methods, future studies should 
also investigate what the minimum number of stimulus presentations are required in 
order to evoke an onset-offset ABR. If it is significantly less than the 1000 presentations 
(per trace) used in our study, then the application of this procedure would certainly be 
more attractive to researchers and clinicians investigating the role of offset responses in 
auditory processing.  
 
8.5 Potential Areas for future research 
Audiological abnormalities indexed by the ABR are common in aetiologies 
associated with atypical SEM and our thesis has identified a number of questions in 
need of further investigation. Clearly, the limitations we outlined earlier in the previous 
sections must be dealt with. For example, correlating the ABR with other cognitive 
assessments and psychometric tests would certainly be beneficial. However, in this next 
section we outline some of the work that could be undertaken to extend the work 
contained here. 
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8.5.1 Extending the systematic measurement of the ABR to a wider group of 
conditions diagnosed with brainstem oculomotor disease 
A natural extension of our study would be application of the auditory techniques 
and methods adopted in this thesis to a wider group of brainstem oculomotor disorders, 
particularly those presenting with slow saccades and opsoclonus. Future research should 
therefore concentrate on the systematic investigation of auditory processing in these 
disorders. 
Another interesting application of our findings would be study of the ABR in 
neonates that are diagnosed with congenital opsoclonus; this could be achieved by using 
the national neonatal hearing screening programme. There is some data to support the 
presence of opsoclonus at birth. Opsoclonus has been reported in as many 3% of healthy 
infants – a statistic that rivals the detection of permanent childhood hearing impairment. 
In the majority of cases, opsoclonus recovers spontaneously (typically within 6 months), 
indicating some maturational component. An interesting question is whether the ABR 
would also show similar abnormalities? Or whether these infants develop auditory 
processing deficits at a later stage in their development? 
 
8.5.2 The encoding of complex ‘speech’ stimuli in children with atypical eye 
movements 
Our earlier experiments have only considered the neural representation of simple 
stimuli. We have not yet considered the significance of more complex or „naturalistic‟ 
sound and how this might be encoded in children with atypical eye movements. 
Recently, a series of studies have been undertaken measuring the ABR recorded using a 
synthetic speech syllable, /da/. The aim of these studies has been to develop a more 
„ecologically valid‟ test of brainstem integrity. Researchers have found that the „speech-
ABR‟ is able to detect subclinical abnormalities in the brainstem that are not evident 
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when using simple stimuli. These studies have been reported in normal hearing children 
with language and learning deficits and in other clinical populations such as autism. 
These studies could provide insight into the accuracy with which the brain stem 
nuclei synchronously respond to acoustic stimulation and the degree to which the 
response reproduces the input. A key question we suggest should be tackled in future 
work is whether neural responses of the brainstem, in children with atypical SEM, are 
sufficiently rich to support detailed phonetic discrimination. 
 
8.5.3 Development of other tests of brainstem function including the application 
of ‘sensory gating’ studies in children with atypical eye movements  
The sensory gating hypothesis asserts that auditory processing anomalies are due 
to deficits in „gating‟ or filtering of external sensory input by the CNS. Sensory gating 
experiments have shown that when two events happen within a short time frame 
(300 ms) of each other, the response to the second event is reduced („gated' out) to allow 
priority processing of the first event. If the responsiveness to the second event is not 
reduced, a deficit in sensory gating may be assumed, and „flooding‟ with irrelevant 
information may result. Two primary methods are used to assess gating: acoustic startle 
inhibition and P50 suppression.  
Both of these measures involve overlapping auditory and oculomotor pathways. 
It is plausible that these pathways will also demonstrate some impairment. Measures of 
sensorimotor gating are assumed to reflect CNS gating mechanisms necessary for 
normal perception. Further gating deficits have been reported in a wide number of 
conditions which share very few clinical characteristics. However they are linked by a 
reduced ability to inhibit or gate sensory, motor, or cognitive information. Further work 
needs to be done to establish whether the gating mechanisms in brainstem oculomotor 
disorders are dysfunctional. 
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9 Appendices 
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9.1 Appendix 1: Systematic review methodology 
We undertook a systematic review of the available literature, using the electronic 
database PUBMED. The search strategy was conducted using medical subject headings 
('MeSH terms') and free text words and included sub-searches of the title, original title 
and abstract. This initial search was further refined using a combination of key words 
with the addition of Boolean operator terms
49
. The inclusion and exclusion criteria, that 
we applied to the original search is shown below. A total of 157 abstracts were returned.  
Inclusion and exclusion criteria applied to the literature search 
Inclusion criteria Exclusion criteria 
Studies that investigated the use of the 
core index test: the auditory brainstem 
response  
Studies  investigating other evoked potentials  
English language Non English publications 
Published between 1970-2010 Conference abstracts 
 Animal studies 
 Not an original research article (ie) review articles, 
systematic review articles, editorials or theoretical 
papers 
 
The title and abstract of each study included was used to determine its relevance 
to this review. Full publications were retrieved for studies that seemed relevant, and for 
those for which relevance was still unclear. Of the original 157 citations, only 49 studies 
were considered relevant. Bibliographies of selected studies were also searched by hand 
in order to identify any further relevant studies not detected by the electronic search.  
Sixteen additional studies were identified from hand searching the 
bibliographies of those studies initially selected. This resulted in a final total of 65 
studies (Miller et al., 1973, King, 1975, Sanders and Lake, 1976, Tripp et al., 1977, 
Cogan et al., 1981, Stowens et al., 1982, Winkelman et al., 1983, Erikson and 
Wahlberg, 1985, Erikson, 1986, Grafe et al., 1988, Gross-Tsur et al., 1989, Conradi et 
al., 1991, Sidransky et al., 1992, Uyama et al., 1992, Brady et al., 1993, Patterson et al., 
                                               
49
 Boolean operator terms ("AND" "OR"): were combined key words for the study population (Gaucher, 
non-neuronopathic, neuronopathic, type-1, type-2, type-3) and the eye movement abnormality (eye, gaze, 
looping, ocular, saccade, saccadic, supranuclear). 
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1993, Abrahamov et al., 1995, Chabas et al., 1995, Harris et al., 1996, Tsai et al., 1996, 
Schiffmann et al., 1997, Harris et al., 1999, Bohlega et al., 2000, Garbutt and Harris, 
2000, Altarescu et al., 2001a, Garbutt et al., 2001, Sinclair et al., 2001, Tayebi et al., 
2001, Accardo et al., 2005a, Accardo et al., 2005b, Pensiero et al., 2005, Alfonso et al., 
2007, Capablo et al., 2008, Accardo et al., 2010, Alonso-Canovas et al., 2010). 
A flow chart summarising the study selection process. 
 
 
Data relating to the study population (genotype, phenotype, age, and gender), 
treatments, eye movement status (and measurement), and key findings were extracted.  
  
Potentially relevant 
studies identified from 
PUBMED database  
(n=157) 
Full text studies retrieved 
from PUBMED 
(n=49) 
Eligible studies 
identified from 
bibliography  
(n=16) 
Total eligible 
studies identified  
(n=65) 
Studies excluded: 
 - Duplications (n=71) 
- Limitations (n=37) 
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9.2 Appendix 2: Normative data  
9.2.1 Pure tone audiometry (PTA) 
Audiometric reference thresholds published in BSA (2004) 
Audiogram Terminology Description 
Type Sensorineural 
hearing loss 
Average air-bone gap of less than 15 dB for 0.5, 1 and 2 kHz 
Conductive hearing 
loss 
Normal BC thresholds and average air-bone gap of 15 dB or more 
for 0.5, 1, and 2 kHz 
Mixed hearing loss BC threshold greater than 20 dB HL in combination with 
averaged air-bone gap 15 dB or more for 0.5, 1, and 2 kHz 
Degree Normal Thresholds were better than 20 dB HL in both ears 
Mild Thresholds were measured between 20-40 dB HL in both ears 
Moderate Thresholds were measured between 40170 dB HL in both ears 
Severe Thresholds were measured between 71-90 dB HL in both ears  
Profound Thresholds were > 90 dB HL in both ears 
 
9.2.2 Tympanometry 
Normative data for tympanometry published in BSA (1992) 
Jerger Pattern Characteristics 
A 
 
Clear peak that occurs at 0 daPa ± 50 daPa with a base-peak compliance 
difference in the range of 0.3-1.6 ml 
 
As 
 
Clear peak that occurs at 0 daPa ± 50 daPa with a base-peak compliance 
difference in the range of < 0.3 ml 
 
Ad 
 
Clear peak that occurs at 0 daPa ± 50 daPa with a base-peak compliance 
difference in the range of > 1.6 ml 
 
B 
 
No clear peak (flat) 
 
C 
 
Clear peak  that occurs at > 100 daPa, with a base-peak compliance difference in 
the range of 0.3-1.6 ml 
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9.2.3 Acoustic reflex thresholds 
Reflex thresholds was judged subjectively by shape and looking for growth, 
although a reduction in compliance of 0.02ml or more was usually observed (BSA, 
1992).  In our study, we used the normative data published in Cohen and Prasher 
(1988). The ART was as 1) elevated for responses > 100 dB HL or 2) abnormal if they 
exceeded 105 dB HL at two or more frequencies or if the inter-aural threshold 
difference exceeded 10 dB on at least two frequencies (Cohen and Prasher, 1988).  
Acoustic reflexes at 4kHz were not considered as they are frequently absent. 
ART patterns interpreted as indicating brainstem lesions were vertical (abnormal 
ART by stimulation of one ear only), horizontal (ART abnormal by contralateral 
stimulation of both ears), inverted L (combined vertical and horizontal) and „full house‟ 
(all ipsilateral and contralateral reflexes abnormal) (Cohen and Prasher, 1988).  
9.2.4 Transient evoked otoacoustic emissions 
The table shown below presents the mean and std. error data for TEAOE . 
Ear Variable Mean Std Err. 95% CI 
    Lower Upper, 
Right ear Resp  16.528 0.6555 15.208 17.848 
Repro 88.326 1.8992 83.688 85.399 
Stim  84.543 0.4247 62.666 65.439 
Stab  89.717 1.9871 85.715 93.720 
Left ear Resp  14.515 0.8659 12.771 16.259 
Repro 88.326 1.8992 77.256 89.788 
Stim  84.609 0.3723 83.859 85.359 
Stab  91.761 1.1939 89.356 94.165 
Abbreviations: Resp – Response (dB SPL), Repro – Reproducibility (%), Stim – Stimulus level (dB), 
Stab – Stability of the response. Data from 46 normal hearing children aged 2-20 years, 20 females. 
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9.2.5 Medial olivocochlear suppression test 
The table shown below presents the mean and std. error data for MOCS test (n=30, 15 
males).  
Ear Variable Mean Std Err. 95% CI 
    Lower Upper, 
Right ear Resp (q) 14.921 1.3873 12.007 17.836 
 Repro (q) 91.105 2.3987 86.066 96.145 
 Stim (q) 64.053 0.6599 62.666 65.439 
 Stab (q) 89.105 3.1175 82.556 95.655 
 Resp (n) 12.505 1.2738 9.8290 15.181 
 Repro (n) 86.895 2.7273 81.165 92.625 
 Stim (n) 64.211 0.7116 62.716 65.705 
 Stab (n) 89.1053 3.1748 82.557 95.654 
 Difference 2.416 0.2998 1.786 3.046 
Left ear Resp (q) 13.826 1.19575 11.311 16.342 
 Repro (q) 91.474 1.7578 87.781 95.167 
 Stim (q) 63.895 0.6393 62.552 65.238 
 Stab (q) 92.053 2.4465 86.913 97.192 
 Resp (n) 11.674 1.1912 9.171 14.176 
 Repro (n) 85.737 3.1473 79.125 92.349 
 Stim (n) 63.895 0.6160 62.600 65.189 
 Stab (n) 92.053 2.4465 86.913 97.192 
 Difference 2.268 0.2644 1.713 2.824 
Abbreviations: (n) – measurement recorded in the presence of contralateral noise, (q) - measurement 
recorded in quiet (i.e. in the absence of any contralateral noise) Resp – Response (dB SPL), Repro – 
Reproducibility (%), Stim – Stimulus level (dB), Stab – Stability of the response. 
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9.2.6 Click-evoked ABR test 
The table below shows the normative latency range for peak waves I, III and V and 
inter-peak intervals (mean ± 2 SD, n=56). 
Waves 
(ms) 
I III V I-III III-V I-V 
 
 
1.47 ± 0.22 3.61 ± 0.29 5.39± 0.46 2.13 ± 0.23 1.78 ± 0.37 3.92 ± 0.40 
 
The table shown below summarises age-related normative ABR latency data recorded at 
75 dB. Data shown in brackets is 2 SD range. Data from Hall (2007) 
 Waves (ms) IPL (ms) 
Age I II III V I-V  
< 3months 1.87 
(1.43-2.31) 
3.11 
(2.39-3.83) 
4.66 
(4.22-5.10) 
6.77 
(6.23-7.31) 
4.90 
(4.22-5.58) 
3 -4 months 1.77 
(1.45-2.09) 
2.87 
(2.51-3.23) 
4.31 
(3.93-4.69) 
6.31 
(5.81-6.81) 
4.54 
(4.12-4.96) 
5-7 months 1.80 
(1.56-2.03) 
2.84 
(2.50-3.18) 
4.25 
(3.87-4.63) 
6.10 
(5.76-6.60) 
4.38 
(4.04-4.72) 
8-11 months 1.69 
(1.43-1.95) 
2.77 
(2.37-3.17) 
4.10 
(3.76-4.44) 
5.98 
(5.52-6.44) 
4.29 
(3.93-4.67) 
> 1 year 1.80 
(1.42-2.18) 
2.79 
(2.33-3.25) 
3.99 
(3.53-4.45) 
5.79 
(5.19-6.39) 
3.99 
(3.63-4.35) 
> 2 years 1.68 
(1.42-1.94) 
2.69 
(2.35-3.03) 
3.86 
(3.46-4.26) 
5.68 
(4.88-6.48) 
3.96 
(3.68-4.24) 
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9.3 Appendix 3: Questionnaire and Listening profiles 
9.3.1 Case history questionnaire 
Text has been removed due to copyright restrictions  
 436 
9.3.2 Modified listening profile 
Text removed due to copyright issues 
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9.4 Appendix 4: Hyperacusis questionnaire 
Text removed due to copyright issues 
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